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Abstract 
Chapter I: Synthesis of the Marine Natural Product 
Hippolachnin A 
Marine organisms are a rich source of structurally diverse secondary metabolites.1-3 In 
this regard, sponges have been intensively studied and have provided a large fraction of 
such natural products. In 2013, Lin and co-workers reported the isolation of the 
polyketide natural product hippolachnin A, together with its proposed biogenetic 
precursor, from the ethanolic extract of the South China Sea sponge Hippospongia 
Lachne collected from the waters at Xisha Islands.4 Hippolachnin A exhibited potent 
antifungal activity against the pathogenic fungi Cryptococcus neoformans, Trichophyton 
rubrum, and Microsporum gypseum with an MIC value of 0.41 µM for each fungus. The 
following work describes the total synthesis of hippolachnin A. The 
bicyclo[3.2.0]hepatadienenone core is installed via a disrotatory 4π-electrocyclization 
followed by excited state rearrangement of -tropolone methyl ether. The synthetically 
challenging installation of the vicinal diethyl groups has been achieved by a [3+2] dipolar 
cycloaddition of a thiocarbonyl ylide to an electron-poor double bond. Chelation 
controlled trapping of an in situ generated carbocation by a tin enolate led to closure of 
the final tetrahydrofuran ring. The synthetic route provided over 100 mg of the natural 
product as well as access to derivatives thereof (Scheme A).  
 
SCHEME A: Synthesis of hippolachnin A. 
  
VI 
Chapter II: Synthetic Studies Towards the Meroterpenoids 
Bisacremin E, F and G. 
Endophytic fungi grow within a plant host and usually live in a symbiotic relationship. 
Their growth involves continual metabolic interaction between fungus and host.5 
Therefore endophytic fungi display a rich source of secondary metabolites often bearing 
interesting bioactivity.6 In 2015, Wei and co-workers discovered bisacremines E–G from 
a culture extract of the soil-derived strain A. persicinum SC0105.7 Bisacremine E and F 
are supposed to be derived from a formal [4+2] cycloaddition of two acremine F 
monomers, followed by dehydration to form the final tetrahydrofuran ring (scheme B). 
Though both the endo and the exo transition state would lead to a natural product, we 
assumed that this reaction would not require enzymatic catalysis but could proceed 
spontaneously in solution.  
 
SCHEME B: Proposed biosynthesis of bisacremine E–G.7 
This work describes the total synthesis of acremine F as well as studies towards its 
dimerization to form bisacremines E and F. Therefore, we investigated several 
mechanistic hypotheses for a biomimetic dimerization, including a cationic cascade, a 
radical cation Diels-Alder reaction and photochemical [2+2]-cycloaddition followed by 
formal Cope rearrangement to form the core of the natural products. Furthermore, 
studies towards the non-biomimetic synthesis of bisacremine G, involving a vinyl quinone 
Diels-Alder (VQDA) reaction, have been conducted (Scheme C). 
VII 
 
SCHEME C: Retrosynthetic analysis of bisacremine G. 
 
 
 
Chapter III: Exerting Photocontrol over G-Protein Coupled 
Receptors 
Chapter three of this thesis describes the synthesis of light tunable modulators of G-
protein coupled receptors (GPCRs). In detail, the synthesis of multiple tethered and non-
tethered photoswitchable congeners derived from the known dopamine receptor (DAR) 
agonist PPHT are described as well as their ability to modulate DAR function in cellulo. 
Furthermore, the synthesis of light tunable derivatives of the known mAChR superagonist 
iperoxo is described as well as their effects when being applied to Langendorff 
preparations and cells transiently expressing mAChRs. The last part of this chapter 
describes the synthesis of photoswitchable derivatives of the TAS2R agonist denatonium 
(Figure A). 
 
FIGURE A: Molecular structures of PPHT, iperoxo and denatonium 
 
  
VIII 
Chapter IV: Development of Photochromic Ion Channel 
Blockers 
Chapter four of this thesis describes the synthesis of photoswitchable modulators of 
voltage gated ion channels and their evaluation in cellular systems. Therefore, we 
designed azobenzene containing derivatives of A-803467, a selective channel blocker of 
Nav1.8, bupivacaine, a local anesthetic used in intensive medicine and raxatrigine, an 
anesthetic in clinical phase three. The ability of azo-bupivacain derivatives to photoblock 
voltage gated ion channels has been examined in HEK293T cells transiently 
overexpressing Kv2.1 and TREK channels as well as in mouse hippocampal neurons. 
The effect of azo-raxatrigine has been evaluated using high-throughput methods on cells 
stably expressing Nav1.5, Nav1.7 and Kv1.3 (Figure B).  
 
FIGURE B: Molecular structures of A-803467, bupivacaine and raxatrigine. 
 
 
 
  
IX 
Chapter V: Studies Towards the Light-Dependent Regulation of 
Cytoskeletal Proteins 
Chapter five of this thesis describes the development of photoswitchable modulators of 
the actin cytoskeleton network. In particular, a variety of light dependent inhibitors of 
Arp2/3 based on the selective inhibitors CK636 and CK666 have been synthesized and 
evaluated in in vitro assays confirming their ability to inhibit Arp2/3 dependent actin 
polymerization. 
 
FIGURE C: Molecular structures of CK-666, CK-636 and blebbistatin. 
Furthermore, we developed a robust route to azobenzene containing derivatives of the 
selective nonmuscular myosin II inhibitor blebbistatin which could be used for the 
investigation of myosin II dynamics in the actin network (Figure C). 
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Chapter I 
 
 
 
Synthesis of the Marine Natural 
Product Hippolachnin A 
  
2 
1.1 Introduction 
1.1.1 Plakortin and Gracilioether natural products 
Marine organisms are a rich source of structurally diverse secondary metabolites.1-3 In 
this regard sponges have been largely studied and have provided a large fraction of such 
natural products. The plakortin family is a large class of polyketide natural products 
possessing high antimicrobial and antifungal activity derived from sponges of the genus 
Plakortis (Figure 1.1). Notably, many members of this family contain a cyclic peroxide.2 
Faulkner reported the first isolation of plakortin (1.1), a six-membered cycloperoxide, 
from P. Halicondrioides in 1978.8 However, it was not until 1999 that the absolute 
stereochemistry was assigned by Fattorusso.9 Subsequently, a series of related 
bioactive molecules have been isolated wherein the side chain at C6 differs by the length 
of the carbon chain demonstrating the diversity of building units that can be incorporated 
by the polyketide synthase.3, 10 While most of the isolated natural products offer some 
bioactivity, the plakortone-series proved to be highly potent activators of cardiac SR-Ca2+ 
ATPase.11  
 
FIGURE 1.1: A selection of plakortin natural products. 
In 2009, in hope of identifying potent leads from marine invertebrates against malaria 
infections, Fusetani and co-workers isolated the first members of the gracilioether family, 
a sub-class of the plakortin natural products, gracilioether A-C.12 While all three isolated 
compounds showed antimalarial activity, only gracilioether A (1.8) featured a structurally 
interesting heterotricyclic ring system containing a six-membered endoperoxide (Figure 
3 
1.2). In 2012 the group of Zampella found further members of the gracilioethers, namely 
gracilioether E-J,13 and in 2013 the further oxidized natural product gracilioether K (1.9).14 
While gracilioether E-G, I and J were almost completely inactive against all screened 
targets, gracilioether H (1.10) showed antimalarial activity against a chloroquine-resistant 
strain, proving the importance of the endoperoxide for bioactivity.13 
 
FIGURE 1.2: Members of the gracilioether family. 
 
1.1.2 Synthetic approaches towards the gracilioether family 
Due to their impressive structures and the diverse bioactivities, synthetic chemists 
immediately pursued de novo syntheses of members of this family. In 2014, Brown and 
co-workers reported the first synthesis of gracilioether F (1.14) (Scheme 1.1),15 relying 
on a late-stage C-H functionalization. Ketene formation from acid chloride 1.18 and 
subsequent [2+2]-cycloaddition with cyclopentene 1.19 furnished bicyclo[3.2.0]heptane 
1.20, which after alkylation and Baeyer-Villiger oxidation gave rise to bicyclic lactone 
1.21. After cleavage of the double bond and oxidative work-up, carboxylic acid 1.22 was 
obtained. C-H oxidation of the tertiary C-H bond then accessed gracilioether F (1.14). 
4 
 
SCHEME 1.1: Brown’s synthesis of gracilioether F (1.14).15 
The first asymmetric total synthesis of gracilioether B (1.11) and C (1.12) was 
accomplished by Sorenson and co-workers in 2015 (Scheme 1.2).16 Alkylation of 
oxazolidinone 1.23 with allyl iodide 1.24 sets the C8 stereocenter providing 1.25 in good 
yield. After dihydroxylation under Sharpless conditions and subsequent 
transesterification, lactone 1.26 was obtained, which could be converted into acetal 1.27 
following reduction with DIBAL-H. Aldehyde 1.28 was then generated by Ley oxidation. 
Weiler alkylation then accessed -ketoester 1.29, which directly underwent 
transacetalization to form hemiacetal 1.30 and dehydration in the same step to furnish 
furanylide 1.31. Transacetalization of 1.31 catalyzed by In(OTf)3, followed by immediate 
Horner−Wadsworth−Emmons olefination with diethyl (2-oxopropyl)phosphonate 
afforded gracilioether B (1.11). Stereoselective reduction using Ru-catalysis then 
afforded gracilioether C (1.12) in good yield. 

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SCHEME 1.2: Sorenson’s synthesis of gracilioether B (1.11) and C (1.12).16 
Carreira and co-workers reported the first total synthesis of gracilioether E (1.13) in 
2016.17 The tetrahydrofuran ring was obtained by a Lewis-acid catalyzed ene-cyclization 
of enone 1.33. Oxidative cleavage of the double bond then provided cyclobutanone 1.34, 
which was then subjected to Baeyer-Villiger oxidation to obtain the full heterocyclic core 
of 1.35. Installation of the (Z)-configured double bond by selenoxide elimination then 
furnished the natural product 1.13 (Scheme 1.3). 
 
SCHEME 1.3: Carreira’s synthesis of gracilioether E (1.13).17 
Carreira applied a similar strategy to access gracilioether F (1.14), a congener lacking 
the vinylogous carbonate moiety. Prins-type cyclization of tertiary alcohol 1.37 with 
paraformaldehyde gave rise to tricycle 1.38 as a 5:1 mixture of diastereoisomers in 
moderate yield. Oxidative cleavage followed by Bayer-Villiger oxidation accessed the full 
core of 1.39. The natural product 1.14 was then obtained after oxidation of the most 
electron-rich C-H bond using CrO3 (Scheme 1.4). 
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SCHEME 1.4: Carreira’s synthesis of gracilioether F (1.14).17 
A biosynthetically-inspired total synthesis of gracilioether F (1.14) was reported by Wong 
and co-workers in 2016.18 Though the plakortin family of natural products contains many 
cyclic peroxides, he proposed that a 1,2-dioxane similar to 1.41 could serve as a common 
precursor to gracilioether members in a plausible biomimetic manner. Reductive 
cleavage of the O-O bond followed by oxidation could then for example access 1.14. The 
synthesis commences with allene 1.42 which was transformed into lactone 1.43 in three 
steps. Further manipulations then gave rise to vinyl iodide 1.44. Heck cyclization then 
provided diene 1.45 which underwent a Diels-Alder cycloaddition with singlet oxygen to 
obtain unstable 1,2-dihydrodioxine 1.46. 1.46 was immediately reduced to the stable 1,2-
dioxane 1.41 utilizing diimide generated from dipotassium azodicarboxylate. 
Gracilioether F (1.14) was then furnished following 
 
7 
SCHEME 1.5: Wong’s synthesis of gracilioether F (1.14).18 
reductive cleavage of the O-O bond and twofold oxidation (Scheme 1.5). 
In 2017, Wu and co-workers reported the syntheses of a variety of gracilioethers based 
on common precursor 1.49 (Scheme 1.6).19 Palladium-catalyzed hydrocarbonylation of 
alkyne 1.50 provided rapid access to lactone 1.51. Further manipulations by alkylation, 
hydroboration and oxidation provided plakilactone C (1.52) which could then undergo a 
Sm(II)-mediated Michael-addition to yield ketone 1.53. Silyl enol ether formation followed 
by oxidative cleavage furnished aldehyde 1.49 as a divergent precursor. Grignard 
addition and C-H oxidation accessed the proposed structure of gracilioether I (1.16). The 
C-H oxidation proved a challenging problem. All methods for this type of transformation 
failed, presumably due to the adjacent carbonyl group. Nevertheless, a mixture of 
Pb(OAc)4 and iodine accomplished the transformation. Unexpectedly, the 1H and 13C 
NMR data were not consistent with those reported by Zampella in 2012, suggesting that 
1.16 had been incorrectly assigned. 
 
SCHEME 1.6: Wu’s synthesis of the proposed structure of gracilioether I (1.16).19 
Starting from alcohol 1.54, Wu was also able to complete the formal synthesis of 
gracilioether F (1.14) (Scheme 1.7). Without the carbonyl group at C1, the C-H oxidation 
proceeded well under standard conditions, giving cyclic ether 1.55. Attempts to oxidize 
the C1 position in order to obtain 1.16 resulted in oxidative cleavage of the C-C bond at 
position C8, providing lactone 1.56. The synthesis of 1.14 was then accomplished as 
previously described by Carreira and Wong.17-18, 20 
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SCHEME 1.7: Wu’s formal synthesis of gracilioether F (1.14).19 
Wu’s entry to gracilioether E (1.13) began with DIBAL-H reduction of aldehyde 1.49 
followed by the addition of TiCl4 and Et3SiH to afford, unexpectedly, acetal 1.57. 
Mukaiyama aldol addition and C-H oxidation, as previously described, accessed 1.58. 
Oxidation of the most electron-rich C-H bond gave lactone 1.59, which could then be 
converted into gracilioether E (1.13) as described by Carreira17 (Scheme 1.8). 
 
SCHEME 1.8: Wu’s formal synthesis of gracilioether E (1.13).19 
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1.1.3 Hippolachnin A – Isolation and Biosynthesis 
In 2013, Lin and co-workers reported the isolation of the polyketide natural product 
hippolachnin A (1.61), together with its proposed biogenetic precursor 1.62, from the 
ethanolic extract of the South China Sea sponge Hippospongia Lachne collected from 
the Xisha Islands (Figure 1.3).4 While 1.62 was already disclosed as a PPAR 
antagonist,21 hippolachnin A (1.61) exhibited potent antifungal activity against the 
pathogenic fungi Cryptococcus neoformans, Trichophyton rubrum, and Microsporum 
gypseum with an MIC value of 0.41 µM for each fungus. The structure 1.61 was 
elucidated based on NMR, IR and mass spectral data, comparison of the calculated and 
measured ECD spectra confirmed the absolute stereochemistry of the molecule. 
Hippolachnin A consists of a heterotricyclic core featuring six contiguous stereocenters 
and bears an unusual array of four ethyl groups on its convex face. It also contains a (Z)-
configured vinylogous carbonate.  
 
FIGURE 1.3: Hippolachnin A (1.61) and its proposed biogenetic precursor 1.62. 
Lin’s biosynthetic proposal of hippolachnin A is shown in Scheme 1.9.4 The ethyl groups 
of the natural product are proposed to be derived from butyrate units (1.63). Kubanek 
and Anderson furthermore, proposed that the activated butyrate arises from a reduction-
dehydration-reduction sequence of -ketoester 1.64.22 1.64 itself is derived from the 
condensation of malonyl CoA (1.65) with acetyl CoA (1.66) followed by decarboxylation. 
Four butyrate and one acetate units are then assembled by a polyketide synthase to form 
tetraene 1.67. Oxidation to epoxide 1.68 followed by cyclization then furnishes 2,3-
dihydrofuran 1.69, which upon elimination and transesterification gives cyclization 
precursor 1.70. 1.70 subsequently undergoes a  
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SCHEME 1.9: Proposed biosynthetic formation of hippolachnin A (1.61).4 
[2+2]-cycloaddition to form the natural product. 
 
1.1.4 Hippolachnin A as a target in total synthesis 
Although hippolachnin A is proposed to be derived from lactone 1.62, the latter had 
already been isolated in 1980 from Plakortis halichondrioides.23 In 2005, Ohira and co-
workers reported the first total synthesis of 1.62, relying on a late-stage C-H insertion.24 
Diol 1.71 was prepared from -caprolactone (1.72) by a four-step sequence. Further 
manipulations gave rise to the key intermediate 1.73. Treatment of 1.73 with dimethyl 
diazomethylphosphonate (DAMP) first generated the vinylidene carbene from the 
aldehyde, which could undergo a 1,2-hydride shift to give alkyne 1.74. A second 
equivalent of DAMP then generated the vinylidene carbene from the ketone that further 
underwent a 1,5 C-H insertion, forming dihydrofuran 1.75. Alkene 1.76 was then obtained 
by a short alkylation and reduction sequence. Further manipulation accessed methyl 
ester 1.77 as an inconsequential mixture of diastereoisomers which could be 
transformed into the natural product 1.62 (Scheme 1.10). 
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SCHEME 1.10: Ohira’s synthesis of lactone 1.62.24 
The first total synthesis of hippolachnin A (1.61) was reported in 2014 by Carreira and 
co-workers (Scheme 1.11).20 His strategy relies on a [2+2]-cycloaddition to access the 
bicyclo[3.2.0]heptane core and a Lewis acid catalyzed ene-reaction to forge the 
tetrahydrofuran ring. The synthesis begins with a photochemical [2+2]-cycloaddition of 
cyclopentenone 1.80 with 3-hexyne (1.81), furnishing bicyclo[3.2.0]heptene 1.82. 
Subsequent elimination under mildly basic conditions provided enone 1.83. 
Stereoselective cuprate addition gave rise to ketone 1.84 that was then alkylated under 
Knochel’s conditions to give tertiary alcohol 1.85. While it proved difficult to alkylate 1.85, 
vinylogous carbonate 1.86 was obtained when 1.85 was stirred neat in (E)-methyl-3-
methoxyacrylate (1.87) in the presence of PPTS for prolonged reaction times. Lewis acid-
catalyzed ene-cyclization accessed key cyclobutane 1.88 that could selectively be 
reduced under heterogeneous hydrogenation conditions to give the 
 
SCHEME 1.11: Carreira’s synthesis of hippolachnin A (1.61).20 
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kinetic product 1.89. Further -phenylselenation followed by oxidation and elimination 
allowed for the clean formation of hippolachnin A (1.61). 
Shortly after Carreira published his synthesis, Gosh reported his studies towards the 
asymmetric total synthesis of 1.61 employing a ring-closing metathesis and a 
photochemical [2+2]-cycloaddition (Scheme 1.12).25 Ethyl ester 1.90 was derived from 
D-mannitol and could be transformed by a three-step procedure into aldehyde 1.91. After 
further manipulations, key triene 1.92 was obtained. Ring-closing metathesis afforded 
2,3-dihydrofuran 1.93a and 1.93b as a 1:1 mixture of diastereoisomers at C7. 1.93b was 
then transformed into the cycloaddition precursor 1.94 by a four-step protocol. 
Photochemical [2+2]-cycloaddition followed by hydrogenation of the vinyl group then 
provided lactone 1.95, which is only lacking the vinylogous carbonate moiety and one 
ethyl group of the natural product. However, using D-mannitol as the starting material 
would lead to the unnatural enantiomer of hippolachnin A (1.61). 
 
SCHEME 1.12: Gosh’s synthetic studies towards hippolachnin A (1.61).25 
In 2016, Brown and Wood reported a collaborative synthesis of hippolachnin A (1.61),26 
the shortest up to date. The cyclobutane ring was formed through a [2+2+2]-cycloaddition 
of quadricyclane (1.95) to acid chloride 1.96 and the heterocycle by a late-stage allylic 
C−H oxidation (Scheme 1.13). Tricycle 1.97 underwent efficient ring-opening metathesis 
employing ethylene to form diene 1.98. Allylic C-H oxidation using White’s catalyst then 
provided lactone 1.99 in good yield. Aldol condensation followed by reduction of both 
double bonds furnished vinylogous carbonate 1.100 as a mixture of (Z)- and (E)- isomers. 
Finally, transesterification yielded the natural product 1.61. 
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SCHEME 1.13: Wood and Brown’s collaborative synthesis of hippolachnin A (1.61).26 
A biomimetic strategy towards 1.61 was reported in early 2017 by Wu (Scheme 1.14).19 
1.101 was obtained by employing conditions previously reported by Ohira with slight 
modifications. Even though hippolachnin A (1.61) is proposed to be derived from lactone 
1.62, irradiation of 1.62 with a mercury lamp did not trigger the desired [2+2]-
cycloaddition but only led to isomerization of the double bond of the side chain. While 
the [2+2]-cycloaddition using the conjugate diene did not proceed, the Cu-catalyzed 
reaction of the isolated double bond gave access to Carreira’s intermediate 1.89 in low 
yield. 
 
SCHEME 1.14: Wu’s attempted biomimetic synthesis of hippolachnin A (1.61).19 
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A more efficient reaction was found however, when lactone 1.102 was irradiated in the 
presence of benzophenone as a photosensitizer (Scheme 1.15). Resultant cyclobutane 
1.99, an advanced intermediate of Brown and Wood’s synthesis was obtained in good 
yield, thus accomplishing a formal synthesis of hippolachnin A 1.61. 
 
SCHEME 1.15: Wu’s formal synthesis of hippolachnin A (1.61).19 
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1.2 Project outline 
Opportunistic infections by ubiquitous fungi represent a major challenge to the 
immunocompromised. The yeast Cryptococcus neoformans, for instance, can cause life-
threatening meningitis and affect the lungs and skin of patients with advanced acquired 
immunodeficiency syndrome (AIDS).27-30 Hippolachnin A (1.61) was recently isolated 
from the South China Sea sponge Hippospongia lachne and proved to be highly potent 
against several pathogenic fungi, including C. neoformans (MIC = 0.41 μM).4 Therefore, 
hippolachnin A (1.61) could provide an important lead in the search for novel drugs 
against these fungi. 
Hippolachnin A (1.61) represents a unique synthetic challenge by virtue of bioactivity and 
molecular scaffold. At the beginning of the project, no complete synthesis of this natural 
product had been reported. Above all, the caged 4-5-5 heterotricyclic core featuring six 
contiguous stereocenters was expected to cause several difficulties in its preparation. 
Furthermore, the thermodynamically less favoured (Z)-double bond provides an 
additional distinct challenge. The goal of this project was to provide a scalable synthetic 
route also enabling the synthesis derivatives of the natural product and probe their 
bioactivity. 
Therefore, we identified two possible retrosynthetic analyses of 1.61. In the first 
retrosynthesis, we envisioned installation of the vinylogous carbonate late in the 
synthesis from lactone 1.99. The cyclobutane and the tetrahydrofuran would 
simultaneously be formed by an intramolecular [2+2]-cycloaddition of a precursor 
containing a cyclopentene scaffold linked to an alkene (Figure 1.4). 
 
FIGURE 1.4: First retrosynthetic analysis of 1.61. 
Alternatively, the tetrahydrofuran ring of the natural product would be forged by a 
chelation-controlled trapping of a -ketoester enolate by an in situ generated 
carbocation,31 forming the kinetic product (Figure 1.5). The vicinal diethyl groups would 
be accessed by a three-component coupling using ,-unsaturated ester 1.104 and an 
ethyl nucleophile and ethyl electrophile. 1.104 should be accessible via 
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bicyclo[2.1.0]heptadienone 1.105 which would be formed from tropolone methyl ether 
1.106 by disrotatory 4-electrocyclization followed by excited state rearrangement.32 
 
FIGURE 1.5: Second retrosynthetic analysis of 1.61. 
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1.3 Results and Discussion 
1.3.1 First generation approach – Retrosynthetic analysis 
The first retrosynthetic analysis of hippolachnin A (1.61) is depicted in Scheme 1.16. It 
was envisioned to access 1.61 through Peterson olefination of lactone 1.99, which would 
be derived by an intramolecular [2+2]-cycloaddition following esterification of acid 1.108 
and tertiary alcohol 1.109. 1.108 would be obtained by hydroalumination of 3-hexyne 
(1.110) followed by trapping with CO2.33 Tertiary alcohol 1.109 would be provided by 
retro-[4+2]-cycloaddition of bicycle 1.111,34 derived from enone 1.112 by conjugate 
addition35 followed by 1,2-addition.36 Additions to 1.112 should be governed by the shape 
of the bicycle and arrive from the convex side of the molecule. Schenk-ene reaction of 
dicyclopentadiene (1.113) with singlet oxygen would provide enone 1.112. 
 
Scheme 1.16: Retrosynthetic analysis of hippolachnin A (1.61). 
Even though the [2+2]-cycloaddition of an acyclic ,-unsaturated ester was anticipated 
to provide a major challenge, we envisioned that, conducting the reaction in an 
intramolecular fashion, might allow efficient trapping of the initial diradical. 
 
1.3.2 The [2+2]-Cycloaddition approach towards hippolachnin A 
The synthesis commenced with the preparation of tertiary alcohol 1.109 from 
dicyclopentadiene (1.113) (Scheme 1.17). Conjugate addition from the convex side of 
enone 1.112 obtained from the Alder-ene reaction of 1.113 with singlet oxygen afforded 
ketone 1.114. Subsequent 1,2-addition of EtMgBr mediated by LaCl3.2LiCl yielded 
tertiary alcohol 1.111 as a single diastereoisomer. While initial attempts of activating the 
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bicycle by heat followed by in situ-trapping of the generated cyclopentadiene resulted 
only in recovered starting material or decomposition, flash vacuum pyrolysis (FVP) 
cleanly provided tertiary alcohol 1.109 in good yield. It is worth noting that a FVP-
apparatus could be improvised, consisting of two vigreux columns connected to a cooled 
S-shaped tube. 
 
SCHEME 1.17: Synthesis of coupling partners 1.109 and 1.108. 
Hydroalumination of 3-hexyne (1.110) followed by aluminate formation allowed efficient 
trapping of carbon dioxide to carboxylic acid 1.108. 
With both building blocks in hand, several conditions for the esterification have been 
screened (Table 1.1). 
TABLE 1.1: Conditions of the esterification of alcohol (1.109) and acid (1.108). 
 
 R = Base Additive Temp. Observation 
1 Cl (1.115) pyridine DMAP 0 °C - RT 
starting 
material 
2 Cl (1.115) i-PrMgCl none 0 °C 
starting 
material 
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3 Cl (1.115) n-BuLi AgSbF6 –78 °C - 0 °C decomposition 
4 
(1.116) 
i-PrMgCl none 0 °C 
starting 
material 
5 
(1.117) 
pyridine DMAP RT - 100 °C 
starting 
material 
6 
(1.118) 
none DMAP RT 
formation of 
1.117 
7 
(1.119) 
NEt3 DMAP 40 °C 
formation of 
1.117 
8 
(1.120) 
NEt3 none 40 °C 
formation of 
1.117 
9 
(1.121) 
NEt3 DMAP RT 
formation of 
1.117 
10 
(1.122) 
n-BuLi none −50 °C - RT decomposition 
Standard esterification conditions utilizing the acid chloride only resulted in isolation of 
the free acid after work up. Attempts to generate the naked acylium ion only led to 
decomposition of the starting materials. Using various mixed anhydrides as an 
electrophile provided anhydride 1.117 instead of the ester (Entry 6-9). 1.117 was found 
to be stable to column chromatography and proved to be inefficient in ester formation, 
even at elevated temperatures. While both the acid chloride and the mixed anhydride 
were able to react sufficiently with t-BuOK to form the t-butyl ester, acetylation of tertiary 
alcohol 1.109 with acetic anhydride and DMAP failed to show any traces of product even 
after prolonged reaction times. 
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As the steric hindrance of the tertiary alcohol could not be overcome, we decided to install 
the fourth ethyl group at a later state of the synthesis. The revised retrosynthesis is 
depicted in Scheme 1.18. 
 
FIGURE 1.18: Revised retrosynthetic analysis of 1.61. 
We envisioned closing the tetrahydrofuran ring by hemiketal-formation of a -ketoester 
and a tertiary alcohol followed by dehydration. The tertiary alcohol would be generated 
by a Grignard addition to a ketone. The -ketoester should be derived by Claisen 
condensation of methyl acetate and lactone 1.124. Lactone 1.124 would be traced back 
to an intramolecular [2+2]-cycloaddition of an ester formed by alcohol 1.125 and acid 
1.108. Allylic alcohol 1.125 would again be derived from cyclopentadiene (1.127). 
Epoxidation of cyclopentadiene (1.127) followed by SN2' displacement with 
ethylcyanocuprate provided allylic alcohol 1.125 in moderate yield (Scheme 1.19). 
Quantitative formation of the lithium alkoxide and subsequent quenching with acid 
chloride 1.115 gave rise to allylic ester 1.128. 
 
SCHEME 1.19: Synthesis of allylic ester 1.128. 
With the desired precursor in hand, we went on to screen the intramolecular [2+2]-
cycloaddition of diene 1.128 (Table 1.2). 
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TABLE 1.2: Screening of the intramolecular [2+2]-cycloaddition of 1.128. 
 
Entry Solution Additive Observation 
1 acetone  starting material + (E) conformer 
2 acetone / acetonitrile 1:1  starting material + (E) conformer 
3 acetone / benzene 1:1  starting material + (E) conformer 
4 acetone / CH2Cl2 1:1  starting material + (E) conformer 
5 benzene benzophenone starting material + (E) conformer 
6 methylene chloride benzophenone starting material + (E) conformer 
7 acetonitrile benzophenone starting material + (E) conformer 
8 acetone benzophenone starting material + (E) conformer 
 CH2Cl2 EtAlCl2 starting material 
 CH2Cl2 TiCl4 starting material 
 CH2Cl2 ZnBr2 starting material 
 CH2Cl2 Tf2NH starting material 
All screening conditions were performed under high dilution conditions at 0.01 M, and 
irradiation was achieved using 310 nm LEDs in a Rayonet®-reactor. Unfortunately, no 
cycloaddition product could be observed, and only starting material commingled with its 
(E)-configured isomer was isolated. The addition of Lewis acids to these types of 
systems is known to activate the carbonyl group of the ester, which could lead to a Prins-
type cyclization. Unfortunately, only starting material was observed. 
While excitation of the system proceeded smoothly as proved by the observation of the 
(E)-configured isomer, we wondered whether π-bond rotation was too fast to allow for 
capture of the diradical by the tethered olefin or whether the linker between the double 
bonds was too short, making it impossible for the double bonds to reach it other. In order 
to prevent isomerization, we wanted to incorporate the enone double bond into a ring 
system. This was achieved by stitching the ends of the ethyl groups together using a 
sulphur bridge. In order to increase the length between the two double bonds and allow 
the molecule to be more flexible, the ester moiety was elongated to a -ketoester 
(Scheme1.19). 
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SCHEME 1.19: Synthesis of cyclization precursor 1.134. 
Ring expansion of tetrahydrothiopyranone 1.129 using ethyl diazoacetate gave rise to 
thiepanone 1.130 which, after reduction, mesylation and elimination provided ethyl ester 
1.132.37 Saponification followed by activation of the carboxylic acid as the acid chloride 
and subsequent esterification accessed enoate 1.134 in moderate yields. With the cyclic 
cyclization precursor in hand, we investigated the [2+2]-cycloaddition (Table 1.3). 
TABLE 1.3: Screening for the [2+2] cycloaddition under 310 nm irradiation. 
 
Entry Solvent Observation 
1 MeCN decomposition 
2 CH2Cl2 decomposition 
3 benzene decomposition 
4 acetone decomposition 
Unfortunately, illumination of 1.134 in different solvents showed no trace of product. After 
irradiation the clear solution became cloudy, and NMR analysis of the mixture indicated 
decomposition of the starting material. While excitation of the molecule was possible, no 
productive pathways could be observed, which might be due to a preferred conformation 
of the molecule where both olefins are pointing into opposite directions. In order to 
provide more flexibility to the molecule, -ketoester 1.136 was prepared (Scheme 1.20). 
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SCHEME 1.20: Preparation of -ketoester 1.136. 
Activation of acid 1.108 with CDI and subsequent Claisen condensation with t-BuOAc 
followed by ketalization gave dioxanone 1.137. Retro-[4+2]-cycloaddition and trapping of 
the resulting ketene with alcohol 1.125 resulted in formation of -ketoester 1.136.  
TABLE 1.4: Screening of the [2+2]-cycloaddition of 1.136 under 310 nm irradiation. 
 
Entry Solvent Observation 
1 MeCN Complex mixture 
2 CH2Cl2 Complex mixture 
3 benzene Complex mixture 
4 acetone Complex mixture 
Irradiation of 1.136 using 310 nm LEDs resulted in a complex mixture (Table 1.4) 
independent of the solvent used. As a result of the unsuccessful formation of the 
bicyclo[3.2.0]heptane core, we decided to modify the strategy as described in the next 
chapter. 
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1.3.3 Second generation synthesis – The tropolone route to 
hippolachnin A 
 
 
 
 
 
 
 
 
 
Reproduced with permission from Nils Winter and Dirk Trauner, J. Am. Chem. Soc. 
2017, 139, 11706–11709. Copyright 2017 American Chemical Society.38 
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1.3.4 Synthesis of synthetic derivatives of hippolachnin A 
Hippolachnin A was reported to offer interesting antifungal activity. In order to investigate 
structure-affinity relationships of hippolachnin A (1.61) and to improve the bioavailability 
of this barely water soluble molecule, we prepared several derivatives of the natural 
product. 
To determine whether the (Z)-configured vinylogous carbonate was necessary for 
activity, derivatives lacking this group or having a different geometry were prepared. To 
improve the solubility in water, the thioether was oxidized to the sulfoxide and the sulfone. 
Scheme 1.21 shows the syntheses of the derivatives. 
 
 
 
SCHEME 1.21: Syntheses of synthetic derivatives of 1.61. 
These compounds, together with intermediates 1.99, 1.139 and the synthetic natural 
product were sent to Prof. Dr. Marc Stadler at the Helmholtz Centre for Infection 
Research in Braunschweig. Unfortunately, none of these compounds, including the 
natural product, showed any antifungal activity. 
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1.4 Conclusion 
In conclusion, a concise, scalable and modular synthesis of the complex polyketidal 
natural product hippolachnin A was achieved, and several derivatives thereof have been 
prepared. These successful studies supported biological investigations of hippolachnin 
A. 
Initial attempts to close the tetrahydrofuran ring as well as the cyclobutane ring in a single 
step by a non-biomimetic [2+2]-cycloaddition failed with multiple precursors. Revising the 
approach and constructing the bicyclo[3.2.0]heptanone core via a 4-electrocyclization 
followed by exited state rearrangement provided rapid access to the core of hippolachnin 
A. While conventional methods to install the geminal diethyl groups suffered from low 
diastereoselectivity, the simultaneously installation of the two ethyl groups through 1,3-
dipolar cycloaddition elegantly solved this problem. In order to close the eastern 
tetrahydrofuran ring, ester elongation was required. Attempted nucleophilic additions to 
the ester failed due to the remarkable steric congestion around this carbonyl group. This 
problem could be solved by converting the ester into the smaller and more reactive 
aldehyde. Chelation-controlled trapping of an in situ generated carbocation by a tin 
enolate of the -ketoester constructed this last ring. Final reductive desulfurization 
yielded hippolachnin A in good yield. Notably, more than 100 mg of hippolachnin A was 
produced in a single pass of the entire synthetic route. 
It was reported that hippolachnin A provides interesting antifungal activity and therefore 
derivatives of the natural product have been prepared in order to figure out structure-
affinity relationships and to increase the bioavailability of the molecule. The thioether, 
installed in the carbonyl ylide cycloaddition, provided a functional handle for further 
transformations which would have been difficult otherwise, considering that the natural 
product is lacking functional groups. Unfortunately, hippolachnin A, as well as all the 
synthetic derivatives proved to be inactive against the proposed target. 
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Chapter II 
 
 
 
Synthetic Studies Towards the 
Meroterpenoids Bisacremin E, F and 
G 
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2.2 Introduction 
2.1.1 Acremine natural products – Isolation and biosynthesis 
Endophytic fungi grow within a plant host and usually live in a symbiotic relationship. 
Their growth involves continuous metabolic interaction between fungus and host.5 
Therefore endophytic fungi display a rich source of secondary metabolites often bearing 
interesting bioactivity.6 The genus Acremonium is part of this family and many bioactive 
natural products, including the -lactam antibiotic cephalosporin, the 
immunosuppresants cyclosporins, the tremorgenic indole-diterpenoids lolitrems and 
some prenylated phenol inhibitors of N-SMase have been isolated from this genus.39 In 
2005, Torta and co-workers reported the isolation of six meroterpenoid natural products, 
acremine A-F (figure 2.1) from A20, a strain of Acreonium bissoides, isolated from 
grapevine leaves artificially inoculated with Plasmopora viticola.40 The structure analysis 
was based on NMR and mass data. Furthermore, an X-ray crystal structure of acremine 
A confirmed the relative stereochemistry. The absolute stereochemistry was determined 
using Mosher’s method. Acremines A-D showed moderate Inhibition of P. viticola 
sporangia germination. All acremines possess either a cyclohexene or aromatic portion, 
which is likely derived via a polyketide pathway, and a prenyl unit. Further cyclization can 
then lead to either the benzofurane or the chromanone ring system. 
 
FIGURE 2.1: Molecular structures of acremine A-F. 
In 2008, Malpezzi and co-workers reported the isolation and structural assignment of 
acremine G (2.7),6 the first dimeric member of the acremine family. It is believed that 
acremine G arises from a Diels-Alder reaction of prenyl benzoquinone 2.8, possibly 
derived from acremine B (2.2), and aromatic diene 2.9. Further oxidation could then 
furnish the natural product (scheme 2.1). Although this hypothesis makes sense from a 
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synthetic point of view, neither of the possible Diels-Alder partners have been isolated to 
date. 
 
SCHEME 2.1: Possible biosynthesis of acremine G (2.7).6 
Five further members, acremines H-N (figure 2.2), have been isolated from the same 
strain in 2008 by Nasini and co-workers.39 Acremine H and I possess one and two 
oxirane rings respectively. Acremine L and M can be derived from these by epoxide 
opening and further reduction or cyclization. 
 
FIGURE 2.2: Molecular structures of acremine H-N.39 
In 2013, the acremine family became even more diverse due to the isolation of 
chlorinated derivatives 5-chloroacremine A (2.16) and 5-chloroacremine H (2.17) 
together with acremine O (2.18), P (2.19), Q (2.20) and R (2.21) by Garson and co-
workers.41 In 2017, Garson revised the structure of acremine P (2.21).42 A further 
expansion of the acremine family was reported in 2014 when Afiyatullov and co-workers 
reported the isolation of acremine S (2.22) from the marine-derived fungus Isaria felina 
KMM 463943 (Figure 2.3). 
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FIGURE 2.3: Molecular structure of 5-chloroacremine A and H and acremine O-R.39, 41-43 
Until 2015, acremine G remained the only dimeric acremine natural product. When Wei 
and co-workers were analyzing a culture extract of the soil-derived strain A. persicinum 
SC0105 that showed activity against Staphylococcus aureus, they discovered 
bisacremines A-D together with their possible biogenic precursor acremine T (2.23).44 
Bisacremines A-D are hypothesized to be derived from acremine T (2.23) and an oxirane 
precursor (2.24). 2.23 is assumed to nucleophilicaly open the epoxide of 2.24, generating 
an allylic cation that can then be intercepted by the generated tertiary alcohol to form 
bisacremines A-D. This hypothesis seems to be substantial, considering that all possible 
stereoisomers are natural products (Scheme 2.2). 
 
SCHEME 2.2: Proposed biosynthesis of bisacremines A-D.44 
Later in 2015, Wei discovered three more bisacremines E-G from the same extract.7 
Bisacremine E (2.25) and F (2.26) are supposed to be derived by a formal [4+2] 
cycloaddition of two acremine F monomers, followed by dehydration to form the final 
tetrahydrofuran ring (scheme 2.3). As both the endo- and the exo-transition state of the 
Diels-Alder reaction lead to different isolated natural products, it might be plausible that 
this reaction is not catalyzed by an enzyme. Oxidation and intramolecular acetalization 
of bisacremine F, followed by aromatizative dehydration would then 
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SCHEME 2.3: Proposed biosynthesis of bisacremine E-G.7 
furnish bisacremine G (2.27). While bisacremine E-G were not cytotoxic against A549, 
MCF-7 and HepG2, bisacremine G showed dose–dependent effects in in vitro anti-
inflammation assays. 
 
2.1.2 Synthetic approaches 
The first total synthesis of acremine A (2.1) was reported in 2010 by Mehta45 and marks 
the first total synthesis of an acremine natural product in general. The synthesis starts 
with bicycle 2.30, which was converted into oxirane 2.31 through epoxidation followed 
by alkylation and reduction from the convex side of the system. Retro Diels-Alder reaction 
followed by oxidation and Wittig olefination gave rise to ,-unsaturated  
 
SCHEME 2.4: Mehta’s synthesis of acremine A (2.1).45 
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ester 2.32 in good yields. Diol 2.33 was then accessed by protection of the enone moiety 
and Grignard addition into the ester. Oxidation and reductive epoxide opening yielded 
ketone 2.34. Reduction of 2.34 using Luche’s conditions and further deprotection of the 
enone accessed acremine A (2.1) together with its epimer 2.35 in a 5:1 dr (Scheme 2.4). 
From intermediate 2.33 Mehta was also able to access acremine I (2.12). Directed 
epoxidation and oxidation of the secondary alcohol gave enone 2.36. In this case, the 
Luche reduction had no preference for any side and provided secondary alcohol 2.37 as 
a 1:1 mixture of diastereoisomers. Hydrolysis of the ketal gave then rise to acremine I 
(2.12) and its stereoisomer 2.38 as a separable mixture (Scheme 2.5). 
 
SCHEME 2.5: Mehta’s synthesis of acremine I (2.12).45 
In 2009, Stratakis and co-workers reported the first biomimetic synthesis of acremine G 
(2.27),46 in support of the proposed biosynthesis. Prenylated benzoquinone 2.9 was 
prepared from protected hydroquinone 2.39 in a five-step protocol and was able to 
undergo a Diels-Alder cycloaddition with unstable diene 2.40 yielding 2.41. Double 
deprotection of the silyl ethers gave rise to hydroquinone 2.42 which upon standing on 
air formed acremine G (2.27), possibly by a radical pathway (Scheme 2.6). Mehta 
showed one year later that the reaction proceeds even at room temperature on silica  
 
37 
 
SCHEME 2.6: Stratakis‘ biomimetic synthesis of acremine G (2.27).46 
support.47 
In 2003, Porco and co-workers described the biomimetic synthesis of the dimeric natural 
product panepophenanthrin (2.42), consisting of two units of enone 2.43, which is 
structurally related to the acremine family (scheme 2.7).48 Phenol 2.44 is converted into 
enone 2.45 by oxidation, transketalization and epoxidation. Further manipulations then 
elaborated tertiary alcohol 2.46 as a key intermediate. Global deprotection using 
aqueous HF uncaged enone 2.43 which spontaneously underwent a Diels-Alder 
cycloaddition to form pentacycle 2.47, which could not be isolated. 2.47 underwent 
further intramolecular hemiketal formation and therefore stabilizes the otherwise 
thermodynamically less stable dimeric structure of panepophenanthrin (2.42). 
 
SCHEME 2.7: Porco’s biomimetic synthesis of panepophenanthrin (2.42).48 
Danishefsky reported a synthesis of dysidiolide (2.48) involving a Gassman Diels-Alder 
reaction to form the core of the natural product.49 Dioxolane 2.49 was prepared by a 
three-component coupling employing alkyne 2.50, dimethyl cuprate and iodide 2.51. 
Reduction followed by protection of the primary alcohol gave dioxolane 2.52 as the key 
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step precursor. 2.52 underwent a cationic Diels-Alder reaction with diene 2.53 to form 
the complete core of dysidiolide. Further manipulations installed the furan moiety that, 
upon oxidation using singlet oxygen, furnished 2.48 (Scheme 2.8). 
 
 
SCHEME 2.8: Danishefsky’s synthesis of dysidiolide (2.48).49 
 
 
2.1.3 Vinyl quinone Diels-Alder reactions in total synthesis 
The first Diels-Alder reaction involving a vinyl quinone as a diene was reported in 1998 
by Irngartinger50 (scheme 2.9). When examining the chemistry of aryl-substituted 
vinylquinones, an unexpected dimerization was observed that proceeded via an inverse 
electron demanding Diels-Alder reaction. This methodology was extended in 1999 by 
Noland,51 when he showed that electron-deficient vinylquinones can undergo a Diels-
Alder reaction with electron-rich alkenes. The resulting isoquinonemethide can be 
trapped with a nucleophile or, in many cases, tautomerize to the corresponding quinone. 
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SCHEME 2.9: Initial observations of VQDA reactions.50-51 
The first application of a VQDA reaction in total synthesis was reported by Trauner and 
co-workers in the synthesis of halenaquinone (2.61) in 2008.52 This report also marks 
the first example of an intramolecular VQDA reaction (scheme 2.10). 2.61 aroused much 
interest in the synthetic community due to its interesting polycyclic framework and 
versatile biological profile. Alcohol 2.62 was derived enantioselectively from 2,3-
diiodofurane (2.63) and aldehyde 2.64 in a three-step protocol. Further manipulations 
yielded aldehyde 2.65 which could undergo an intramolecular Heck reaction to give 
alkene 2.66 as a single diastereoisomer. Nucleophilic addition followed by oxidation then 
gave rise to protected hydroquinone 2.67. The key-step precursor was obtained by 
oxidation using AgO and HNO3 and smoothly underwent the desired VQDA reaction 
under elevated pressure. Even though the reaction proceeded at room temperature, the 
yield could be significantly improved using high pressure conditions. The initial resulting 
isoquinonemethide could not be isolated but underwent fast tautomerization to the 
corresponding hydroquinone 2.68. Halenaquinone (2.61) was obtained in good yields 
after further oxidation. 
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SCHEME 2.10: Trauner’s synthesis of halenaquinone (2.61).52 
In 2009, Trauner expanded this methodology to the biomimetic total synthesis of (–)-
pycnanthuquinone C (2.71)53 anticipating that this reaction plays a significant role in the 
biosynthesis of secondary metabolites. Heck coupling of hydroquinone 2.72 with (–)-
linalool (2.73) yielded styrene 2.74 that could be further oxidized to the key vinyl quinone 
2.75 using MnO2. When 2.75 was slightly heated in a mixture of PhMe and H2O, the 
VQDA reaction proceeded smoothly to give isoquinonemethide 2.76 which was directly 
intercepted by water in a nonstereospecific manner. The resulting hydroquinone 2.77 
could not be isolated as it was spontaneously oxidized upon  
 
SCHEME 2.11: Trauner’s synthesis of (–)-pycnanthuquinone C (2.71).53 
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exposure to air to give (–)-pcynanthuquinone C (2.71) and its epimer 2.78, which Trauner 
predicted to be another natural product (Scheme 2.11). 
In the same publication, Trauner proposed that a VQDA reaction is a plausible pathway 
for the biosynthesis of rosinone B (2.79) as well, and in 2010, Zhang and co-workers 
reported the biomimetic synthesis of 2.79.54 Enone 2.80 was obtained by a three-step 
protocol from 2.81 and yielded acetate 2.82 after further manipulations. Hydrolysis of the 
acetate proceeded smoothly under basic conditions and gave protected hydroquinone 
2.83 in good yields. 1,3-Allylic isomerization towards the thermodynamically more stable 
styrene followed by MOM deprotection and oxidation afforded vinyl quinone 2.84 in 
excellent yield. Heating a solution of 2.84 in PhMe gave rise to isoquinonemethide 2.85 
which was directly treated with p-TsOH in a mixture of MeOH and H2O. SN2’ 
displacement of methoxide afforded quinone 2.86, that could undergo a second 
intramolecular SN2’ displacement to give rosinone B (2.79) (Scheme 2.12). 
 
SCHEME 2.12: Zhang’s synthesis of rosinone B (2.79).54 
In 2013, Trauner and co-workers reported the total synthesis of (–)-isoglaziavianol 
(2.87),55 marking the first example of trapping of the in situ generated isoquinonemethide 
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by an intramolecularly provided nucleophile (Scheme 1.13). Enone 2.88 is derived from 
primary alcohol 2.89 by a two-step protocol. Acetate cleavage and oxidation afforded 
vinylquinone 2.90 that spontaneously underwent the VQDA reaction at room temperature 
to form the isoquinonemethide 2.91. Intramolecular attack of the primary hydroxyl group 
and tautomerization gave hydroquinone 2.92 that was oxidized upon work-up, affording 
quinone 2.93. (–)-Isoglaziavianol (2.87) was obtained in good yield after removal of the 
PMB protecting group and reduction of the quinone moiety. 
 
SCHEME 2.13: Trauner’s synthesis of isoglaziovianol (2.87).55 
 
 
2.2 Project outline 
Acremines are a rich class of meroterpenoid natural products mainly isolated from the 
Acremonium fungal species A. byssoides and A. persicinum.6-7, 39-44 They are mainly 
simple meroterpenoids comprising an isopentenyl unit linked to a C7 tetraketide ring and 
can be defined as C12 merohemiterpenoids. Acremines A–F and H–T are monomers 
containing a single C12 unit, acremine G (2.7) was the first dimeric derivative consisting 
of two C12 units. It is presumably generated from acremine A (2.1) and B (2.2) by a Diels-
Alder reaction and subsequent oxidative coupling. Bisacremines E (2.25) and F (2.26) 
consist of an unusual tetracyclic core that is highly oxidized and features ten stereogenic 
centers. Bisacremine G (2.27), bearing six stereogenic centers, consists of a 
heteropentacyclic core and exhibits inhibitory effects on the production of TNF-, IL-6, 
and nitric oxide in LPS-stimulated macrophages. 2.25 and 2.26 are supposed to be 
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biosynthetically derived from two acremine F (2.6) units which undergo a formal [4+2] 
cycloaddition to install the full carbon core and further condensation to complete the 
southern tetrahydrofuran ring. 2.27 is proposed to be derived from 2.25 through further 
oxidation and cyclization. Even though this biosynthesis seems to be appealing, it 
remained unclear how this [4+2] cycloaddition would occur in nature. As both the endo 
and the exo transition state would give natural products, we assumed that this reaction 
would not occur in an enzymatic pocket but could proceed spontaneously in solution. In 
order to prove these hypotheses, we wanted to synthesize 2.25 and 2.26 starting from 
2.6 (Figure 2.4). 
 
FIGURE 2.4: Proposed biosynthetic pathway of bisacremine E (2.25). 
In addition, we thought we might as well be able to get access to the more bioactive 
natural product bisacremine G (2.27). We envisioned that a vinyl quinone Diels-Alder 
reaction could give fast excess to the core of the natural product (Figure 2.5) and 
therefore expand the scope of this powerful methodology. 
 
FIGURE 2.5: Retrosynthetic bond disconnections of bisacremine G (2.27). 
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2.3 Results and discussion 
2.3.1 The cationic cascade 
Bisacremine E (2.25) and its isomer bisacremine F (2.26) are supposed to be derived 
from acremine F (2.6) by a formal [4+2] cycloaddition followed by condensation to 
implement the final tetrahydrofuran ring.7 Though the electronic properties would not be 
matching for a classical Diels-Alder reaction involving an electron-poor dienophile and 
an electron-rich diene, we thought that this reaction might be ionic in nature. We 
envisioned to synthesize 2.25 through a cationic cascade, depicted in Scheme 2.14.  
 
SCHEME 2.14: Proposed biomimetic cascade to form bisacremine E (2.25). 
Upon treatment with acid the tertiary allylic alcohol 2.6 was supposed to expel water 
forming a stabilized allylic cation 2.96 which could be trapped by the trisubstituted double 
bond of a second molecule of 2.6, again forming a stabilized cation 2.97. 2.97 should 
then be intercepted by the neighbouring trisubstituted double bond, forming the six-
membered ring of 2.98. Trapping of the tertiary cation by the alcohol should then yield 
the natural product. Depending on whether the initial attack would come from the top or 
the bottom face, either 2.25 or 2.26 should be formed. 
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The prenyl side chain of 2.6 should be installed via Stille coupling of vinyl iodide 2.99, 
which could be obtained after stereoselective reduction from enone 2.100. 2.100 could 
be accessed from 2.101 after protection and Segusa oxidation. 2.101 could be traced 
back to protected m-cresol (2.106) by Birch reduction followed by asymmetric 
dihydroxylation56 (scheme 2.15). 
 
SCHEME 2.15: Retrosynthetic analysis of acremine F (2.6). 
TIPS protection of 2.106 followed by Birch reduction gave rise to silyl enol ether 2.104 
which could be dihydroxylated under Sharpless conditions to yield diol 2.101. The diol 
was obtained in modest optical purity of 25% ee as determined at the stage of enone 
2.100. Unfortunately, all attempts to improve the enatioselectivity failed. Nevertheless, 
we kept this route because CBS reduction at a later state could improve the optical purity. 
Enone 2.100 as obtained from 2.101 after diol protection and Segusa oxidation of the  
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SCHEME 2.16: Synthesis of acremine F (2.6). 
silyl enol ether. Alpha-iodination then accessed -iodoenone 2.102 which could 
stereoselectively be reduced to allylic alcohol 2.108 that was obtained in 95% ee. 
Deprotection followed by Stille cross coupling with vinyl stannane accessed 300 mg 
quantities of 2.6 in a single pass (Scheme 2.16). 
With this material in hand, we turned our focus onto the biomimetic cascade to form 2.25. 
Table 2.1 shows the screening conditions. 
TABLE 2.1: Screening for the biomimetic cascade 
 
entry solvent additive temperature observation 
1 H2O none 45 °C starting material 
2 H2O none 65 °C starting material 
3 H2O none 85 °C 2.23 
4 H2O none 100 °C decomposition 
5 PBS none 65 °C starting material 
6 PBS none 85 °C 2.23 
7 PhMe none 110 °C starting material 
8 PhMe none 110 °C to 
150 °C 
2.23 
9 o-DCB none 160 °C decomposition 
10 o-DCB Hg(OAc)2 190 °C decomposition 
11 Et2O 4 M LiClO4 RT 2.23 
12 neat none 45 °C 2.23 
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13 neat none 50 °C to 100 °C starting material 
14 neat none 110 °C complex mixture 
15 neat none 130 °C decomposition 
16 MeCN 12 kbar RT starting material 
17 CH2Cl2 ZnBr2, 14 kbar RT starting material 
18 MeCN AcOH, 7 kbar RT starting material 
19 MeCN HCOOH, 
12 kbar 
60 °C decomposition 
20 MeCN AcOH, 12 kbar 60 °C decomposition 
21 MeCN CSA –40 °C to RT 2.23 
22 neat CSA RT decomposition 
23 MeCN AcOH RT starting material 
24 MeCN AcOH 45 °C 2.23 
25 MeCN AcOH 85 °C elimination + acetate 
incorperation 
26 MeCN/ H2O AcOH 85 °C elimination + acetate 
incorporation 
27 MeCN HCOOH 90 °C 2.23 
28 MeCN/PhMe AcOH 90 °C 2.23 
29 H2O H2SO4 85 °C decomposition 
30 TFE none RT to 60 °C TFE incorporation 
31 neat PPTS 40 °C to 60 °C decomposition 
Attempts to trigger the ionization of the tertiary allylic alcohol showed that the compound 
was stable until 65 °C in H2O. 2.6 was originally obtained as a colourless oil, but when 
heated to 45 °C in H2O the compound started to crystallize as colourless needles. 
Unfortunately, the crystals were not suitable for X-ray diffraction. At 85 °C the ionization 
took place but only elimination to triene 2.23 could be observed. Further heating to 
100 °C resulted in rapid decomposition. The application of physiological salt 
concentrations had no beneficial effect. While 2.6 was only stable until 65 °C in H2O it 
proved to be stable until 110 °C in toluene. At higher temperatures only decomposition 
of the starting material was observed. Using solvents with a high ionic strength led only 
to rapid elimination to the triene. 
At this point, we realized that ionization of the tertiary allylic alcohol was feasible, but 
high temperatures seemed to favour elimination over dimerization. We thought that 
ionization under acidic conditions should be possible at lower temperatures and, in case 
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that elimination would occur, it might be reversible under these conditions. To our 
disappointment, strong acids led to elimination at low temperatures and to decomposition 
of the starting material at room temperature. 2.6 was stable towards weak acids at room 
temperature and showed elimination at 45 °C. When 2.6 was heated to 85 °C in the 
presence of acetic acid, acetate was incorporated into the molecule. Even though this 
showed that the allylic cation could be trapped by a nucleophile, the nucleophilic attack 
appeared selectively at the tertiary position of the molecule and not at the potentially less 
hindered secondary site. When 2.6 was stirred in TFE at 60 °C, TFE incorporation at the 
same site of the molecule could be observed. We thought that the application of high 
pressure might alter the selectivity. At room temperature under 14 kbar in the presence 
of either a nucleophilic or a non-nucleophilic acid did not lead to any conversion. At 60 °C 
only decomposition was observed.  
We next wanted to see whether different protecting groups could have an influence on 
the stability and therefore allow higher reaction temperatures without decomposition. 
They might also help to improve the solubility in organic solvents and force the molecule 
to adapt the desired conformation. In order to see whether the syn-diol moiety was 
problematic, it was protected as an acetonide. Stille coupling of 2.108 with vinyl stannane 
2.110 yielded diol 2.111 (scheme 2.17). 
 
SCHEME 2.17: Synthesis of diol 2.111. 
2.111 was unstable in organic solvents at high temperatures and only triene 2.112 could 
be observed using normal glassware. While silica-based glassware can be slightly acidic 
we added an amine base which indeed could supress elimination but unfortunately, no 
product could be observed under these conditions either. The same result was observed 
when 2.111 was heated without any solvent. The addition of Lewis acids was not well 
tolerated and mainly resulted in decomposition. When 2.111 was heated in either H2O or 
a mixture of H2O and MeOH deprotection of the acetonide was observed. This reaction 
had to be carefully monitored as rapid decomposition was observed after the starting 
material had been consumed (table 2.2). 
  
49 
TABLE 2.2: Screening for the dimerization of 2.111. 
 
entry solvent additive temperature observation 
1 PhMe none 110 °C 2.112 
2 PhMe Net3 130 °C starting material 
3 DMF CuTc/Pd(PPh3)4 150 °C 2.112 
4 CH2Cl2 EtAlCl2 –78 °C to RT decomposition 
5 neat none RT starting material + elimination 
6 neat none 120 °C 2.112 
7 neat Net3 130 °C starting material 
8 neat Er(fod)3 120 °C decomposition 
9 CH2Cl2 15 kbar RT starting material 
10 H2O none 65 °C starting material 
11 H2O none 100 °C decomposition 
12 H2O/MeOH none 65 °C starting material 
13 H2O/MeOH none 100 °C 
acetal deprotection then 
decomposition 
14 H2O H2SO4 RT decomposition 
 
We therefore thought that the allylic alcohol might be unstable at temperatures needed 
to form the cation using Brønsted- or weak Lewis acid catalysis. We therefore protected 
the remaining secondary alcohol as a TBS-ether (scheme 2.18). 
 
SCHEME 2.18: Synthesis of silyl ether 2.115. 
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The addition of catalytic amounts of BF3.Et2O or SnCl4 at cryogenic temperatures 
efficiently generated the allylic cation. When the reaction was quenched with EtOH 
stabilized CH2Cl2, the cation was intercepted at the tertiary position and besides some 
elimination, the corresponding ethyl ether was obtained. The analogous result was 
observed when MeOH was used instead of EtOH. The allylic cation was stable at  
–78 °C but was not trapped by a second molecule of 2.115. Warming of the reaction 
mixture showed that the cation was stable until –30 °C and decomposed upon warming 
to room temperature. While a dimerization was not possible, we wanted to know whether 
a smaller diene might be reactive enough to undergo a formal [4+2] reaction at all and 
therefore proving the general mechanism. The addition of 2,3-dimethyl-1,3-butadiene to 
the cation did not show any conversion at –78 °C and the reaction mixture decomposed 
upon slow warming to room temperature (table 2.3). 
TABLE 2.3: Screening for the dimerization of 2.115. 
 
entry solvent additive temperature observation 
1 CH2Cl2 BF3 OEt2 then ethanol –78 °C 2.118 + 2.117 
2 CH2Cl2 BF3 OEt2 then methanol –78 °C 2.1189+ 2.117 
3 CH2Cl2 SnCl4 then ethanol –78 °C 2.118 + 2.117 
4 CH2Cl2 BF3 OEt2 then methanol –78 °C to 0 °C decomposition 
5 CH2Cl2 BF3 OEt2 then 2.120 –78 °C 2.117 
6 CH2Cl2 BF3 OEt2 then 2.120 –78 °C to RT decomposition 
2.120 = 2,3-dimethyl-1,3-butadiene 
Even though we found conditions under which the allylic cation was stable, it was still too 
unreactive to dimerize. Gassman and co-workers did extensive work on ionic Diels-Alder 
reactions using allylic acetals and ketals as precursors.57-59 We hoped that this motif 
would prove to be more stable and yet reactive enough. We thus prepared dioxolane 
2.121 as depicted in scheme 2.19. Acetylation of 2.108 under Steglich conditions gave 
rise to acetate 2.122 that could smoothly be transformed to allylic alcohol 2.123 by Stille 
coupling as a mixture of diastereoisomers. Enone 2.124 was obtained after Dess-Martin 
oxidation. Deprotection of the acetonide followed by reprotection as a carbonate 
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accessed 2.125. The protecting group swap was necessary due to the instability of the 
acetonide group towards strong Lewis acids. Acetalization using Noyori’s conditions 
resulted in dioxolane 2.121. 
 
SCHEME 2.19: Synthesis of dioxolane 2.121. 
Under Lewis acid catalysis the dioxolane was partially opened forming a carbocation as 
proven by the obtained deprotected ketone. The cation was stable to at least –45 °C and 
decomposed upon warming to room temperature. Unfortunately, no trace of the  
TABLE 2.4: Screening for the ionic Diels-Alder reaction. 
 
entry solvent additive temperature observation 
1 Et2O 4 M LiClO4 ,CSA RT 2.125 
2 CH2Cl2 Ti(OiPr)4, TiCl4 –78 °C to –45 °C 2.125 
3 CH2Cl2 TMSOTf –78 °C 2.125 
4 CH2Cl2 BF3 OEt2 –78 °C to –45 °C 2.125 
5 CH2Cl2 BF3 OEt2 –78 °C to RT decomposition 
6 CH2Cl2 TMSOTf, 2.120 –78 °C to 0 °C 2.125 
2.120 = 2,3-dimethyl-1,3-butadiene 
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desired dimerization product was observed. Addition of the smaller and more reactive 
2.3-dimethyl-1,3-butadiene (2.120) showed that the cation is probably still not reactive 
enough (Table 2.4). 
As we could not observe any trace of product until this point, we deemed unlikely to 
access 2.25 or 2.26 via a cationic Diels-Alder reaction.  
 
 
2.3.2 The radical cation Diels-Alder reaction approach 
While electron neutral Diels-Alder reaction are rarely described in the literature, the Diels-
Alder reaction of radical cations are well known,60-63 although they have been hardly ever 
utilized in natural product synthesis.64 Figure 2.6 shows the envisioned radical cascade 
Diels-Alder reaction. One electron oxidation of the diene moiety of 2.128 should lead to 
a radical cation, that should act as a dienophile in the Diels-Alder reaction with 2.128. 
The newly formed radical should then result in 2.129 after electron transfer.  
 
FIGURE 2.6: Proposed mechanism of the radical cation Diels-Alder reaction of 2.128. 
We chose allylic alcohol 2.128 as a reasonable substrate to explore the radical cation 
Diels-Alder reaction. TMS-protection of 2.108 followed by Stille-coupling yielded diene 
2.128 in excellent yields (Scheme 2.20). 
53 
 
SCHEME 2.20: Synthesis of allylic alcohol 2.128. 
Attempts to generate a radical cation from the diene portion using Ledwith-Weitz salt 
resulted only in decomposition when the reaction was run a room temperature. In case 
the reaction was carried out at 0 °C, the only isolable product was triene 2.112. Gassman 
and co-workers reported that in some cases reactions that were considered to run via a 
radical cation proceeded via a cation generated by acid residues in the Ledwith-Weitz 
salt. In order to see whether the elimination proceeded via a radical cation or was simply 
acid-catalyzed, we added 2,6-di-tert-butylpyridine to neutralize any residual acid. Under 
these conditions, no starting material was consumed, so we concluded that the redox 
potential of the Ledwith-Weitz salt was not sufficiently high to oxidize the diene. The use 
of TPPBF4 resulted only in deprotection of the silyl ether, proving this catalyst is 
insufficient for the oxidation of the diene. When 1,4-dicyanobenzene (DCB) was used the 
starting material was decomposed (table 2.5). 
TABLE 2.5: Screening for the radical cation Diels-Alder reaction. 
 
entry solvent additive temperature observation 
1 CH2Cl2 Ledwith-Weitz salt RT decomposition 
2 CH2Cl2 Ledwith-Weitz salt 0 °C 
TMS deprotection 
and 2.112 
3 CH2Cl2 
Ledwith-Weitz salt, 2,6-di-
tertbutylpyridine 
0 °C starting material 
4 MeCN DCB, light RT decomposition 
5 CH2Cl2 TPPBF4, light 0 °C TMS deprotection 
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We next wanted to check whether the steric bulk of the TMS group was preventing any 
reaction. Using the strong photooxidation catalyst 9-mesityl-3,6-di-tert-butyl-10-
phenylacridinium tetrafluoroborate (Mes-Acr-Ph) in combination with different additives 
on the free alcohol 2.111 only decomposition could be observed. The use of Ledwith-
Weitz salt did not improve the reaction outcome (Table 2.6). 
TABLE 2.6: Screening for the radical cation Diels-Alder reaction of 2.111. 
 
entry solvent catalyst temperature observation 
1 CH2Cl2 
Mes-Acr-Ph, DIPEA, 
PhSH, light 
RT 
starting material + partial 
decomposition 
2 CH2Cl2 
Mes-Acr-Ph, 
naphthalene, light 
RT decomposition 
3 DCE Mes-Acr-Ph, light RT decomposition 
4 DCE 
Mes-Acr-Ph, TEMPO, 
light 
RT decomposition 
5 CH2Cl2 Ledwith-Weitz salt RT decomposition 
At this point we reasoned that decomposition pathways set in faster than dimerization of 
the potential radical cation might occur. We therefore prepared a tethered substrate 
where the second diene would be in close proximity to the presumably generated radical 
cation. Disiloxane 2.138 could be synthesized from tertiary alcohol 2.128 in moderate 
yields using dichlorodiphenylsilane and DMAP (Scheme 2.21). 
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SCHEME 2.21: Synthesis of disiloxane 2.138. 
Using Ledwith-Weitz salt as an oxidant, all silyl groups were removed from the molecule. 
This experimental result could be supressed by the addition of base. When 2,6-di-tert-
butylpyridine or NaHCO3 were added to the reaction, no conversion was detected at all, 
again showing that the catalyst is insufficient for this oxidation. When a photocatalyst 
with a higher oxidation potential was applied, only decomposition could be observed 
(table 2.7). As the intramolecular radical cation Diels-Alder reaction was unable to 
produce any product, we were wondering whether the electron-neutral Diels-Alder 
reaction could be carried out on a tethered substrate. The application of 14 kbar did not 
give any conversion at all. Even though the substrate proved to be remarkably stable  
TABLE 2.7: Screening for the intramolecular radical cation Diels-Alder reaction. 
 
entry solvent additive temperature observation 
1 CH2Cl2 Ledwith-Weitz salt 0 °C 
complete silyl 
deprotection 
2 CH2Cl2 
Ledwith-Weitz salt, basic 
quench 
0 °C 
complete silyl 
deprotection 
3 CH2Cl2 
Ledwith-Weitz salt, 2,6-di-
tertbutylpyridine 
0 °C to RT starting material 
4 CH2Cl2 Ledwith-Weitz salt, NaHCO3 0 °C to RT starting material 
5 MeCN DCB, light RT decomposition 
6 CH2Cl2 TPPBF4, light 0 °C decomposition 
7 PhMe none 200 °C partial deprotection 
8 CH2Cl2 14 kbar RT starting material 
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towards heat, no product was identified in the reaction mixture when 2.138 was heated 
to 200 °C. 
At this point we were convinced that a radical cation Diels-Alder reaction would not be 
suitable to deliver the product and we revised our strategy. 
 
 
2.3.3 The divinylcyclobutane rearrangement 
Conjugated dienes are known to undergo an excited state [2+2]-cycloaddition when 
exposed to UV-light in the presence of a photosensitizer.65-67 The resulting 
divinylcyclobutane could then undergo a formal Cope rearrangement,68-69 leading to our 
desired product (Figure 2.7). While the stereochemistry next to the cyclohexane rings 
might be inconsequential for the cycloaddition step, we were optimistic that the tertiary 
alcohols would be on opposite faces due to steric repulsion. 
 
FIGURE 2.7: Predicted reaction pathway towards 2.25. 
When 2.6 was exposed to blue light in the presence of Fukuzumi’s catalyst (Mes-Acr-
Ph), only decomposition was observed (table 2.8). Metal-catalyzed reactions using Ni0 
did not show any conversion at all. When 2.6 was irradiated with a mercury lamp in the 
presence of different photosensitizers and in various solvents, 1H-NMR analysis only 
suggested isomerization of the disubstituted double bond. These experiments  
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TABLE 2.8: Screening for the [2+2]-cycloaddition. 
 
entry solvent additive temperature observation 
1 DMF Mes-Acr-Ph, light RT decomposition 
2 PhMe Ni(cod)2, PPh3 80 °C starting material 
3 Benzene Ni(cod)2, PPh3 60 °C starting material 
4 DMF DCB, light RT 2.141 
5 MeCN DCB, light RT 2.141 
6 MeCN Benzophenone, light RT 2.141 
7 Acetone light RT 2.141 
Light source: medium pressure Hg lamp 
showed it was indeed possible to excite the diene and form the diradical needed for the 
[2+2]-cycloaddition to proceed. Unfortunately, isomerization of the double bond was 
faster than any intermolecular reaction. 
In order to see whether the dimerization would proceed in an intramolecular reaction we 
prepared the tethered substrate 2.142.70-72 As we were not sure whether the acetonide 
groups were sterically to demanding we exchanged them by carbonates. Deprotection 
of 2.122 followed by reprotection delivered carbonate 2.143 that underwent a Stille-
coupling with vinyl stannane 2.110 to give tertiary alcohol 2.144. The disiloxane 2.142 
could be obtained after reacting 2.144 with dichlorodiphenylsilane in the presence of 
DMAP (scheme 2.22). 
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SCHEME 2.22: Synthesis of disiloxane 2.142. 
Unfortunately, when 2.142 was exposed to UV light in the presence of either 
benzophenone or acetone as a photosensitizer, the starting material decomposed 
completely within 1 h (table 2.9). As we knew from the previous experiments that the 
diene could be excited under these conditions, we concluded that the substrate was not 
suitable for the desired cycloaddition. 
TABLE 2.9: Screening for the intramolecular [2+2]-cycloaddition. 
 
entry solvent additive temperature observation 
1 MeCN benzophenone, light RT decomposition 
2 acetone light RT decomposition 
As we could not detect any trace of product, we decided to change our route as depicted 
in the next chapter. 
 
 
2.3.4 The classical Diels-Alder reaction route 
After all attempts to dimerize a monomeric building block in order to form a symmetrical 
or unsymmetrical dimer had failed, we considered a classical Diels-Alder reaction, 
utilizing an electron-rich diene and an electron-poor dienophile, suitable to form the 
natural product.73 We first prepared ethyl ester 2.146 by Stille coupling of vinyl iodide 
2.108 with vinyl stannane 2.147 (scheme 2.23). 
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SCHEME 2.23: Synthesis of ethyl ester 2.146. 
We attempted to react 2.146 with diene 2.111 to form the cyclohexene ring of 2.25. We 
further expected the cycloaddition product to undergo spontaneous lactonization due to 
the close proximity of the tertiary alcohol and the ester group. The reactants were stable, 
yet unreactive in PhCF3 up to 110 °C. At 130 °C, alcohol 2.111 underwent elimination to 
triene 2.112. The elimination could be prevented by the addition of NEt3. Unfortunately, 
no reaction occurred under these conditions, either. When the reactants were heated 
without solvents, no cycloaddition occurred and only the eliminated product could be 
observed (table 2.10). 
TABLE 2.10: Screening for the Diels-Alder reaction between 2.111 and 2.112. 
 
entry solvent additive temperature observation 
1 PhCF3 Eu(fod)3 110 °C starting material 
2 PhCF3 Eu(fod)3 130 °C 2.112 
3 PhMe Net3 110 °C starting material 
4 neat none 130 °C 2.112 
We wondered whether the ,-unsaturated ester was not reactive enough and if the 
acetonide groups were creating too much steric hindrance. Therefore, we prepared 
enone 2.149 by Stille-coupling of vinyl iodide 2.109 with vinyl stannane 2.150 (Scheme 
2.24). 
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SCHEME 2.24: Synthesis of enone 2.149. 
When 14 kbar in the presence of ZnBr2 were applied to the reactants, the formation of a 
complex mixture was observed. The same was obtained when the reaction was carried 
out neat at 50 °C. Both reactants were stable in H2O up to 50 °C and decomposed when 
heated to 100 °C. While the ketone was stable in PhMe at 110 °C, the alcohol 
decomposed without entering any productive reaction pathway (Table 2.11). 
TABLE 2.11: Screening for the reaction of 2.149 with 2.6. 
 
entry solvent additive temperature observation 
1 CH2Cl2 ZnBr2, 14 kbar RT complex mixture 
2 neat none 50 °C complex mixture 
3 H2O none 50 °C starting material 
4 H2O none 100 °C decomposition 
5 PhMe none 110 °C decomposition 
Sorbic acid is known to form dimers by a Diels-Alder reaction to give a mixture of regio- 
and stereoisomers. We were interested whether we could also dimerize enone 2.125 in 
a similar manner (Table 2.12). 
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TABLE 2.12: Screening for the dimerization of 2.125. 
 
entry solvent additive temperature observation 
1 o-DCB none 180 °C starting material 
2 DCE EtAlCl2 -30 °C to 80 °C starting material 
3 neat none 180 °C complex mixture 
Even though sorbic acid dimerizes at 110 °C in the absence of any solvent, 2.125 was 
still unreactive at 180 °C in o-DCB. When heated neat, the starting material was directly 
converted into a complex mixture which did not show any characteristic signals in the 1H-
NMR spectrum. Lewis acid catalysis did also not prove to be successful and resulted in 
unreacted starting material. 
At this point we investigated whether 2.125 was able to undergo a Diels-Alder reaction 
as a dienophile. To our delight, the reaction of 2.125 with 2,3-dimethyl-1,3-butadiene 
proceed smoothly under either thermal or Lewis acid-catalyzed conditions giving 2.153 
as a 1.4:1 mixture of diastereoisomers (Scheme 2.25).  
 
SCHEME 2.25: Diels-Alder reaction of 2.125 and 2,3-dimethyl-1,3-butadiene. 
We hoped that protecting the tertiary alcohol as a methyl ether would prevent elimination 
and reduce the Lewis basicity of the alcohol. 2.154 did not react with 2.125 in the 
presence of EtAlCl2 at low temperatures. When the reaction mixture was gradually 
heated, elimination to triene 2.155 could be observed at 80 °C. When both reactants 
were heated neat, no reaction occurred until both compounds decomposed at 200 °C 
(Table 2.13).   
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TABLE 2.13: Reaction of 2.125 with alcohol 2.154. 
 
entry solvent additive temperature observation 
1 DCE EtAlCl2 –30 °C to 80 °C 2.155 
2 neat none 60 °C to 100 °C starting material 
3 neat none 100 °C to 200 °C decomposition 
Next, we wanted to figure out whether the tertiary alcohol would be too hindered for the 
reaction to proceed. We therefore prepared the shorter diene 2.157 by Stille coupling of 
vinyl iodide 2.158 and tetravinyltin (scheme 2.26). 
 
SCHEME 2.26: Synthesis of diene 2.157. 
Even though we were expecting high temperatures to be needed for the reaction to 
proceed, no conversion could be detected until 180 °C. The addition of EtAlCl2 could not 
enforce the reaction at low temperatures and decomposition of the reactants was 
observed upon heating (scheme 2.27). 
 
SCHEME 2.27: Attempted reaction of 2.125 with 2.157. 
These results showed that the low reactivity of the diene was not due to the steric 
hindrance of the tertiary alcohol, as initially expected Although we could not see any 
desired reactivity of the diene portion by now, we wanted to investigate the reactivity of 
this part in a Diels-Alder reaction. Therefore, we synthesized the strong dienophile 2.160 
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as depicted in Scheme 2.28. 3-butyn-2-ol (2.161) was TBS-protected under standard 
conditions and gave 2.162 in good yields. Further hydroboration using in situ-generated 
dicyclohexylborane followed by oxidation to the boronic acid and esterification with 
pinacol accessed boronic ester 2.163. Enone 2.160 was obtained after TBS deprotection 
under mild conditions and further allylic oxidation.74 
 
SCHEME 2.28: Synthesis of boronic ester 2.160. 
With 2.160 in hand, we went on screening different protecting patterns on 2.6 in order to 
investigate the reactivity of the substrate (table 2.14). 
TABLE 2.14: Investigation of 2.160 as a dienophile. 
 
entry R= R‘= solvent temperature observation 
1 (CH3)2C TBS PhMe 110 °C starting material 
2 (CH3)2C H PhMe 110 °C starting material 
3 H H PhMe 80 °C product 
4 H H PhMe 110 °C product 
Protection of the secondary allylic alcohol had no effect, at least in case that the syn diol 
moiety was still protected. As long as the acetonide was still part of the molecule, no 
reaction with 2.160 was observed using standard conditions. To our delight, unprotected 
diol 2.6 reacted already at 80 °C smoothly with 2.160. The reaction required prolonged 
reaction times and was not significantly accelerated at 110 °C. Even though, NMR data 
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clearly suggested the formation of a Diels-Alder product as a single diastereoisomer, we 
were unable to completely purify the compound by column chromatography, probably 
due to the instability of the boronic ester towards silica. The regio selectivity may possibly 
be explained by coordination of the boronic ester to the free diol. 
At this point we decided that either the sterical or electronical properties of the substrates 
were not sufficient for the reaction to proceed. Both characteristics should improve 
drastically, in case the reaction would be carried out in an intramolecular fashion. We 
therefore decided to link the two monomeric building blocks via an ester bond. While all 
attempts to form the ester from a tertiary alcohol failed, we utilized the primary alcohol 
and planned to install the dimethyl groups later in the synthesis. Stille coupling between 
vinyl iodide 2.108 and vinyl stannane 2.168 followed by TBS protection gave ethyl ester 
2.169 that upon saponification gave acid 2.170. 2.170 could be esterified with allylic 
alcohol 2.171, which was obtained by Stille coupling between vinyl iodide 2.114 and vinyl 
stannane 2.172. The silyl ethers of allylic ester 2.173 were then deprotected under 
standard conditions giving free diol 2.174 (Scheme 2.29). 
 
SCHEME 2.29: Synthesis of allylic ester 2.174. 
The protected alcohol 2.173 was first applied to the intramolecular Diels-Alder reaction 
(Table 2.15). No reaction proceeded by exposure of 2.173 to 14 kbar and resulted in 
recovered starting material. Heating a solution 2.173 in o-DCB to high temperatures 
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decomposed the compound. The free diol 2.174 was also not stable at high temperatures 
and decomposed at 180 °C. Addition of Sc(OTf)3 had no effect on the reaction. Upon 
exposure of 2.174 to EtAlCl2, no conversion was detected when the  
TABLE 2.15: Screening for the intramolecular cycloaddition. 
 
entry R= solvent additive temperature observation 
1 TBS CH2Cl2 14 kbar RT starting material 
2 TBS o-DCB BHT 180 °C decomposition 
3 TBS o-DCB BHT 200 C decomposition 
4 H o-DCB BHT 180 °C decomposition 
5 H CH2Cl2 Sc(OTf)3 –78 °C - RT starting material 
6 H CH2Cl2 Sc(OTf)3 RT - 70 °C starting material 
7 H CH2Cl2 EtAlCl2 –78 °C - RT starting material 
8 H PhMe Sm(OTf)3 70 °C starting material 
9 H PhMe Sm(OTf)3 110 °C decomposition 
reaction was warmed from –78 °C to room temperature. When Sm(OTf)3 was used as a 
Lewis acid, the starting material was not consumed until 70 °C but decomposed upon 
heating to 110 °C. The instability of the substrate to heat is most likely to the labile allylic 
ester used to link the two fragments. Unfortunately, at this point we were running out of 
time to revise our retrosynthesis. 
With acremine F (2.6) in hand we were wondering whether we could transform the 
compound into the related natural product acremine B (2.2). Treatment of 2.6 with excess 
IBX smoothly accessed acremine B (2.2) (Scheme 2.30). 
 
 
66 
SCHEME 2.30: Synthesis of acremine B (2.2). 
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2.3.5 Synthetic studies towards bisacremine G 
The retrosynthetic analysis of bisacremine G (2.27) is depicted in scheme 2.31. It was 
envisioned to install the four methyl groups through Grignard addition into ester 2.177 
followed by oxidation of the resulting primary alcohol, a second Grignard attack and acid 
catalysed ring closure of the tetrahydrofuran ring. 2.177 would be derived from hemiketal 
2.178 by reductive aromatization. Tetrahydropyran 2.178 would be formed from diketone 
2.179 by acetal formation and migration of the double bond to the thermodynamically 
more stable position. An intramolecular vinyl quinone Diels-Alder reaction of allylic ester 
2.180, derived from acid 2.181 and allylic alcohol 2.171, would give access to the tricyclic 
core of 2.27 and setting all remaining stereogenic centers. Allylic alcohol 2.171 would be 
obtained via Stille coupling of vinyl iodide 2.114 whereas carboxylic acid 2.181 would be 
derived from methylhydroquinone (2.182) by Vilsmeier-Haack formylation followed by 
HWE olefination. 
 
SCHEME 2.31: Proposed cascade reaction leading to 2.27. 
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The key cyclization precursor 2.180 could be generated from 2.183 via global 
deprotection and further oxidation of the hydroquinone moiety. 
Methylation of methylhydroquinone 2.182 using dimethyl sulfate gave methyl ether 2.39 
that could be formylated under Vilsmeier-Haack conditions to yield aldehyde 2.184. 
Carboxylic acid 2.181 was obtained after Wittig-reaction followed by hydrolysis and was 
esterified with alcohol 2.114 to give allylic ester 2.183 (Scheme 2.32). 
 
SCHEME 2.32: Synthesis of allylic ester 2.183. 
The next step of the synthesis would require the oxidation of the protected hydroquinone. 
Unfortunately, attempts to oxidize the dimethyl hydroquinone using CAN or 4-
iodophenoxyacetic acid and oxone in various solvent mixtures resulted either in 
decomposition or recovered starting material. The same results were observed upon 
attempts to deprotect the methyl ethers without direct oxidation. 
As this protecting group pattern proved to be unsuitable for our synthesis, we switched 
the protecting groups (Scheme 2.33). 2.184 was demethylated to hydroquinone 2.186 
using BBr3 and reprotected to give TIPS-ether 2.187. Allylic ester 2.188 was obtained by 
a similar sequence as described above. 
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SCHEME 2.33: Synthesis of cyclization precursor 2.180. 
Vinylquinone 2.189 was obtained after removal of all three silyl ethers followed by 
oxidation using Ag2O. As 2.189 turned out to be unstable towards column 
chromatography, the crude material was used to investigate the cyclization cascade 
(Table 2.16). 
TABLE 2.16: Screening for the VQDA reaction 
 
entry solvent additive temperature observation 
1 PhMe none 110 °C 2.190 
2 H2O/THF none 60 °C 2.190 
3 PhMe BHT 150 °C decomposition 
4 o-DCB BHT 200 °C ester cleavage 
5 CH2Cl2 12 kbar RT decomposition 
6 MeCN Sc(OTf)3 RT no reaction 
7 Et2O LiClO4 RT no reaction 
Most literature known VQDA reactions proceed either at room temperature or in 
moderately heated solutions.52, 55 Heating a solution of 2.180 in PhMe, H2O or THF gave, 
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besides decomposition, hydroquinone 2.190. When a solution 2.180 in PhMe was heated 
to 150 °C in a sealed tube, only decomposition could be observed. Upon further heating 
of 2.180 in o-DCB to 180 °C, alcohol 2.114 could be isolated from the reaction mixture, 
suggesting that the allylic ester had been cleaved. We therefore assumed that vinyl 
quinone 2.180 was not stable enough at temperatures required for a Diels-Alder 
cycloaddition. Trauner reported that VQDA reaction can benefit from Lewis acid catalysis 
or high pressure. Unfortunately, when 12 kbar were applied to a solution of 2.180 in 
CH2Cl2, only decomposition was observed. The addition of Sc(OTf)3 could also not 
accelerate the reaction. Diels-Alder reactions are known to be facilitated by the use of 
solvents containing a high ionic strength, such as 4 M LiClO4 in Et2O. Unfortunately, when 
these conditions were applied to 2.180 no conversion could be detected. 
While the electronic character of the substrate seems to match the requirements of an 
inverse electron demanding Diels-Alder reaction, it is known that electron deficient vinyl 
quinones dimerize easily. Trauner and co-workers also showed that changing the 
electronic properties of the substrate may help the reaction to proceed.55 We therefore 
redesigned our substrate by swapping the place of the carbonyl group in the allylic ester 
and therefore change the polarity of the substrate (Scheme 2.34).  
 
SCHEME 2.34: Synthesis of allylic ester 2.197. 
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TBS protection of hydroquinone 2.186 gave access to aldehyde 2.191 which could 
undergo a Wittig-reaction to yield methyl ester 2.192. 2.192 could be reduced to allylic 
alcohol 2.193 using DIBAL-H which could then be esterified with acid 2.194 to obtain 
allylic ester 2.195. While the deprotection of the silyl ethers under strongly basic 
conditions using TBAF resulted in hydrolysis of the ester, using HF.pyridine as a fluoride 
source smoothly yielded triol 2.196. It turned out that the oxidation of the hydroquinone 
moiety could best be obtained by the use of PIFA as the oxidant, giving rise to vinyl 
quinone 2.197. 2.197 was unstable towards chromatography and was therefore used 
crude in the following cyclization attempts (Table 2.17). 
TABLE 2.17: Screening for the VQDA reaction of 2.197. 
 
entry solvent additive temperature observation 
1 PhMe none 60 °C decomposition 
2 o-DCB none 180 °C decomposition 
3 CH2Cl2 12 kbar RT complex mixture 
Unfortunately, attempts to trigger a VQDA reaction thermally or under high pressure 
resulted in complete decomposition of the starting material. Therefore, we reasoned that 
vinyl quinone 2.197 is unstable under conditions required for a VQDA reaction. 
As we had only investigated intramolecular VQDAs we thought it might be worthwhile 
examining intermolecular reactions. We therefore wanted to see whether a VQDA 
reaction between vinyl quinone 2.200 and allylic alcohol 2.111 would be feasible (Table 
2.18).  
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Table 2.18: Screening for the VQDA reaction of 2.111 and 2.200. 
 
entry solvent additive temperature observation 
1 PhMe none 60 °C starting material 
2 PhMe none 110 °C complex mixture 
3 neat Eu(fod)3 60 °C complex mixture 
4 CH2Cl2 Sm(OTf)3 –78 °C - RT starting material 
5 CH2Cl2 Sc(OTf)3, MS 5 A –78 °C - RT decomposition of alcohol 
6 H2O/THF none 60 °C quinone dimerization 
While a solution of 2.111 and 2.200 in PhMe showed no conversion until 60 °C, both 
compounds were converted to a complex mixture upon heating to 110 °C. The addition 
of Sm(OTf)3 could not accelerate the reaction as well as Eu(fod)3. The addition of 
Sc(OTf)3 in combination with molecular sieves as a desiccant were supposed to 
accelerate the acetalization in order to facilitate the following VQDA reaction. 
Unfortunately, this combination led to decomposition of alcohol 2.111. When 2.111 and 
2.200 were heated in a mixture of H2O and THF the 1H-NMR data suggested the 
dimerization of the vinyl quinone.  
These results suggested that the reaction is most likely to proceed when both partners 
are electron-deficient. In order to prove this hypothesis a reaction between enone 2.203 
and vinyl quinone 2.200 could be carried out (scheme 2.35). 
 
SCHEME 2.35: VQDA reaction between 2.203 and 2.200.  
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2.4 Summary and outlook 
In conclusion, we investigated the biomimetic dimerization of acremine F (2.6) to 
bisacremines E (2.25) and F (2.26). We proposed an ionic cascade that could lead to the 
natural product and therefore examined the reactivity of 2.6. An allylic cation could be 
generated under various conditions and trapped with different nucleophiles. 
Nevertheless, the generated cation was trapped with the wrong regiochemistry making 
the proposed biosynthesis unlikely. We next investigated a radical cation Diels-Alder 
reaction as a possible mechanistic pathway. Our experiments on a variety of substrates 
showed that this pathway is unlikely or at least not feasible with the substrates examined. 
Furthermore, we examined a photochemical pathway in which 2.6 was supposed to 
dimerize in a [2+2]-cycloaddition forming a divinylcyclobutane that should then undergo 
a formal Cope rearrangement to form the core of the natural product. Intensive 
experiments showed the difficulties in forming the 4-membered ring necessary for the 
cope rearrangement. We conducted further studies on the nonbiomimetical synthesis of 
2.25 and 2.26 employing several monomeric and tethered substrates. Even though the 
biogenic synthesis remains unclear we gained inside into the reactivity of 2.6. In addition, 
we were able to establish the first asymmetric total syntheses of acremines B (2.2) and 
F (2.6). The route proved to be robust and therefore provides access to the whole class 
of the acremine natural product family. 
Furthermore, we conducted synthetic studies towards the asymmetric total synthesis of 
bisacremine G (2.27) employing a VQDA reaction. To this end, we prepared three highly 
sophisticated vinyl quinones as substrates for the cyclization cascade. Even though we 
were unable to induce the reaction, we gained a strong inside into this largely unexplored 
methodology. While a VQDA reaction using an electron-rich partner did not lead to any 
product, it remains to be investigated whether the reaction proceeds with an electron-
poor dienophile as indicated by the homodimerization of 2.200. This reaction could 
provide a fast excess to the core of bisacremine G and extend the scope of this powerful 
methodology.  
74 
  
75 
 
 
 
 
 
Chapter III 
 
 
 
Exerting Photocontrol over G-Protein 
Coupled Receptors 
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3.1 G-Protein coupled receptors (GPCRs) 
Signal transduction presents one of the most important processes in all organisms and 
is required to ensure coordination of cellular activity and maintain cellular homeostasis.75-
77 The transmission from the external to the internal environment is usually rendered by 
membrane proteins at the cell surface that sense signalling molecules such as 
hormones, neurotransmitters or paracrine factors. The probably largest and most diverse 
class of transmembrane proteins is the heterotrimeric guanine nucleotide binding protein 
(G-protein) coupled receptors (GPCRs).78-79 More than 1000 GPCRs are encoded in the 
mammalian genomes with most of them coding for sensory receptors like taste or 
olfactory receptors.76 They are considered as major contributors to the information flow 
into the cells and, as such, are associated with a range of diseases.80 Therefore, it is not 
surprising that GPCRs are one of major drug targets and account for more than 50% of 
human therapeutics currently on the market.79 GPCRs can be divided into three main 
classes A, B and C based on protein sequence homologies.78 Class A GPCRs comprise 
the largest group, accounting for almost 85% of all GPCR genes, whose archetype is 
rhodopsin.75 Despite the lack of homology in between the classes, all GPCRs share a 
conserved transmembrane structure comprising seven -helices between an 
extracellular N-terminus and an intracellular C-terminus.77 GPCRs can detect a variety 
of extracellular signals including photons, ions, small organic molecules and entire 
proteins. Upon ligand binding, the receptor undergoes a conformational change leading 
to activation of the heterotrimeric G-protein.76 It consists of a-subunit as well as a -  
 
FIGURE 3.1: Functional cycle of G-protein activity.76 
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and a -subunit which are forming an undissociable complex. In the resting state, the 
GDP-bound -subunit and the -complex are associated. Binding of an effector to the 
GPCR promotes exchange of GDP for GTP on the -subunit that triggers the dissociation 
from the -complex. Both subparts are then able to modulate effector functions. The 
inherent GTPase activity of the -subunit then hydrolyses GTP to GDP leading to 
reassociation of the  subunits (Figure 3.1). The basic properties of G-proteins are 
defined by the -subunits which can be divided into four families: Gs, Gi/Go, Gq/G11 
and G12/G13.77  
Gs and Gi/Go both affect the adenylate cyclase and therefore the intracellular level of 
cAMP. While Gs has an activating effect, Gi/Go shows inhibiting function the enzyme. 
Gq/G11 activates phospholipase C which catalyses the cleavage of 
phosphatidylinositol-4,5-biphosphate (PIP2) into inositoltrisphosphate (IP3) and 
diacylglycerol (DAG).76 IP3 leads to the release of Ca2+ from the ER and therefore 
increases the intracellular Ca2+-level while DAG activates protein kinase C. G12/G13 
has activating effects on RhoGEF. Although G had been considered to be passive for 
a long time, it can affect various ion channels such as the G-protein regulated inwardly 
rectifying potassium channel (GIRK), voltage gated Ca2+-channels, isoforms of adenylyl 
cyclase phospholipase C as well as isoforms of phosphoinositide-3-kinase.76 Most 
receptors can activate multiple G-protein subtypes and activation results therefore in 
activation of several signal transduction cascades. 
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3.2 Dopamine receptors (DARs) 
3.2.1 Introduction 
3.2.1.1 Dopamine receptors (DARs) 
Dopamine (DA) is a fundamental neurotransmitter that is part of the catecholamine family 
and plays a major role in the mammalian brain.81 It controls a multiplicity of functions 
such as locomotor activity, cognition, emotion, positive reinforcement, food intake and 
endocrine regulation.82 DA is also abundant in the periphery where it acts as a modulator 
of cardiovascular function, catecholamine release, hormone secretion, vascular tone, 
renal function and gastrointestinal motility.81 Disorders in the dopamine homeostasis are 
related to several diseases, such as Parkinson’s disease, schizophrenia and attention 
deficit hyperactivity disorder (ADHD).83 Dopamine receptors (DARs) are part of the family 
A G protein coupled receptors (GPCRs) which makes up the majority of the GPCR 
superfamily (ca. 85%) and represent the target of 25–30% of all available medications.84 
DARs are divided into two subfamilies, the D1-like receptors and the D2-like receptors, 
based on sequence homology and function.85 D1-like receptors (D1/D5) couple to Gs/olf 
and therefore have a stimulating effect on the adenylyl cyclase which catalyses the 
synthesis of the secondary messenger cyclic AMP (cAMP).81 They are found exclusively 
postsynaptically on dopamine receptive cells, such as GABA-ergic medium spiny 
neurons (MSNs) in the stratium.81 D2-like receptors (D2/D3/D4) couple to Gi/o/z resulting 
in an inhibitory effect on the enzyme. They are found postsynaptically on dopamine target 
cells as well as presynaptically on dopaminergic neurons. Changes in the cAMP level 
directly and indirectly modulate an array of downstream proteins, including kinases, ion 
channels and transcription factors.82 Despite from the cAMP pathway, DARs can directly 
control downstream proteins such as GIRK channels via the G subunits.81 DARs also 
recruit arrestins, which terminate G protein signalling and facilitate G protein-
independent signalling and can therefore directly take control over downstream proteins. 
Although DARs within a given subfamily couple to similar downstream signalling 
transducers, they diverge functionally by interacting with unique accessory proteins via 
their intracellular loops and C-termini (e.g. D1R and D5R can interact directly with NMDA 
and GABA receptors, respectively) and have distinct cellular localization patterns.82 
The individual members of the subfamilies of the D1 and D2 class receptor share a high 
level of homology of their heptahelical transmembrane domains.86 D1 and D5 are 80% 
homologous in this domain whereas D3 and D4 share 75% and 53% homology with the 
D2 receptor respectively.81 The number of amino acid residues in the N-terminal domain  
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FIGURE 3.2: Structure of a D1-like receptor. E1-E3, extracellular loops; 1-7, transmembrane 
domains; I2-I3, intracellular loops.82 
is largely consistent all over DARs whereas the C-terminal domain of the D1 class is 
seven times longer than that of the D2 class. DARs possess two cysteine residues in the 
extracellular loops 2 and 3 that are supposed to form an intramolecular disulphide bridge 
stabilising the structure.82 D2 like receptors are characterized by a long third intracellular 
loop whereas the third loop in D1 like receptors is shortened (Figure 3.2). The core of 
the protein contains highly conserved residues defining a narrow binding pocket that 
corresponds to the agonist binding site. The binding of the amino group of the 
catecholamine is likely to happen via an aspartate residue in the transmembrane domain 
3 (TM3). TM5 provides two serine residues which act as hydrogen bond donors to bind 
the hydroxyl groups of the catechol moiety. A phenylalanine residue in TM6 is highly 
conserved over all receptors and is supposed to form stabilizing orthogonal interactions 
with the aromatic core of the ligand. An allosteric interaction is suggested to be provided 
by an aspartate residue in TM2.82 
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3.2.2.1 Structure-affinity relationship for 2-aminotetralines 
The dopaminergic activity of 2-aminotetralins was identified in the late 1960s and led to 
active synthetic affords optimizing the structures over the following decades.87-89 The 
development of dopamine receptor agonists follows two main strategies: Rigidification of 
the dopamine (3.1) skeleton, arresting the -conformation of the molecule and dissection 
of the semisynthetic agonist apomorphine (3.2). The design of aminotetralines presents 
a combination of both approaches.89 The class of phenolic 2-aminotetralines has been 
studied intensively and showed comparatively high dopaminergic activity. Structure 
affinity relationships aimed on the determination of the positional effect of the hydroxyl 
moiety, the effect of substituents on the nitrogen atom and the absolute configuration.90 
The hydroxyl group on the aromatic ring turned out to be crucial most likely due to 
hydrogen bond donation to residues in the ligand binding site. Hydroxyl groups in position 
5, 6 and 7 increased the potency and showed a maximum effect when the hydroxyl group 
was in position 5. Alkyl substituents at the nitrogen showed an increase in efficacy with 
an optimum for a propyl chain. While the first substituent should not exceed the length of 
a propyl group, variations on the second substituent are well tolerated. Lipophilic motives 
such as homobenzylic residues showed best results.90 Figure 3.3 shows the natural DAR 
agonist dopamine (3.1), the semisynthetic agonist apomorphine (3.2) and the synthetic 
agonist PPHT (3.3). 
 
FIGURE 3.3: DA receptor agonists. 
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3.2.2 Project outline 
Dopamine receptors (DARs) provide a promising target for debilitating disorders such as 
Parkinson’s disease, schizophrenia, addiction, ADHD, obsessive compulsive disorder 
and Tourette’s syndrome.84 Even though DARs have been intensively studied over the 
last decades, the role of individual DARs in vivo remains not fully understood. However, 
there are few ligands that selectively bind individual DARs due to the highly conserved 
orthosteric dopamine binding site. Additionally, diffusible ligands are not cell-type specific 
and therefore are unable to differentiate between DARs that have distinct and, in some 
cases, opposing roles in neighbouring neurons or brain regions. In order to obtain spatio-
temporally precise activation of DARs, we sought to implement a photoswitchable moiety 
into the known DA receptor agonist PPHT (3.3). This should be achieved by extension 
of the homobenzylic residue to an azobenzene (Figure 3.4). Structure-affinity 
relationships suggested that large residues would be tolerated at that site without great 
loss of activity.89 Upon irradiation with UV light the molecule should undergo a 
conformational change altering its shape and therefore its ability to activate the receptor. 
In order to obtain cell-type specificity, we wanted to install a molecular anchor at the end 
of the photoswitch which can react with a cysteine residue that is genetically engineered 
near to the binding site of a desired receptor. This strategy needs only a single point 
mutation and therefore maintains all features of a wild type receptor, including their 
endogenous DA binding site and receptor elements that control signaling, localization 
and trafficking. In a second approach, we sought to implement a SNAP-tag motif enabling 
the use a fully wild type receptor. 
 
FIGURE 3.4: Azologization strategy for photoswitchable DAR agonists. 
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3.2.3 Results and discussion 
3.2.3.1 Azobenzene-PPHT (AP) and Maleimide-Azobenzene-
PPHT (MAD) 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from Prashant Donthamsetti, Nils Winter, Matthias 
Schönberger, Joshua Levitz, Cherise Stanley, Jonathan A. Javitch, Ehud Y. Isacoff, 
and Dirk Trauner, J. Am. Chem. Soc. 2017, 139, 18522–18535. Copyright 2017 
American Chemical Society.91 
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3.2.3.2 Red-Shifted Azobenzene-PPHT (DMS-PPHT) 
Using UV light to switch the ligand in vivo has several disadvantages such as tissue 
damaging caused by high energy photons and low penetration depth. To avoid these 
insufficiencies of a regular substituted azobenzene, we sought to increase the 
wavelength needed for photo-switching. The bathochromic shift can be achieved by the 
introduction of a dimethylamino group in the 4-position of the azobenzene. 
Our retrosynthetic analysis of DMS-PPHT is depicted in Scheme 3.1. The azobenzene 
should be introduced by diazonium ion formation and subsequent trapping with 
dimethylaniline. The aniline was supposed to be derived by reduction of nitrobenzene 
3.4. The ethylphenyl residue should be installed by reductive amination of aldehyde 3.5 
and aminotetraline 3.6.  
 
SCHEME 3.1: Retrosynthetic analysis of 3.7. 
Following these considerations, reductive amination of aldehyde 3.5 with aminotetraline 
3.6 gave nitro benzene 3.4 in moderate yields (Scheme 3.2). Further reduction of the 
nitro group under heterogeneous conditions gave access to aniline 3.8. Diazonium ion 
generation and subsequent trapping with dimethylaniline furnished azobenzene 3.9. 
Lewis acid-mediated deprotection of the methyl ether completed the synthesis of DMS-
PPHT (3.7). 
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SCHEME 3.2: Synthesis of 3.7. 
With DMS-PPHT (3.7) in hand, we next investigated the photophysical properties of the 
molecule. Irradiation of 3.7 in DMSO with 420 nm sufficiently switched the compound 
from its trans- to its cis-conformation. When the cis-conformation was left in the dark, 
thermal relaxation restored the trans-configuration within 10 min. This process could be 
accelerated by illuminating the molecule with 600 nm light (Figure 3.5). 
  
FIGURE 3.5: UV/Vis absorption spectra of cis- and trans-3.7 (left), reversible photoswitching of 
3.7 (right). 
While DMSO would not necessarily be the solvent of choice for biological applications, 
we were interested in solvent dependencies on the photophysical properties. We 
therefore repeated the experiments in two protic and unprotic solvents with increasing 
polarity (Figure 3.6). The absorption maximum proved to be solvent dependent but was 
unfortunately lacking any trend. The switching kinetics as well as the photostationary 
states both provided a maximum in CHCl3 and no switching was observed in MeOH. The 
switching properties in DMSO proved to be similar to those recorded in i-PrOH. 
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FIGURE 3.6: Solvent dependence on the absorption (up) switching kinetics (down) of 3.7. 
The effect of DMS-PPHT on HEK293T cells overexpressing DARs was then evaluated 
by Dr. Mathias Schönberger. Upon irradiation with 420 nm (purple bars), the molecule 
was converted into the active conformation and activated DARs. The molecule could 
then be truncated by illumination with 600 nm (yellow bars). This process could be 
repeated over several cycles without any loss of activity (Figure 3.7).  
 
 
FIGURE 3.7: Current clamp (left) and voltage clamp (right) experiments on HEK293T cells 
overexpressing DARs. 
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3.2.3.3 Benzylguanine-Azobenzene-PPHT (BGAP) 
The SNAP Tag tethering motif is becoming increasingly popular for the connection of a 
specific ligand to a protein of interest (POI). Therefore, an anchoring protein is genetically 
engineered to the POI which can react with a benzylguanine moiety attached to the 
ligand, forming a covalent bond. In this approach, it is possible to use a native, fully 
functional protein. Therefore, we decided to synthesize a photoswitchable PPHT  
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SCHEME 3.3: Synthesis of BGAP (3.18). 
derivate providing a benzylguanine attached via a polyethylene glycol (PEG) linker. The 
synthesis of benzylguanine-azobenzene-PPHT (BGAP) is outlined in Scheme 3.3. 
Acetylation of aniline 3.10 using bromoacetyl bromide gave bromoacetamide 3.11 which 
could undergo nucleophilic displacement by ammonia to yield glycine 3.12. Previous 
attempts to install the glycine moiety by amide coupling with Fmoc-protected glycine 
resulted in cleavage of the amide bond under conditions needed for the following 
deprotection. The PEG linker was installed by amide coupling of 3.12 and PEGylated 
NHS ester 3.13. Copper(I)-mediated click reaction92 of 3.14 with 4-pentynoic acid (3.15) 
accessed carboxylic acid 3.16. BGAP (3.18) was obtained after TBTU mediated amide 
bond formation of 3.16 with benzylguanine 3.17.93 Purification of 3.18 proved to be 
challenging due to cleavage of the benzylguanine in several conditions used for 
chromatography. 
We next evaluated the photophysical properties of the molecule. BGAP was efficiently 
converted from its trans- to cis-configuration by irradiation with 360 nm light and vice 
versa by 460 nm light. The compound could efficiently be switched over several cycles 
without any loss of activity (Figure 3.8). As BGAP lacks any strong auxochromic groups, 
the cis-configuration of the compound is sufficiently stable towards thermal relaxation  
 
 
FIGURE 3.8: UV/Vis-spectra of cis and trans BGAP (left), switching BGAP over several cycles 
followed by thermal relaxation (right).  
min 
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(T1/2>1 h), and thus the compound is considered bistable. 
The biological properties of BGAP were subsequently evaluated by Dr. Prashant 
Donthamsetti in the Isacoff lab at UC Berkeley. When the compound was attached to 
D1R, irradiation with 460 nm light evoked a photocurrent that disappeared upon 
illumination with 360 nm light. The effect was reversible and could be repeated over at 
least two cycles without any loss of function. The application of DA further increased the 
current showing that BGAP is a partial agonist in its trans-configuration on D1R (Figure 
3.9). When BGAP was attached to D2R, the current evoked by DA was photoblocked in 
response to 460 nm light and returned to its former state in response to 360 nm light, 
showing that BGAP is an antagonist in its trans-configuration on D2R. 
The UV/Vis-spectrum proposed that the compound can efficiently be switched to its cis-
configuration with 360 nm light. Nevertheless, the broad absorption band of the π-π* 
transition indicates that other wavelengths would be suitable as well, albeit with reduced 
efficiency. The wavelength screening on D1R revealed that switching is possible in a 
range from 320–390 nm with a maximum efficiency between 360 nm and 370 nm. 
 
 
 
FIGURE 3.9: BGAP is a partial agonist on D1R (top left); BGAP is an antagonist on D2R (top 
right); wavelength dependence on the deactivation of BGAP (bottom). 
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3.2.3.4 Maleimide-Azobenzene-Dopamine (MADA) 
Although PPHT is a DAR agonist, MAP behaved either as an inverse agonist or as an 
antagonist depending on the attachment site. In order to create a photoswitchable 
tethered DAR agonist we changed our initial strategy and attached the azobenzene to 
the natural ligand dopamine. We were confident that the substituent on the primary amine 
would be tolerated as many DAR agonists contain secondary amines. Even though we 
knew that catechols are prone to oxidation we sought agonism might benefit from this 
moiety. 89-90 The synthesis of maleimide azobenzene dopamine (MADA, 3.19) is depicted 
in Scheme 3.4. 
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SCHEME 3.4: Synthesis of MADA (3.19). 
The synthesis commences with amide coupling of homoveratrylamine (3.20) and 4-
nitrophenylacetic acid (3.21). Reduction of the amide using DMS borane and subsequent 
Boc-protection gave nitrobenzene 3.24 in good yields. Reduction of the aromatic nitro 
group under heterogenic hydrogenation conditions, followed by Baeyer-Mills coupling 
with 1-nitro-4-nitrosobenzene (3.26) yielded azobenzene 3.27. The nitro group was then 
chemoselectively reduced utilizing Na2S as reductant. The free catechol moiety, which 
was obtained upon demethylation using BBr3, turned out to be unstable under a variety 
of conditions. Boc-protection of the secondary amine followed by reprotection of the 
catechol as TBS-ethers afforded aniline 3.29. Amide bond formation with acid chloride 
3.3094 gave access to silyl ether 3.31. Global deprotection using aqueous HF smoothly 
yielded 3.19. 
MADA was then sent to Dr. Prashant Donthamsetti from the Isacoff lab at UC Berkeley, 
where it is currently under investigation for its biological properties. 
 
 
3.2.3.5 Maleimide-Azobenzene-ADTN (MAAD) 
As MAP was not showing any agonistic effects, we were interested to see if we could 
design a photoswitchable tethered agonist based on the known DAR agonist ADTN. 95 
The molecule shares similarities with MAP but contains the catechol moiety which we 
sought might be beneficial for agonism. The synthesis of maleimide-azobenzene-ADTN 
(MAAD 3.32) is depicted in Scheme 3.5. 
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SCHEME 3.5: Synthesis of MAAD (3.32). 
-Tetralone 3.34 was obtained by acid chloride formation of 3,4-dimethoxphenylacetic 
acid (3.33) and subsequent double Friedl-Crafts acylation of ethylene.96 Reductive 
amination with benzylamine furnished secondary amine 3.35 which could then undergo 
a second reductive amination with propionaldehyde to yield tertiary amine 3.36. 
Cleavage of the benzyl group furnished secondary amine 3.37 which could undergo a 
reductive amination with freshly prepared aldehyde 3.38 to give azobenzene 3.39 in good 
yield. Reduction of the aromatic nitro group under mild conditions accessed aniline 3.40 
which, after protecting group swap, furnished silyl ether 3.41. MAAD (3.32) was obtained 
after amide bond formation with acid chloride 3.3094 followed by global deprotection using 
aqueous HF. 3.32 proved to be air-sensitive in solution and was transformed into an 
unidentified oxidation product after  being allowed to stand in MeOH for a few days.  
The biological properties of the compound are currently being investigated in the Isacoff 
lab at UC Berkeley by Dr. Prashant Donthamsetti. 
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3.2.4 Summary and outlook 
In summary, we have synthesized and characterized the first photoswitchable ligand for 
a class A GPCR. To this end, we have developed four different photoswitchable DAR 
modulators based on the known DAR agonist PPHT. The synthesis is based on a three 
step sequence to install the amino tetralone core which can be employed into modular 
synthetic pathways to vary the substitution pattern on the azobenzene. The synthesis 
proved to be reliable and scalable and allows for the rapid installation of various tethering 
motifs at the eastern end of the molecule. DMS-PPHT could evoke currents in HEK293T 
cells overexpressing the DAR/GIRK system in response to blue light. While all diffusible 
molecules lacked selectivity, we could overcome this issue by the addition of a tethering 
unit. MAP can directly be attached to the binding site of the receptor, carrying only a 
single point mutation. Depending on the tethering site, the molecule can either act as 
neutral antagonist or an inverse agonist. BGAP can be attached via a SNAP-TAG to the 
native molecule. When attached to D1R the molecule behaves as a partial agonist and 
as an antagonist on D2R. 
As the PPHT derived tethered ligand MAP showed antagonistic activity or behaved as 
inverse agonists we additionally developed a route of the photoswitchable DA derivative 
MADA. The 11-step synthesis proved to be scalable and diversifiable with regard to 
many sides of the molecule. However, the biological properties of the molecule remain 
to be evaluated.  
Furthermore, we developed a scalable 11-step synthesis of a photoswitchable derivative 
of the DAR agonist ADTN. The key -tetralone 3.34 is formed by a nowadays rarely used 
method employing ethylene as a nucleophile. Changes in the substitution pattern of the 
molecule can be introduced at various steps, underlying the modularity of the synthetic 
plan. In the future we will evaluate the biological properties of the molecule in terms of 
DAR activation in response to light. 
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3.3 Muscarinic acetylcholine receptor (mAChR) 
3.3.1 Introduction 
3.3.1.1 Muscarinic acetylcholine receptor (mAChR) 
Acetylcholine (ACh) is one of the most abundant neurotransmitter in the central nervous 
system (CNS) as well as in the peripheral nervous system (PNS).97-98 The effects of ACh 
are mediated by two classes of receptors, namely the nicotinic acetylcholine receptor 
(nAChR) and the muscarinic acetylcholine receptor (mAChR).98 The nAChR belongs to 
the superfamily of pentameric ion-channels and is besides ACh also responsive to 
nicotine.99 The mAChRs are responding to ACh and muscarine and are part of the large 
class of G-protein coupled receptors.100 They are widely expressed in both the CNS and 
in the periphery and mediate a variety of physiological functions ranging from nervous 
functions such as arousal, memory and alertness to vegetative processes such as 
regulation of heart rate and cardiac output, blood pressure and temperature regulation.101 
mAChRs can be divided into two classes based on their coupling to different G-proteins. 
M1, M3 and M5 activate Gq/11 and therefore predominantly activate phospholipase C (PLC) 
via their -subunit.101-102 Activation of PLC leads to cleavage of phosphatidyl-inositol-4,5-
biphosphate (PIP2) to diacylglycerol (DAG) and inositol triphosphate (IP3). 
 
FIGURE 3.10: Canonical signalling pathways of mAChRs. 
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M2 and M4 preferentially couple to Gi/o, inhibit the adenylyl cyclase via the -subunit and 
therefore reduce the intracellular level of cAMP. Furthermore, mAChRs can modulate 
the activity of either K+- or Ca2+-channels by means of the -subunit (Figure 3.10).103-105 
M1 and M4 are predominantly expressed in the CNS while M2 is mainly localized in the 
heart slowing the heart rate down to normal sinus rhythm.104, 106 M3 was mostly found in 
the smooth muscle of blood vessels and in the lungs.105 
The genes encoding for mAChRs are highly compact and lack the abundance of 
introns.98, 107 The structure of the muscarinic receptor is highly conserved over the 
different subtypes. The high degree of sequence similarity in the transmembrane core of 
those receptors creates a significant challenge for the development of small molecule 
ligands which can discriminate between specific mAChRs.104 Due to the close homology 
of the orthosteric binding site, most drugs target to non-classical (allosteric) binding sites 
of certain mAChR subtypes located in the less conserved extracellular loops of the 
receptor. The overall structure of all mAChRs is similar to that of other GPCRs revealing 
a network of hydrogen bonding interactions extending from the binding pocket to the 
cytoplasmic surface.104 In mAChRs, this network is part of long aqueous channel leading 
into the membrane accommodating the ligand binding pocket.104 The channel is 
extended beyond the binding pocket and separated from the cytoplasmic surface by a 
hydrophobic amino acid layer. Figure 3.11 shows the crystal structure of M2 bound to 
the orthosteric ligand QNB. 
 
Figure 3.11: Crystal structure of M2 bound to QNB.104  
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3.3.1.2 Iperoxo 
In 1999, during the search for novel subtype-selective agonists of mAChRs Impicciatore 
and co-workers developed the muscarinic superagonist iperoxo (3.42)108 (Figure 3.12). 
3.42 provided an activity which is more than two orders of magnitude higher than the 
activity of the endogenous ligand acetylcholine even though it proved to be unable to 
differentiate between different receptor subtypes.109 The molecular scaffold has later 
been incorporated into dualsteric hybrid agonist combining receptor subtype preference 
and signalling pathway selectivity.110-111 Therefore, Mohr and co-workers showed that 
linkage of voluminous residues to the iperoxo skeleton does not severely compromise 
agonist efficacy.112  
 
FIGURE 3.12: Molecular structure of iperoxo (3.42). 
 
 
3.3.2 Project-outline 
mAChRs are abundant in the CNS as well as in the PNS and therefore present an 
interesting target for the treatment of Alzheimer’s disease and pain.97 Furthermore, they 
are involved in controlling a variety of physiological functions.100 While the structure of 
mAChRs was sufficiently determined by X-ray crystallography,104-106 the specific role of 
a receptor in an individual cell remains still not fully understood mainly due to the lack of 
subtype specific agonist. Spatio-temporally precision can be obtained by the use of a 
photoswitchable ligand which can undergo a configurational change upon light irradiation 
and therefore alter its ability to activate a certain receptor. In order to obtain such a light-
dependent ligand we wanted to incorporate a photoswitchable azobenzene in the known 
mAChR superagonist iperoxo (3.42) (Figure 3.13). 
 
FIGURE 3.13: General design of photoswitchable mAChR agonist based on iperoxo (3.42). 
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The molecule can then be used as a tool to investigate mAChR signalling in a time 
resolved manner in a cell of interest. Furthermore, such a molecule could be of clinical 
interest in the development of artificial cardiac pacemaker.  
 
 
3.2.3 Results and discussion 
Iperoxo appeared to be a promising template for the design of a photoswitchable M2R 
agonist. From personal communications with Prof. Sasse we knew that the optimal length 
of a linker between the ammonium portion and the azobenzene should be around 6 to 8 
methylene units. Based on this information, we decided to design our photoswitch as 
depicted in Figure 3.14. In order to get a more rapid access to the desired building blocks 
and facilitate the syntheses, we incorporated an additional oxygen atom next to the 
azobenzene. 
 
FIGURE 3.14: Generalized structure of azoiperoxo. 
Scheme 3.6 shows the synthesis iperoxo base (3.43), the common synthetic precursor 
for all photoswitchable derivatives. Mannich reaction employing formaldehyde, 
dimethylamine and propargyl alcohol (3.44) accessed alcohol 3.45 in moderate yield. 2-
isoxazoline 3.46 was accessed by reaction of 1-bromo-3-chloropropane (3.47) with 
isoamylnitrite in the presence of NaNO2. Nucleophilic displacement then afforded  
 
SCHEME 3.6: Synthesis of iperoxo base (3.43). 
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iperoxo base (3.43) in good yields.113 
The first derivative, azoiperoxo1 (3.48) could be accessed by nucleophilic displacement 
of benzylic bromide 3.49 with 3.43. Carbon linkers were attached to phenol 3.44 by 
reaction of the corresponding dibromides 3.45-3.49 and gave alkyl bromides 3.50-3.54 
generally in good yields. Nucleophilic substitution of 3.50-3.54 with iperoxo base (3.43) 
gave access to azoiperoxos 3.55-3.59 (Scheme 3.7). This reaction proved to be 
satisfying to the operator as the product was the only insoluble part in this reaction and 
could easily be purified by washing the precipitate with EtOAc. 
 
 
 
SCHEME 3.7: Synthesis of azoiperoxo1-11 (3.55-3.59). 
3.55-3.59 showed similar UV/Vis-absorbance spectra and switching behaviour as 
expected for azobenzenes lacking auxochromic substituents. Exemplary spectra are 
depicted in Figure 3.15, illustrated on azoiperoxo7 (3.57) and azoiperoxo11 (3.59). All 
compounds could efficiently be converted from their trans- to their cis-conformer by 
irradiation with 370 nm and vice versa by 460 nm. Switching was independent on 
whether the experiment was performed in DMSO or aqueous buffer with the exception 
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of azoiperoxo11 (3.59). When the experiment was performed in aqueous buffer, 
precipitate formation was observed and the intensity of the absorption dropped 
significantly upon irradiation with 370 nm light. This result indicates a decreasing 
solubility of the cis-conformer in aqueous buffer. This effect should be general for all 
other compounds made as well, but exceeds the limit of solubility with the eleven 
membered carbon chain. 
  
  
FIGURE 3.15: UV/Vis-spectra of azoiperoxo7 (3.57) in DMSO (top left) and buffer (top right) and 
azoiperoxo11 (3.59) in DMSO (bottom left) and aqueous buffer (bottom right). 
In the next step, we were evaluating the ability of the compounds to activate M2Rs. These 
experiments were performed by Dr. Arunas Damijonaitis. To be able to observe GPCR 
activation with an electrophysiological readout, the experiments were conducted using 
HEK293T cells overexpressing M2 and GIRK. After activation of the trimeric G-protein, 
dissociation of the -unit leads to opening the ion-channel. When cis-azoiperoxo3 (3.55) 
was applied under constant illumination with 360 nm light, receptor activation could not 
be observed. Irradiation with 460 nm light evoked a current, indicating activation of M2 
(Figure 3.16). The same observation was made, when azoiperoxo5 (3.56) was applied 
under the same experimental conditions, with the exception that the evoked photocurrent 
became larger and therefore showed that 3.56 is a more effective activator of M2. Both 
experiments were conducted using a concentration of 10 µM of the photoswitchable 
agonist. The activation was even more sufficient when azoiperoxo7 (3.57) was applied 
to the same experimental conditions proving the influence of linker (data not shown). 
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FIGURE 3.16: 3.55 (left) and 3.56 (right) act as a trans-agonist on M2Rs. 
Like the parental molecule our compounds could activate M2 in the M2 GIRK assay. 
Nevertheless, the concentrations needed for the activation were significantly higher. We 
then sent azoiperoxo7 (3.57) to Prof. Philipp Sasse at the university of Bonn who 
performed ex vivo experiments in Langendorff preparations (Figure 3.17).  
  
FIGURE 3.17: The application of 3.57 enables the light-dependent modulation of the heart rate in 
Langendorff preparations. 
The application of 3.57 (50 nM) led to intense cardiac arrhythmia with av-blocks and a 
slow heart rate which was not photo-tunable by irradiation with either 360 nm or 440 nm 
light. Nevertheless, after washing for approximately 10 min, the sinus rhythm was 
restored and it became possible to modulate the heart rate by irradiation with light. 
Illumination with 360 nm light slowed down the heart beat while illumination with 440 nm 
restored the heart. 
Although these results appeared promising, they raised several questions. Application 
of the compound led to a massive effect which was not photo-tunable and, after wash-
out, the desired effect was observed. This observation might either propose that 3.57 is 
highly potent and the initially applied concentration was reduced to an optimal range after 
wash-out, or that the sample has been contaminated and this contamination causes 
serious side effects. In the initial patch-clamp experiments, concentrations in the µM 
range and illumination with 460 nm light were necessary to sufficiently activate the 
receptor, while nM concentrations were sufficient in Langendorff-preparations and 
activation occurred upon irradiation with 360 nm light. This contrast might hardly be 
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explained by the different assays used and the different origins of the receptors. 
Nevertheless, it might be plausible that 3.57 is less potent on M2 but more effective on 
an unknown receptor which is responsible for the change in heart rhythm observed in 
the Langendorff experiments. 
 
 
3.3.4 Summary and outlook 
In conclusion, we have developed a photoswitchable M2R agonist based on the known 
M2R superagonist iperoxo and prepared six derivatives thereof. These derivatives differ 
in the carbon spacer length between the pharmacophore and the photoswitchable 
moiety. We could demonstrate that ligand efficiency depends on the length of the spacer. 
In addition, we evaluated the photophysical and biological properties of the synthesized 
molecules. Prof. Sasse showed that 3.57, when being applied to Langendorff-
preparations, has an effect on the heart rate, which can be modulated with 360 nm and 
440 nm light. However, the exact origin of this effect still has to be investigated. 
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3.4 TAS2R 
3.4.1 Introduction 
The evaluation of nutritional value or potential toxicity of food prior to ingestion is 
essential for mammals.114 The detection of relevant food components is mediated by five 
basic taste qualities, sweet, sour, salty, umami and bitter.115 Although no clear correlation 
between bitterness and toxicity has yet been established, it is generally believed that 
bitter taste prevents mammals from poisoning.116 The gene family of human taste 
receptors (hTAS2Rs) consists of approximately 25 members belonging to the 
superfamily of G-protein coupled receptors (GPCRs).116-117 TAS2Rs are predominantly 
expressed in the oral cavity but can also be found in the urethra as this presents another 
potential entry for bacteria and harmful substances.118 TAS2Rs are activating gustducin, 
a G-protein found in taste receptor cells.117 Dissociation of the -subunit leads to 
activation of a phosphodiesterase (PDE) and therefore to a decrease in cNMP (cyclic 
nucleotide) level. The -subunit mediates an increase in the levels of inositol 
triphosphate (IP3) and diacylglycerol (DAG).117  
Denatonium (3.60) is the most bitter chemical compound known and was discovered by 
J. R. Smith in 1958 during the search for local anesthetics (Figure 3.18). As the benzoate 
salt, it provides a bitterness threshold of 0.05 ppm. It is used to denature alcohol and 
harmful liquids.119 
 
FIGURE 3.18: Structure of denatonium benzoate (3.60). 
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3.4.2 Project outline 
One of the important questions in taste research remains how thousands of structurally 
diverse compounds are detected by only 25 receptors of the human TAS2R family.116-117 
While some receptor subtypes recognise only a few agonists, other are more 
promiscuous.116 This contrariness proposes a complementary interaction of the 
receptors. We wanted to develop a photoswitchable TAS2R agonist in order to be able 
to study receptor activation in a spatio-temporal manner. Therefore, we wanted to 
incorporate an azobenzene moiety into the known TAS2R agonist denatonium (3.60). 
 
 
3.4.3 Results and discussion 
We chose denatonium as a template to develop a photoswitchable TAS2R agonist. The 
molecule contains two aromatic rings and therefore two possible sites for the extension 
to an azobenzene (Figure 3.19). Because we did not know at which side the azobenzene 
would be tolerated by the receptor, we decided to evaluate both possibilities. 
 
FIGURE 3.19: Azologization of denatonium (3.60). 
The synthesis of 3.61 is depicted in Scheme 3.8. Diazonium ion formation of aniline 
(3.63) followed by subsequent trapping with 2,6-dimethylaniline furnished azobenzene 
3.64 in moderate yield. Diethylamine 3.65 was obtained after acylation with bromoacetyl 
bromide followed by nucleophilic displacement with diethylamine. Formation of the 
quaternary ammonium ion using benzylbromide accessed the desired product in good 
yield. 
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SCHEME 3.8: Synthesis of 3.61. 
The synthesis of 3.62 could be accomplished by nucleophilic displacement of benzyl 
bromide 3.67 with lidocaine (3.68) (Scheme 3.9). 
 
SCHEME 3.9: Synthesis of 3.62. 
With both compounds in hand, we went on to investigate the photophysical properties of 
the molecules. Both molecules had similar photophysical properties. The exemplary 
UV/Vis-spectra of 3.62 is shown in Figure 3.20. Upon irradiation with 360 nm light, 3.62 
could efficiently be converted from its trans- to its cis-conformer and vice versa upon 
irradiation with 420 nm light. Additionally, the compound was sufficiently bistable in the 
dark as no change in the absorption spectrum could be observed after 30 min. 
  
FIGURE 3.20: UV/Vis-spectra of 3.62 after irradiation with 360 nm light (left) and after 
subsequent irradiation with 420 nm light (right).  
nm nm 
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Both compounds were sent to Dr. Maik Behrens at the German Institute of Human 
Nutrition. Preliminary results (data not shown) indicate that both compounds are able to 
activate TAS2Rs and that the cis-isomer is less potent in activating the receptor. 
3.4.4 Summary and outlook 
In conclusion we have developed a photoswitchable TAS2R agonist based on the known 
TAS2R agonist denatonium. Two derivatives differing in the position of the attached 
azobenzene have been synthesized. Both compounds have been fully characterized 
regarding their photophysical properties. Preliminary data recorded by Dr. Maik Behrens 
indicate that both molecules possess agonistic behaviour on TAS2Rs and that the 
irradiated form exhibits less activity. Future experiments have to confirm these results 
and validate the data. These molecules could then be used as a tool to confirm the 
orientation of mobile groups inside the receptor. 
130 
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Development of Photochromic Ion 
Channel Blockers 
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4.1 Introduction 
The detection and transmission of noxious stimuli from the periphery to the brain or within 
local circuits is essential for the protection from injuries.120 Chemical, mechanical or 
thermal stimuli can activate specific receptors and ion channels in peripheral nerve 
endings resulting in the initiation of action potentials which propagate along axons of 
primary afferent pain fibres and trigger activation of second-order neurons by the release 
of neurotransmitters such as glutamate.121 Action potential initiation and propagation is 
mediated by voltage-gated ion channels (VGICs). 123-124 Inflammation or nerve injury can 
cause maladaptive changes in the expression pattern of VCICs resulting in 
hyperexcitability of afferent pain-signaling neurons.121 Therefore VGICs present a 
promising target for the treatment of pathogenic pain.122 There are three main classes of 
VGICs, which can be grouped according to their specificity for a certain type of ion they 
conduct, e.g. Na+, K+ and Ca2+.123-124 NaV channels are responsible for the initiation of 
the action potential whereas KV channels are regulators of resting membrane potential 
and action potential repolarization. CaV-channels are important for the triggering of 
intracellular signalling pathways and heart contraction. The precisely timed opening and 
closing of Nav- and KV-channels is represented by the unique shape of action potentials. 
If the resting membrane potential, due to external stimuli, e.g. neurotransmitter release, 
reaches a certain threshold, Nav-channels open followed by Na+ ion influx, which leads 
to the characteristic upstroke of the action potential. This is immediately followed by the 
opening of Kv-channels and a K+-ions efflux to repolarize the cell to the resting membrane 
potential levels. 123-124 
Nav-channels (Figure 4.1) consist of an -subunit of approximately 260 kDa associated 
with auxiliary -subunits.125 The -subunit comprises four homologous domains (I-IV) 
each containing six transmembrane -helices (S1-S6) and an additional pore loop 
located between the S5 and S6 segments. The S5 and S6 segments of four domains 
form the pore module whereas the voltage-sensing domains are constructed by the S1-
S4 segments. The outer, narrow entry to the pore is sized by the pore loops forming the 
Na+-ion selectivity filter whereas the inner, wider exit of the pore is lined by the S5 and 
S6 segments. Channel activation in response to depolarization of the membrane is 
initiated by the positively charged amino acid residues (gating charges) in the S4 
segments of each domain.126 
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FIGURE 4.1: General structural topology of NaV+- and KV+- channels.122 
During sustained depolarization of the membrane, the intracellular loop between III and 
IV folds into the channel structure blocking the pore from the inside.125 The kinetics and 
the voltage dependence of the channel gating are modified by the -subunits. KV- and 
CaV-channels, share common topology and function. NaV-channels consist of a single -
subunit bearing four transmembrane domains which are expressed as a contiguous 
polypeptide. The family of mammalian NaV-channels consist of the members NaV1.1–
NaV1.9 and a designated Nax encoded by ten different genes. In contrast, KV-channels 
are encoded by approximately 70 genes grouped into 12 families, KV1–KV12 depending 
on their -subunit.122, 125 Kv-channel diversity is further broadened by the assembly of 
different subunits into homo- or heterotetrameric structures. 
Characterized by conduction behaviour at different voltage potentials, Nav channels can 
exists either in open, resting or inactivated state.121 At resting membrane potential 
(approximately –70 mV), the channel is in a non-conducting closed state. When the cell 
becomes depolarized i.e. the membrane potential increases to reach a certain threshold, 
(approximately –40 mV), the pore is pulled open by an outward movement of the voltage 
sensing units (S1-S4). Subsequently, the channel is intrinsically converted into a non-
conductive inactive state. To reactivate the channel, i.e. relieve the inactivation block, the 
membrane potential needs to return to resting levels.126-127  
It is not surprising that NaV-channels, as fundamental components of action potentials, 
are targets of various natural toxins derived from terrestrial and marine organisms such 
as spiders, scorpion or snakes.128 These aim at paralysing their prey in an effective and 
fast way (Figure 4.2). 
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FIGURE 4.2: Selected toxins targeting NaV channels.  
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4.2 Project outline 
Voltage-gated sodium channels are involved in action potential firing in excitable cells, 
displaying them as potential targets for the pharmacological treatment of pain.123, 128-129 
Pain disorders are frequently associated with a malfunction in NaV-channels resulting in 
a gain of function such as inherited erythromelalgia, paroxysmal extreme pain disorder 
or congenital insensitivity to pain.120 NaV1.7, NaV1.8 and NaV1.9 are of special interest 
as they are preferentially expressed in peripheral sensory neurons of the trigeminal and 
dorsal root ganglia (DRG), but are not essential for the function of CNS neurons or 
cardiac myocytes.130 Therefore a photoswitchable channel blocker would enable the 
light-dependent control of ion-flux through Nav-channels and undoubtedly become a 
valuable tool in order to study the role of NaV-channels in pain sensation.  
 
FIGURE 4.3: Structure of raxatrigine (4.4), bupivacaine (4.5) and A-803467 (4.6). 
The aim of this project was to incorporate a light switchable azobenzene moiety into the 
known small molecule Nav-channel blockers raxatrigine (4.4), bupivacaine (4.5) and A-
803467 (4.6) (Figure 4.3) without disrupting the overall structure of the compound. These 
blockers have in common that they all are bearing azologable moieties, i.e. aryl amides 
which can be conservatively substituted with an azobenzene. These azologs can be 
switched between their cis and trans configuration using light. This structural change 
alters then the efficacy towards their target structure (Nav-channels). Ultimately, we 
evaluated their ability to control ion-flux through Nav- and KV-channels in a light manner 
using cell cultures overexpressing these channels.  
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4.3 A-803467 
The TTX-resistant NaV1.8 channel is the primary contributor of Na+-flux during the 
upstroke of the action potential in DRG neurons.131-132 Altered expression levels can lead 
to faster recovery from the inactivation state and a shift in the voltage dependence of 
activation to a more hyperpolarized potential, producing hyperexcitability of DRG 
neurons. Icagen and Abbott developed a small molecule inhibitor A-803467 (4.6) which 
showed selectivity for NaV1.8 over other NaV-channels.133 The molecule comprises a 
largely expanded -system containing a diaryl amide bond. This structural motif can be 
displaced by a diazene unit incorporating an azobenzene to make the molecule 
photoswitchable. Therefore, we chose 4.6 as a template for the development of a 
photoswitchable NaV1.8 inhibitor (4.7) (Figure 4.4). 
 
FIGURE 4.4: Azologization of A-803467 (4.6). 
Pd-catalyzed cross coupling of lithiated furan (4.8) with 4-chlorobromobenzene (4.9) 
using Feringa’s method134 gave biaryl 4.10 which could further be brominated to yield  
 
SCHEME 4.1: Synthesis of azo-A-803467 (4.7). 
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4.11. Azobenzene 4.7 was obtained after halogen magnesium exchange using i-
PrMgCl.LiCl followed by trapping of diazonium salt 4.12 (Scheme 4.1). 
The UV/Vis spectra of 4.7 revealed bathochromic shift of the absorption maximum, 
compared to an unsubstituted azobenzene, to approximately 415 nm. Irradiation with 
420 nm light sufficiently converted trans 4.7 to its cis-conformer. In the dark, the 
compound underwent fast thermal relaxation within seconds (Figure 4.5). 
  
FIGURE 4.5: UV/Vis spectra of trans and cis 4.7 (left) and thermal relaxation of 4.7 (right). 
Together with Dr. Andrea Brüggemann at Nanion we evaluated the biological properties 
of the compound on a SynchroPatch 768PE, which allows for the recording of electrical 
signal in theoretically 768 cells at a time. These experiments were conducted on cells 
stably expressing NaV1.8 channels. We could show that 4.7 was unable to reduce current 
flow after depolarization of the membrane with and without irradiation at 420 nm (data 
not shown). 
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4.4 Bupivacain 
Bupivacain (4.5) is a local anaesthetic discovered in 1957 and is part of the world health 
organization’s list of essential medicines.135 4.5 acts by blocking NaV-channels but is also 
a potent inhibitor of KV- and TREK-channels.136-139 Bupivacain contains an aryl amide 
linked to a piperidin ring. In order to render the molecule photoresponsive, we planned 
to extend the aromatic portion to an azobenzene (Figure 4.6). 
 
FIGURE 4.6: Azologization of bupivacain (4.5). 
In situ protonation of homoproline (4.13) followed by acid chloride formation and amide 
bond formation delivered amide 4.14 which was directly alkylated to give aryl bromide 
4.15 in moderate yield. 4.15 then underwent Pd-catalyzed amination, using LiHMDS  
 
SCHEME 4.2: Synthesis of 4.17 and 4.18. 
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as a nucleophile, furnishing aniline 4.16 in good yields after deprotection of the 
disilazane. Azobenzene 4.17 was obtained from 4.16 by Baeyer-Mills coupling with 
nitrosobenzene in moderate yield. Aniline 4.16 could also be converted into 
dimethylaminoazobenzene 4.18 by azocoupling with dimethylaniline (Scheme 4.2). 
Azobenzene 4.20 could be obtained from aniline 4.16 by Baeyer-Mills coupling with 4-
nitronitrosobenzene. Reduction of the nitro group using sodium sulphide accessed 
aniline 4.21 in good yield which was then acetylated with chloroacetylchloride to furnish 
-chloro amide 4.22. Finkelstein reaction followed by nucleophilic displacement with 
ammonia accessed glycine derivative 4.23 (Scheme 4.3). Purification of 4.23 proved 
difficult as the molecule decomposed on silica but could be purified on C18 silica. 
 
SCHEME 4.3: Synthesis of 4.23. 
The UV/Vis-spectra of 4.17, 4.18 and 4.23 show a gradual bathochromic shift of the n→π* 
transition reflecting the increasing electron-donating character of the substituents in the 
4-position of the azobenzene. Therefore, photoisomerization occurs at increasing 
wavelength and is in all cases fully reversibly. Half-lives of the thermal stability are 
decreasing and range from hours to seconds within this series (Figure 4.7). 
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FIGURE 4.7: UV/Vis-spectra of 4.17 (top), 4.23 (middle) and 4.18 (bottom). 
The effect of 4.17 on HEK293T cells overexpressing Kv2.1 and on mouse hippocampal 
CA1 neurons was then evaluated by Philipp Leippe and Dr. Martin Sumser. When 4.17 
was applied under 360 nm illumination to HEK293T cells transiently overexpressing 
Kv2.1, potassium currents were slightly reduced, indicating that the cis-conformer has a 
small effect on these channels already. However, when applying irradiation with 420 nm 
light the K+-current was completely blocked and could be restored to previous levels 
using 360 nm. After washout of 4.17 currents returned to starting levels (Figure 4.8). In 
summary, we could effectively photosensitize K+-currents using 4.17. 
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FIGURE 4.8: a) 4.17 reversibly isomerizes from trans- to cis- by illumination with UV-light and 
blue light respectively. b) Kv2.1 currents are blocked by 4.17 (100 µM) to 22% ±4% (blue light, 
trans) and 64% ±4% (UV light, cis) of initial current before application of the blocker. c) Currents 
are recorded before compound application followed by wash-in of 4.17 under UV-light 
irradiation. Irradiation with blue light leads to a channel block which is reversible under UV-light 
application. After wash-out the amplitude returns to its original value. 
In hippocampal neurons action potentials, elicited through current injection, could be 
effectively blocked using 4.17 (100 µM) and 360 nm light illumination. Action potential 
firing could be restored upon irradiation with 420 nm (Figure 4.9). Noticeably, in this 
experimental setting the cis-conformer presents the active blocker. We then tested 
whether 4.17 shows the same logic when blocking intrinsic KV+-channels in these 
neurons. We found that cis 4.17 is more potent in blocking K+-currents that trans 4.17 
(Figure 4.9). 
 
FIGURE 4.9: Effect of 4.17 (100 µM) on mouse hippocampal CA1 neurons. a) Action potentials 
are inhibited under UV-light illumination. b) Voltage-gate currents are blocked under UV-light 
irradiation. 
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4.5 Raxatrigine 
CNV1014802 (raxatrigine 4.4) is an oral state-dependent NaV+-channel blocker being 
developed by Convergence. 4.4 has completed Phase II trials for lumbosacral 
radiculopathy and entered Phase II trials for trigeminal neuralgia.140-143 It has been shown 
for NaV1.7 that 4.4 works in a state-dependent manner with a nine-fold shift between the 
resting state inhibition (IC50 54 µM) and the open/inactive state inhibition (IC50 6.3 µM) 
with a clear preference for the open/inactivated state.140 Raxatrigine (4.4) consists of a 
disubstituted pyrolidine and a methylene bridged diaryl ether. The latter motif offers an 
opportunity for the incorporation of an azobenzene into the molecule without any major 
changes in the overall shape of the molecule (Figure 4.10). 
 
FIGURE 4.10: Azologization of raxatrigine (4.24). 
The synthesis of a photoresponsive raxatrigine derivative is outlined in Scheme 4.4. 
Protection of the carboxylic acid as the ethyl ester followed by N-Boc protection of the 
amine allowed for the formation of lactam 4.25 from L-pyroglutamate (4.26). Halogen 
metal exchange of 4-bromo-iodobenzene (4.27) with n-BuLi followed by reverse addition 
of 4.25 delivered ketone 4.28. Boc-deprotection followed by intramolecular imide 
formation and stereoselective reduction using Adam’s catalyst furnished pyrrolidine 4.29 
as a single diastereoisomer. PMB protection of 4.29 under nucleophilic catalysis 
delivered aryl bromide 4.30 which then underwent Pd-catalyzed amidation under 
Buchwald’s conditions to access carbamate 4.31 in good yield. Acid mediated 
deprotection of the Boc group liberated aniline 4.32 which was directly subjected to 
Baeyer-Mills coupling with nitrosobenzene 4.33 to furnish azobenzene 4.34. 
Saponification of the ethyl ester followed by amide formation allowed for the formation of 
amide 4.35. The final PMB-deprotection step proved rather difficult. Standard oxidative 
conditions resulted in low yields and the formation of several side products complicated 
the purification. Utilizing 1-chloroethyl chloroformate in the reaction could not significantly 
improve the yield but facilitated the removal of the generated side products. 
143 
 
SCHEME 4.4: First generation synthesis of 4.24. 
The developed synthesis proved to be robust and scalable except for the final 
deprotection step. In order to get sufficient access to the desired molecule we decided 
to explore a second synthesis as depicted in Scheme 4.5. 
Diphenylhydrazine 4.39 is derived from pyrrolidine 4.29 after Boc protection followed by 
Pd-catalyzed amination with phenylhydrazine 4.40. Saponification of the ethyl ester 
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accessed carboxylic acid 4.41 which was directly converted into amide 4.42. 
Regioselective deprotection of the Boc group followed by oxidation of the resulting 
phenylhydrazine allowed for the formation of azobenzene 4.43. Further deprotection of 
the pyrrolidine under acidic conditions delivered 4.24. The two-step deprotection 
sequence was necessary as the phenylhydrazine was not sufficiently freed under acidic 
conditions. 
 
SCHEME 4.5: Second generation synthesis of 4.24. 
Furthermore, using a similar route, we synthesized the corresponding photoswitch 
containing the azobenzene in the 3-position (Figure 4.11).  
 
FIGURE 4.11: Structure of meta-substituted azobenzene 4.45. 
With the 4.24 in hand we examined the photophysical properties of the compound. 4.24 
showed a maximum absorption for the n→π* transition at 340 nm and was efficiently 
converted from its trans- to its cis-conformer by irradiation with 360 nm light and vice 
versa by 420 nm light. The compound could efficiently be switched over several cycles 
without any loss of activity (Figure 4.12). As 4.24 lacks any strong auxochromic groups, 
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the cis-configuration of the compound is sufficiently stable towards thermal relaxation 
(T1/2>1 h) and thus, the compound is considered bistable. 
  
FIGURE 4.12: UV/Vis-spectra of 4.24 (left) and continuous switching (right). 
The ability to block voltage gated ion channels was evaluated together with Dr. Andrea 
Brüggemann at Nanion Technologies on a SynchroPatch768PE. When 4.24 was applied 
to CHO cells stably overexpressing hNav1.7, Na+-currents evoked through membrane 
depolarization, were efficiently reduced (Figure 4.13 a and c). When 4.24 was 
preirradiated under 360 nm and then applied to the same experimental setup, 4.24 had 
only a small effect on Na+-currents (Figure 4.13 b and d), illustrating the difference in 
binding efficacy between the trans and the cis conformer. 
We then tested whether 4.24 is also able to block KV1.3-channels expressed in jurkat 
cells. Trans 4.24 showed as well higher potency to reduce K+-currents than its cis 
conformer (Figure 4.14 b and c). The IC50 value was reduced to half its value upon 
irradiation with UV light. Furthermore, the IC50 value of trans 4.24 increased 
approximately three times for KV1.3 compared to NaV1.7. This observation indicates that 
4.24 has a slightly higher ability to block NaV1.7 than KV1.3 (Figure 4.14 a and b). 
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FIGURE 4.13: Effect of 4.24 on CHO cells overexpressing hNav1.7. a) Dose-response plot of 
trans 4.24 (dark adapted) and b) cis 4.24 (UV-pre-treated). c) and d) (top) Plot of Na+-current 
peak values before (white area) and after wash-in (blue area) of c) trans and d) cis 4.24. 
(bottom) Example trace of depolarization evoked Na+-currents before (black trace) and after 
(blue trace) wash-in of c) trans and d) cis 4.24. 
 
 
a 
b 
c d 
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FIGURE 4.14: Effect of 4.24 on jurkat cells expressing hKv1.3. a) Dose-response plot of trans 
4.24 (dark adapted) and b) cis 4.24 (UV-pre-treated). c) and d) (top) Plot of K+-current peak 
values before (white area) and after wash-in (blue area) of c) trans and d) cis 4.24. (bottom) 
Example trace of depolarization evoked K+-currents before (black trace) and after (blue trace) 
wash-in of c) trans and d) cis 4.24. 
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4.6 Conclusion 
In conclusion, we have synthesized photoswitchable derivatives of three known blockers 
of voltage-gated ion channels. We developed synthetic routes, which proved to be 
sufficiently robust and scalable. Furthermore, all compounds have been fully 
characterized in terms of their photophysical properties and their ability to inhibit voltage-
gated ion channels light-dependently. 
4.7, a photoswitchable derivative of A-803467 has been synthesized by a three steps 
protocol employing the addition of an aryl magnesium species into a diazonium salt, a 
method that has been rarely investigated beforehand and optimized in our laboratory. 
Unfortunately, unlike its parental molecule, 4.7 showed no ability to block currents 
evoked upon depolarization of cells overexpressing NaV1.8. 
A robust route to photoswitchable derivatives of bupivacaine has been developed, 
employing Hartwig’s amination protocol utilizing LiHMDS simultaneously as a 
nucleophile and as a base. Further derivatization delivered three photoswitches differing 
in their switching behaviour. Compound 4.17 has been electrophysiologically 
characterized in cells overexpressing VGICs as well as in mouse hippocampal neurons. 
Compound 4.17 in its trans configuration showed a substantial block of K+-currents in 
cultured cells, with the cis conformer being less potent. Strikingly, the logic of this 
photoswitch is inverted when applied to hippocampal neurons, i.e. the cis conformer is 
the more potent configuration of 4.17. Currently, we do not have an explanation for this 
sign inversion. Neurons express a large variety of VGICs as well as other types of ion 
channels and we do not know the exact target of 4.17. But most likely 4.17 affects more 
than one specific type of channel.  
Additionally, we developed and optimized an 11-step synthetic route to photoswitchable 
derivatives of the Phase II channel blocker raxatrigine. This route contains a 
stereoselective reduction of an imine as well as a Pd-catalyzed cross coupling to install 
the azobenzene moiety. The ability of 4.24 to block voltage-gated ion channels was 
evaluated by extensive electrophysiological investigations. 4.24 proved to be a sufficient 
blocker of NaV1.7 as well as KV1.3. This ability was repealed when the compound was 
irradiated with UV-light.  
Therefore, we have developed a new kit of pharmacological tools which can be used to 
investigate neuronal pathways. 
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5.1 Development of Photoswitchable Arp2/3 Inhibitors 
5.1.1 Introduction 
5.1.1.1 Actin 
The cytoskeleton is responsible for the ability of eukaryotic cells to resist deformation, 
transport intracellular cargo and change shape during movement.144 The machinery of 
these processes relies on the assembly of proteins where actin, a globular protein that 
forms filaments of different types of organization, is of significant relevance.145 Actin is 
one of the most abundant proteins in eukaryotic cells reaching concentrations of 300 µM, 
and its structure is highly conserved across species. Monomeric actin (globular- or G-
actin) assembles under physiological salt concentrations to form polymers (filamentous- 
or F-actin) which can be assembled into branched and cross-linked networks, parallel 
bundles, and anti-parallel contractile structures.146 The cell cortex, a thin layer of actin, 
coats the plasma membrane at the back side of the cell and is important for maintenance 
and changes in the shape of the cell. The rest of the cell contains a three-dimensional 
network of cross-linked filaments blended with contractile bundles which are connected 
to the extracellular matrix by focal adhesion sites.147 Actin monomers are proteins of 
42 kDa usually loaded with MgATP. Polymerization of actin monomers at filament ends 
is followed by ATP hydrolysis and dissociation of the phosphate, leaving behind bound 
ADP.146 Actin filaments assemble in a right-handed helix possessing two dynamically 
different ends, the barbed end and the pointed end. As the more dynamic end, the barbed 
end elongates 10 times faster than the pointed end at a rate of up to 3,000 subunits/s. 
 
FIGURE 5.1: Structure of uncomplexed G-actin in the ADP bound state.146 
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Actin filament assembly is limited by the nucleation step, consisting of the formation of 
dimers and trimers.147 Once trimers are formed, the elongation proceeds rapidly as a 
function of the concentration of actin monomers. G-actin comprises four subdomains I-
IV which are assembled around the ATP binding site. The exposed areas of I and III 
comprise the barbed end whereas II and IV refer to the pointed end (Figure 5.1). 146 
 
5.1.1.2 The Arp 2/3 complex 
The actin cytoskeleton plays important roles in cell processes, such as cell migration, 
endocytosis, vesicle trafficking and cytokinesis in eukaryotes.148 To control these crucial 
functions, precise regulation of both the initiation of actin polymerization and organization 
of the resulting filaments is required. The dynamic assembly and disassembly of 
filaments as well as the formation of larger scale filament structures are crucial aspects 
of the actin network and therefore controlled by over one hundred actin-binding 
proteins.149-151 They mediate structural changes such as nucleation, capping, bundling, 
crosslinking or depolymerisation. Polymerization appears mainly on the barbed ends of 
actin filaments which can be created from existing filaments by uncapping or severing or 
by de novo nucleation. Spontaneous nucleation of actin monomers is kinetically 
unfavored and therefore requires initiator proteins such as formins, spires or the actin-
related-protein-2/3 (Arp2/3) complex.148 The Arp2/3 complex comprises seven subunits 
ARPC1-5, Arp2 and Arp3, ranging in size from 16 to 50 kDa, with the latter two giving 
the complex its name. The complex weighs around 220 kDa and is highly conserved 
across species.152 ARPC2 and  
  
FIGURE 5.2: Crystal structure of bovine Arp2/3 complex.152 
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ARPC4 form the structural core of the complex while the remaining subunits organize 
around them. Arp2 and Arp 3 each contain a nucleotide binding cleft and share structural 
similarities to actin. The two are supposed to come together to form an actin-like dimer 
which serves as a template for filament formation (Figure 5.2). 
The Arp2/3 complex on its own possesses little actin-nucleating activity and is activated 
by nucleation promoting factors (NPFs), such as ActA or Wiskott-Aldrich syndrome family 
protein (WASP).149 WASP family proteins, the best characterized of the NFPs, bind the 
Arp2/3 complex and monomeric actin as well as upstream signalling molecules and 
therefore control where and when new actin filaments are created in the cell.150 The 
activity of the so-formed complex is further stimulated by binding to the side of an existing 
actin filament. Upon binding to an existing mother filament, Arp2/3 initiates the formation 
of a Y-branched daughter filament in a characteristic angle of 70 °.152 WASP activation 
is mediated by chemotactic signalling pathways that guide the direction of cellular 
movement (Figure 5.3).  
 
FIGURE 5.3: Actin filament nucleation and organization by Arp2/3 complex.149 
In the absence of NPFs, the two actin-related subunits Arp2 and Arp3 are splayed apart 
from each other. Upon activation, Arp2 moves approximately 25 Å to form a dimer with 
Arp3 which mimics a short pitch actin-dimer within a filament and therefore provides a 
template for the nucleation of a new filament.149 
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5.1.1.3 CK-636 and CK-666 
CK-636 and CK-666 are small molecules which inhibit the ability of the Arp2/3 complex 
to nucleate actin filaments. CK-636 was discovered in 2009 by screening efforts involving 
over 400,000 small molecules for inhibition of actin polymerization stimulated by human 
(Hs) Arp2/3 and was able to inhibit bovine (Bt) Arp2/3 complex with an IC50 value of 
32 µM.153  
 
FIGURE 5.4: Molecular structures of CK-636 (5.1) and CK-666 (5.2). 
In the same study, CK-666 was revealed as a more potent inhibitor by compound 
screening in a Listeria motility assay. CK-666 inhibited BtArp2/3 mediated actin 
polymerization with an IC50 value of 17 µM (Figure 5.4). Both compounds were shown to 
have no effect on actin or WASP directly as well as on Arp2/3 binding to WASP.153 
Furthermore, neither compound disrupted the microtubule network in THP.1 cells or 
showed irreversible off-target morphological effects, such as apoptosis, at 
concentrations up to 100 µM. CK-636 and CK-666 function as allosteric effectors by 
stabilization of the inactive state of the complex.154 Crystal structures of CK-636 and CK-
666 bound to Arp2/3 indicate that stabilization is achieved by binding of the inhibitors to 
a pocket at the interface of Arp2 and Arp3 and therefore block the formation of the Arp2-
Arp3 short pitch dimer (Figure 5.5).153, 155 
 
FIGURE 5.5: Crystal structure of BtArp2/3 complex with bound CK-636.153 
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5.1.2 Project Outline 
The actin-network is responsible for multiple cellular functions ranging from cell motility 
and the maintenance of cell shape and polarity to the regulation of transcription.145 
Furthermore, the interaction of myosin with filamentous actin constitutes the basic 
principle of muscle contraction. It is subject to complex dynamics which are resembled 
by a steady polymerization and depolymerization of filaments.147 These dynamics are 
partially directed by polymerization of actin filaments directed by the Arp2/3 complex. 
The Arp2/3 complex comprises of seven subunits and catalyzes the kinetically unfavored 
process of actin filament nucleation, which allows the precise spatial and temporal 
control of the assembly of actin filament networks.152  
While many aspects of actin polymerization have been revealed over the last decades, 
the dynamics of the actin network still remain not fully understood. A photoswitchable 
inhibitor of the Arp2/3 complex could help to unravel several questions about its 
dynamics, as it would reversibly allow and preclude Arp2/3-mediated actin 
polymerization in real time. We chose CK-636 and CK-666 as a template for such an 
inhibitor as both compounds were shown to selectively target the Arp2/3 complex. 153-155 
Furthermore, crystal structures of both compounds bound to Arp2/3 are available 
suggesting which portions of the molecule are necessary for binding and which areas 
may be modified. Based on crystal structures, we sought to extend the eastern aryl amide 
of CK-636 and CK-666 to an azobenzene in order to obtain a photoswitchable inhibitor 
of Arp2/3 (Figure 5.6). This work was carried out in collaboration with Dr. Cenbin Lu.  
 
FIGURE 5.6: Design of photoswitchable inhibitors based on CK-636 (5.1) and CK-666 (5.2).  
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5.1.3 Results and discussion 
The synthesis of photoswitchable Arp2/3 inhibitors based on CK-636 is depicted in 
Scheme 5.1. The thiophene moiety is pharmacologically considered to be equal to a 
benzene ring and the 2,5-substitution pattern resembles a 1,4-disubstituted benzene 
ring. Amine 5.5 is derived from thiophene 5.6 by methyl ester formation followed by 
reduction of the nitro group under heterogeneous conditions. Diazoniumion formation 
and subsequent trapping with either dimethylaniline (5.7) or N-phenyldiethanolamine 
(5.8) gave azobenzenes 5.9 and 5.10. Amides 5.11 and 5.12 were obtained after 
hydrolysis of the methyl ester followed by amide bond formation with 2-methyltryptamine 
(5.13) in moderate yields. 
 
SCHEME 5.1: Synthesis of azologues 5.11 and 5.12. 
To examine the ability to inhibit Arp2/3 dependent actin polymerization, we send 
compound 5.12, together with azobenzenes 5.17, 5.18, 5.19 and 5.20 synthesized by 
Dr. Cenbin Lu, to Dr. Julie Plastino at the Institut Curie-Section de Recherche in Paris. 
To examine whether the compounds would prevent actin polymerization they were 
applied to 3 µm carboxylated polystyrene beads coated with GST-pVCA of WASP beads 
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which are placed in a motility mix (Arp2/3 complex, profilin, capping protein) with 
monomeric red actin (Alexa 594). The sample is then mounted and viewed by 
epifluorescence over approximately 15 minutes. Actin growth was then plotted over time 
(Figure 5.7). 
  
  
 
  
 
FIGURE 5.7: 5.12 (top), 5.17 (middle left) and 5.18 (middle right) do not inhibit actin 
polymerization; 5.19 (bottom left) and 5.20 (bottom left) inhibit actin polymerization. 
Thiophene 5.12, azobenzene 5.17 and dimethylaniline 5.18 showed no inhibition of 
Arp2/3 dependent actin polymerization while azobenzene 5.20 and dimethylaniline 5.19 
sufficiently suppressed actin polymerization. We therefore reasoned that the meta-
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substitution pattern is crucial for inhibition. This is consistent with the result for thiophene 
5.12, as its structure resembles that of a para-substituted azobenzene. Further studies 
indicated that 5.20 loses its ability to inhibit Arp2/3 upon illumination with 360 nm light 
(data not shown). Even though this result appeared to be quite promising, all compounds 
suffered from poor solubility in aqueous buffers.  
To improve the solubility, we thought to install a morpholine unit as a solubility tag at the 
eastern end of the molecule, under the premise that substitutions would most likely be 
tolerated at that position. Azobenzene 5.21 was obtained after diazoniumion formation 
from aniline 5.22 followed by trapping with phenol. 5.21 was then subjected to amide 
bond formation with 2-methyltryptamine (5.13) to give amide 5.23 which was then 
transformed to morpholine 5.24 by nucleophilic displacement of chloride 5.25 (Scheme 
5.2). 
 
SCHEME 5.2: Synthesis of morpholine 5.24. 
The photophysical properties of 5.24 are consistent with those expected for 
azobenzenes bearing auxochromic groups which are not in direct conjugation. 5.24 was 
efficiently converted from its trans- to its cis-configuration by irradiation with 370 nm light 
and vice versa by 460 nm light. The compound could also efficiently be switched over 
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FIGURE 5.8: UV/Vis-spectra of 5.24 before and after irradiation with 370 and 420 nm light (left). 
5.24 can be efficiently switched over several cycles (right). 
several cycles without any loss and is sufficiently stable towards thermal relaxation 
(T1/2>1 h) and is thus considered bistable (Figure 5.8). 
 
5.1.4 Conclusion 
In conclusion we have developed a photoswitchable Arp2/3 inhibitor based on the known 
compound CK-666 and derivatives thereof. We showed that attachment of an 
azobenzene at the meta position of the benzene ring of CK-666 led to retention of its 
ability to inhibit Arp2/3-dependent actin polymerization while attachment of an 
azobenzene at the para position of CK-666 led to complete loss of activity. However, all 
prepared compounds suffered from poor solubility in aqueous buffers. We therefore 
currently pursue the synthesis of more water soluble derivatives which can be used to 
study actin network dynamics in vivo. 
  
nm 
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5.2 Development of Photoswitchable Inhibitors of Myosin 
II 
5.2.1 Introduction 
5.2.1.1 Myosin 2 
Myosin is a molecular motor protein, identified over 100 years ago, which can generate 
pulling forces by mutual sliding of actin and myosin filaments.156 The myosin superfamily 
consist of approximately 35 classes, found across all eukaryotic cells, that is responsible 
for diverse functions in the cell such as vesicle and organelle transport, muscle 
contraction, photo transduction, cell-cell adhesion, cell migration and cell division.157 The 
most expressed subclass of the myosin superfamily is myosin II (M2). M2 is responsible 
for the production of muscle contractions in muscle cells, where it forms the thick 
filaments of the sarcomeres158. Non-muscle M2 (NM II) plays an important role in cell 
motility, cytokinesis, cell shape determination and cell-cell junction formation.159 The M2 
subclass is the only member of the myosin superfamily which assembles into bipolar 
filaments and consists of a hexameric structure derived from two heavy chains, each 
with a weight of 230 kDa, and two pairs of tightly, but non-covalently, bound light 
chains.156 The heavy chains contain the domains required for myosin function while the 
light chains are responsible for stabilization (essential light chain, 17 kDa) and regulation 
(regulatory light chain, 20 kDa) of the enzymatic activity. Three different isoforms of NM 
II are known which can be differentiated based on their three different heavy chains, NM 
II-A (Myh9), NM II-B (Myh10) and NM II-C (Myh4).160 The N-terminal heavy chain is 
characterized by a global shaped, conserved, catalytic head domain containing both an 
 
160 
FIGURE 5.9: Structure of myosin II (M2).158 
MgATP binding domain and a nearby actin binding Domain (Figure 5.9). The C-terminal 
region comprises a double-stranded, -helical coiled-coil rod which terminates in a non-
helical tail region.157, 160 The ATPase activity is activated by actin and is crucial to slide 
actin-filaments past myosin and exert tension on actin-filaments. M2’s affinity to bind 
actin is regulated by ATP hydrolysis whereby the ADP bound state provides a strong 
interaction between the myosin head and the actin filament.158 Actin affinity drops 
significantly when ATP or ADP-Pi is bound to the catalytic domain. Furthermore, the 
enzymatic activity of M2 is regulated primarily by phosphorylation of the two conserved 
residues Ser19 and Thr18 in the regulatory light chain.156 Malfunction in NM II activity 
has been associated with alterations in cell division and therefore with cancer. 
 
5.2.1.2 Blebbistatin 
Blebbistatin (5.26) was discovered by means of a high-throughput screening targeting 
non-muscle myosin II by Mitchison in 2003 (Figure 5.10). 5.26 showed inhibition of the 
adenosine triphosphatase (ATPase) and gliding motility activities of human platelet non-
muscle myosin II without inhibiting myosin light chain kinase.161 While the (–)-enantiomer 
provided an IC50 value of 2 µM, the (+)-enantiomer was completely inactive. 5.26 
inhibited NM II without showing any effects on the human myosin isoforms Ib, Va and X. 
The compound’s name is derived from its ability to reversibly block cell blebbing.162 
Blebbistatin was shown to block myosin II-dependent cell processes such as cell 
migration and cytokinesis.  
 
FIGURE 5.10: Molecular structure of (–)-blebbistatin (5.26). 
Blebbistatin acts as an uncompetitive inhibitor and binds to a hydrophobic pocket at the 
apex of the 50 kDa cleft, which is located close to the -phosphate binding pocket.163-164 
5.26 stabilizes a state where ADP and pi are both bound to myosin and which precedes 
the force-generating step catalyzed by the release of phosphate when myosin rebinds to 
actin.165 Binding of 5.26 is controlled by the hydrophobic affect, with the phenyl ring of 
blebbistatin being enclosed by Leu262, Phe466, Glu467 and Val630.166 The 
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tetrahydropyrrolo ring mainly interacts with the residues of the side chains Ser456 and 
Ile471, while the methylquinolinone interacts with Tyr261, Thr474, Tyr634, Gln637 and 
Leu641.167 Furthermore, the chiral hydroxyl group forms a hydrogen bond to the main 
chain carboxylate of Leu262 (Figure 5.11). 
 
FIGURE 5.11: (–)-Blebbistatin (5.26) bound within the myosin cleft (left). Interaction of 5.26 with 
important amino acid residues (right). 
It was shown, that blebbistatin undergoes photoconversion upon irradiation with blue 
light (<500 nm), accompanied by the generation of reactive oxygen species responsible 
for its phototoxicity.168 Additionally, 5.26 showed cytotoxic side effects even without 
irradiation.169 Substitution of the C15 position by either a nitro or an amino group gave 
access to derivatives lacking the undesirable side effects while maintaining the level of 
myosin inhibition.162, 170 Furthermore, a photo-crosslinkable derivative of 5.26, 
azidoblebbistatin, bearing an azide at the C15 position, has been developed.171 
 
5.2.2 Project outline 
Blebbistatin (5.26) is a cell-permeable, specific inhibitor of class II myosin. Myosin II is a 
group of actin-based ATP-driven motor proteins which are responsible for various 
biological processes such as muscle contraction, cell migration, differentiation and 
cytokinesis.161 5.26 blocks myosin in a state of low actin-affinity and therefore prevents 
the formation of strongly-bound non-functional actomyosin complexes.163, 165-166 While 
blebbistatin showed side effects such as cellular phototoxicity and cytotoxicity in 
response to blue light,168-169 it has been shown that substitution at C15 by either a nitro 
or an amino group supressed these undesirable effects while maintaining the ability to 
inhibit myosin II.162, 170  
A reversible, photoswitchable, small molecule myosin II inhibitor would provide a 
powerful tool to study dynamic processes within in the actomyosin network. We sought 
to develop such a molecule by incorporating an azobenzene photoswitch into the scaffold 
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of known myosin II inhibitor blebbistatin (5.26). While substitutions at the 
methylquinolinone reduced the affinity of the molecule to bind myosin, substitutions at 
C15 were well tolerated and removed the photolability of the molecule. Therefore, we 
planned to incorporate the existing phenyl ring of 5.26 into the photoswitchable moiety 
by extending it to an azobenzene (Figure 5.12).  
 
FIGURE 5.12: Design of photoswitchable inhibitors based on blebbistatin (5.26). 
 
 
5.2.3 Results and discussion 
The synthesis starts with methyl ester formation of 5-methyl-2-nitrobenzoic acid (5.27) 
followed by reduction of the nitro group under heterogeneous conditions to from aniline 
5.28. Activation of 1-phenyl-2-pyrrolidinone (5.29) using phosphoryl chloride followed by 
subsequent trapping with 5.28 gave amidine 5.30 in good yield. Base mediated 
intramolecular ring closure and enantioselective -oxygenation gave access to (–)-
blebbistatin (5.26). Aniline 5.31 was obtained after nitration of 5.26 in HNO3 and Pd-
catalyzed reduction of the nitro group (Scheme 5.3). 
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SCHEME 5.3: Synthesis of (S)-aminoblebbistatin (5.31). 
Diazoniumion formation followed by trapping with dimethylaniline resulted in a complex 
mixture and did not furnish the desired azobenzene. Attempts to install the azobenzene 
by Baeyer-Mills coupling were only successful using 4-nitro-nitrosobenzene (5.36) and 
resulted in decomposition when nitrosobenzene was employed in the reaction. 
Unfortunately, attempts to selectively reduce the nitro group of 5.37 resulted either in 
cleavage of the diazene unit, deoxygenation or decomposition (Scheme 5.4). 
 
SCHEME 5.4: Attempted derivatization of 5.31. 
As the installation of the azobenzene late in the synthesis proved difficult, we wanted to 
start with an azobenzene as the starting material. Amidine formation using azobenzenes 
5.41 and 5.42 gave amidines 5.43 and 5.44 in low yields but significantly lowered the 
step count compared to the previous synthesis. Base mediated ring closure accessed 
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5.45 and 5.46 which could sufficiently be oxydized using Davis’ oxaziridine 5.34 (Scheme 
5.5). 
 
SCHEME 5.5: Synthesis of tertiary alcohols 5.47 and 5.48. 
 
 
5.2.4 Conclusion 
In conclusion, we have synthesized four blebbistatin analogues containing a 
photoswitchable azobenzene moiety. The direct derivatization of blebbistatin itself 
proved difficult and was only possible for a narrow substrate scope. Furthermore, we 
could show that the reaction sequence could be carried out with substrates already 
containing the azobenzene and therefore giving a fast entry into this class of compounds. 
It remains to be examined whether the azologue still contains the inhibitory properties of 
the parent compound and whether these can be altered by light application.  
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Chapter VI 
 
 
 
Experimental Procedures 
And Analytical Data 
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6.1 General experimental details 
All reactions were carried out with magnetic stirring, and, if moisture- or air- sensitive, 
under nitrogen or argon atmosphere using standard Schlenk techniques in oven-dried 
glassware (140 °C oven temperature). External bath temperatures were used to record 
all reaction temperatures. Low temperature reactions were carried out in a Dewar vessel 
filled with acetone/dry ice (–78 °C) or distilled water/ice (0 °C). High temperature 
reactions were conducted using a heated silicon oil bath in reaction vessels equipped 
with a reflux condenser or in a sealed flask. Tetrahydrofuran (THF) and diethyl ether 
(Et2O) were distilled over sodium and benzophenone prior to use. Dichloromethane 
(CH2Cl2), triethylamine (Et3N), diisopropylethylamine (DIPEA) and diisopropylamine 
(DIPA) were distilled over calcium hydride under a nitrogen atmosphere. All other 
solvents were purchased from Acros Organics as ‘extra dry’ reagents. All other reagents 
with a purity > 95% were obtained from commercial sources (Sigma Aldrich, Acros, Alfa 
Aesar and others) and used without further purification.  
Photochemical reactions were performed with a medium pressure mercury lamp 
(150 W) using a Heraeus power supply at room temperature. 
Flash column chromatography was carried out with Merck silica gel 60 (0.040-
0.063 mm). Analytical thin layer chromatography (TLC) was carried out using Merck 
silica gel 60 F254 glass-backed plates and visualized under UV light at 254 nm. Staining 
was performed with ceric ammonium molybdate (CAM) or by oxidative staining with an 
aqueous basic potassium permanganate (KMnO4) solution and subsequent heating. 
High performance liquid chromatography (HPLC). HPLC was performed with HPLC 
grade solvents and deionized H2O that was purified on a TKA MicroPure H2O 
purification system. All solvents were degassed with helium gas prior to use. Unless 
noticed otherwise, all experiments were carried out at room temperature. 
Chiral HPLC spectra were recorded on a high performance liquid chromatography 
(HPLC) system from the Shimadzu 20A series (DGU-20A3R degasser, LC-20AD Binary 
Pump VL, SIL-20AHT autosampler, CTO-20A thermostated column compartment, SPD-
M20A DAD diode array detector), which was computer controlled through Shimadzu 
LabSolutions Software (Version 5.42 SP5). 
Optical rotation. Perkin-Elmer 241 or Krüss P8000-T polarimeter were used to measure 
optical rotation at the Sodium D-line (589 nm) at the given temperature (T in °C) and 
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concentrations (c in g/100 mL) using spectroscopic grade solvents. The measurements 
were carried out in a cell with a path length (d) of 0.5 dm. 
NMR spectra (1H NMR and 13C NMR) were recorded in deuterated chloroform (CDCl3) 
on a Bruker Avance III HD 400 MHz spectrometer equipped with a CryoProbe™, a Varian 
VXR400 S spectrometer, a Bruker AMX600 spectrometer or a Bruker Avance III HD 800 
MHz spectrometer equipped with a CryoProbe™ and are reported as follows: chemical 
shift δ in ppm (multiplicity, coupling constant J in Hz, number of protons) for 1H NMR 
spectra and chemical shift δ in ppm for 13C NMR spectra. Multiplicities are abbreviated 
as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, br = broad, m 
= multiplet, or combinations thereof. Residual solvent peaks of CDCl3 (δH = 7.26 ppm, 
δC = 77.16 ppm), C6D6 (δH = 7.16 ppm, δC = 128.06 ppm), d6-DMSO (δH = 2.50 ppm, 
δC = 39.52 ppm), d6-acetone (δH = 2.05 ppm, δC = 29.84 ppm, 206.26), and d4-MeOH 
(δH = 3.31 ppm, δC = 49.00 ppm) were used as an internal reference. NMR spectra were 
assigned using information ascertained from COSY, HMBC, HSQC and NOESY 
experiments. 
High resolution mass spectra (HRMS) were recorded on a Varian MAT CH7A or a 
Varian MAT 711 MS instrument by electron impact (EI) or electrospray ionization (ESI) 
techniques at the Department of Chemistry, Ludwig-Maximilians-University Munich. 
Infrared spectra (IR) were recorded from 4000 cm−1 to 600 cm−1 on a PERKIN ELMER 
Spectrum BX II, FT-IR instrument. For detection, a SMITHS DETECTION DuraSamplIR 
II Diamond ATR sensor was used. Samples were prepared as a neat film or a thin powder 
layer. IR data in frequency of absorption (cm−1) is reported as follows: w = weak, m = 
medium, s = strong, br = broad or combinations thereof. 
All yields are isolated unless otherwise specified. 
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6.2 Experimental data for chapter I 
 
Enone 1.112: A solution of dicyclopentadiene (20.0 g, 151 mmol). Ac2O (15.0 mL, 
159 mmol), pyridine (6.20 mL, 76.8 mmol), TPP (100 mg, 0.160 mmol) and DMAP 
(400 mg, 3.27 mmol) in CH2Cl2 (50 mL) was stirred under an O2-atmosphere at room 
temperature for 3 d while being irradiated with reptile lamp. The reaction was diluted with 
Ch2Cl2 and washed with saturated aqueous NaHCO3, aqueous HCl (1 M), saturated 
aqueous CuSO4 and brine. The organic phase was dried over MgSO4 and concentrated 
under reduced pressure. Purification by flash column chromatography (pentane:EtOAc 
9:1, Rf= 0.2) gave enone 1.112 (14.7 g, 101 mmol, 67%) as a colorless oil. 
Data for 1.112: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.37 (dd, J = 5.7, 2.6 Hz, 1H, 6), 
5.97 – 5.89 (m, 2H, 7 & 2), 5.76 (dd, J = 5.7, 3.0 Hz, 1H, 1), 3.46 – 3.36 (m, 1H, 8), 3.20 
(s, 2H, 4), 2.95 (s, 2H, 9), 2.79 (t, J = 5.0 Hz, 1H, 5), 1.74 (d, J = 8.4 Hz, 1H, 3), 1.61 (d, 
J = 8.4 Hz, 1H, 3). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 210.9, 164.8, 137.0, 132.6, 
132.5, 52.8, 50.3, 48.4, 45.1, 44.1. IR (ATR): 𝜈max (cm−1) = 3060 (w), 2959 (m), 2930 (w), 
2874 (w), 1727 (s), 1460 (w), 1402 (w), 1380 (w), 1340 (w), 1307 (w), 1231 (w), 1191 
(m), 1158 (w), 1137 (w), 1089 (w), 1067 (w), 1022 (w), 957 (w)9, 909 (w), 860 (w), 779 
(w), 730 (s). HRMS (EI): calc. for C10H10O [M]+: 146.0732, found: 146.0733. 
 
 
 
Ketone 1.114:35 CuI (426 mg, 2.24 mmol) was added to EtMgBr (0.9 M in THF, 73.8 mL, 
66.4 mmol) at 0 °C and the mixture was stirred for 30 min at that temperature. The 
reaction was cooled to –78 °C and a solution of enone 1.112 (2.00 g, 13.7 mmol) in THF 
(60 mL) was added slowly. The reaction was stirred for 3 h at that temperature, quenched 
with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic phases 
were washed with brine, dried over MgSO4 and concentrated under reduced pressure. 
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Purification of the resulting residue by flash column chromatography (pentane:EtOAc 
95:5, Rf = 0.2) gave ketone 1.114 (2.22 g, 12.6 mmol, 92%) as a colorless oil. 
Data for 1.114: 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.15 (dd, J = 5.8, 2.9 Hz, 1H, 1), 
6.11 (dd, J = 5.8, 2.8 Hz, 1H, 2), 3.15 (s, 1H, 4), 3.01 (s, 1H, 9), 2.91 (ddd, J = 9.7, 4.8, 
1.8 Hz, 1H, 5), 2.61 (dt, J = 9.4, 4.0 Hz, 1H, 8), 2.19 (dd, J = 18.6, 9.0 Hz, 1H, 6), 1.92 
(ddd, J = 18.6, 6.7, 2.0 Hz, 1H, 6), 1.66 – 1.56 (m, 1H, 7), 1.53 (d, J = 8.2 Hz, 1H, 3), 
1.50 – 1.42 (m, 1H, 3), 1.41 – 1.32 (m, 2H, 10), 0.90 (t, J = 7.3 Hz, 3H, 11). 13C-NMR 
(101 MHz, CDCl3): δ (ppm) = 136.2, 135.4, 55.0, 52.4, 48.6, 48.1, 47.3, 46.3, 38.7, 30.7, 
12.1. IR (ATR): 𝜈max (cm−1) = 3062 (w), 2977 (w), 2872 (w), 1691 (s), 1580 (m), 1453 (w), 
1348 (m), 1336 (m), 1297 (w), 1223 (m), 1195 (m), 1175 (m), 1125 (w), 1084 (w), 1052 
(w), 1016 (m), 949 (w), 907 (m), 851 (m), 816 (w), 779 (s), 738 (m), 721 (s), 690 (w). 
HRMS (EI): calc. for C12H12O [M]+: 176.1201, found: 176.1204. 
 
 
 
Tertiary alcohol 1.111: LaCl3.2LiCl (0.6 M in THF, 21.0 mL, 12.60 mmol) was added to 
a solution of ketone 1.114 (2.22 g, 12.6 mmol) in THF (30 mL) and the solution was 
stirred for 1 h at room temperature. The solution was cooled to 0 °C, EtMgBr (0.60 M in 
THF, 28.0 mL, 25.2 mmol) was added slowly and the reaction was stirred for 1 h at 0 °C. 
The reaction was quenched by the addition of saturated aqueous NH4Cl and extracted 
with Et2O. The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to give tertiary alcohol 1.111 (2.33 g, 11.3 mmol, 
90%) as a colorless oil. 
Data for 1.111: 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.42 (dd, J = 5.8, 3.0 Hz, 1H), 
6.13 (dd, J = 5.7, 3.2 Hz, 1H), 2.77 (s, 2H, 4 & 9), 2.51 (dd, J = 10.7, 3.8 Hz, 1H, 5), 2.32 
(td, J = 10.5, 9.9, 4.1 Hz, 1H, 8), 1.72 (dd, J = 12.6, 5.7 Hz, 1H, 6), 1.60 (d, J = 7.9 Hz, 
1H, 3), 1.55 (q, J = 7.4 Hz, 2H, 12), 1.50 (s, 1H, OH), 1.45 (d, J = 7.9 Hz, 1H, 3), 1.39 – 
1.25 (m, 3H, 10 & 6), 1.18 (ddt, J = 12.6, 9.0, 6.2 Hz, 1H, 7), 0.96 (t, J = 7.4 Hz, 3H, 13), 
0.88 (t, J = 7.4 Hz, 3H, 11). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 136.8, 135.4, 80.5, 
57.9, 55.2, 54.9, 50.7, 45.4, 45.1, 41.9, 35.2, 28.3, 13.2, 9.0. IR (ATR): 𝜈max (cm−1) = 
3484 (w, b), 3057 (w), 2958 (s), 2920 (s), 2873 (m), 1459 (m), 1377 (m), 1345 (w), 1335 
170 
(w), 1304 (w), 1250 (w), 1229 (w), 1201 (w), 1147 (m), 1062 (w), 985 (m), 961 (m), 947 
(m), 917 (w), 869 (w), 836 (w), 819 (w), 793 (w), 777 (w), 744 (s), 724 (w), 696 (w). 
HRMS (EI): calc. for C14H22O [M]+: 206.1665, found: 206.1622. 
 
 
 
Cyclopentene 1.109: A solution of tertiary alcohol 1.111 (100 mg, 0.485 mmol) in Et2O 
(2.0 mL) was subjected to flash vacuum pyrolysis. Purification of the resulting residue by 
flash column chromatography (pentane:Et2O 3:1, Rf= 0.25) gave cyclopentene 1.109 
(54 mg, 0.388 mmol, 80%) as a solution in pentane and ether. 
Data for 1.109: 1H NMR (400 MHz, CDCl3): δ (ppm) = 5.85 (dd, J = 5.6, 2.0 Hz, 1H), 
5.68 (dd, J = 5.6, 2.4 Hz, 1H), 2.79 (dddt, J = 14.2, 8.1, 6.2, 2.2 Hz, 1H), 2.06 – 2.00 (m, 
1H), 1.68 (qd, J = 7.5, 1.3 Hz, 2H), 1.54 – 1.49 (m, 1H), 1.43 (d, J = 2.7 Hz, 1H), 1.34 – 
1.28 (m, 1H), 0.93 (dt, J = 9.7, 7.4 Hz, 6H). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 138.8, 
135.4, 86.5, 46.0, 43.7, 33.8, 28.7, 12.5, 9.1. IR (ATR): 𝜈max (cm−1) = 3374 (br), 2961 
(vs), 2924 (s), 2875 (s), 2856 (m), 1730 (w), 1651 (w), 1461 (m), 1378 (m), 1326 (w), 
1147 (w), 1030 (w), 996 (w), 834 (w), 757 (w). MS (EI): calc. for C9H15 [M–OH]+: 123.13, 
found: 123.12. 
 
 
 
Carboxylic acid 1.108:33 DIBAL-H (1 M, in PhMe, 25.0 mL, 25.0 mmol) was added 
slowly to a solution of 3-hexyne (2.84 mL, 25.0 mmol) in cyclohexane (12.5 mL) and the 
reaction was stirred at 60 °C for 2.5 h. The mixture was cooled to room temperature, 
MeLi (1.6 M in Et2O, 15.6 mL, 25.0 mmol) was added and the solution was stirred for 
15 min at room temperature. The reaction was cooled to –30 °C, purged with CO2 and 
stirred for 3 h at that temperature. The mixture was poured into a mixture of aqueous 
conc. HCl and ice and extracted with Et2O. The combined organic phases were dried 
over MgSO4 and concentrated under reduced pressure. Purification of the resultant 
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residue by flash column chromatography (pentane:EtOAc 9:1, Rf= 0.3) gave carboxylic 
acid 1.108 (1.93 g, 15.0 mmol, 60%) as a colorless oil. 
Data for 1.108: 1H NMR (400 MHz, CDCl3): δ (ppm) = 11.92 (s, 1H, OH), 6.87 (t, J = 7.5 
Hz, 1H, 1), 2.31 (q, J = 7.5 Hz, 2H, 4), 2.23 (p, J = 7.5 Hz, 2H, 2), 1.06 (t, J = 7.6 Hz, 3H, 
5), 1.02 (t, J = 7.4 Hz, 3H, 3). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 173.8, 146.6, 132.9, 
22.0, 19.8, 14.1, 13.4. IR (ATR): 𝜈max (cm−1) = 2969 (m), 2937 (m), 2877 (m), 2654 (s), 
2581 (s), 2539 (s), 1682 (h), 1638 (m), 1463 (s), 1418 (m), 1377 (s), 1304 (m), 1288 (m), 
1166 (s), 1107 (s), 1072 (s), 1041 (s), 949 (s), 816 (s), 781 (s), 645 (s), 574 (s), 564 (s). 
MS (EI): calc. for C7H12O2 [M]+: 128.0832, found: 128.0849. 
 
 
 
Allylic alcohol 1.125: Peracidic acid (40% in AcOH, 9.5 mL, 56.9 mmol) was added to 
a suspension of freshly distilled cyclopenta-1,3-dien (15.8 g, 238 mmol), Na2CO3 (30.8 g, 
290 mmol) and NaOAc (390 mg, 4.76 mmol) in CH2Cl2 (150 mL) and the reaction was 
stirred for 1 h at room temperature. The CH2Cl2 was removed under reduced pressure 
and the resulting mixture was extracted with EtOAc. The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated under reduced pressure to give 
crude oxirane S1.1 (3.19 g) as a colorless oil that was used in the next step without 
further purification. 
EtMgBr (3.2 M inEt2O, 15.8 mL, 50.6 mmol) was added slowly to a solution of CuCN 
(5.22 g, 58.3 mmol) in Et2O (100 mL) at –40 °C and the mixture was stirred for 1 h at that 
temperature. A solution of crude oxirane S1.1 (3.19 g) in Et2O (10 mL) was added slowly 
and the reaction was allowed to warm to room temperature overnight. The mixture was 
extracted with Et2O and the combined organic phases were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (pentane:Et2O 3:1, Rf = 0.2) gave allylic alcohol 
1.25 (2.21 g, 19.7 mmol, 35% over 2 steps) as a colorless oil. 
Data for 1.25: 1H NMR (400 MHz, CDCl3): δ (ppm) = 5.95 (ddd, J = 5.6, 2.1, 0.8 Hz, 1H), 
5.82 (dt, J = 5.6, 2.2 Hz, 1H), 4.85 (dd, J = 7.1, 2.4 Hz, 1H), 2.80 (ddt, J = 5.3, 4.4, 2.2 
Hz, 1H), 1.89 (dd, J = 7.5, 2.7 Hz, 1H), 1.79 (dd, J = 7.0, 1.8 Hz, 1H), 1.45 – 1.37 (m, 
2H), 0.90 (t, J = 7.4 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 140.1, 132.7, 77.4, 
45.8, 40.3, 28.6, 12.2. IR (ATR): 𝜈max (cm−1) = 3341 (m), 3055 (w), 2959 (vs), 2931 (s), 
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2874 (s), 2359 (w), 2341 (w), 2205 (w), 2167 (w), 2102 (w), 2049 (w), 2016 (w), 1981 
(w), 1725 (m), 1616 (w), 1460 (s), 1408 (m), 1378 (s), 1325 (m), 1307 (m), 1264 (m), 
1159 (m), 1112 (m), 1095 (m), 1069 (s), 1031 (vs), 1001 (vs), 948 (m), 907 (m), 867 (m), 
832 (m), 795 (s), 777 (m), 750 (s), 726 (s), 709 (s), 668 (s), 645 (s), 622 (s), 615 (s), 607 
(s), 597 (s), 580 (s), 572 (s), 564 (s), 556 (s). MS (EI): calc. for C7H11 [M–OH]+: 95.08, 
found: 95.12. 
 
 
 
Allylic ester 1.128: n-BuLi (2.36 M in hexanes, 1.53 mL, 3.60 mmol) was added 
dropwise to an ice cooled solution of allylic alcohol 1.125 (337 mg, 3.00 mmol) in THF 
(17 mL) and the solution was stirred for 30 min at 0 °C. A solution of acid chloride 1.115 
(540 mg, 3.68 mmol) in THF (5 mL) was added dropwise and the reaction was stirred for 
2 h at 0 °C before the reaction was quenched with aqueous saturated NH4Cl and 
extracted with Et2O. The combined organic phases were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resulting residue 
by flash column chromatography (hexanes:Et2O 99:1, Rf= 0.2) gave allylic ester 1.128 
(447 mg, 2.01 mmol, 67%) as a colorless oil. 
Data for 1.128: 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.66 (t, J = 7.5 Hz, 1H), 6.05 (ddd, 
J = 5.6, 2.1, 0.8 Hz, 1H), 5.84 (dt, J = 5.6, 2.3 Hz, 1H), 5.74 (dq, J = 7.4, 2.8 Hz, 1H), 
2.88 – 2.77 (m, 1H), 2.28 (q, J = 7.5 Hz, 2H), 2.17 (p, J = 7.5 Hz, 2H), 2.04 (ddd, J = 
14.3, 7.7, 2.8 Hz, 1H), 1.85 (ddd, J = 14.4, 7.4, 5.1 Hz, 1H), 1.45 (ddd, J = 13.9, 7.6, 6.5 
Hz, 1H), 1.38 – 1.30 (m, 1H), 1.04 (t, J = 7.6 Hz, 3H), 0.98 (t, J = 7.5 Hz, 3H), 0.92 (t, J 
= 7.4 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 168.2, 143.4, 142.2, 133.9, 129.1, 
80.3, 77.5, 76.8, 46.1, 36.9, 28.6, 21.8, 20.1, 14.2, 13.6, 12.23, 12.21. 
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Ethyl ester 1.130:37 BF3.OEt2 (3.27 mL, 25.8 mmol) and ethyl diazoacetate (8.36 M in 
CH2Cl2, 4.02 mL, 33.6 mmol) were sequentially added to a solution of tetrahydro-4H-
thiopyran-4one (3.00 g, 25.8 mmol) in Et2O at –30 °C and the solution was stirred for 2 h 
at that temperature. The reaction was warmed to room temperature, quenched with 
aqueous K2CO3 (30%) and extracted with EtOAc. The combined organic phases were 
dried over Na2SO4 and concentrated under reduced pressure. Purification of the resultant 
residue by flash column chromatography (pentane:EtOAc 4:1, Rf= 0.3) gave ethyl ester 
1.130 (4.14 g, 20.5 mmol, 79%) as a colorless oil. 
Data for 1.130: 1H NMR (400 MHz, CDCl3): δ (ppm) = 12.84 (s, 1H), 4.18 (q, J = 6.9 Hz, 
2H), 4.11 (q, J = 7.1 Hz, 2H), 3.74 (dd, J = 10.5, 3.3 Hz, 1H), 3.02 – 2.89 (m, 2H), 2.89 
– 2.75 (m, 3H), 2.75 – 2.66 (m, 1H), 2.59 – 2.56 (m, 3H), 2.35 (m, 1H), 2.14 (m, 1H), 
1.30 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ (ppm) = 
206.1, 169.7, 61.5, 60.9, 57.2, 47.1, 39.2, 32.8, 31.0, 29.1, 28.0, 26.9, 25.5, 14.4, 14.2. 
IR (ATR): 𝜈max (cm−1) = 2980 (w), 2926 (w), 2363 (w), 1738 (vs), 1705 (vs), 1638 (w), 
1465 (w), 1428 (m), 1368 (m), 1353 (m), 1325 (m), 1301 (s), 1268 (s), 1220 (vs), 1180 
(vs), 1142 (vs), 1094 (s), 1055 (w), 1030 (s), 1005 (m), 963 (w), 932 (w), 852 (m), 838 
(m), 818 (w), 728 (w), 650 (w), 607 (w), 591 (w), 575 (w), 567 (w), 560 (w). HRMS (EI): 
calc. for C9H14O3S [M]+: 202.0658, found: 202.0656. 
 
 
 
Thiepane 1.131:37 NaBH4 (550 mg, 14.7 mmol) was added to a solution of ethyl ester 
1.130 (2.38 g, 11.7 mmol) in EtOH (72 mL) at –78 °C and the mixture was stirred for 
10 min at that temperature and for 2 h at room temperature. The reaction was quenched 
with saturated aqueous NaHCO3 and the ethanol was removed under reduced pressure. 
The aqueous phase was extracted with EtOAc, the combined organic phases were 
washed with aqueous HCl (1 M), saturated aqueous NaHCO3 and brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resulting residue 
by flash column chromatography (pentane:EtOAC 5:1, Rf= 0.35) gave thiepane 1.131 
(800 mg, 3.92 mmol, 33%) as a colorless oil. 
Data for 1.131: 1H NMR (400 MHz, CDCl3): δ (ppm) = 4.36 (br, 1H, H-9), 4.17 (q, J = 7.1 
Hz, 2H, H-2), 2.98 – 2.88 (m, 3H, H-4,6,10), 2.86 – 2.78 (m, 1H, H-7), 2.77 – 2.69 (m, 
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1H, H-6), 2.58 – 2.51 (m, 1H, H-7), 2.38 – 2.25 (m, 2H, H-5,8), 2.13 – 2.03 (m, 1H, H-5), 
1.97 – 1.87 (m, 1H, H-8), 1.27 (t, J = 7.1 Hz, 2H, H-1). 13C-NMR (101 MHz, CDCl3): δ 
(ppm) = 176.4, 70.0, 61.0, 48.2, 38.1, 31.0, 27.2, 27.2, 14.3. IR (ATR): 𝜈max (cm−1) = 3471 
(m), 2923 (m), 1720 (vs), 1425 (m), 1368 (m), 1276 (m), 1207 (s), 1190 (s), 1156 (s), 
1076 (m), 1031 (s), 931 (w), 908 (w), 858 (w), 628 (w), 601 (w), 581 (w), 567 (w). HRMS 
(EI): calc. for C9H16O3S [M]+: 204.0815, found: 204.0816. 
 
 
 
Alkene 1.13237: NEt3 (2.08 mL, 15.1 mmol) and MsCl (0.93 mL, 12.0 mmol) were 
sequentially added to an ice cooled solution of thiepane 1.131 (1.23 g, 6.02 mmol) in 
CH2Cl2 (40 mL) and the mixture was stirred for 4 h at that temperature before the reaction 
was quenched with saturated aqueous NaHCO3 and extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure to give crude mesylate S1.2 (1.74 g) that was used in the next 
step without further purification. 
DBU (1.10 mL, 5.20 mmol) was added to a solution of crude mesylate S1.2 (1.74 g) in 
THF (35 mL) and the reaction was stirred at room temperature for 2 h. The reaction 
mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl and brine. 
The organic phase was dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (pentane:Et2O 97:3, 
Rf= 0.34) gave alkene 1.132 (873 mg, 4.68 mmol, 76% over 2 steps) as a colorless oil. 
Data for 1.132: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.17 (t, J = 6.8 Hz, 1H), 4.18 (q, 
J = 7.1 Hz), 3.03 – 2.99 (m, 2H), 2.80 – 2.74 (m, 2H), 2.67 – 2.62 (m, 4H), 1.29 (t, J = 
7.1 Hz, 3H. 13C-NMR (101 MHz, CDCl3): δ (ppm) = 167.9, 142.5, 135.9, 61.0, 32.6, 31.1, 
28.2, 27.1, 14.4. IR (ATR): 𝜈max (cm−1) = 2979 (w), 2907 (w), 2359 (w), 1703 (vs), 1645 
(w), 1442 (w), 1377 (w), 1283 (m), 1254 (s), 1205 (s), 1173 (w), 1154 (w), 1094 (w), 1057 
(m), 1029 (w), 921 (w), 864 (w), 752 (w), 668 (w), 628 (w), 601 (w), 582 (w), 568 (w). 
HRMS (EI): calc. for C9H14O2S [M]+: 186.0709, found: 186.0705. 
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Acid 1.133: An aqueous solution of LiOH (1 M, 40.3 mL, 40.3 mmol) was added to a 
solution of alkene 1.132 (150 mg, 0.805 mmol) in THF (53 mL) and the solution was 
stirred at room temperature for 17 h. The reaction acidified with aqueous HCl (1 M) and 
extracted with EtOAc. The combined organic phases were dried over Na2SO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (pentane:Et2O 3:2, Rf = 0.3) gave acid 1.133 (127 mg, 
0.799 mmol, 99%) as a colorless solid. 
Data for 1.133: 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.40 (br, 1H), 7.33 (t, J = 6.7 Hz, 
1H), 3.04 – 2.99 (m, 2H), 2.86 – 2.77 (m, 2H), 2.71 – 2.64 (m, 4H). 13C-NMR (101 MHz, 
CDCl3): δ (ppm) = 172.8, 145.7, 134.9, 32.8, 30.7, 28.2, 26.9. IR (ATR): 𝜈max (cm−1) = 
2359 (m), 1683 (m), 668 (m), 600 (m), 590 (m), 568 (vs). HRMS (EI): calc. for C7H10O2S 
[M]+: 158.0396, found: 158.0399. 
 
 
 
Allylic ester 1.134: DMF (1 drop) was added to an ice cooled solution of acid 1.133 
(107 mg, 0.676 mmol) and oxalyl chloride (0.08 mL, 0.946 mmol) in CH2Cl2 (5.5 mL) and 
the reaction mixture was stirred for 15 min at that temperature and for 1 h at room 
temperature. Evaporation of the volatiles under reduced pressure gave crude acid 
chloride S1.3 that was used in the next step without further purification. 
n-BuLi (2.36 M in hexanes, 0.30 mL, 0.686 mmol) was added dropwise to an ice cooled 
solution of allylic alcohol 1.133 (63 mg, 0.563 mmol) in THF (3.5 mL) and the solution 
was stirred for 30 min at 0 °C. The mixture was added to an ice cooled solution of crude 
acid chloride S1.3 in THF (5 mL) and the reaction was stirred at that temperature for 2 h. 
The reaction was quenched with MeOH (0.5 mL) and aqueous NaOH (1 M) and extracted 
with Et2O.The combined organic phases were dried over MgSO4 and concentrated under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
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(pentane:Et2O 95:5, Rf= 0.32) gave allylic ester 1.134 (36 mg, 0.143 mmol, 21% over 2 
steps) as a colorless oil. 
Data for 1.134: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.13 (t, J = 6.7 Hz, 1H), 6.07 (ddd, 
J = 5.6, 2.1, 0.8 Hz, 1H), 5.83 (dt, J = 5.7, 2.3 Hz, 1H), 5.71 (dtd, J = 7.3, 3.0, 2.2 Hz, 
1H), 3.02 – 2.96 (m, 2H), 2.85 – 2.78 (m, 1H), 2.78 – 2.72 (m, 2H), 2.66 – 2.61 (m, 4H), 
2.03 (ddd, J = 14.3, 7.6, 2.7 Hz, 1H), 1.85 (ddd, J = 14.4, 7.4, 5.2 Hz, 1H), 1.50 – 1.40 
(m, 1H), 1.32 (dq, J = 13.6, 7.4 Hz, 1H), 0.92 (t, J = 7.4 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3): δ (ppm) = 168.0, 142.6, 136.1, 128.8, 80.9, 46.1, 36.8, 32.7, 31.2, 28.5, 28.3, 
27.1, 12.2. IR (ATR): 𝜈max (cm−1) = 3050 (w), 2958 (m), 2925 (m), 2873 (w), 2358 (w), 
2333 (w), 2173 (w), 2148 (w), 2102 (w), 2048 (w), 2016 (w), 1968 (w), 1702 (vs), 1644 
(w), 1460 (w), 1439 (w), 1420 (w), 1379 (w), 1367 (w), 1337 (w), 1296 (w), 1283 (m), 
1252 (vs), 1204 (s), 1154 (m), 1093 (w), 1053 (m), 1021 (w), 968 (w), 943 (w), 911 (w), 
887 (w), 831 (w), 800 (w), 752 (m), 667 (w), 646 (w), 632 (w), 623 (w), 614 (w), 607 (w), 
597 (w), 580 (w), 570 (w), 556 (w). HRMS (EI): calc. for C14H20O2S [M]+: 252.1179, found: 
252.1177. 
 
 
 
Dioxanone 1.137: CDI (151 mg, 0.936 mmol) was added to a solution of acid 1.108 
(100 mg, 0.780 mmol) in THF (5 mL) and the reaction was stirred at room temperature 
for 17 h before it was diluted with saturated aqueous NaHCO3 and extracted with Et2O. 
The combined organic phases were dried over MgSO4 and concentrated under reduced 
pressure to give crude amide S1.4 that was used in the next step without further 
purification. 
n-BuLi (2.36 M in hexanes, 0.37 mL, 0.87 mmol) was added dropwise to an ice cooled 
solution of DIPA (0.12 mL, 0.87 mmol) in THF (5 mL) and the solution was stirred for 
30 min at 0 °C. The reaction mixture was cooled to –78 °C, t-BuOAc (0.12 mL, 
0.87 mmol) was added dropwise and the resulting solution was stirred at –78 °C for 
30 min. A solution of crude amide S1.4 in THF (5 mL) was added and the reaction mixture 
was allowed to warm to room temperature overnight before the reaction was diluted with 
saturated aqueous NH4Cl (5 mL) and aqueous HCl (1 M, 5 mL) and extracted with EtOAc. 
The combined organic phases were washed with brine, dried over MgSO4 and 
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concentrated under reduced pressure. Purification of the resulting residue gave crude -
keto ester S.1.5 (51 mg) that was used in the next step without further purification. 
H2SO4 (conc. 20 µL, 0.448 mmol) was added to an ice cooled solution of crude -keto 
ester S1.5 (51 mg) and Ac2O (0.7 mL, 7.41 mmol) in acetone (0.7 mL) and the reaction 
mixture was slowed to warm to room temperature overnight. The reaction was diluted 
with aqueous K2CO3 and stirred for 30 min at room temperature before it was extracted 
with EtOAc. The combined organic phases were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (pentane:Et2O 6:1, Rf= 0.3) gave dioxanone 1.137 (28 mg, 
0.133 mmol, 59%) as a colorless oil. 
Data for 1.137: 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.32 (t, J = 7.5 Hz, 1H), 5.45 (s, 
1H), 2.24 (p, J = 7.5 Hz, 4H), 1.71 (s, 6H), 1.08 – 1.01 (m, 6H). 13C-NMR (101 MHz, 
CDCl3): δ (ppm) = 165.4, 162.8, 139.3, 133.3, 106.1, 91.3, 25.1, 21.8, 19.8, 14.0, 13.7. 
IR (ATR): 𝜈max (cm−1) = 2970 (w), 2937 (w), 2876 (w), 2360 (w), 2340 (w), 1726 (vs), 
1633 (m), 1593 (m), 1457 (w), 1392 (m), 1376 (m), 1339 (m), 1280 (m), 1254 (m), 1206 
(m), 1147 (w), 1065 (w), 1039 (w), 1019 (w), 997 (w), 962 (w), 905 (w), 865 (w), 809 (w), 
695 (w), 668 (w), 601 (w), 590 (w), 568 (w), 560 (w). 
 
 
 
-Keto ester 1.136: A solution of dioxanone 1.137 (90 mg, 0.427 mmol) and allylic 
alcohol 1.125 (47 mg, 0.427 mmol) in PhMe (10 mL) was stirred at 100 °C overnight. 
Evaporation of the volatiles under reduced pressure and purification of the resulting 
residue by flash column chromatography (penatane:Et2O 99:1, Rf= 0.2) gave -keto ester 
1.136 (42 mg, 0.159 mmol, 37%) as a colorless oil. The product was obtained as mixture 
of tautomers. 
Data for 1.136: 1H NMR (400 MHz, CDCl3): δ (ppm) = 12.30 (s, 0H), 6.51 (d, J = 7.2 Hz, 
1H), 6.45 (t, J = 7.4 Hz, 0H), 6.10 (dd, J = 5.6, 2.1 Hz, 0H), 5.84 (dt, J = 5.2, 2.3 Hz, 0H), 
5.80 (dt, J = 5.2, 2.3 Hz, 1H), 5.73 (dt, J = 7.4, 2.4 Hz, 1H), 5.68 – 5.65 (m, 0H), 3.68 (s, 
1H), 3.66 (s, 2H), 2.78 (dddd, J = 8.9, 6.6, 4.8, 2.8 Hz, 1H), 2.29 (qd, J = 7.5, 3.4 Hz, 
5H), 2.20 (ddd, J = 15.0, 10.6, 7.2 Hz, 1H), 2.04 (ddd, J = 15.0, 7.6, 2.6 Hz, 1H), 1.81 
(ddd, J = 14.5, 7.4, 5.3 Hz, 1H), 1.45 – 1.40 (m, 1H), 1.35 – 1.24 (m, 2H), 1.08 (t, J = 7.6 
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Hz, 4H), 1.03 – 0.98 (m, 1H), 0.92 (dt, J = 11.5, 7.4 Hz, 9H). 13C-NMR (101 MHz, CDCl3): 
δ (ppm) = 193.9, 168.3, 146.2, 143.0, 142.7, 128.3, 81.4, 46.0, 45.4, 36.6, 28.4, 22.3, 
18.9, 13.9, 13.5, 12.2. IR (ATR): 𝜈max (cm−1) = 2965 (m), 2934 (m), 2875 (m), 2360 (w), 
2340 (w), 1735 (vs), 1671 (s), 1636 (m), 1461 (m), 1413 (m), 1366 (m), 1318 (m), 1298 
(m), 1262 (m), 1237 (m), 1191 (m), 1150 (m), 1094 (m), 1068 (m), 1035 (m), 975 (m), 
895 (w), 801 (m), 753 (w), 667 (w), 628 (w), 601 (w), 582 (w), 567 (w). HRMS (EI): calc. 
for C16H24O3 [M]+: 264.1720, found: 264.1719. 
 
 
 
α-Tropolone methyl ester (11)172: Methyl iodide (16.0 mL, 257 mmol) was added to a 
suspension of -tropolone (6.43 g, 52.7 mmol), potassium carbonate (21.8 g, 158 mmol) 
and dicyclohexyl-18-crown-6 (2.00 g, 5.37 mmol) in acetonitrile (265 mL). The resulting 
mixture was stirred at 82 °C overnight, then cooled to room temperature, filtered and 
concentrated. The resulting residue was redissolved in methylene chloride and washed 
with saturated aqueous potassium carbonate. The organic phase was dried over 
magnesium sulfate and concentrated under reduced pressure. Purification by flash 
column chromatography (ethyl acetate) gave α-tropolone methyl ester 11 as a white solid 
(6.26 g, 46.0 mmol, 87%). 
Data for 11: Rf: 0.2 (EtOAc); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.26-7.23 (m, 2H), 
7.09 (ddt, J = 10.9, 9.9, 1.0 Hz, 1H), 6.90-6.84 (m, 1H), 6.74 (dt, J = 9.9, 0.7 Hz, 1H), 
3.96 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 180.7, 165.6, 137.1, 136.8, 132.8, 
128.1, 112.5, 56.5. IR (ATR): 𝜈max (cm−1) = 3476 (br w), 2942 (w), 1624 (m), 1590 (s), 
1568 (vs), 1494 (s), 1470 (s), 1400 (m), 1278 (s), 1264 (s), 1231 (m), 1211 (vs), 1164 
(s), 1078 (s), 986 (m), 948 (m), 906 (m), 870 (m), 851 (w), 769 (s), 706 (s), 665 (m). 
HRMS (EI): calc. for C8H8O2 [M]+: 136.0524, found: 136.0515. 
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Bicycle 1032: A stirred solution of -tropolone methyl ester 11 (2.00 g, 14.7 mmol) in 
MeOH (160 mL) was irradiated at room temperature for 13 h using a medium pressure 
mercury lamp (150 W) in an immersion well photoreactor containing a Pyrex® filter. After 
evaporation of the solvent, the crude product was purified by flash column 
chromatography (hexanes:EtOAc 5:1) to afford bicycle 10 (1.05 g, 7.71 mmol, 52%) as 
a colorless oil. 
Data for 10: Rf: 0.4 (hexanes:EtOAc 5:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.69 
(dd, J = 5.8, 2.3 Hz, 1H), 5.98 (d, J = 5.7 Hz, 1H), 5.01 (s, 1H), 3.62 (d, J = 2.9 Hz, 1H), 
3.60 (s, 3H), 3.58 (t, J = 2.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 204.9, 
165.1, 155.6, 133.2, 100.9, 56.3, 54.5, 40.8. IR (ATR): 𝜈max (cm−1) = 2937 (br w), 1737 
(w), 1693 (vs), 1628 (vs), 1573 (w), 1453 (w), 1435 (w), 1342 (w), 1296 (s), 1259 (m), 
1208 (m), 1175 (m), 1150 (w), 1118 (w), 1078 (m), 1021 (s), 998 (m), 972 (w), 956 (m), 
930 (w), 898 (w), 851 (w), 790 (s), 748 (s), 708 (m). HRMS (EI): calc. for C8H8O2 [M]+: 
136.0524, found: 136.0520. 
 
 
 
Ketone 13: EtMgBr (3.0 M in Et2O, 15.31 mL, 45.92 mmol) was added dropwise to 
solution of CuI (4.37 g, 22.96 mmol) in Et2O (190 mL) cooled to –5 °C and stirred for 
30 min at that temperature. The solution was cooled to –78 °C and a solution of enone 
10 (1.56 g, 11.48 mmol) in Et2O (62 mL) was added dropwise. The reaction was stirred 
for 2 h at –78 °C before it was quenched with saturated aqueous NH4Cl and extracted 
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with Et2O. The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to give ketone 13, which was used in the next step 
without further purification. 
Enol ether S1: KOtBu (3.86 g, 34.44 mmol) was added to an ice cooled suspension of 
ethyl triphenylphosphonium bromide (12.78 g, 34.44 mmol) in THF (67 mL) and stirred 
for 30 min at that temperature. A solution of crude ketone 13 in THF (38 mL) was added 
dropwise and the reaction was stirred for 2 h at room temperature before it was quenched 
with saturated aqueous NH4Cl and extracted with Et2O. The organic phase was dried 
over MgSO4 and concentrated under reduced pressure to give crude enol S1 ether which 
was used in the next step without further purification. 
Ketone 14: A solution of p-TSA.H2O (360 mg, 1.89 mmol) in water (80 mL) was added 
to a solution of crude enol ether S1 in acetone (80 mL) and stirred for 2 h at room 
temperature. The reaction mixture was extracted with Et2O. The combined organic 
phases were washed with saturated aqueous NaHCO3 and brine and dried over MgSO4. 
Evaporation of the solvent and purification by flash column chromatography 
(hexanes:Et2O 94:6) afforded ketone 14 (1.12 g, 6.81 mmol, 59% over 3 steps, Z:E = 
10:1 mixture of diastereomers at the double bond) as a colorless oil. 
Data for 14: Rf: 0.4 (hexanes:Et2O 94:6); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 5.46 
(qt, J = 7.0, 1.7 Hz, 1H), 4.17 – 4.05 (m, 1H), 3.15 (ddd, J = 18.1, 8.7, 4.9 Hz, 1H), 2.73 
(ddd, J = 17.8, 5.6, 3.0 Hz, 1H), 2.69 – 2.60 (m, 2H), 2.20 (d, J = 15.7 Hz, 1H), 1.92 – 
1.81 (m, 1H), 1.23 (dq, J = 17.1, 6.9 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 207.6, 138.0, 120.0, 66.5, 51.2, 45.8, 37.7, 35.3, 27.8, 15.3, 
12.2. IR (ATR): 𝜈max (cm−1) = 2960 (m), 2918 (m), 1778 (s), 1724 (w), 1460 (w), 1381 (w), 
1170 (w), 1079 (m), 816 (w), 777 (w). HRMS (EI): calc. for C11H15O [M-H]+: 163.1117, 
found: 163.1118. 
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Vinyl triflate S2: KHMDS (0.5 M in toluene, 10.8 mL, 5.42 mmol) was added to a 
solution of ketone 14 in THF (36 mL) at –78 °C and stirred for 30 min at 0 °C before a 
solution of Comins’ reagent (2.13 g, 5.42 mmol) in THF (32 mL) was added slowly at –
78 °C. The solution was stirred for 2 h at 0 °C, quenched with saturated aqueous 
NaHCO3 and extracted with Et2O. The combined organic phases were washed with 
brine, dried over MgSO4 and concentrated. Purification by flash column chromatography 
(hexanes:NEt3 999:1) on silica gave vinyl triflate S2 (1.21 g, 4.07 mmol, 91%, 10:1 
mixture of diastereomers at the double bond) as a colorless liquid. 
Data for S2: Rf: 0.4 (hexanes); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 5.47 (d, J = 10.3 
Hz, 2H), 4.02 – 3.97 (m, 1H), 2.81 (d, J = 3.2 Hz, 1H), 2.64 (ddd, J = 16.7, 5.5, 2.4 Hz, 
1H), 2.04 (d, J = 15.1 Hz, 1H), 1.71 – 1.64 (m, 4H), 1.13 (pd, J = 7.2, 2.2 Hz, 2H), 0.87 
(t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 139.4, 135.1, 121.7, 119.0, 
51.2, 45.9, 38.3, 35.3, 26.3, 14.7, 12.0. IR (ATR): 𝜈max (cm−1) = 2962 (w), 2924 (w), 
2860 (w), 1623 (m), 1424 (s), 1382 (w), 1277 (w), 1248 (m), 1205 (s), 1180 (m), 
1138 (s), 1098 (w), 1076 (w), 1062 (w), 985 (w), 928 (s), 910 (m), 860 (s), 806 (m), 
769 (w), 717 (m), 670 (w). HRMS (EI): calc. for C12H15F3O332S [M]+: 296.0694, found: 
296.0701. 
 
 
Methyl ester 9: Pd(OAc)2 (36.6 mg, 0.163 mmol), PPh3 (85.4 mg, 0.326 mmol) and NEt3 
(1.13 mL, 8.14 mmol) were sequentially added to a stirred solution of vinyl triflate S2 
(1.21 g, 4.07 mmol) in DMF (70 mL) and MeOH (70 mL). The solution was purged with 
CO gas and stirred for 1 h at 50 °C under 1 atm CO pressure. The reaction mixture was 
cooled to room temperature and extracted with Et2O. The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated. Purification by flash column 
chromatography (hexanes:Et2O:NEt3 969:30:1) gave methyl ester 9 (742 mg, 3.60 mmol, 
88%) as a colorless liquid.  
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Data for 9: Rf: 0.3 (hexanes:Et2O 95:5); 1H-NMR (400 MHz, CDCl3): δ (ppm) =  6.81 (s, 
1H), 5.43 – 5.35 (m, 1H), 3.89 – 3.84 (m, 1H), 3.70 (s, 3H), 2.95 (d, J = 3.2 Hz, 1H), 2.58 
(ddd, J = 13.7, 5.7, 2.8 Hz, 1H), 1.98 (d, J = 15.0 Hz, 1H), 1.74 (dd, J = 6.8, 2.6 Hz, 3H), 
1.72 – 1.64 (m, 1H), 1.12 (p, J = 7.4 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 162.5, 148.9, 139.0, 138.0, 119.7, 51.3, 50.9, 46.1, 38.3, 36.0, 
26.2, 14.7, 12.0. IR (ATR): 𝜈max (cm−1) =2955 (m), 2859 (w), 1725 (s), 1604 (w), 
1459 (w), 1435 (m), 1380 (w), 1309 (m), 1276 (m), 1247 (m), 1213 (w), 1190 (w), 
1164 (m), 1125 (m), 1105 (m), 988 (w), 838 (s), 753 (m). HRMS (EI): calc. for C13H18O2 
[M]+: 206.1307, found: 206.1291. 
 
 
(1-chloroethyl)trimethylsilane (S3): s-BuLi (1.4 M in cyclohexane, 51.2 mL. 
71.66 mmol) was added slowly to a solution of (chloromethyl)trimethylsilane (10 mL, 
71.66 mmol) in THF (235 mL) at –78 °C and the reaction was stirred for 30 min before 
methyl iodide (4.4 mL, 71.66 mmol) was slowly added. The cloudy mixture was stirred 
for 20 min at that temperature and then warmed to room temperature. The reaction 
mixture was diluted with ether, washed five times with water and dried over MgSO4. Most 
of the solvent was first removed at 300 mbar on a rotary evaporator (bath temperature 
40 °C) and the residual solvent was distilled over a vigreux column to give (1-
chloroethyl)trimethylsilane S3 as a colorless liquid which was used in the next step 
without further purification. 
Thioether S4: Tetrabutylammonium bromide (1.39 g, 4.30 mmol), water (15 mL) and 
sodium sulphide nonahydrate (8.61 g, 35.83 mmol) were added to (1-chloroethyl)-
trimethylsilane S3 and the resulting mixture was stirred at 100 °C overnight in a pressure 
tube. The mixture was cooled to room temperature and extracted with hexanes. The 
combined organic phases were washed with saturated aqueous NaHCO3, dried over 
MgSO4 and evaporated to dryness. Purification by flash column chromatography 
(hexanes) gave thioether S4 (3.80 g, 16.19 mmol, 45% over 2 steps, 1:1 mixture of 
diastereomers) as a colorless liquid. 
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Data for S4: Rf: 0.3 (hexanes); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 2.06 (q, 
J = 7.2 Hz, 1H), 1.82 (q, J = 7.4 Hz, 1H), 1.34 (d, J = 7.5 Hz, 3H), 1.20 (d, J = 7.1 Hz, 
3H), 0.06 (s, 9H), 0.06 (s, 9H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 29.0, 22.0, 18.5, 
15.8, −2.8, −2.9. IR (ATR): 𝜈max (cm−1) = 2954 (m), 2924 (w), 2898 (w), 2863 (w), 
1446 (w), 1405 (w), 1372 (w), 1246 (s), 1147 (w), 1118 (w), 1052 (w), 1004 (w), 955 (w), 
830 (vs), 751 (s), 716 (m), 688 (m). HRMS (EI): calc. for C10H2632SSi2 [M]+: 234.1294, 
found: 234.1287. 
 
 
Sulfoxide 15: A solution of mCPBA (3.35 g, 19.47 mmol) in CH2Cl2 (42 mL) was added 
to a solution of thioether S4 (4.15 g, 17.69 mmol) in CH2Cl2 (42 mL) at −78 °C. After 
stirring at −78 °C for 30 min, the reaction was warmed to 0 °C and stirred at 0 °C for 
2 min. The reaction mixture was diluted with CH2Cl2, washed twice with saturated 
aqueous NaHCO3 and dried over MgSO4. Evaporation of the solvent under reduced 
pressure gave sulfoxide 15 as a colorless oil that was used without further purification. 
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Tricycle 17: A mixture of crude sulfoxide 15 (4.42 g) and DMPU (1.8 mL) was added 
dropwise to a solution of methyl ester 9 (604 mg, 2.93 mmol) in DMPU (4.3 mL) at 
100 °C. The reaction was stirred for further 10 min at 100 °C, cooled to room 
temperature, diluted with ether and washed with water and brine. The organic phase was 
dried over magnesium sulfate and evaporated to dryness. Flash column chromatography 
(hexanes:Et2O 94:6 and hexanes:Et2O 96:4) gave tricycle 17 (589 mg, 2.00 mmol, 68%) 
as a colorless oil that crystallized upon standing at –20 °C. 
Data for 17: Rf: 0.3 (hexanes:Et2O 94:6); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 5.39 (q, 
J = 6.3 Hz, 1H), 3.71 (q, J = 6.5, 6.1 Hz, 1H), 3.59 (s, 3H), 3.28 (d, J = 7.2 Hz, 1H), 
2.96 (q, J = 7.0 Hz, 1H), 2.90 (d, J = 5.0 Hz, 1H), 2.70 − 2.59 (m, 1H), 2.16 − 2.11 (m, 
1H), 2.02 (d, J = 15.1 Hz, 1H), 1.66 (q, J = 7.2 Hz, 1H), 1.55 (d, J = 3.2 Hz, 3H), 1.53 (d, 
J = 3.4 Hz, 3H), 1.27 (d, J = 7.1 Hz, 3H), 1.03 (p, J = 7.3 Hz, 2H), 0.80 (t, J = 7.3 Hz, 
3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 174.0, 142.5, 119.2, 61.2, 56.5, 51.6, 49.0, 
46.4, 45.2, 45.0, 39.0, 37.1, 26.9, 23.1, 15.0, 14.2, 12.2. IR (ATR): 𝜈max (cm−1) = 
2961 (m), 2940 (m), 2914 (m), 2884 (w), 2850 (w), 1725 (s), 1682 (w), 1456 (m), 
1432 (m), 1379 (m), 1328 (w), 1271 (s), 1226 (s), 1206 (s), 1191 (m), 1170 (m), 
1150 (w), 1115 (m), 1067 (s), 1023 (m), 986 (w), 942 (w), 912 (m), 846 (w), 796 (w), 
761 (m), 733 (m), 667 (w). HRMS (EI): calc. for C17H26O232S [M]+: 294.1654, found: 
294.1645. 
 
 
 
Alcohol S5: DIBAL-H (1 M in PhMe, 3.76 mL, 3.76 mmol) was added dropwise to a 
stirred solution of tricycle 17 (539 mg, 1.83 mmol) in CH2Cl2 (26 mL) at –78 °C and the 
185 
reaction was stirred for 1 h at –78 °C and 1 h at room temperature. The reaction was 
quenched by the addition of 1M HCl and stirred until a clear solution formed. The resulting 
mixture was extracted with CH2Cl2 and the combined organic phases were washed with 
brine, dried over MgSO4 and evaporated to dryness. Purification by flash column 
chromatography (hexanes: Et2O 75:25) gave alcohol S5 (454 mg, 1.70 mmol, 93%) as 
a colorless oil that solidified upon standing at –20 °C. 
Data for S5: Rf: 0.3 (hexanes:Et2O 75:25); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 5.49 
– 5.36 (m, 1H), 3.75 (q, J = 6.7 Hz, 1H), 3.62 – 3.45 (m, 2H), 3.06 (d, J = 7.0 Hz, 1H), 
2.90 (q, J = 7.1 Hz, 1H), 2.72 – 2.59 (m, 1H), 2.17 – 2.07 (m, 3H), 1.64 (d, J = 7.1 Hz, 
1H), 1.56 (dd, J = 6.8, 2.6 Hz, 3H), 1.48 (s, 1H), 1.40 (d, J = 6.7 Hz, 3H), 1.26 (d, J = 7.1 
Hz, 3H), 1.06 (p, J = 7.3 Hz, 2H), 0.81 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 143.8, 118.3, 65.1, 57.4, 56.1, 49.4, 46.9, 45.5, 45.1, 40.5, 35.7, 27.4, 23.8, 
15.2, 13.8, 12.3. IR (ATR): 𝜈max (cm−1) = 3411 (br), 2957 (s), 2919 (s), 2872 (m), 1447 
(s), 1376 (s), 1328 (w), 1268 (w), 1251 (w), 1229 (w), 1210 (w), 1119 (w), 1096 (w), 1033 
(s), 1009 (vs), 952 (w), 926 (w), 832 (m), 809 (w), 774 (m), 734 (m), 671 (m). HRMS (EI): 
calc. for C16H26O32S [M]+: 266.1704, found: 266.1700.671 (m). HRMS (EI): calc. for 
C16H26O32S [M]+: 266.1704, found: 266.1700. 
 
 
Aldehyde 18: Dess-Martin periodinane (1.51 g, 3.56 mmol) was added to a stirred 
solution of alcohol S5 (474 mg, 1.78 mmol) in CH2Cl2 (28 mL) and the resulting solution 
was stirred at room temperature for 2 h. Water (5 mL) and Na2S2O3 (1 g) were added 
and the mixture was stirred until it became a clear solution. The reaction was diluted with 
CH2Cl2 and the phases were separated. The organic layer was dried over MgSO4 and 
evaporated to dryness. Purification by flash column chromatography (hexanes: Et2O 
98:2) gave aldehyde 18 (353 mg, 1.33 mmol, 75%) as a colorless oil. 
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Data for 18: Rf: 0.2 (hexanes:Et2O 98:2); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 9.59 
(s, 1H), 5.54 – 5.44 (m, 1H), 3.71 (q, J = 6.7 Hz, 1H), 3.36 (d, J = 7.3 Hz, 1H), 3.00 (q, J 
= 7.1 Hz, 1H), 2.67 (d, J = 4.8 Hz, 1H), 2.56 – 2.45 (m, 1H), 2.24 – 2.18 (m, 1H), 2.12 (d, 
J = 15.5 Hz, 1H), 1.69 (q, J = 7.3 Hz, 1H), 1.61 (dd, J = 6.8, 2.8 Hz, 3H), 1.50 (d, J = 6.7 
Hz, 3H), 1.25 (d, J = 7.1 Hz, 3H), 1.06 (p, J = 7.3 Hz, 2H), 0.82 (t, J = 7.3 Hz, 3H). 13C-
NMR (100 MHz, CDCl3): δ (ppm) = 202.6, 140.7, 119.9, 63.6, 55.4, 49.7, 46.9, 45.1, 
44.1, 38.9, 36.5, 27.2, 23.2, 15.2, 13.6, 12.1. IR (ATR): 𝜈max (cm−1) = 2959 (m), 2924 (m), 
2874 (w), 2718 (w), 1712 (vs), 1448 (m), 1377 (m), 1320 (w), 1251 (w), 1251(w), 1226 
(w), 1125 (w) 1066 (w), 1031 (w), 987 (w), 835 (w), 775 (w), 667 (w) HRMS (EI): calc. 
for C16H24O32S [M]+: 264.1548, found: 264.1544. 
 
 
β-hydroxy ester S6: n-BuLi (2.21 M in hexanes, 0.89 mL, 1.96 mmol) was added an ice 
cooled solution of diisopropylamine (0.28 mL, 1.93 mmol) in THF (5.8 mL). The resulting 
solution was stirred at 0 °C for 30 min and then cooled to –78 °C. MeOAc (0.15 mL, 
1.86 mmol) was added dropwise and the reaction was stirred at –78 °C for 30 min. A 
solution of aldehyde 18 (246 mg, 0.930 mmol) in THF (4.3 mL) was added dropwise and 
the solution was stirred for 2 h at the same temperature before it was quenched with 
saturated aqueous NH4Cl and extracted with Et2O. The combined organic phases were 
washed with brine, dried over MgSO4 and evaporated to dryness to yield -hydroxy ester 
S6 that was used in the next step without further purification. 
β-keto ester 19: Dess-Martin periodinane (791 mg, 1.86 mmol) was added to a stirred 
solution of -hydroxyl ester S6 in CH2Cl2 (17 mL) and the resulting solution was stirred 
at room temperature for 2 h. Water (5 mL) and Na2S2O3 (1 g) was added and the mixture 
was stirred until it became a clear solution. The reaction was diluted with CH2Cl2 and the 
phases were separated. The organic layer was dried over MgSO4 and evaporated to 
dryness. Purification by flash column chromatography (hexanes: Et2O 92:8) gave β-keto 
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ester 19 (208 mg, 0.618 mmol, 66%, β-keto ester to enol ether = 1.4:1) as a colorless oil 
that solidifies upon standing at –20 °C. 
Data for 19: Rf: 0.2 (hexanes:Et2O 98:2); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 12.00 
(s, 1H), 5.45 (d, J = 6.7 Hz, 1H), 5.37 (d, J = 6.5 Hz, 1H), 4.96 (s, 1H), 3.72 (d, J = 3.6 
Hz, 7H), 3.66 (qd, J = 6.6, 3.7 Hz, 3H), 3.42 (s, 3H), 3.34 (d, J = 7.3 Hz, 1H), 3.26 (d, J 
= 7.3 Hz, 1H), 3.04 – 2.95 (m, 2H), 2.87 (d, J = 4.7 Hz, 1H), 2.58 (d, J = 4.5 Hz, 1H), 2.41 
(s, 3H), 2.13 – 1.97 (m, 5H), 1.66 (dd, J = 6.8, 2.6 Hz, 4H), 1.63 (d, J = 7.1 Hz, 2H), 1.59 
(dd, J = 6.8, 2.5 Hz, 4H), 1.57 – 1.46 (m, 9H), 1.32 (dd, J = 10.4, 7.1 Hz, 8H), 1.04 (ddt, 
J = 10.6, 7.4, 3.3 Hz, 5H), 0.81 (t, J = 7.3 Hz, 7H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 203.1, 179.8, 173.3, 167.8, 142.2, 142.0, 120.3, 119.4, 87.4, 67.8, 59.7, 57.6, 52.5, 
51.3, 49.6, 49.3, 48.1, 46.4, 46.1, 46.0, 45.3, 45.2, 45.2, 39.6, 39.2, 37.6, 37.5, 26.9, 
26.8, 23.3, 23.3, 15.5, 15.3, 13.9, 13.7, 12.2, 12.1. IR (ATR): 𝜈max (cm−1) = 2957 (m), 
2927 (m), 2874 (w), 1750 (m), 1700 (m), 1615 (s), 1443 (s), 1396 (m), 1378 (m), 1312 
(w), 1267 (m), 1226 (vs), 1196 (m), 1168 (m), 1133 (m), 1106 (w), 1058 (w), 1031 (m), 
942 (w), 835 (m), 803 (m), 775 (w), 733 (w), 708 (w), 680 (w). HRMS (EI): calc. for 
C19H28O332S [M]+: 336.1759, found: 336.1756. 
 
 
Vinylogous carbonate 20: SnCl4 (1 M in CH2Cl2, 0.12 mL, 0.120 mmol) was added 
dropwise to an ice-cooled solution of β keto ester 19 (200 mg, 0.594 mmol) in CH2Cl2 
(12 mL) and the resulting solution was stirred for 2 h at room temperature. The reaction 
was diluted with CH2Cl2, washed with water and brine, dried over MgSO4 and evaporated 
to dryness. Purification by flash column chromatography (hexanes: Et2O 80:20) gave 
vinylogous carbonate 20 (162 mg, 0.481 mmol) as a colorless oil that solidified upon 
standing at –20 °C. 
Data for 20: Rf: 0.3 (hexanes:Et2O 4:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.69 (s, 
1H), 3.68 (s, 3H), 3.57 (q, J = 6.6 Hz, 1H), 3.08 (q, J = 7.2 Hz, 1H), 2.85 (d, J = 7.9 Hz, 
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1H), 2.46 (dd, J = 14.1, 6.7 Hz, 1H), 2.35 (d, J = 2.7 Hz, 1H), 2.09 (ddt, J = 14.3, 11.6, 
7.1 Hz, 1H), 1.90 (ddd, J = 7.7, 4.7, 2.8 Hz, 1H), 1.77 – 1.68 (m, 2H), 1.45 (dd, J = 14.1, 
9.8 Hz, 1H), 1.34 (dd, J = 8.0, 3.0 Hz, 5H), 1.17 (d, J = 6.6 Hz, 3H), 1.00 (t, J = 7.4 Hz, 
3H), 0.86 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) =174.3, 166.8, 104.1, 
84.9, 67.8, 65.7, 50.8, 48.6, 48.2, 45.8, 45.4, 45.0, 44.7, 31.6, 28.5, 24.9, 13.1, 12.6, 9.5. 
IR (ATR): 𝜈max (cm−1) = 2960 (s), 2921 (s), 2874 (w), 1719 (vs), 1691 (s), 1637 (vs), 1459 
(w), 1434 (w), 1364 (w), 1273 (m), 1243 (m), 1226 (m), 1210 (m), 1186 (m), 1162 (s), 
1141 (s), 1101 (w), 1059 (m) 1036 (w), 1107 (w), 979 (m), 953 (w), 916 (w), 856 (vw), 
799 (w), 696 (vw).  HRMS (EI): calc. for C19H28O332S [M]+: 336.1759, found: 336.1731. 
 
 
Hippolachnin A (1): Raney® nickel (suspension in water 2800, Aldrich, 1 g) was added 
to a solution of vinylogous carbonate 20 (145 mg, 0.431 mmol) in THF (9 mL) and the 
resulting suspension was stirred at room temperature for 1 h. The mixture was filtered 
over celite and the resulting filtrate was washed with brine, dried over MgSO4 and 
evaporated to dryness. Purification by flash column chromatography (hexanes: EtOAc 
98:2 to 94:6) gave hippolachnin A 1 (104 mg, 0.339 mmol, 79%) as a colorless oil. 
Data for 1: Rf: 0.3 (hexanes:Et2O 4:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.56 (s, 
1H), 3.66 (s, 3H), 2.59 (d, J = 8.0 Hz, 1H), 2.43 (dd, J = 13.8, 6.4 Hz, 1H), 1.99 (ddd, J 
= 9.9, 7.2, 5.0 Hz, 1H), 1.79 (ddt, J = 20.9, 18.5, 6.9 Hz, 4H), 1.69 – 1.60 (m, 2H), 1.51 
(dq, J = 14.3, 7.3 Hz, 1H), 1.43 – 1.37 (m, 1H), 1.37 – 1.27 (m, 3H), 1.02 (t, J = 7.4 Hz, 
3H), 0.87 (t, J = 7.3 Hz, 6H), 0.79 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 181.3, 167.4, 104.3, 83.6, 56.8, 53.0, 50.6, 49.5, 47.6, 46.4, 45.2, 30.9, 28.4, 
24.7, 23.4, 13.2, 11.9, 9.8, 8.8. IR (ATR): 𝜈max (cm−1) = 2961 (s), 2925 (m), 2876 (w), 
1717 (s), 1688 (s), 1633 (vs), 1461 (m), 1433 (m), 1365 (m), 1335 (w), 1267 (m), 1214 
(m), 1183 (m), 1151 (s), 1139 (s), 1083 (w), 1038 (m), 979 (m), 970 (m), 908 (w), 852 
(w), 799 (m), 726 (w). HRMS (EI): calc. for C19H30O3 [M]+: 306.2195, found: 306.2189.  
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Ester S7: EtMgBr (3 M in Et2O, 0.33 mL, 0.990 mmol) was added dropwise to a solution 
of CuI (93 mg, 0.488 mmol) in Et2O (4 mL) cooled to –5 °C and stirred for 30 min at that 
temperature. The solution was cooled to –78 °C and a solution of methyl ester 9 (50 mg, 
0.243 mmol) in dry Et2O (1.3 mL) was added dropwise. The reaction mixture was stirred 
for 2 h at –78 °C before it was quenched with saturated aqueous NH4Cl and extracted 
with Et2O. The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to give ester S7 which was used in the next step 
without further purification. 
Alkene S8: n-BuLi (2.36 M in hexanes, 0.23 mL, 0.548 mmol) was added to an ice 
cooled solution of diisopropylamine (75 µL, 0.532 mmol) in THF (1 mL). The resulting 
solution was stirred at 0 °C for 30 min and then cooled to –78 °C. A solution of freshly 
prepared S7 in THF (4.3 mL) was added dropwise and the reaction was stirred for 45 min 
at –78 °C. Ethyl iodide (37 µL, 0.462 mmol) was added and the reaction was stirred for 
2 h at –78 °C before being quenched with saturated aqueous NH4Cl and extracted with 
Et2O. The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to give alkene S8 which was used in the next step 
without further purification. 
Lactone S9: A solution of crude alkene S8 and pTSA.H2O (46 mg, 0.243 mmol) in DCE 
(5.3 mL) was stirred at 84 °C for 2 h. The solution was cooled to room temperature and 
extracted with Et2O. The combined organic phases were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification by flash column 
chromatography (hexanes: Et2O 9:1) gave lactone S9 (21 mg, 0.085 mmol, 35% over 3 
steps) as a colorless oil. 
190 
Data for S9: Rf: 0.4 (hexanes:Et2O 9:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 2.71 (d, 
J = 8.2 Hz, 1H), 2.32 (dd, J = 13.7, 6.2 Hz, 1H), 2.05 − 1.95 (m, 1H), 1.93 − 1.84 (m, 2H), 
1.83 − 1.73 (m, 2H), 1.67 − 1.57 (m, 3H), 1.42 − 1.29 (m, 4H), 1.00 (t, J = 7.5 Hz, 3H), 
0.89 (t, J = 7.3 Hz, 6H), 0.82 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
182.5, 96.2, 51.9, 49.6, 49.3, 47.6, 46.7, 45.0, 31.0, 28.3, 24.8, 21.7, 13.2, 11.6, 9.33, 
9.31. IR (ATR): 𝜈max (cm−1) = 2962 (m), 2925 (m), 2876 (w), 2858 (w), 1753 (s), 
1461 (m), 1380 (w), 1311 (w), 1214 (m), 1185 (m), 1145 (w), 1113 (m), 949 (s), 931 (m), 
860 (w), 784 (w), 740 (w), 617 (w), 511 (m). HRMS (EI): calc. for C16H26O2 [M]+: 
250.1933, found: 250.1930. 
 
1H- and 13C-NMR chemical shifts in CDCl3 of natural vs. synthetic hippolachnin A (1). 
No. 
1H-NMR 
Isolated 
500 MHz, CDCl3 
[ppm] 
1H-NMR Synthetic 
400 MHz, CDCl3 
[ppm] 
13C-NMR 
Isolated 
125 MHz, 
CDCl3 
[ppm] 
13C-NMR 
Synthetic 
100 MHz, 
CDCl3 
[ppm] 
1   167.3 167.4 
2 4.56 (s, 1H) 4.56 (s, 1H) 83.5 83.6 
3   181.1 181.3 
4   56.6 56.8 
5 
2.59 (d, J = 
8.0 Hz, 1H) 
2.59 (d, J = 8.0 Hz, 1H) 49.4 49.5 
6   104.2 104.3 
7a 
2.44 (q, J= 
7.5 Hz, 1H) 
2.43 (dd, J = 13.8 Hz, 
6.4 Hz, 1H) 
45.1 45.2 
7b 1.40 (m, 1H)a 1.39 (m, 1H)   
8 1.98 (m, 1H) 
1.99 (ddd, J = 9.9, 7.2, 
5.0 Hz, 1H) 
47.5 47.6 
9 1.79 (m, 1H) 1.79 (m, 1H) 46.3 46.4 
10 1.82 (m, 1H) 1.81 (m, 1H) 52.9 53.0 
11a 1.64 (m, 1H) 1.64 (m, 1H) 24.6 24.7 
11b 1.32 (m, 1H) 1.32 (m, 1H)   
12 
0.88 (t, J = 
7.5 Hz, 3H) 
0.87 (t, J = 7.3 Hz, 3H) 11.8 11.9 
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13a 1.75 (m, 1H) 1.75 (m, 1H) 23.3 23.4 
13b 1.52 (m, 1H) 
1.51 (dq, J = 14.3, 
7.3 Hz, 1H) 
  
14 
0.80 (t, J = 
7.5 Hz, 3H) 
0.79 (t, J = 7.3 Hz, 3H) 8.6 8.8 
15a 1.82 (m, 1H) 1.82 (m, 1H) 30.8 30.9 
15b 1.67 (m, 1H) 1.66 (m, 1H)   
16 
1.02 (t, J = 
7.5 Hz, 3H) 
1.02 (t, J = 7.4 Hz, 3H) 9.6 9.8 
17a 1.30 (m, 1H) 1.32 (m, 1H) 28.3 28.4 
17b 1.30 (m, 1H) 1.31 (m, 1H)   
18 
0.88 (t, J = 
7.5 Hz, 3H) 
0.87 (t, J = 7.3 Hz, 3H) 13.0 13.2 
19 3.66 (s, 3H) 3.66 (s, 3H) 50.4 50.6 
a Carreira20 et al. already reported a erroneously-reported H-7b proton shift of 1.32 ppm 
in the table of the isolation paper by S.-J. Piao et al.4 The shift of 1.40 ppm is taken 
directly from the reported spectrum 
 
 
 
 
Lactone 1.143: A solution of tetrahydrothiophene 1.139 (10.0 mg, 0.034 mmol) and 
pTSA.H2O (6.4 mg, 0.034 mmol) in DCE (0.74 mL) was stirred for 2 h at 84 °C. After 
cooling to room temperature the reaction mixture was diluted with H2O and extracted with 
Et2O, the combined organic phases were dried over MgSO4 and concentrated under 
reduced pressure. Purification by flash column chromatography (hexanes:Et2O 94:6-
92:8) gave lactone 1.143 (8.6 mg, 0.307 mmol, 90%) as a colorless oil. 
Data for 1.143: Rf= 0.3 (hexanes:Et2O 92:8) 1H NMR (400 MHz, CDCl3): δ (ppm) 3.85 
(q, J = 6.6 Hz, 1H), 3.14 (q, J = 7.1 Hz, 1H), 2.91 (d, J = 7.3 Hz, 1H), 2.53 (d, J = 2.4 Hz, 
1H), 2.38 (dd, J = 14.2, 6.3 Hz, 1H), 2.10 – 2.05 (m, 2H), 1.72 (qd, J = 7.4, 3.6 Hz, 2H), 
1.56 – 1.45 (m, 2H), 1.39 – 1.31 (m, 5H), 1.19 (d, J = 6.7 Hz, 3H), 0.98 (t, J = 7.4 Hz, 
3H), 0.88 (t, J = 7.4 Hz, 3H). δ (ppm) = 13C-NMR (101 MHz, CDCl3): δ (ppm) = 177.8, 
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97.3, 63.8, 62.1, 49.3, 48.1, 46.3, 44.9, 44.3, 43.7, 32.2, 28.4, 24.9, 13.0, 12.7, 9.1. IR 
(ATR): 𝜈max (cm−1) = 2960 (m), 2924 (m), 1755 (vs), 1458 (m), 1378 (w), 1318 (w), 1246 
(m), 1152 (w), 1126 (w), 1102 (w), 974 (m), 935 (m). HRMS (EI): calc. for C16H24O2S 
[M]+: 280.1492, found: 280.1493. 
 
 
 
Sulfone 1.140a and 1.140b: A solution of mCPBA.H2O (77%, 30 mg, 0.132 mmol) in 
CH2Cl2 (2.0 mL) was added to an ice cooled solution of vinylogous carbonate 1.139 
(20.0 mg, 0.059 mmol) in CH2Cl2 (1 mL) and the reaction was stirred at 0 °C for 30 min 
and at room temperature overnight. The mixture was diluted with CH2Cl2 and washed 
with aqueous Na2S2O3, saturated aqueous NaHCO3 and brine. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure. Purification 
of the resulting residue by flash column chromatography (hexanes:EtOAc 3:1) gave 
sulfone 1.140a (10.9 mg, 0.030 mmol, 50%) and sulfone 1.140b (9.1 mg, 0.025 mmol, 
42%) as a colorless oils. 
Data for 1.140a: Rf= 0.25 (hexanes:Et2O 92:8) 1H NMR (400 MHz, CDCl3): δ (ppm) = 
5.40 (s, 1H), 4.56 (q, J = 6.8 Hz, 1H), 3.63 (s, 3H), 3.41 (d, J = 8.2 Hz, 1H), 3.20 (qd, J 
= 7.6, 1.4 Hz, 1H), 2.22 (dd, J = 13.7, 6.0 Hz, 1H), 2.11 (ddd, J = 8.4, 6.7, 1.9 Hz, 1H), 
2.05 – 1.93 (m, 1H), 1.72 (dq, J = 14.8, 7.4 Hz, 1H), 1.70 – 1.56 (m, 6H), 1.49 – 1.33 (m, 
3H), 1.20 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.5 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H). 13C-NMR 
(101 MHz, CDCl3): δ (ppm) = 177.6, 167.6, 101.2, 89.8, 63.0, 56.1, 54.2, 52.3, 51.2, 
48.6, 48.2, 48.0, 45.4, 30.4, 27.8, 17.1, 13.2, 9.6, 5.7. IR (ATR): 𝜈max (cm−1) = 2958 (m), 
1699 (m), 1623 (s), 1458 (w), 1363 (w), 1306 (m), 1240 (w), 1191 (w), 1166 (w), 1119 
(vs), 1087 (w), 1064 (w), 951 (w), 829 (w), 758 (w). HRMS (EI): calc. for C19H28O5S [M]+: 
368.1652, found:368.1652. 
Data for 1.140b: Rf= 0.6 (hexanes:Et2O 92:8) 1H NMR (400 MHz, CDCl3): δ (ppm) = 
4.68 (s, 1H), 3.68 (s, 3H), 3.24 (q, J = 6.8 Hz, 1H), 3.13 (qd, J = 7.3, 1.7 Hz, 2H), 2.51 
(dd, J = 14.1, 6.6 Hz, 1H), 2.25 (dd, J = 3.2, 1.8 Hz, 1H), 2.19 (ddd, J = 11.5, 5.8, 2.8 Hz, 
1H), 2.08 (ddd, J = 12.0, 9.3, 5.8 Hz, 1H), 1.73 (ddp, J = 21.7, 14.3, 7.4 Hz, 2H), 1.45 – 
1.34 (m, 6H), 1.31 (d, J = 6.8 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 7.3 Hz, 3H). 
193 
13C-NMR (101 MHz, CDCl3): δ (ppm) = 173.7, 166.3, 104.9, 85.7, 60.6, 55.5, 55.4, 54.8, 
51.0, 48.7, 46.3, 46.0, 45.0, 31.25, 28.3, 17.5, 13.1, 9.4, 5.9. IR (ATR): 𝜈max (cm−1) = 
2957 (m), 2877 (w), 1717 (s), 1638 (s), 1457 (m), 1436 (m), 1377 (w), 1310 (s), 1248 
(w), 1232 (w), 1181 (m), 1168 (m), 1124 (s), 1107 (m), 1084 (w), 1053 (m), 1011 (w), 
980 (w), 918 (w), 812 (w), 764 (w), 730 (w). HRMS (EI): calc. for C19H28O5S [M]+: 
368.1652, found:368.1649. 
 
 
 
Sulfoxide 1.141: A solution of mCPBA.H2O (77%, 14.8 mg, 0.066 mmol) in CH2Cl2 
(2.0 mL) was added to a stirred solution of vinylogous carbonate 1.139 (20.0 mg, 
0.059 mmol) in CH2Cl2 (1 mL) at –78 °C and the reaction was stirred at that temperature 
for 45 min. The mixture was diluted with aqueous Na2S2O3 and extracted with CH2Cl2. 
The combined organic phases were washed with saturated aqueous NaHCO3 and brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (hexanes:EtOAc 1:2) gave sulfoxide 1.141 
(20.3 mg, 0.058 mmol, 98%) as a colorless oil. The product was obtained as a 5:1 
mixture of diastereoisomers. 
Data for 1.141: Rf= 0.3 (hexanes:Et2O 92:8) 1H NMR (400 MHz, CDCl3): δ (ppm) = 4.77 
(s, 1H), 4.63 (s, 0H), 3.68 (s, 0H), 3.67 (s, 3H), 3.39 (t, J = 7.7 Hz, 0H), 3.26 (qd, J = 7.3, 
2.9 Hz, 1H), 3.13 (q, J = 7.0 Hz, 1H), 3.00 (q, J = 6.9 Hz, 0H), 2.72 (d, J = 7.9 Hz, 1H), 
2.56 – 2.44 (m, 2H), 2.36 (ddd, J = 8.2, 5.1, 3.1 Hz, 0H), 2.05 (dddd, J = 23.3, 11.4, 9.6, 
5.9 Hz, 1H), 1.91 (ddd, J = 8.0, 5.2, 2.8 Hz, 1H), 1.82 – 1.63 (m, 3H), 1.41 – 1.34 (m, 
5H), 1.32 (d, J = 7.3 Hz, 4H), 0.98 (t, J = 7.4 Hz, 4H), 0.86 (t, J = 7.4 Hz, 4H). 13C-NMR 
(101 MHz, CDCl3): δ (ppm) = 173.9, 166.5, 104.5, 86.2, 60.2, 58.0, 57.8, 56.9, 50.9, 
48.2, 46.8, 45.4, 45.3, 31.3, 28.2, 13.1, 11.1, 10.0, 9.5. IR (ATR): 𝜈max (cm−1) = 3478 (br), 
2962 (m), 2927 (m), 2875 (w), 1713 (s), 1687 (m9, 1635 (s), 1458 (m), 1435 (m), 1373 
(m), 1280 (m9, 1224 (m), 1177 (s), 1159 (m), 1044 (vs), 1008 (m), 879 (m), 917 (m), 877 
(w), 816 (w), 730 (m), 689 (w). HRMS (EI): calc. for C19H27O3S [M]+: 352.1703, found: 
352.1700. 
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6.3 Experimental data for chapter II 
 
Silyl ether 2.105: TIPSCl (11 mL), 51.87 mmol) was added to a stirred solution of 
imidazole (7.10 g, 104 mmol) and m-cresol (6.25 mL, 59.70 mmol) in DMF (25 mL) and 
the reaction was stirred at room temperature for 20 h before it was poured into a mixture 
of Et2O (50 mL), hexanes (50 mL) and 1M aqueous H2SO4 (75 mL). The organic layer 
was separated and washed three times with 1M aqueous NaOH and brine. Drying of the 
solvent over Na2SO4 and removal of the solvent under reduced pressure gave silyl ether 
2.105 (13.1 g, 49.5 mmol, 95%) as a colorless oil. 
Data for 2.105: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.09 (t, J = 7.7 Hz, 1H), 6.77 – 
6.64 (m, 3H), 2.30 (s, 3H), 1.32 – 1.19 (m, 3H), 1.10 (d, J = 7.3 Hz, 18H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 156.1, 139.4, 129.1, 121.9, 120.8, 116.9, 21.6, 18.1, 12.8. IR 
(ATR): 𝜈max (cm−1) = 2944 (m), 2893 (w), 2867 (m), 1304 (m), 1586 (m), 1487 (s), 1463 
(m), 1384 (w), 1368 (w), 1280 (vs), 1165 (s), 1158 (s), 1071 (w), 1006 (m), 996 (w), 956 
(s), 920 (w), 882 (s), 859 (w), 813 (s), 776 (s), 734 (w), 688 (vs), 680 (s), 660 (m). HRMS 
(EI): calc. for C16H28OSi [M]+: 264.1909, found: 264.1906. 
 
 
 
Silyl enol ether 2.10456: Li (4.34 g, 6.21 mmol) was added to a solution of THF 
(285 mL), t-BuOH (64 mL) and NH3 (500 mL) at –78 °C and the mixture was stirred until 
all metal was dissolved. Silyl ether 2.105 (27.4 g, 104 mmol) was added slowly added 
and the reaction was stirred at –30 °C for 1 h. The solution was recooled to –78 °C and 
t-BuOH (30 mL) was added. After stirring for 30 min at –30 °C the solution was again 
cooled to –78 °C and NH4Cl (32 g) was added portionwise until the blue colour 
disappeared. The mixture was slowly warmed to room temperature and the ammonia 
was evaporated under a slight stream of nitrogen. The reaction was diluted with H2O and 
extracted with pentane. The organic phase was dried over Na2SO4 and the solvent was 
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removed under reduced pressure to give silyl enol ether 2.104 (26 g, 97.6 mmol, 94%) 
as a colorless oil.  
Data for 2.104: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 5.36 (tp, J = 3.2, 1.6 Hz, 1H), 4.85 
(tq, J = 3.6, 1.3 Hz, 1H), 2.72 (tdq, J = 6.3, 3.1, 1.7 Hz, 2H), 2.64 – 2.55 (m, 2H), 1.69 (s, 
3H), 1.19 – 1.12 (m, 3H), 1.10 – 1.07 (m, 19H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
148.2, 131.1, 118.6, 100.1, 35.5, 27.4, 23.1, 18.2, 12.8. IR (ATR): 𝜈max (cm−1) = 3040 
(w), 2944 (w), 2891 (w), 2866 (m), 2822 (w), 1699 (w), 1667 (w), 1463 (w), 1384 (w), 
1346 (w), 1240 (w), 1217 (s), 1137 (s), 1071 (w), 1014 (w), 996 (w), 960 (w), 936 (w), 
927 (w), 882 (s), 822 (w), 776 (m), 682 (m). HRMS (EI): calc. for C16H30OSi [M]+: 
266.2066, found: 266.2061. 
 
 
 
Diol 2.10156: Methansulfonamide (2.36 g, 24.84 mmol) was added to a solution of 
ADmix(50.0 g) in t-BuOH (93 mL), MTBE (47 mL) and H2O (142 mL) and the resulting 
solution was stirred for 15 min at room temperature before it was cooled to –8 °C. Silyl 
enol ether 2.104 (9.37 g, 35.17 mmol) was added and the reaction was stirred at–8 °C 
for 7 d, diluted with H2O and extracted with EtOAc. The combined organic phases were 
sequentially washed with 10% aqueous Na2S2O3, saturated NaHCO3 and brine and dried 
over MgSO4. Removal of the solvent under reduced pressure and purification of the 
resultant residue by flash column chromatography (EtOAc:hexanes 1:1, Rf = 0.4) gave 
diol 2.101 (4.42 g, 14.71 mmol, 42%, 77% brsm, 25% ee) as a colourless oil. 
Data for 2.101: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.72 – 4.62 (m, 1H), 3.56 (t, J = 
5.0 Hz, 1H), 2.39 – 2.12 (m, 6H), 1.22 (s, 3H), 1.16 – 1.09 (m, 3H), 1.08 – 1.01 (m, 18H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 148.2, 98.2, 72.4, 72.0, 41.7, 29.7, 25.0, 18.1, 
12.7. IR (ATR): 𝜈max (cm−1) = 3409 (m, br), 2946 (m), 2867 (m), 2361 (w), 1715 (m), 1659 
(s), 1464 (w), 1377 (w), 1325 (w), 1257 (m), 1201 (m), 1165 (w), 1060 (m), 968 (w), 950 
(w), 884 (m), 685 (w). HRMS (EI): calc. for C16H32O3Si [M]+: 300.2121, found: 300.2119. 
[𝛂]𝑫
𝟐𝟎 = +1.6 (c = 0.06) 
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Acetonide 2.10756: PPTS (307 mg, 1.21 mmol) was added to a stirred solution of diol 
2.101 (7.30 g, 24.3 mmol) and 2,2-DMP (29.2 mL) in DMF (245 mL) and the solution was 
stirred for 2 h at room temperature before it was quenched with NEt3 (18.2 mL). The 
reaction was diluted with aqueous NaHCO3 and extracted with Et2O. The combined 
organic phases were washed with brine and dried over Na2SO4. Removal of the solvent 
under reduced pressure and purification by flash column chromatography 
(EtOAc:hexanes 5:95, Rf = 0.4) gave acetonide 2.107 (6.28 g, 18.4 mol, 76%) as a 
colourless oil.  
Data for 2.107: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.67 (dd, J = 2.2, 1.2 Hz, 1H), 
3.93 (dt, J = 3.4, 1.6 Hz, 1H), 2.46 – 2.33 (m, 1H), 2.14 (dddd, J = 14.4, 5.4, 3.6, 1.6 Hz, 
1H), 1.84 (ddd, J = 16.6, 6.0, 1.5 Hz, 1H), 1.79 – 1.67 (m, 1H), 1.37 (d, J = 3.5 Hz, 6H), 
1.32 (s, 3H), 1.21 – 1.11 (m, 3H), 1.10 – 1.05 (m, 18H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 151.2, 107.6, 107.2, 80.1, 77.3, 27.9, 27.7, 26.6, 24.4, 24.3, 18.2, 18.1, 12.7. IR 
(ATR): 𝜈max (cm−1) = 2943 (m), 2893 (w), 2867 (m), 2361 (w), 1663 (m), 1464 (w), 1374 
(w), 1326 (w), 1297 (w), 1239 (w), 1208 (s), 1191 (w), 1167 (w), 1132 (w), 1086 (s), 1066 
(w), 1006 (m), 991 (m), 956 (w), 908 (w), 883 (s), 860 (w), 826 (w), 815 (w), 784 (w), 757 
(w), 682 (m), 665 (w). HRMS (EI): calc. for C16H32O3Si [M]+: 340.2434, found: 340.2424. 
[𝛂]𝑫
𝟐𝟎 = +24 ° (c = 0.01 g/mL). 
 
 
 
Ketone 2.10056: Pd(OAc)2 (4.14 g, 18.44 mmol) was added to a solution of acetonide 
2.107 (6.28 g, 18.44 mmol) in DMSO (13.7 mL). The reaction was set under vacuum and 
backfilled with O2 for three cycles and stirred at room temperature overnight before it was 
submitted to flash column chromatography (EtOAc:hexanes 15:85, Rf = 0.2) to give 
ketone 2.100 (2.67 g, 14.65 mmol, 79%) as a colorless oil. 
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Data for 2.100: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.75 (dd, J = 10.2, 3.7 Hz, 1H), 
6.08 (dd, J = 10.2, 1.1 Hz, 1H), 4.41 (dd, J = 3.8, 1.1 Hz, 1H), 2.84 (d, J = 16.2 Hz, 1H), 
2.49 (d, J = 16.3 Hz, 1H), 1.42 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = 197.1, 143.9, 130.7, 110.3, 80.7, 76.1, 47.5, 28.5, 28.4, 26.1. IR 
(ATR): 𝜈max (cm−1) = 3362 (w, br), 2985 (w), 2936 (w), 1681 (s), 1459 (w), 1380 (m), 1312 
(w), 1270 (w), 1233 (s), 1212 (m), 1180 (w), 1160 (w), 1144 (w), 1109 (w), 1082 (m), 
1046 (s), 1020 (m), 988 (w), 956 (w), 944 (w), 894 (w), 866 (w), 830 (m), 807 (w), 772 
(w), 705 (w), 668 (w). HRMS (EI): calc. for C10H14O3 [M]+: 182.0943, found: 182.0935. 
[𝛂]𝑫
𝟐𝟎 = +12 ° (c = 0.01 g/mL). 
 
 
 
Vinyl iodide 2.102: A solution of iodine (11.18 g, 44.01 mmol) in CH2Cl2 (45 mL) and 
pyridine (11.83 mL) was added slowly to a solution of ketone 2.100 (2.67 g, 14.65 mmol) 
and DMAP (1.80 g, 14.65 mmol) in CH2Cl2 (100 mL) and the resulting solution was 
stirred for 36 h at room temperature in the dark before it was diluted with CH2Cl2 and 
washed with a 20% aqueous solution of Na2S2O3, 1M aqueous HCl and brine. The 
organic phase was dried over Na2SO4 and the solvent was removed under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 1:5, Rf = 0.3) gave vinyl iodide 2.102 (2.83 g, 9.18 mmol, 63%, 73% 
brsm) as a colorless oil). 
Data for 2.102: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.51 (d, J = 3.9 Hz, 1H), 4.41 (d, 
J = 3.8 Hz, 1H), 3.12 (d, J = 16.1 Hz, 1H), 2.70 (d, J = 16.1 Hz, 1H), 1.46 (d, J = 0.8 Hz, 
3H), 1.43 (s, 3H), 1.38 – 1.35 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 190.1, 
152.9, 110.9, 106.5, 81.2, 78.6, 45.9, 28.7, 28.5, 26.1. IR (ATR): 𝜈max (cm−1) = 2987 (w), 
2935 (w), 1693 (s), 1599 (w), 1459 (w), 1377 (m), 1327 (w), 1296 (w), 1269 (w), 1235 
(s), 1215 (s), 1181 (m), 1145 (w), 1113 (w), 1092 (m), 1053 (m), 1035 (m), 986 (w), 949 
(w), 924 (w), 892 (w), 842 (w), 781 (w), 729 (w). HRMS (EI): calc. for C10H13IO3 [M]+: 
307.9909, found: 307.9908. [𝛂]𝑫
𝟐𝟎 = –17 ° (c = 0.05 g/mL). 
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Allylic alcohol 2.108: BH3.SMe2 (0.87 mL, 9.18 mmol) was added dropwise to an ice-
cooled solution of (R)-CBS catalyst (1.27 g, 4.58 mmol) in THF (126 mL) and the solution 
was stirred for 15 min at that temperature before a solution of vinyl iodide 2.102 (2.83 g, 
9.18 mmol) in THF (35 mL) was slowly added. The reaction was stirred at 0 °C for 2 h 
before it was quenched with MeOH and poured into brine and extracted with EtOAc. The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. Purification of the resultant residue by flash column chromatography 
gave allylic alcohol 2.108 (1.81 g, 5.84 mmol, 64%, 95% ee) as a colorless oil. 
Data for 2.108: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.43 (d, J = 3.6 Hz, 1H), 4.17 (dd, 
J = 3.6, 0.8 Hz, 1H), 4.12 (dt, J = 9.2, 4.3 Hz, 1H), 3.32 (d, J = 10.0 Hz, 1H), 2.36 (dd, J 
= 14.6, 3.8 Hz, 1H), 2.10 (dd, J = 14.6, 4.7 Hz, 1H), 1.45 (s, 6H), 1.37 (s, 3H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 137.1, 110.7, 107.4, 79.4, 79.1, 72.7, 39.7, 29.2, 28.9, 
26.3. IR (ATR): 𝜈max (cm−1) = HRMS (EI): calc. for C10H15IO3I [M]+: 310.0066, found: 
310.0056. [𝛂]𝑫
𝟐𝟎 = –105.9 (c = 0.03) 
 
The enantiomeric excess was determined using chiral HPLC (chiralpak Od-h) i-PrOH:n-
heptane 0.5:99.5-2:98 (over 30 min, 1 mL/min). 
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Triol 2.109: Aqueous 1M HCl (3.7 mL) was added to a stirred solution of vinyl iodide 
2.108 (575 mg, 1.85 mmol) in MeOH (7.4 mL) and the solution was stirred overnight at 
room temperature in the dark. The reaction mixture was directly submitted to flash 
column chromatography (EtOAc) to give triol 2.109 (455 mg, 1.68 mmol, 91%) as a 
colorless oil. 
Data for 2.109: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 6.40 (dd, J = 3.7, 0.8 Hz, 1H), 
4.04 (tt, J = 5.4, 1.0 Hz, 1H), 3.73 (dt, J = 3.7, 0.9 Hz, 1H), 2.05 (dd, J = 13.6, 5.3 Hz, 
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1H), 1.97 (ddd, J = 13.6, 5.3, 0.7 Hz, 1H), 1.20 (s, 3H). 13C-NMR (100 MHz, d4-MeOH): 
δ (ppm) = 141.5, 107.2, 74.8, 73.5, 70.9, 41.8, 25.5. IR (ATR): 𝜈max (cm−1) = 3270 (s), 
2971 (w), 2922 (w), 2863 (w), 1706 (w), 1625 (w), 12449 (w), 1431 (w), 1696 (w), 1374 
(w), 1329 (w), 1284 (w), 1253 (m), 1142 (s), 1108 (m), 1066 (s), 1053 (vs), 1036 (s), 
1000 (s), 934 (s), 908 (m), 869 (m), 833 (m), 742 (w). HRMS (ESI): calc. for C7H10IO3 
[M–H]–: 268.9680, found: 298.9684. [𝛂]𝑫
𝟐𝟎 = +14.0 ° (c = 0.0043 g/mL). 
 
 
 
Vinyl stannane 2.110: Bu3SnH (1.58 mL, 5.96 mmol) was added dropwise to a 
suspension of 2-methyl-3-butyn-2-ol (0.58 mL, 5.94 mmol) and (PPh3)2PdCl2 (83 mg, 
0.119 mmol) in THF (17 mL) and the resultant solution was stirred for 1 h at room 
temperature before it was concentrated under reduced pressure. The resultant residue 
was purified by flash column chromatography (EtOAc:hexanes 8:92, Rf = 0.3) to yield 
vinyl stannane 2.110 (1.70 g, 4.53 mmol, 76%) as a colorless oil. 
Data for 2.110: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.19 – 5.97 (m, 2H), 1.71 (s, 1H), 
1.54 – 1.41 (m, 6H), 1.33 – 1.23 (m, 5H), 0.86 (td, J = 7.7, 1.6 Hz, 15H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 155.7, 122.4, 72.5, 29.5, 29.2, 27.3, 13.8, 9.5. IR (ATR): 𝜈max 
(cm−1) = 3357 (w, br), 2956 (s), 2923 (s), 2871 (w), 2853 (w), 1600 (w), 1521 (w), 1463 
(w), 1417 (w), 1374 (m), 1292 (w), 1201 (w), 1147 (w), 1071 (w), 989 (m), 960 (w), 904 
(w), 874 (w), 781 (w), 667 (m). HRMS (EI): calc. for C17H36OSn [M]+: 376.1788, found: 
376. 
 
 
 
Acremine F (2.6): A solution of triol 2.109 (430 mg, 1.59 mmol), vinyl stannane 2.110 
(1.20 g, 3.19 mmol), Pd(PPh3)4 (177 mg, 0.153 mmol) and CuTc (381 mg, 2.00 mmol) in 
DMF (37 mL) was stirred at 65 °C overnight in the dark. The reaction was cooled to room 
temperature, diluted with MeOH and filtered through a pad of celite. Evaporation of the 
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solvent under reduced pressure and purification of the resulting residue by flash column 
chromatography (EtOAc, Rf = 0.25) gave acremine F (2.6) (350 mg, 1.53 mmol, 96%) as 
a colorless oil. 
Data for 2.6: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 6.19 (d, J = 16.1 Hz, 1H), 6.08 
(d, J = 16.1 Hz, 1H), 5.63 (d, J = 2.8 Hz, 1H), 4.35 (t, J = 3.9 Hz, 1H), 3.95 (d, J = 2.8 
Hz, 1H), 2.09 (dd, J = 14.3, 3.3 Hz, 1H), 1.85 (dd, J = 14.3, 4.5 Hz, 1H), 1.33 (s, 3H), 
1.32 (s, 3H), 1.27 (s, 3H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 139.4, 139.2, 130.8, 
127.1, 73.8, 72.0, 71.4, 65.6, 42.0, 30.0, 29.9, 26.5. IR (ATR): 𝜈max (cm−1) = 3372 (br), 
2971 (s), 2927 (m), 2360 (m), 2168 (w), 2012 (w), 1622 (w), 1373 (m), 1264 (w), 1150 
(s), 1072 (m), 1038 (s), 999 (m), 971 (m), 883 (w), 832 (w), 658 (w). HRMS (EI): calc for 
[M–H]–: 227.1289, found: 227.1292 [𝛂]𝑫
𝟐𝟎 = –46.6 ° (c = 0.009 g/mL). 
 
 
 
Diene 2.111: A mixture of alcohol 2.108 (100 mg, 0.322 mmol), vinyl stanine 2.110 
(364 mg, 0.971 mmol), Pd(PPh3)4 (35 mg, 0.030 mmol), and CuTc (75 mg, 0.393 mmol) 
in DMF (10 mL) was stirred at 65 °C overnight in the dark. The reaction was diluted with 
brine and extracted with EtOAc. The combined organic phases were dried over Na2SO4 
and concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (EtOAc:hexanes 1:1, Rf = 0.3) gave diene 2.111 (62 mg, 
0.231 mmol, 72%) as a colourless oil. 
Data for 2.111: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.12 (q, J = 16.1 Hz, 2H), 5.58 
(d, J = 3.5 Hz, 1H), 4.33 (d, J = 3.5 Hz, 1H), 4.24 (ddd, J = 10.6, 4.6, 2.7 Hz, 1H), 3.44 
(d, J = 10.6 Hz, 1H), 2.37 (dd, J = 15.1, 2.7 Hz, 1H), 1.84 (dd, J = 15.0, 4.5 Hz, 1H), 1.40 
(s, 3H), 1.34 (s, 3H), 1.33 (s, 3H), 1.31 (s, 3H), 1.29 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 139.3, 139.0, 126.7, 126.3, 110.2, 80.2, 78.5, 71.1, 63.6, 39.6, 30.1, 29.6, 
29.2, 26.9. IR (ATR): 𝜈max (cm−1) = 3429 (m), 2974 (s), 2934 (m), 1458 (w), 1374 (s), 
1314 (w), 1274 (w), 1238 (s), 1210 (m), 1164 (m), 1134 (w), 1085 (m), 1070 (m), 1027 
(vs), 1004 (m), 971 (m), 914 (w), 887 (w), 860 (w), 828 (m), 800 (w). HRMS (EI): calc. 
for [M–CH3]+: 253.1434, found: 253.1425. [𝛂]𝑫
𝟐𝟎 = –29.3 ° (c = 0.006 g/mL). 
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Silyl ether 2.114: 2,6-lutidine (0.56 mL, 4.84 mmol) and TBSOTf (0.56 mL, 2.42 mmol) 
were sequentially added to an ice-cooled solution of vinyl iodide 2.108 (300 mg, 
0.967 mmol) and the reaction was stirred at that temperature for 2 h before it was 
quenched with saturated aqueous NH4Cl and extracted with CH2Cl2. The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (EtOAc:hexanes 
2:98) gave silyl ether 2.114 (456 mg, 0.931 mmol, 96%) as a colourless oil. 
Data for 2.114: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.57 (dd, J = 4.9, 1.8 Hz, 1H), 
4.05 – 3.97 (m, 1H), 3.91 (dd, J = 5.0, 1.2 Hz, 1H), 1.98 (d, J = 7.8 Hz, 2H), 1.48 – 1.46 
(m, 3H), 1.37 (d, J = 0.7 Hz, 3H), 1.32 (s, 3H), 0.94 (s, 9H), 0.20 (s, 3H), 0.12 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 133.7, 115.6, 110.0, 78.5, 71.2, 42.8, 28.7, 27.3, 
26.0, 23.9, 18.3, –4.0, –4.3. IR (ATR): 𝜈max (cm−1) = 2985 (w), 2952 (w), 2931 (m), 2886 
(w), 2857 (w), 1625 (w), 1472 (w), 1461 (w), 1378 (w), 1369 (w), 1362 (w), 1352 (w), 
1334 (w), 1295 (w), 1273 (w), 1250 (m), 1240 (m), 1219 (m), 1180 (m), 1119 (m), 1089 
(s), 1070 (vs), 1031 (s), 1008 (w), 992 (m), 975 (w), 946 (m), 914 (w), 877 (s), 868 (s), 
837 (s), 824 (m), 814 (m), 798 (m), 774 (s), 726 (w), 674 (w). HRMS (EI): calc. for [M–
CH3]+: 409.0690; found: 409.0680. [𝛂]𝑫
𝟐𝟎 = –7.4 ° (c = 0.023 g/mL). 
 
 
 
Diene 2.115: A mixture of silyl ether 2.114 (100 mg, 0.236 mmol), vinyl stanine 2.110 
(177 mg, 0.472 mmol), Pd(PPh3)4 (26 mg, 0.022 mmol), and CuTc (55 mg, 0.288 mmol) 
in DMF (5.5 mL) was stirred at 65 °C overnight in the dark. The reaction was diluted with 
brine and extracted with EtOAc. The combined organic phases were dried over MgSO4 
and concentrated under reduced pressure. Purification of the resulting residue by flash 
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column chromatography (EtOAc:hexanes 20:80, Rf = 0.3) gave diene 2.115 (87 mg, 
0.227 mmol, 96%) as a colourless oil. 
Data for 2.115: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.30 (dd, J = 16.0, 0.9 Hz, 1H), 
6.11 (d, J = 16.0 Hz, 1H), 5.87 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 4.23 – 4.16 (m, 1H), 4.15 
– 4.10 (m, 1H), 1.96 – 1.89 (m, 2H), 1.50 – 1.44 (m, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 1.34 
(s, 3H), 1.29 (s, 3H), 0.90 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 144.6, 139.2, 124.4, 118.3, 109.3, 78.4, 76.9, 71.1, 68.8, 42.6, 29.9, 29.7, 
28.8, 27.3, 26.0, 23.9, 18.3, –3.9, –4.6. IR (ATR): 𝜈max (cm−1) = 3450 (w), 2960 (m), 2931 
(m), 2858 (m), 1473 (w), 1463 (w) 1369 (m), 1244 (m), 1212 (m), 1179 (m), 1118 (m), 
1088 (s), 1073 (vs), 1032 (s), 991 (m), 973 (m), 915 (w), 879 (m), 859 (w), 837 (s), 774 
(s), 728 (w), 672 (w). HRMS (EI): calc for [M–H]+: 381.2456, found: 381.2447. [𝛂]𝑫
𝟐𝟎 = –
6.9 ° (c = 0.008 g/mL). 
 
 
 
Acetate 2.122: Pyridine (1.40 mL, 16.12 mmol) and AcCl (0.64 mL, 8.06 mmol) were 
sequentially added to an ice-cooled solution of vinyl iodide 2.108 (500 mg, 1.61 mmol) 
and DMAP (20 mg, 0.161 mmol) in CH2Cl2 (13 mL) and the reaction was stirred for 
10 min at that temperature and for 3 h at room temperature before it was hydrolysed with 
H2O. The solution was diluted with CH2Cl2 and washed with aqueous HCl (1 M), aqueous 
saturated NaHCO3 and brine. The organic phase was dried over Na2SO4 and the solvent 
was removed under reduced pressure. Purification of the resulting residue by flash 
column chromatography (EtOAc:hexanes 10:90, Rf = 0.25) gave acetate 2.122 as a 
colorless oil. 
Data for 2.122: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.66 (dd, J = 4.8, 1.4 Hz, 1H), 
5.37 – 5.29 (m, 1H), 3.99 (d, J = 4.7 Hz, 1H), 2.14 (s, 3H), 2.06 (dd, J = 7.4, 3.8 Hz, 2H), 
1.46 (s, 3H), 1.39 (s, 3H), 1.36 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 170.1, 
137.2, 110.3, 105.3, 78.5, 77.8, 71.7, 38.5, 28.6, 27.66, 24.3, 21.4. IR (ATR): 𝜈max (cm−1) 
= 2983 (w), 2934 (w), 2860 (w), 1741 (s), 1629 (w), 1456 (w), 1377 (m), 1367 (m), 1211 
(vs), 1181 (s), 1116 (m), 1080 (m), 1065 (m), 1028 (s), 990 (m), 955 8m), 914 (m), 877 
204 
(m), 842 (w), 819 (w), 800 (w), 738 (w), 655 (w) HRMS (EI): calc. for C11H14O4I [M–CH3]+: 
336.9931, found: 336.9937. [𝛂]𝑫
𝟐𝟎 = –7.2 ° (c = 0.009 g/mL). 
 
 
 
Allylic alcohol 2.123: A solution of acetate 2.122 (500 mg, 1.42 mmol), vinyl stannane 
2.126 (769 mg, 2.13 mmol), Pd(PPh3)4 (160 mg, 0.138 mmol) and CuTc (340 mg, 
1.78 mmol) in DMF (34 mL) was stirred at 65 °C overnight in the dark. After cooling to 
room temperature the mixture was diluted with EtOAc and filtered over a pad of celite. 
The filtrate was washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 1:2) gave allylic alcohol 2.123 (351 mg, 1.18 mmol, 83%) as mixture of 
diastereoisomers as a colourless oil. 
Data for 2.123: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.11 (dd, J = 16.0, 6.1 Hz, 1H), 
5.92 (d, J = 4.3 Hz, 1H), 5.72 (dd, J = 16.0, 6.0 Hz, 1H), 5.51 (q, J = 5.6 Hz, 1H), 4.34 
(h, J = 6.2 Hz, 1H), 4.25 (d, J = 4.4 Hz, 1H), 2.15 (dd, J = 13.8, 6.8 Hz, 1H), 2.04 (d, J = 
1.4 Hz, 3H), 1.97 (dd, J = 13.8, 5.4 Hz, 1H), 1.42 (d, J = 2.8 Hz, 6H), 1.33 (s, 3H), 1.26 
(d, J = 6.9 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 170.9, 170.9, 137.7, 137.6, 
135.7, 135.6, 127.2, 127.2, 127.0, 126.9, 109.9, 77.8, 77.0, 68.7, 68.6, 66.7, 66.6, 37.7, 
28.8, 28.3, 28.3, 25.5, 25.5, 23.5, 23.5, 21.4. IR (ATR): 𝜈max (cm−1) = 3373 (s), 2971 (m), 
2928 (m), 2872 (w), 1717 (m), 1684 (m), 1636 (m), 1527 (w), 1457 (m), 1419 (s), 1373 
(s), 1265 (s), 1150 (s), 1094 (m), 1072 (m), 1037 (s), 998 (m), 973 (m), 940 (m), 922 (m), 
882 (m), 833 (m), 724 (m), 696 (m). HRMS (EI): Mass peak could not be found. [𝛂]𝑫
𝟐𝟎 = 
+0.85 ° (c = 0.014 g/mL). 
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Enone 2.124: Dess-Martin periodinane (983 mg, 2.32 mmol) was added to a stirred 
solution of allylic alcohol 2.123 (351 mg, 1.18 mmol) in CH2Cl2 (10 mL) and the reaction 
was stirred at room temperature for 1 h. The mixture was diluted with H2O and Na2S2O3 
(500 mg, 3.16 mmol) was added and the reaction was stirred until it became a clear 
solution. The solution was extracted with CH2Cl2 and the combined organic phases were 
washed with brine. Evaporation of the solvent under reduced pressure and purification 
of the resulting residue by flash column chromatography (EtOAc:hexanes 1:2) gave 
enone 2.124 (333 mg, 1.13 mmol, 96%) as a colourless oil. 
Data for 2.124: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.05 (d, J = 16.3 Hz, 1H), 6.29 
(d, J = 4.1 Hz, 1H), 6.14 (d, J = 16.3 Hz, 1H), 5.54 (t, J = 5.5 Hz, 1H), 4.33 (d, J = 4.1 
Hz, 1H), 2.31 – 2.23 (m, 4H), 2.09 – 1.97 (m, 4H), 1.44 (s, 3H), 1.41 (s, 3H), 1.36 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 198.2, 170.8, 141.3, 136.3, 135.6, 128.5, 110.5, 
77.7, 76.9, 65.5, 37.3, 28.8, 28.6, 28.1, 26.0, 21.3. IR (ATR): 𝜈max (cm−1) 2934 (w), 1734 
(s), 1673 (s), 1601 (w), 1426 (w), 1370 (m), 1242 (vs), 1174 (m), 1081 (w), 1033 (m), 
991 (w), 923 (w), 864 (w). HRMS (EI): calc. for C14H16O6S [M–CH3]+: 279.1227, found: 
279.1218. [𝛂]𝑫
𝟐𝟎 = –10.0 ° (c = 0.015 g/mL). 
 
 
 
Carbonate 2.125: Aqueous 1 M HCl (4 mL) was added to a solution of enone 2.124 
(333 mg, 1.13 mmol) in MeOH (2 mL) and THF (2 mL) and the solution was stirred at 
room temperature overnight. The solution was filtered over a pad of celite which was 
subsequently washed with EtOAc. The solvent was removed under reduced pressure 
and the resulting residue was redissolved in CH2Cl2 (11 mL) and pyridine (0.52 mL, 
6.44 mmol). The solution was cooled to –78 °C and treated with a solution of triphosgene 
(159 mg, 0.552 mmol) in Ch2Cl2 (4.5 mL). The reaction was stirred for 30 min at that 
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temperature and at room temperature for 16 h. before it was quenched with an aqueous 
saturated solution of NH4Cl and extracted with CH2Cl2. The combined organic phases 
were washed with aqueous HCl (1 M), saturated aqueous NaHCO3 and brine. The 
organic phase was dried over Na2SO4 and the solvent was removed under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 2:1, Rf = 0.4) gave carbonate 2.125 (185 mg, 0.660 mmol, 58% over 2 
steps) as a colourless solid. 
Data for 2.125: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.08 (d, J = 16.2 Hz, 1H), 6.35 – 
6.20 (m, 2H), 5.65 (t, J = 3.5 Hz, 1H), 4.89 (d, J = 4.3 Hz, 1H), 2.61 (dd, J = 16.0, 2.9 Hz, 
1H), 2.31 (s, 3H), 2.08 (s, 3H), 1.92 (dd, J = 16.0, 4.1 Hz, 1H), 1.57 (s, 3H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 197.7, 170.7, 153.34, 139.9, 138.8, 131.1, 129.7, 79.4, 
77.2, 76.6, 62.3, 35.6, 28.4, 26.9, 21.3. IR (ATR): 𝜈max (cm−1) = 1797 (vs), 1735 (s), 1672 
(m), 1602 (m), 1370 (m), 1229 (s), 1203 (m), 1187 (m), 1135 (w), 1075 (m), 1020 (s), 
772 (w). HRMS (EI): calc. for C12H14O5 [M–Ac]+: 237.0757; found: 237.0769. [𝛂]𝑫
𝟐𝟎 = –
90.0 ° (c = 0.0064 g/mL). 
 
 
 
Dioxolane 2.121: 1,2-bis(trimethylsiloxy)ethane (0.078 mL, 0.324 mmol) and TMSOTf 
(0.06 mL, 0.332 mmol) were sequentially added to a stirred solution of carbonate 2.125 
(60 mg, 0.214 mmol) at –78 °C and the reaction was stirred at that temperature for 8 h 
before it was quenched with NEt3 (0.3 mL). The mixture was diluted with H2O and 
extracted with EtOAc. The combined organic phases were washed with brine and dried 
over MgSO4. Evaporation of the solvent under reduced pressure and purification of the 
resulting residue by flash column chromatography (EtOAc:hexanes 1:1) gave dioxolane 
2.121 (53 mg, 0.163 mmol, 76%) as a colourless solid. 
Data for 2.125: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 1H NMR (400 MHz, Chloroform-
d) δ 6.32 (d, J = 16.0 Hz, 1H), 5.97 (d, J = 4.4 Hz, 1H), 5.76 (d, J = 16.0 Hz, 1H), 5.61 (t, 
J = 3.6 Hz, 1H), 4.84 (d, J = 4.4 Hz, 1H), 4.02 – 3.94 (m, 2H), 3.92 – 3.79 (m, 2H), 2.56 
(dd, J = 15.8, 3.1 Hz, 1H), 2.07 (s, 3H), 1.89 (dd, J = 15.9, 4.2 Hz, 1H), 1.55 (s, 3H), 1.46 
(s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 207.2, 170.9, 153.7, 139.5, 133.9, 127.6, 
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124.8, 107.2, 79.5, 77.2, 77.2, 64.9, 64.7, 62.9, 35.8, 31.1, 26.9, 25.1, 21.3. IR (ATR): 
𝜈max (cm−1) = 2983 (w), 2935 (w), 1799 (vs), 1736 (s), 1676 (w), 1635 (w), 1426 (w), 1734 
(w), 1388 (w), 1227 (s), 1202 (m), 1135 (w), 1101 8w), 1075 (m), 1022 (s), 918 (w), 868 
(w), 772 (w). HRMS (EI): Mass peak could not be found. [𝛂]𝑫
𝟐𝟎 = –55.4 ° (c = 0.019 g/mL). 
 
 
 
Silyl ether 2.132: 2,6-lutidine (0.20 mL, 1.72 mmol) and TMSOTf (0.16 mL, 0.861 mmol) 
were sequentially added to an ice-cooled solution of vinyl iodide 2.108 (107 mg, 0.345 
mmol) and the reaction was stirred for 90 min at that temperature before it was quenched 
with saturated aqueous NH4Cl and extracted with CH2Cl2. The combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Purification of the 
resulting residue by flash column chromatography (EtOAc:hexanes 4:96) gave silyl ether 
2.132 (118 mg, 0.309 mmol, 90%) as a colourless oil. 
Data for 2.132: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.57 (dd, J = 4.9, 1.8 Hz, 1H), 
4.04 – 3.97 (m, 1H), 3.90 (dt, J = 4.9, 1.3 Hz, 1H), 2.07 – 1.89 (m, 2H), 1.46 (d, J = 0.7 
Hz, 3H), 1.37 (d, J = 0.7 Hz, 3H), 1.32 (d, J = 0.8 Hz, 3H), 0.21 (s, 9H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 133.7, 115.6, 110.0, 78.5, 78.4, 71.2, 42.7, 28.7, 27.3, 23.8, 0.6. 
IR (ATR): 2963 (w), 2858 (w), 1627 (w), 1458 (w), 1378 (m), 1368 (m), 1251 (s), 1217 
(s), 1183 (m), 1123 (m), 1094 (s), 1073 (s), 1032 (m), 992 (w), 949 (w), 916 (w), 887 
(vs), 841 (vs), 803 (w), 749 (w). IR (ATR) 𝜈max (cm−1) = HRMS (EI): calc. for C12H20O3ISi 
[M–CH3]+: 367.0221, found: 367.0225. [𝛂]𝑫
𝟐𝟎 = +109 ° (c = 0.017 g/mL). 
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Diene 2.128: A mixture of silyl ether 2.132 (178 mg, 0.466 mmol), vinyl stanine 2.110 
(349 mg, 0.931 mmol), Pd(PPh3)4 (51 mg, 0.044 mmol), and CuTc (108 mg, 
0.566 mmol) in DMF (11 mL) was stirred at 65 °C overnight in the dark. The reaction was 
diluted with brine and extracted with EtOAc. The combined organic phases were dried 
over Na2SO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (EtOAc:hexanes 20:80, Rf = 0.2) gave diene 
2.128 (156 mg, 0.458 mmol, 98%) as a colourless oil. 
Data for 2.128: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.29 – 6.09 (m, 2H), 5.86 (ddd, J 
= 4.7, 1.6, 0.8 Hz, 1H), 4.27 (ddt, J = 10.7, 5.8, 1.5 Hz, 1H), 4.12 (dd, J = 4.8, 1.2 Hz, 
1H), 1.94 (dd, J = 5.9, 1.0 Hz, 1H), 1.65 – 1.61 (m, 1H), 1.48 – 1.44 (m, 3H), 1.39 – 1.38 
(m, 3H), 1.35 (d, J = 1.4 Hz, 6H), 1.29 – 1.28 (m, 3H), 0.17 (s, 9H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = 143.94, 139.8, 124.4, 119.9, 109.2, 78.3, 71.1, 68.6, 42.6, 29.9, 29.9, 
28.8, 28.0, 27.3, 27.0, 23.7, 17.7, 13.8, 0.6. IR (ATR): 𝜈max (cm−1) = 3433 (w), 2961 (m), 
2932 (w), 2858 (w), 1458 (w), 1369 (m), 1249 (m), 1212 (m), 1179 (w), 1165 (w), 1119 
(w), 1088 (m), 1073 (s), 1027 (s), 991 (w), 971 (m), 886 (s), 860 (s), 838 (vs), 749 (m), 
725 (w), 683 (w). HRMS (EI): calc for [M]+: 340.2064; found: 340.2081. [𝛂]𝑫
𝟐𝟎 = –10.3 ° 
(c = 0.012 g/mL). 
 
 
 
Siloxane 2.138: Ph2SiCl2 (25 µL, 0.118 mmol) was added to an ice-cooled solution of 
diene 2.128 (80 mg, 0.235 mmol), DMAP (5 mg, 0.041 mmol) and NEt3 (32 µL, 
0.238 mmol) in CH2Cl2 (1 mL) and the reaction was stirred 10 min at that temperature 
and 1 h at room temperature before it was quenched with H2O and extracted with CH2Cl2. 
The combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
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(EtOAc:hexanes 10:90) gave siloxane 2.138 (42 mg, 0.049 mmol, 42%) as a colourless 
oil. 
Data for 2.138: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.73 – 7.59 (m, 4H), 7.35 (dddd, 
J = 15.2, 8.3, 5.9, 1.2 Hz, 6H), 6.28 – 6.06 (m, 2H), 5.73 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H), 
4.19 (dd, J = 10.2, 5.9 Hz, 1H), 4.08 (d, J = 4.7 Hz, 1H), 2.00 – 1.86 (m, 2H), 1.47 (s, 
3H), 1.44 (s, 3H), 1.41 (s, 3H), 1.39 (s, 3H), 1.28 (s, 3H), 0.13 (s, 9H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 144.0, 140.2, 137.0, 135.4, 129.6, 127.5, 123.8, 119.2, 109.1, 
78.3, 76.8, 75.3, 68.5, 42.6, 30.7, 30.5, 28.8, 27.3, 23.7, 0.6. IR (ATR): 𝜈max (cm−1) = 
2976 (w), 2932 (w), 2858 (w), 1594 (w), 1458 (w), 1430 (w), 1378 (m), 1368 (m), 1342 
(w), 1304 (w), 1250 (m), 1240 (m), 1211 (m), 1179 (m), 1164 (m), 1114 (s), 1087 (m), 
1072 (s), 1026 (vs), 997(m), 969 (m), 894 (m), 839 (s), 804 (w), 743 (m), 719 (m), 701 
(s). HRMS (EI): calc. for [M]+: 860.4535, found: 860.4517. [𝛂]𝑫
𝟐𝟎 = –16.8 ° (c = 
0.008 g/mL). 
 
 
 
Carbonate 2.146: A solution of acetate 2.122 (270 mg, 1.767 mmol) in MeOH (1 mL), 
THF (1 mL) and aqueous HCl (1 M, 2 mL) was stirred at room temperature overnight. 
The reaction mixture was directly submitted to flash column chromatography 
(hexanes:EtOAC 1:1) giving diol 2.145 (229 mg, 0.734 mmol) as a colorless oil. 
A solution of triphosgene (110 mg, 0.379 mmol) in CH2Cl2 (3 mL) was added dropwise 
to stirred solution of triol 2.145 (229 mg, 0.734 mmol) and pyridine (0.36 mL, 4.45 mmol) 
in CH2Cl2 (7.7 mL) at –78 °C. The reaction was stirred for 30 min at –78 °C and overnight 
at room temperature before it was quenched by the addition of aqueous saturated NH4Cl 
(7 mL). The organic phase was separated and washed with aqueous HCl (1 M), aqueous 
saturated NH4Cl and brine and dried over MgSO4. Evaporation of the solvent under 
reduced pressure and purification of the resulting residue by flash column 
chromatography (EtOAc:hexanes 3:7, Rf = 0.3) gave carbonate 2.146 (174 mg, 
0.515 mmol, 67% over 2 steps) as a colorless oil. 
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Data for 2.146: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.59 (d, J = 2.9 Hz, 1H), 5.44 (t, 
J = 4.6 Hz, 1H), 3.84 – 3.77 (m, 1H), 2.14 (d, J = 3.6 Hz, 4H), 2.08 (dd, J = 14.8, 5.3 Hz, 
1H), 1.27 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 169.6, 144.1, 97.0, 73.8, 72.6, 
68.8, 39.0, 25.1, 21.1. IR (ATR): 𝜈max (cm−1) = 1789 (s), 1772 (s), 1752 (s), 1730 (s), 
1623 (s), 1556 (s), 1461 (s), 1432 (s), 1340 (s), 1385 (s), 1372 (s), 1346 (s), 1306 (s), 
1290 (m), 1242 (s), 1206 (vs), 1153 (w), 1110 (m), 1077 (w), 1057 (m), 1018 (vs), 996 
(s), 970 8m), 959 (s), 940 (m), 899 (m), 860 (m), 814 (w)=, 778 (m), 760 (m), 715 (w). 
HRMS (EI): calc. for [M+H]+: 338.9724, found: 338.9722. [𝛂]𝑫
𝟐𝟎 = –72 ° (c = 
0.0125 g/mL). 
 
 
 
Allylic alcohol 2.144: A solution of carbonate 2.146 (50 mg, 0.148 mmol), vinyl 
stannane 2.110 (111 mg, 0.296 mmol), Pd(PPh3)4 (15 mg, 0.013 mmol) and CuTc 
(35 mg, 0.184 mmol) in DMF (4.5 mL) was stirred at 65 °C overnight in the dark. The 
reaction was cooled to room temperature, diluted with EtOAc and filtered through a pad 
of celite. Evaporation of the solvent under reduced pressure and purification of the 
resulting residue by flash column chromatography (EtOAc:hexanes 2:1, Rf = 0.25) gave 
allylic alcohol 2.144 (41 mg, 0.140 mmol, 95%) as a colorless oil. 
Data for 2.144: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.25 (d, J = 16.1 Hz, 1H), 5.99 – 
5.92 (m, 2H), 5.65 (s, 1H), 4.85 (d, J = 4.5 Hz, 1H), 2.58 – 2.51 (m, 1H), 2.07 (s, 3H), 
1.89 (dd, J = 15.9, 4.1 Hz, 1H), 1.55 (s, 3H), 1.34 (s, 6H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 171.0, 153.8, 141.4, 140.0, 124.4, 123.6, 79.5, 77.4, 71.1, 62.9, 36.0, 29.9, 
29.9, 27.0, 21.4. IR (ATR): 𝜈max (cm−1) = 3482 (w), 2973 (w), 2932 (w), 1782 (s), 1732 
(s), 1457 (w), 1426 (w), 1373 (m), 1338 (m), 1304 (w), 1224 (s), 1202 (s), 1187 (s), 1133 
(m), 1075 (m), 1017 (vs), 996 (m), 971 (m), 912 (w), 847 (w), 816 (w), 752 (s). HRMS 
(EI): mass could not be found. [𝛂]𝑫
𝟐𝟎 = –65.9 ° (c = 0.06 g/mL). 
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Siloxane 2.142: NEt3 (18 µL, 0.129 mmol) and Ph2SiCl2 (12 µL, 0.057 mmol) were 
sequentially added to an ice-cooled solution of allylic alcohol 2.144 (40 mg, 0.135 mmol) 
in CH2Cl2 (1 mL) and the reaction was stirred for 10 min at that temperature and for 3 h 
at room temperature. The mixture was diluted with H2O and extracted with CH2Cl2. The 
organic phase was washed with brine and dried over MgSO4. Evaporation of the solvent 
and purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 2:2-1:1) gave siloxane 2.142 (24 mg, 0.031 mmol, 46%) as a colourless 
oil. 
Data for 2.142: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.59 (dt, J = 6.6, 1.5 Hz, 2H), 7.41 
– 7.35 (m, 1H), 7.31 (dd, J = 7.8, 6.5 Hz, 2H), 6.14 (dd, J = 16.0, 13.2 Hz, 1H), 5.92 – 
5.76 (m, 2H), 5.51 (t, J = 3.6 Hz, 1H), 4.83 (d, J = 4.3 Hz, 1H), 2.52 (dd, J = 15.9, 3.1 Hz, 
1H), 1.98 (d, J = 3.0 Hz, 3H), 1.85 (dt, J = 15.9, 4.5 Hz, 1H), 1.54 (s, 3H), 1.34 (d, J = 
2.4 Hz, 3H), 1.31 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 170.8, 153.9, 141.6, 
140.0, 136.2, 135.3, 130.0, 127.7, 124.3, 123.2, 79.6, 77.4, 77.2, 75.1, 62.9, 35.8, 30.4, 
30.3, 26.9, 21.3. IR (ATR): 𝜈max (cm−1) = 2974 (m), 2156 (w), 1802 (vs), 1737 (s), 1429 
(m), 1382 (m), 1234 (s), 114 (m), 1076 (m), 1024 (s), 752 (m), 704 (m).) HRMS (EI): 
Mass could not be found. [𝛂]𝑫
𝟐𝟎 = –86.4 ° (c = 0.004 g/mL). 
 
 
 
Vinyl stannanes 2.147 and 2.147b: Bu3SnH (2.97 mL, 11.3 mmol) and Et3B (1M in 
hexanes, 10.2 mL, 10.2 mmol) were sequentially added to a solution of ethyl propiolate 
(1.03 mL, 10.19 mmol) in PhMe (102 mL) at –78 °C. The solution was warmed to room 
temperature overnight and the solvent was removed under reduced pressure. 
Purification of the resulting residue by flash column chromatography (hexanes:CH2Cl2 
9:1 to 4:1) gave vinyl stannane as its (Z) – isomer 2.147b (2.03 g, 5.22 mmol, 51%) and 
its (E) – isomer 2.147 (911 mg, 2.34 mmol, 23%) as a colorless oil.  
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Data for (Z) 2.147b: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.15 (d, J = 12.9 Hz, 1H), 
6.73 (d, J = 12.9 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 1.52 – 1.44 (m, 7H), 1.34 – 1.23 (m, 
13H), 1.00 – 0.94 (m, 6H), 0.88 (t, J = 7.3 Hz, 13H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 167.8, 157.2, 135.5, 60.6, 29.3, 27.5, 14.5, 13.9, 11.2. IR (ATR): 𝜈max (cm−1) = 2955 
(m), 2920 (m), 2872 (w), 2853 (w), 1711 (s), 1464 (w), 1368 (w), 1334 (s), 1199 (vs), 
1142 (w), 1072 (w), 1030 (m), 961 (w), 874 (w), 865 (w), 824 (m), 752(w), 723 (w), 668 
(m). HRMS (EI): HRMS could not be found. 
 
Data for (E) 2.147: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.74 (d, J = 19.4 Hz, 1H), 6.30 
(d, J = 19.4 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 1.61 – 1.39 (m, 7H), 1.36 – 1.25 (m, 10H), 
1.00 – 0.94 (m, 5H), 0.89 (t, J = 7.3 Hz, 10H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
165.1, 152.6, 136.5, 60.5, 29.1, 27.4, 14.4, 13.8, 9.8. IR (ATR): 𝜈max (cm−1) =2955 (m), 
2920 (m), 2871 (w), 2853 (w), 2360 (w), 1711 (m), 1583 (w), 1463 (w), 1419 (w), 1368 
(w), 1334 (m), 1292 (w), 1199 (s), 1153 (w), 1096 (w), 1071 (w), 1030 (w), 960 (w), 939 
(w), 923 (w), 874 (w), 823 (m), 751 (w), 723 (w), 667 (w) cm-1. HRMS (EI): calc for [M+H]+: 
391.1654; found: 391.1666. 
 
 
 
Ethyl ester 2.146: A solution of alcohol 2.108 (200 mg, 0.645 mmol), stannane 2.147 
(502 mg, 1.29 mmol), Pd(PPh3)4 (65 mg, 0.056 mmol) and CuTc (153 mg, 0.802 mmol) 
in DMF (20 mL) was stirred at 65 °C overnight. After cooling to room temperature, the 
mixture was diluted with EtOAc, filtered over a pad of celite and concentrated. The 
resulting residue was purified by flash column chromatography (EtOAc:hexanes 1:4, Rf 
= 0.2) to give ethyl ester 2.146 (152 mg, 0.538 mmol, 83%) as a slightly yellowish oil. 
Data for 2.146: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.28 (d, J = 15.7 1H), 6.24 (d, J 
= 16.0 Hz, 1H), 5.99 (dt, J = 3.3, 0.7 Hz, 1H), 4.43 (d, J = 3.3 Hz, 1H), 4.31 (ddd, J = 
10.8, 4.6, 2.4 Hz, 1H), 4.21 (qq, J = 7.2, 3.7 Hz, 2H), 3.56 (d, J = 10.9 Hz, 1H), 2.48 (dd, 
J = 15.2, 2.4 Hz, 1H), 1.93 (dd, J = 15.2, 4.5 Hz, 1H), 1.47 (d, J = 0.7 Hz, 3H), 1.42 (s, 
3H), 1.37 – 1.35 (m, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 167.2, 144.0, 138.1, 134.1, 120.7, 110.6, 80.1, 78.0, 63.2, 60.6, 39.1, 29.5, 29.2, 26.9, 
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14.4. IR (ATR): 𝜈max (cm−1) = 3462 (w), 2956 (m), 2827 (m), 2871 (w), 2855 (w), 1628 
(w), 1458 (w), 1412 (w), 1376 (s), 1330 (w), 1308 (w), 1271 (w), 1237 (s), 1219 (s), 1181 
(m), 1162 (m), 1134 (w), 1106 (s), 1063 (s), 1049 (m), 1029 (vs), 1006 (m), 991 (m), 
9401 (m), 915 (m), 890 (w), 874 (m), 846 (w), 825 (m), 799 (w), 774 (w), 747 (w), 723 
(w), 694 (m). HRMS (EI): Mass peak could not be found. [𝛂]𝑫
𝟐𝟎 = –70.0 ° (c = 0.049 g/mL). 
 
 
 
Enone 2.150: AlMe3 (2M in hexanes, 0.083 mL, 0.166 mmol) was added to a solution of 
vinyl stannane 2.126 (600 mg, 1.66 mmol) in PhMe (7 mL) and the solution was stirred 
for 30 min at room temperature. 2-nitrobenzaldehyde (753 mg, 4.98 mmol) was added 
and the reaction was stirred 1 h at room temperature and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 4:96-6:94) gave enone 2.150 (369 mg, 1.03 mmol, 62%) as a colorless 
oil. 
Data for 2.150: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.55 (d, J = 19.8 Hz, 1H), 6.52 
(d, J = 19.8 Hz, 1H), 2.27 (s, 3H), 1.59 – 1.39 (m, 7H), 1.31 (dq, J = 14.5, 7.3 Hz, 7H), 
1.08 – 0.94 (m, 6H), 0.89 (t, J = 7.3 Hz, 10H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
197.8, 151.4, 146.6, 29.1, 27.4, 25.9, 13.8, 9.8.  IR (ATR): 𝜈max (cm−1) = 2956 (m), 2822 
(m), 2872 (m), 2852 (m), 1694 (w), 1676 (s), 1569 (w), 1464 (w)(, 1419 (w), 1377 (w), 
1357 (m), 1282 (w), 1245 (vs), 1198 (m), 1169 (w), 1073 (w), 996 (s), 961 (w), 875 (w), 
865 (w), 790 (w), 769 (w), 665 (s). HRMS (EI): mass could not be found. 
 
 
 
Ketone 2.149: Triol 2.109 (50 mg, 0.185 mmol), enone 2.150 (133 mg, 0.370 mmol), 
Pd(PPh3)4 (21 mg, 0.018 mmol) and CuTc (44 mg, 0.231 mmol) in DMF (4 mL) was 
stirred at 65 °C overnight. The reaction mixture was cooled to room temperature, diluted 
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with EtOAc and filtered over a pad of celite. Evaporation of the solvent under reduced 
pressure and purification of the resulting residue by flash column chromatography 
(EtOAc, Rf = 0.3) gave ketone 2.149 (16 mg, 0.075 mmol, 41%) as a yellowish oil. 
Data for 2.149: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.22 (d, J = 16.2 Hz, 1H), 6.42 
(d, J = 16.2 Hz, 1H), 6.11 (d, J = 2.7 Hz, 1H), 4.38 (t, J = 3.7 Hz, 1H), 4.00 (d, J = 2.7 
Hz, 1H), 2.31 (s, 3H), 2.11 (dd, J = 14.5, 3.0 Hz, 1H), 1.88 (dd, J = 14.5, 4.6 Hz, 1H), 
1.27 (s, 3H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 201.6, 145.5, 141.1, 138.8, 
128.8, 73.9, 71.9, 64.9, 41.8, 27.3, 26.4. IR (ATR): 𝜈max (cm−1) = 3374 (br), 2926 (m), 
2511 (br), 1661 (s), 1638 (s), 1595 (s), 1423 (m), 1362 (m), 1260 (s), 1150 (s), 1097 (w), 
1040 (s), 998 (w), 974 (s), 939(m), 884 (w), 835 (m), 725 (w). HRMS (EI/ESI): mass peak 
could not be found.  [𝛂]𝑫
𝟐𝟎 = –68-9 ° (MeOH, c = 0.02 g/mL). 
 
 
 
Vinyl stannane 2.126: Bu3SnH (0.74 mL, 3.71 mmol) was added dropwise to a stirred 
solution of 3-butyn-2-ol (0.22 mL, 2.85 mmol) and Pd(PPh3)2Cl2 (200 mg, 0.285 mmol) 
in THF (9 mL). The solution was stirred at –78 °C for 3 h and then warmed to room 
temperature and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (EtoAc:hexanes 4:96 to 6:94, Rf = 0.25) gave 
vinyl stannane 2.126 (728 mg, 2.02 mmol, 71%) as a colorless oil. 
Data for 2.126: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.33 – 5.79 (m, 2H), 4.26 (dtd, J 
= 10.7, 6.5, 4.2 Hz, 1H), 1.60 – 1.38 (m, 8H), 1.35 – 1.25 (m, 9H), 0.89 (t, J = 7.3 Hz, 
14H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 152.2, 126.7, 71.5, 29.2, 27.4, 23.2, 13.9, 
9.6.  IR (ATR): 𝜈max (cm−1) = 3324 (m), 2956 (s), 2924 (vs), 2872 (m), 2853 (m), 1603 
(w), 1464 (m), 1457 (m), 1418 (w), 1376 (m), 1327 (w), 129 (w), 1250 (w), 1182 (w), 
1121 (m), 1071 (w), 988 (w), 630 (w), 936 (m), 874 (m), 864 (m), 840 (w), 828 (w), 767 
(w), 746 (w), 688 (s). HRMS (EI): calc. for C16H34OSn [M]+: 361.1548; found: 361.1567. 
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Methyl ether S2.1: NaH (60% in mineral oil, 3.05 g, 76.0 mmol) was added portionwise 
to a stirred solution of 2-methyl-3-butyn-2-ol (4.84 mL, 50.0 mmol) in DMF (50 mL) and 
the reaction was stirred for 30 min at that temperature. Dimethylsulfate (7.25 mL, 
76.0 mmol was added dropwise and the solution was stirred for 1 h at room temperature 
before it was quenched with AcOH (2.5 mL). The desired product was directly distilled 
out of the reaction mixture (b.p. 78-80 °C) to give methyl ether S2.1 (3.61 g, 36.75 mmol, 
73%) as a colorless liquid. 
Data for S2.1: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 3.37 (s, 3H), 2.42 (s, 1H), 1.46 (s, 
6H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 85.8, 72.2, 70.4, 51.8, 28.3. IR (ATR): 𝜈max 
(cm−1) = 3896 (w), 2987 (m), 2939 (w), 2828 (w), 1746 (w), 1683 (w), 1466 (w), 1380 (w), 
1362 (w), 1237 (m), 1201 (w), 1174 (s), 1150 (s), 1074 (vs), 940 (w), 844 (s), 688 (m). 
HRMS (EI): calc for [M–H]+: 97.0648; found: 97.0649. 
 
 
 
Vinyl stanine S2.2: Bu3SnH (1.27 mL, 4.74 mmol) was added dropwise to a stirred 
solution of methyl ether S2.1 (500 mg, 5.09 mmol) and Pd(PPh3)2Cl2 (36 mg, 
0.052 mmol) in THF (20 mL) and the reaction was stirred for 1 h at room temperature 
before it was concentrated under reduced pressure. Purification of the resulting residue 
by flash column chromatography (EtOAc:hexanes 4:96) gave vinyl stanine S2.2 (1.07 g, 
2.75 mmol, 54%) as a colorless oil. 
Data for S2.2: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.19 – 5.78 (m, 2H), 3.15 (s, 3H), 
1.55 – 1.39 (m, 6H), 1.31 (dt, J = 14.7, 7.3 Hz, 6H), 1.25 (s, 6H), 0.89 (td, J = 7.7, 7.3, 
3.8 Hz, 16H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 153.2, 126.9, 50.6, 29.2, 27.4, 25.5, 
13.9, 9.6. IR (ATR): 𝜈max (cm−1) = 2956 (s), 2825 (s), 2872(m), 2854 (m), 2822 (w), 1592 
(w), 1524 (w), 1464 (m), 1418 (w), 1376 (m), 1360 (m), 1292 (w), 1246 (w), 1232 (w), 
1166 (m), 1128 (w), 1076 (vs), 1000 (s), 960 (w), 874 (w), 852 (w), 778 (w), 749 (w), 664 
(s). HRMS (EI): Mass peak could not be found. 
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Methyl ether 2.154: A solution of carbonate 2.146 (50 mg, 0.148 mmol), vinyl stannane 
S2.2 (115 mg, 0.296 mmol), Pd(PPh3)4 (15 mg, 0.013 mmol) and CuTc (35 mg, 
0.184 mmol) in DMF (4.5 mL) was stirred at 65 °C overnight in the dark. The reaction 
was cooled to room temperature, diluted with EtOAc and filtered through a pad of celite. 
Evaporation of the solvent under reduced pressure and purification of the resulting 
residue by flash column chromatography (EtOAc:hexanes 1:1, Rf = 0.25) gave methyl 
ether 2.154 (46 mg, 0.147 mmol, 99%) as a colorless oil. 
Data for 2.154: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.11 (d, J = 16.4 Hz, 1H), 5.93 (d, 
J = 4.3 Hz, 1H), 5.81 (d, J = 16.4 Hz, 1H), 5.66 (t, J = 3.7 Hz, 1H), 4.85 (d, J = 4.3 Hz, 
1H), 3.14 (s, 3H), 2.57 (dd, J = 15.9, 3.0 Hz, 1H), 1.91 (dd, J = 15.9, 4.2 Hz, 1H), 1.55 
(s, 3H), 1.28 (s, 3H), 1.28 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 170.9, 153.8, 
139.9, 139.5, 126.8, 123.6, 79.6, 75.0, 62.8, 50.7, 35.8, 26.9, 26.1, 25.6, 21.3.  IR (ATR): 
𝜈max (cm−1) = 2955 (w), 2925 (w), 2870 (w), 2855 (w), 1779 (s), 1728 (s), 1633 (w), 1587 
(w), 1572 (w), 1528 (w), 1516 (w), 1464 (w), 1420 (w), 1371 (m), 1331 (m), 1304 (w), 
1280 (w), 1235 (m), 1220 (m), 1200 (s), 1188 (s), 1132 (m), 1109 (m), 1074 (s), 1016 
(s), 997 (m), 959 (m), 938 (w), 915 (w), 888 (w), 862 (w), 850 (w), 800 (w), 778 (w), 768 
(m), 746 (w), 737 (w), 724 (w), 712 (w). HRMS (EI): Mass peak could not be found. 
[𝛂]𝑫
𝟐𝟎 = –71.1 ° (c = 0.013 g/mL). 
 
 
 
Diene 2.157: A solution of carbonate 2.146 (50 mg, 0.148 mmol), tetravinyl stannane 
(87 µL, 0.296 mmol), Pd(PPh3)4 (15 mg, 0.013 mmol) and CuTc (35 mg, 0.184 mmol) in 
DMF (4.5 mL) was stirred at 65 °C overnight in the dark. The reaction was cooled to room 
temperature, diluted with EtOAc and filtered through a pad of celite. Evaporation of the 
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solvent under reduced pressure and purification of the resulting residue by flash column 
chromatography (EtOAc:hexanes 1:2, Rf=0.25) gave diene 2.157 (32 mg, 0.134 mmol, 
91%) as a colorless oil. 
Data for 2.157: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.33 (dd, J = 17.6, 11.0 Hz, 1H), 
5.95 (dd, J = 4.5, 0.7 Hz, 1H), 5.73 – 5.66 (m, 1H), 5.39 (d, J = 17.6 Hz, 1H), 5.30 (d, J 
= 10.9 Hz, 1H), 4.85 (d, J = 4.4 Hz, 1H), 2.57 (dd, J = 15.9, 3.0 Hz, 1H), 2.07 (s, 3H), 
1.89 (dd, J = 15.9, 4.2 Hz, 1H), 1.55 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
170.9, 153.8, 140.4, 134.7, 124.2, 118.1, 79.6, 77.3, 62.1, 35.9, 27.0, 21.4. IR (ATR): 
𝜈max (cm−1) = 2959 (w), 1979 (vs), 1734 (s), 1609 (w), 1425 (w), 1374 (w), 1336 (w), 1301 
(w), 1238 (s), 1202 (m), 1187 (m), 1136 (w), 1117 (w), 1073 (m), 1021 (s), 996 (m), 940 
(w), 918 (w), 893 (w), 772 (w). HRMS (EI): calc. for [M]+: 238.0836; found: 238.0853. 
[𝛂]𝑫
𝟐𝟎 = –63.9 ° (c = 0.019 g/mL). 
 
 
 
Silyl ether 2.162: Imidazole (1.50 g, 22 mmol) and TBSCl (3.0 g, 20 mmol) were 
sequentially added to an ice-cooled solution of 3-butyn-2-ol (1.56 mL, 20 mmol) and the 
reaction was stirred at room temperature overnight before it was diluted with H2O (21 mL) 
and extracted with pentane. The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (Et2O:pentane 2:98) gave silyl ether 2.162 
(3.25 g, 17.63 mmol, 88%) as a colorless oil. 
Data for 2.162: 1H-NMR (400 MHz, CDCl3): δ (ppm) = δ 4.51 (qd, J = 6.5, 2.1 Hz, 1H), 
2.37 (d, J = 2.1 Hz, 1H), 1.42 (d, J = 6.5 Hz, 3H), 0.90 (s, 10H), 0.12 (d, J = 5.3 Hz, 6H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 86.6, 71.3, 58.9, 25.9, 25.5, –4.5, –4.9. IR (ATR): 
𝜈max (cm−1) = 1716 (w), 1473 (w), 1362 (w), 1252 (m), 1121 (m), 1102 (s), 1058 (m), 1006 
(w), 975 (s), 939 (w), 835 (vs), 804 (m), 776 (vs). HRMS (EI): calc. for C10H19OSi+ [M–
H]+: 183.1200, found: 183.1197. 
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Vinyl boronate 2.163: Cyclohexane (0.55 mL, 5.42 mmol) was added to a stirred 
solution of BH3.Me2S (0.26 mL, 2.71 mmol) in DME (2.7 mL) and the reaction was stirred 
at room temperature for 1 h. Silyl ether 2.162 (500 mg, 2.71 mmol) was added and the 
solution was stirred at room temperature until it became clear. TMANO (407 mg, 5.42 
mmol) was added and the solution was stirred at room temperature for 1 h before pinacol 
(0.33 mL, 2.71 mmol) was added and the solution was stirred at room temperature 
overnight and concentrated under reduced pressure. Purification by flash column 
chromatography (EtOAc:hexanes 5:95) gave vinyl boronate 2.163 (634 mg, 2.03 mmol, 
75%) as a colorless oil. 
Data for 2.163: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.60 (dd, J = 17.9, 4.0 Hz, 1H), 
5.61 (dd, J = 17.9, 1.7 Hz, 1H), 4.38 – 4.28 (m, 1H), 1.27 (s, 12H), 1.21 (d, J = 6.5 Hz, 
3H), 0.89 (s, 10H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 157.2, 83.3, 69.9, 26.1, 25.0, 
24.9, 23.8, 18.4, –4.6, –4.7. IR (ATR): 𝜈max (cm−1) = 2978 (m), 2957 (m), 2930 (m), 2857 
(m), 1642 (m), 1472 (s), 1390 (w), 1362 (s), 1336 (s), 1319 (s), 1256 (), 1213 (w), 1144 
(vs), 1094 (s), 1052 (m), 989 (m), 968 (m), 899 (m), 850 (m), 833 (vs), 806 (m), 774 (vs). 
HRMS (EI): calc. for C15H30O3BSi [M–CH3]+: 297.2052, found: 297.2052. 
 
 
 
Allyl alcohol 2.164: Citric acid (425 mg, 2.02 mmol) was added to a stirred solution of 
vinyl boronate 2.163 (630 mg, 2.02 mmol) in MeOH (2 mL) at room temperature for 3 h. 
The reaction was diluted with EtOAc and washed with H2O (2x) and brine. The organic 
phase was dried over MgSO4 and the solvent was removed under reduced pressure. 
Purification by flash column chromatography (EtOAc:hexanes 1:4) gave allyl alcohol 
2.164 (272 mg, 1.37 mmol, 68%) as a colorless oil.  
Data for 2.164: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.65 (dd, J = 18.1, 4.9 Hz, 1H), 
5.62 (dd, J = 18.1, 1.5 Hz, 1H), 4.34 (dtd, J = 6.5, 4.8, 1.7 Hz, 1H), 1.54 (d, J = 4.6 Hz, 
1H), 1.27 (s, 15H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 156.3, 83.5, 69.8, 25.0, 24.9, 
22.8. IR (ATR): 𝜈max (cm−1) = 3428 (br), 2978 (m), 2929 (w), 1643 (m), 1449 (w), 1358 
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(s), 1323 (s), 1272 (w), 1213 (w), 1145 (s), 1058 (w), 997 (m), 970 (m), 898 (w), 850 (m). 
HRMS (EI): calc. for C9H16O3B [M–CH3]+: 183.1187, found: 183.1184. 
 
 
 
Enone 2.160: A solution of allyl alcohol 2.164 (100 mg, 0.505 mmol) in CH2Cl2 (0.5 mL) 
was added to a suspension of PCC (163 mg, 0.756 mmol) in CH2Cl2 (1 mL) and the 
reaction was stirred at room temperature for 2 h. The reaction mixture was diluted with 
Et2O and filtered over a pad of silica to give enone 2.160 (89 mg, 0.455 mmol, 90%) as 
yellowish oil. 
Data for 2.160: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.80 (d, J = 18.6 Hz, 1H), 6.54 
(d, J = 18.6 Hz, 1H), 2.29 (s, 3H), 1.29 (s, 12H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
199.3, 146.7, 84.3, 26.89, 24.9. IR (ATR): 𝜈max (cm−1) = 2980 (w), 1683 (w), 1341 (s), 
1247 (m), 1144 (m), 1002 (w), 848 (w). HRMS (EI): calc. for C9H14O3B [M–CH3]+: 
1831.1031, found: 181.1029. 
 
 
 
Silyl ether 2.167: 2,6-Lutidine (0,16 mL, 1.42 mmol) and TBSOTf (0.13 mL, 
0.710 mmol) were sequentially added to an ice cooled solution of ethyl ester 2.146 
(80 mg, 0.283 mmol) in CH2Cl2 (2 mL) and the reaction was stirred for 2 h at 0 °C and 
quenched with saturated aqueous ammonium chloride. The mixture was extracted with 
CH2Cl2, the organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 6:94) gave silyl ether 2.167 (99 mg, 0.250 mmol, 88%) as a colorless 
oil. 
Data for 2.167: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.37 (d, J = 16.0 Hz, 1H), 6.16 
(d, J = 16.0 Hz, 1H), 6.13 – 6.10 (m, 1H), 4.32 – 4.25 (m, 1H), 4.21 (qt, J = 7.1, 3.7 Hz, 
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2H), 4.16 (d, J = 4.4 Hz, 1H), 2.00 – 1.88 (m, 2H), 1.47 (s, 3H), 1.40 (s, 3H), 1.31 – 1.26 
(m, 6H), 0.90 (s, 9H), 0.14 (s, 3H), 0.11 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
166.7, 143.0, 142.5, 124.6, 120.9, 109.7, 78.3, 68.1, 60.5, 42.4, 28.8, 27.4, 25.9, 24.1, 
18.2, 14.4, –3.7, –4.7. IR (ATR): 𝜈max (cm−1) = 2958 (m), 2932 (m), 2858 (m), 1717 (s), 
1640 (w), 1463 (w), 1369 (m), 1307 (m), 1252 (m), 1211 (m), 1174 (s), 1090 (s), 1075 
(s), 1034 (s), 993 (w), 879 (m), 837 (s), 776 (m). HRMS (EI): calc. for C20H33O5Si [M–
CH3]+: 381.2092, found: 381.2109. [𝛂]𝑫
𝟐𝟎 =–0.65 ° (c = 0.925 g/mL). 
 
 
 
Vinyl stannane 2.172: Bu3SnH (2.88 mL, 10.8 mmol, 1.2 eq) was added to a mixture of 
propargyl alcohol (0.52 mL, 9.0 mmol, 1.0 eq) and AIBN (22 mg, 0.13 mmol, 0.015 eq) 
in dry toluene (34 mL) and the reaction was stirred at 110 °C for 2.5 h. Concentration 
under reduced pressure ad purification by flash column chromatography (Et2O:hexanes 
= 15:85, Rf = 0.3) gave vinyl stannane 2.172 (1.57 g, 4.51 mmol, 51%) as a colorless 
liquid. 
Data for 2.172: 1H-NMR (400 MHz, CDCl3): 6.35 – 6.01 (m, 2H), 4.23 – 4.12 (m, 2H), 
1.58 (s, 1H), 1.52 – 1.40 (m, 6H), 1.35 – 1.26 (m, 6H), 0.89 (td, J = 7.7, 7.3, 2.6 Hz, 15H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 147.1, 128.5, 77.2, 66.6, 29.2, 27.4, 13.9, 9.6. IR 
(ATR): 𝜈max (cm−1) = 3297 (w, br), 2955 (s), 2922 (s), 2871 (w), 2851 (w), 2361 (w), 1603 
(w), 1463 (m), 1417 (w), 1376 (w), 1357 (w), 1340 (w), 1292 (w), 1248 (w), 1179 (w), 
1071 (m), 990 (m), 960 (w), 873 (w), 725 (w), 689 (m), 664 (m) cm-1. HRMS (ESI): calc 
for [M-H]–: 347.1402; found: 347.1405. 
 
 
 
Allylic alcohol 2.171: A solution of silyl ether 2.114 (200 mg, 0.471 mmol), vinyl 
stannane 2.172 (245 mg, 0.707 mmol), Pd(PPh3)4 (51 mg, 0.044 mmol) and CuTc 
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(110 mg, 0.324 mmol) in DMF (10 mL) was stirred at 65 °C overnight in the dark. After 
cooling to room temperature the mixture was diluted with EtOAc and washed with brine. 
The organic phase was dried over MgSO4 and concentrated under educed pressure. 
Purification of the resulting residue by flash column chromatography (EtOAc:hexanes 
2:8) gave allylic alcohol 2.171 (120 mg, 0.338 mmol, 72%) as a colourless oil. 
Data for 2.171: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.35 – 6.27 (m, 1H), 6.10 (dt, J = 
15.8, 5.6 Hz, 1H), 5.88 (dt, J = 4.8, 1.2 Hz, 1H), 4.26 – 4.18 (m, 3H), 4.13 (d, J = 4.6 Hz, 
1H), 1.93 (d, J = 7.9 Hz, 2H), 1.39 (s, 3H), 1.28 (s, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 
(s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 144.3, 130.6, 128.9, 128.5, 119.1, 109.3, 
78.4, 68.6, 63.9, 42.5, 28.8, 27.4, 26.0, 23.9, 18.3, –3.7, –4.6. IR (ATR): 𝜈max (cm−1) = 
3427 (w), 2956 (m), 2930 (m), 2857 (m), 1613 (w), 1472 (w), 1463 (w), 1420 (w), 1369 
(m), 1321 (w), 1276 8w), 1244 (m), 1212 (m), 1178 (m), 1118 (m), 1089 (s), 1072 (vs), 
1030 (s), 992 (w), 971 (w), 918 (w), 878 (s), 856 (m), 836 (s), 802 (m), 774 (s), 672 (w). 
HRMS (EI): Mass could not be found. [𝛂]𝑫
𝟐𝟎 = –6.1 ° (c = 0.001 g/mL). 
 
 
 
Allylic ester 2.173: LiOH.H2O (36.5 mg, 0.870 mmol) was added to a solution of ethyl 
ester 2.169 (34 mg, 0.087 mmol) in THF (1 mL), MeOH (1 mL) and H2O (1 mL) and the 
solution was stirred at 60 °C for 3 h. The reaction was acidified with aqueous HCl (1 M) 
and extracted with EtOAc. The combined organic phases were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure to give crude acid 2.170 that was 
used in the next step without further purification. 
A solution of DCC (20 mg, 0.096 mmol) in CH2Cl2 (0.65 mL) was added dropwise to an 
ice-cooled solution of crude acid 2.170, allylic alcohol 2.171 (31 mg, 0.087 mmol) and 
DMAP (5.5 mg, 0.045 mmol) in CH2Cl2 (0.65 mL) and the reaction was stirred for 30 min 
at that temperature and for 17 h at room temperature. The reaction mixture was filtered 
over a pad of celite and concentrated under reduced pressure. Purification of the 
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resulting residue by flash column chromatography (EtOAc:hexanes 1:9) gave allylic ester 
2.173 (41 mg, 0.058 mmol, 67% over 2 steps) as a colorless solid. 
Data for 2.173: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.16 (d, J = 16.0 Hz, 1H), 6.11 
(dd, J = 4.4, 1.2 Hz, 1H), 4.68 (d, J = 6.0 Hz, 2H), 4.25 (dt, J = 26.2, 8.2 Hz, 2H), 4.14 
(dd, J = 16.6, 4.6 Hz, 2H), 3.47 (q, J = 7.0 Hz, 3H), 1.97 – 1.89 (m, 4H), 1.46 (s, 6H), 
1.39 (d, J = 4.6 Hz, 6H), 1.28 (d, J = 7.1 Hz, 6H), 1.20 (t, J = 7.0 Hz, 4H), 0.88 (s, 9H), 
0.88 (s, 9H), 0.13 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.09 (s, 3H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = 166.4, 144.1, 143.1, 142.9, 131.7, 125.6, 125.0, 120.5, 120.0, 109.7, 
109.3, 78.4, 78.3, 76.8, 76.6, 68.5, 68.0, 66.0, 65.1, 42.5, 42.4, 28.8, 28.8, 27.4, 27.4, 
26.0, 25.9, 24.1, 23.9, 18.3, 18.2, 15.4, -3.7, –3.8, –4.6, –4.6. IR (ATR): 𝜈max (cm−1) = 
2955 (w), 2931 (m), 2886 (w), 2857 (w), 1718 (m), 1637 (w), 1472 (w), 1463 (w), 1377 
(m) 1369 (m), 1306 (w), 1274 (w), 1243 (m), 1211 (m), 1161 (s), 1118 (w), 1088 (s), 1072 
(s), 1031 (s), 992 (m), 938 (w), 918 (w), 878 (m), 836 (s), 814 (w), 801 (w), 774 (s), 735 
(w), 670 (w). HRMS (ESI): calc for [M+NH4]+: 722.4478; found: 722.4481. [𝛂]𝑫
𝟐𝟎 = –6.7 ° 
(c = 0.0081 g/mL). 
 
 
 
Diol 2.174: TBAF (1 M in THF, 0.09 mL, 0.09 mmol) was added dropwise to an ice cooled 
solution of allylic ester 2.173 (20 mg, 0.028 mmol9 in THF (3 mL) and the solution was 
stirred for 30 min at that temperature and for 3 h at room temperature. The reaction was 
quenched with a saturated aqueous solution of NH4Cl and extracted with EtOAc. The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (EtOAc:hexanes 1:1, Rf 0.3) gave diol 2.174 (11.3 mg, 0.024 mmol, 
86%) as a colorless solid. 
Data for 2.174: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.29 (d, J = 15.9 Hz, 1H), 6.27 
(dd, J = 15.9, 8.6 Hz, 2H), 6.09 (dt, J = 15.9, 6.0 Hz, 1H), 5.99 (d, J = 3.4 Hz, 1H), 5.67 
(d, J = 3.5 Hz, 1H), 4.78 – 4.72 (m, 2H), 4.41 (dd, J = 12.8, 3.4 Hz, 2H), 4.30 (s, 2H), 
3.55 (s, 2H), 2.45 (td, J = 15.0, 2.5 Hz, 2H), 1.91 (ddd, J = 15.1, 12.3, 4.5 Hz, 2H), 1.47 
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(s, 3H), 1.46 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 166.8, 144.5, 138.6, 138.1, 134.4, 133.3, 128.0, 125.4, 120.3, 
110.6, 110.3, 80.2, 80.1, 78.3, 78.0, 64.9, 63.5, 63.2, 39.4, 39.10, 29.6, 29.5, 29.2, 29.2, 
26.9, 26.8. IR (ATR): 𝜈max (cm−1) = 3528 (w), 2984 (w), 2931 (m), 1715 (s), 1638 (w), 
1459 (w), 1374 (m), 1307 (w), 1280 (m), 1239 (s), 1207 (m), 1165 (s), 1135 (w), 1072 
(m), 1056 (m), 1029 (s), 1006 (m), 919 (w), 863 (w), 827 (m). HRMS (ESI): calc for calc. 
for C26H40O8N [M+NH4]+: 494.2748, found: 494.2746. [𝛂]𝑫
𝟐𝟎 = –14.7 ° (c = 0.0039 g/mL). 
 
 
 
Acremine B (2.2): A suspension of acremine F (2.6) (30 mg, 0.131 mmol) and IBX 
(149 mg, 0.526 mmol) was vigorously stirred at 80 °C for 9 h. After cooling to room 
temperature, the solids were removed by filtration and the solvent was evaporated under 
reduced pressure. Purification by flash column chromatography (EtOAc:hexanes 1:1, Rf 
= 0.25) gave acremine B (2.2) (25 mg, 0.111 mmol, 85%) as a colourless solid. 
Data for 2.2: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.80 (d, J = 16.1 Hz, 1H), 6.75 (s, 
1H), 6.53 (dd, J = 16.0, 0.7 Hz, 1H), 3.67 (s, 1H), 3.19 – 2.99 (m, 2H), 1.66 (s, 1H), 1.43 
(d, J = 0.9 Hz, 3H), 1.40 (s, 3H), 1.39 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
201.8, 195.6, 149.5, 147.9, 130.0, 118.5, 75.3, 71.6, 53.2, 29.7, 27.8. IR (ATR): 𝜈max 
(cm−1) = 3380 (br), 2975 (m), 2931 (w), 1681 (vs), 1634 (m), 159 (m), 1459 (w), 1373 
(m), 1254 (m), 1129 (s), 1053 (w), 974 (m), 906 (w), 851 (w), 824 (w), 780 (w), 754 (w), 
668 (w). HRMS (EI): calc for [M–CH3]+: 209.0808, found: 209.0824. [𝛂]𝑫
𝟐𝟎 = –64.9 ° (c = 
0.021 g/mL). 
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Methyl ether 2.39: Me2SO4 (23.0 mL, 242 mmol) was added to a suspension of K2CO3 
(39.0 g, 282 mmol) and methyl hydroquinone (10.0 g, 80.55 mmol) in acetone (120 mL) 
and the reaction was stirred at 60 °C overnight. The solids were removed by filtration and 
the solvent was evaporated under reduced pressure. The resulting residue was 
redissolved in EtOAc and washed with aqueous 1M NaOH and brine. Drying of the 
organic phase over Mg2SO4, evaporation of the solvent under reduced pressure and 
purification of the resulting residue by flash column chromatography (EtOAc:hexanes 
4:96) gave methyl ether 2.39 (11.9 g, 78.5 mmol, 97%) as a colorless solid. 
Data for 2.39: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.79 – 6.73 (m, 2H), 6.69 (dd, J = 
8.7, 3.1 Hz, 1H), 3.79 (s, 3H), 3.76 (s, 3H), 2.22 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 153.5, 152.2, 128., 117.2, 111.0, 110.8, 56.0, 55.8, 16.6. IR (ATR): 𝜈max (cm−1) 
=2996 (w), 2984 (w), 2832 (w), 2361 (w), 2339 (w), 1968 (w), 1592 (w), 1502 (m), 1465 
(w), 1442 (w), 1419 (w), 1378 (w), 1305 (w), 1280 (w), 1222 (s), 1180 (w), 1157 (w), 
1130 (w), 1049 (w), 1032 (w), 923 (w), 866 (w), 797 (w), 752 (w), 711 (w), 699 (w), 668 
(w) cm-1. HRMS (EI): calc for C9H12O2 [M]+: 152.0837; found: 152.0831. 
 
 
 
Aldehyde 2.184: POCl3 (14.6 mL, 160 mmol, 4.2 eq) was slowly added to a solution of 
methyl ether 2.39 (5.824 g, 38.45 mmol, 1.0 eq) in DMF (11.6 mL, 151 mmol, 3.9 eq) at 
0 °C. The mixture was stirred at rt for 2.5 h, heated at 80 °C overnight, and poured into 
ice water after cooling down to rt. Extraction with Et2O (3 × 15 mL), washing with H2O (2 
× 5 mL) and brine (5 mL), drying over Na2SO4 and the removal of the solvent under 
reduced pressure afforded aldehyde 2.184 (5.862 g, 32.53 mmol, 85%) as a yellow solid. 
Data for 2.184: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 10.40 (s, 1H, b), 7.25 (s, 1H, c), 
6.81 (d, J = 0.9 Hz, 1H, a), 3.88 (s, 3H, e), 3.83 (s, 3H, f), 2.28 (d, J = 0.7 Hz, 3H, d) 13C-
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NMR (100 MHz, CDCl3): δ (ppm) = 189.4, 156.8, 152.1, 136.7, 123.0, 114.8, 107.8, 56.3, 
55.9, 17.4. IR (ATR): 𝜈max (cm−1) =3009 (w), 2943 (w), 2921 (w), 2858 (w), 2832 (w), 
2780 (w), 2047 (w), 1738 (w), 1659 (s), 1611 (s), 1499 (s), 1484 (w), 1469 (m), 1404 (s), 
1373 (w), 1329 (w), 1269 (m), 1252 (w), 1213 (s), 1170 (w), 1121 (w), 1043 (s), 1011 
(w), 868 (w), 850 (w), 747 (w), 679 (w) cm-1. HRMS (EI): calc C10H12O3 for [M]+: 180.0786; 
found: 180.0792. 
 
 
 
Methyl ester 2.185: A solution of aldehyde 2.184 (500 mg, 2.77 mmol) and methyl 
(triphenylphosphoranylidene) acetate (1.40 g, 4.16 mmol) in PhMe was stirred for 5 h at 
100 °C, cooled to room temperature and concentrated under reduced pressure. 
Purification by flash column chromatography (EtOAc:hexanes 7:93) gave methyl ester 
2.185 (480 mg, 2.03 mmol, 73%) as a colorless solid. 
Data for 2.185: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.98 (d, J = 16.1 Hz, 1H), 6.93 (s, 
1H), 6.73 (d, J = 0.8 Hz, 1H), 6.46 (d, J = 16.1 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.80 
(s, 3H), 2.24 (d, J = 0.7 Hz, 3H).  13C-NMR (100 MHz, CDCl3): δ (ppm) = 168.2, 152.7, 
151.8, 140.4, 131.2, 121.0, 117.1, 114.6, 109.7, 56.2, 55.9, 51.7, 16.9. IR (ATR): 𝜈max 
(cm−1) = 1714 (m), 1697 (m), 1607 (w), 1505 (m), 1468 (m), 1437 (m), 1406 (m), 1376(w), 
1320 (w), 1251 (w), 1214 (s), 1195 (m), 1162 (m), 1044 (s), 999 (w), 899 (w), 872 (w), 
856 (w), 833 (w), 668 (w). HRMS (EI):  calc C13H16O4 for [M–OMe]+: 205.0859; found: 
205.0859. 
 
 
 
Acid 2.181: A solution of methyl ester 2.185 (207 mg, 0.876 mmol) and LiOH hydrate 
(310 mg, 12.93 mmol) in THF (1 mL), MeOH (1 mL) and H2O (1 mL) was stirred at 60 °C 
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overnight. After cooling to room temperature the reaction was acidified using aqueous 
1M HCl and extracted with EtOAc. The organic phase was washed with brine and dried 
over MgSO4. Evaporation of the solvent under reduced pressure gave acid 2.181 
(184 mg, 0.828 mml, 95%) as a colourless solid. 
Data for 2.181: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 11.89 (s, 1H), 8.09 (d, J = 16.1 
Hz, 1H), 6.96 (s, 1H), 6.75 (s, 1H), 6.49 (d, J = 16.0 Hz, 1H), 3.85 (s, 3H), 3.82 (d, J = 
2.2 Hz, 3H), 2.26 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 172.9, 153.0, 151.9, 
142.6, 131.9, 120.7, 116.4, 114.6, 109.8, 56.3, 56.0, 17.0.  IR (ATR): 𝜈max (cm−1) = 2954 
(w), 2936 (w), 2830 (w), 2703 (w), 2585 (w), 1690 (s), 1617 (s), 1506 (m), 1463 (w)k 
1452 (w), 1401 (m), 1366 (w), 1337 (m), 1294 (m), 1265 (m), 1205 (vs), 1191 (s), 1180 
(m), 1121 (w), 1040 (s), 1103 (w), 892 (w), 944 (s), 851 (s), 754 (w), 705 (w), 662 (m). 
HRMS (EI): calc for C12H14O [M]+: 222.0887; found: 222.0887. 
 
 
 
Allylic alcohol 2.114: A solution of alcohol 2.108 (316 mg, 1.02 mmol), stannane 2.172 
(708 mg, 2.04 mmol), Pd(PPh3)4 (110 mg, 0.056 mmol) and CuTc (238 mg, 0.802 mmol) 
in DMF (20 mL) was stirred at 65 °C overnight. After cooling to room temperature, the 
mixture was diluted with EtOAc, filtered over a pad of celite and washed with brine. 
Concentration of the resulting residue and purification by flash column chromatography 
(EtOAc:hexanes 2:1, Rf = 0.3) to give allylic alcohol 2.114 (241 mg, 1.00 mmol, 98%) as 
a colourless oil. 
Data for 2.114: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.26 (d, J = 16.0 Hz, 1H), 6.16 
(dt, J = 15.9, 5.2 Hz, 1H), 5.66 (d, J = 3.5 Hz, 1H), 4.41 (d, J = 3.4 Hz, 1H), 4.36 – 4.30 
(m, 1H), 4.27 (d, J = 5.2 Hz, 2H), 3.58 (d, J = 10.6 Hz, 1H), 2.45 (dd, J = 15.1, 2.6 Hz, 
1H), 1.91 (dd, J = 15.2, 4.5 Hz, 1H), 1.58 (s, 1H), 1.48 – 1.46 (m, 3H), 1.41 (s, 3H), 1.40 
– 1.38 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 138.8, 130.6, 130.5, 127.1, 110.3, 
80.2, 78.4, 77.2, 63.7, 63.5, 39.4, 29.6, 29.2, 26.9. IR (ATR): 𝜈max (cm−1) = 3391 (m), 
2984 (w), 2933 (m), 2868 (w), 1726 (w), 1460 (w), 1375 (m), 1314 (w), 1275 (w), 1239 
(m), 1211 (m), 1163 (w), 1134 (w), 1070 (w), 1054 (w), 1027 (s), 1004 (m), 971 (m), 917 
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(w), 886 (w), 857 (w), 827 (m).HRMS (EI): calc. for [M+H]+: 241.1434, found: 241.1086. 
[𝛂]𝑫
𝟐𝟎 = –32.0 ° (c = 0.0043 g/mL). 
 
 
 
Allylic ester 2.183: A solution of DCC (95 mg, 0.460 mmol) in Ch2Cl2 (3 mL) was added 
dropwise to an ice-cooled solution of allylic alcohol 2.114 (100 mg, 0.416 mmol) and acid 
2.181 (93 mg, 0.416 mmol) in CH2Cl2 (3 mL) and the reaction was stirred 30 min at 0 °C 
and at room temperature for 17 h. The resulting solids were removed by filtration and the 
solvent was evaporated under reduced pressure. Purification by flash column 
chromatography (EtOAc:hexanes 1:3 Rf =0.3) gave allylic ester 2.183 (175 mg, 
0.394 mmol, 95%) as a colorless solid. 
Data for 2.183: 1H-NMR (400 MHz, CDCl3): δ (ppm) =  7.99 (d, J = 16.1 Hz, 1H), 6.93 
(s, 1H), 6.73 (s, 1H), 6.49 (d, J = 16.1 Hz, 1H), 6.32 (d, J = 15.9 Hz, 1H), 6.15 (dt, J = 
15.9, 6.0 Hz, 1H), 5.69 (d, J = 3.4 Hz, 1H), 4.80 (dt, J = 6.2, 1.6 Hz, 2H), 4.40 (d, J = 3.4 
Hz, 1H), 4.34 (ddd, J = 10.7, 4.5, 2.6 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.55 (d, J = 10.7 
Hz, 1H), 2.45 (dd, J = 15.1, 2.6 Hz, 1H), 2.24 (s, 3H), 1.91 (dd, J = 15.1, 4.5 Hz, 1H), 
1.47 (s, 3H), 1.41 (s, 3H), 1.40 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 167.4, 
152.8, 151.9, 140.7, 138.7, 133.2, 131.3, 127.9, 125.7, 121.0, 117.2, 114.6, 110.3, 109.8, 
78.3, 76.8, 64.8, 63.5, 56.3, 56.0, 39.4, 29.6, 29.3, 26.9, 16.9.  IR (ATR): 𝜈max (cm−1) = 
3520 (w), 2982 (w), 2934 (w), 1705 (s), 1626 (m), 1572 (w), 1507 (m), 1466 (m), 1403 
(m), 1374 (m), 1333 (w), 1291 (w), 1256 (m), 1339 (m), 1212 (vs), 1156 (vs), 1070 (m), 
1042 (s), 1027 (s), 1003 (m), 969 (m9, 856 (m), 827 (m), 736 (w), 663 (w). HRMS (ESI): 
calc. for C25H36O7N [M+NH4]+: 462.2486, found: 462.4286. [𝛂]𝑫
𝟐𝟎 = –29.6 ° (c = 
0.0108 g/mL). 
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Diol 2.186: BBr3 (6.5 mL, 68 mmol, 4.9 eq) was added dropwise to a –78 °C cold solution 
of aldehyde 2.184 (2.485 g, 13.79 mmol, 1.0 eq) in CH2Cl2 (85 mL). After stirring the 
mixture at –78 °C for 1 h and at rt for another 2 h, MeOH (30 mL) was added. The 
reaction was washed with H2O and brine and dried over MgSO4. Evaporation of the 
solvent under reduced pressure and column chromatography (EtOAc:hexanes 1:4, Rf = 
0.2), gave diol 2.186 (1.535 g, 10.09 mmol, 73%) as a yellow solid. 
Data for 2.186: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 10.64 (s, 1H), 9.76 (d, J = 0.6 Hz, 
1H), 6.91 (s, 1H), 6.79 (s, 1H), 4.57 (s, 1H), 2.30 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 195.4, 156.1, 147.1, 136.7, 119.7, 118.8, 117.3, 17.0. IR (ATR): 𝜈max (cm−1) 
=3386 (m, br), 2874 (w), 1645 (m), 1630 (s), 1567 (w), 1491 (s), 1469 (w), 1444 (w), 
1450 (w), 1355 (w), 1289 (w), 1249 (s), 1200 (w), 1153 (m), 1036 (w), 1008 (w), 885 (w), 
866 (w), 834 (w), 801 (w), 720 (w), 670 (w) cm-1. HRMS (EI): calc for C8H8O3 [M]+: 
152.0473; found: 152.0461. 
 
 
 
Silyl ether 2.187: TIPSCl (1.22 mL, 5.78 mmol) was added to a solution of diol 2.186 
(350 mg, 2.30 mmol) and imidazole (547 mg, 8.03 mmol) in DMF (2 mL) and the solution 
was stirred at 80 °C overnight. After cooling to room temperature the solution was diluted 
with H2O and extracted with Et2O. The combined organic phases were washed with brine 
and dried over Na2SO4. Evaporation of the solvent under reduced pressure and 
purification of the resulting residue by flash column chromatography (Et2O:hexanes 2:98) 
gave silyl ether 2.187 (820 mg, 1.76 mmol, 77%) as a colourless solid. 
Data for 2.187: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.16 (s, 1H), 6.66 (d, J = 0.8 Hz, 
1H), 2.24 (s, 3H), 1.31 (dddd, J = 16.2, 8.3, 6.8, 1.2 Hz, 7H), 1.10 (dd, J = 7.4, 6.2 Hz, 
36H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 189.8, 153.7, 148.8, 138.6, 125.0, 122.1, 
115.0, 18.2, 18.1, 13.1, 13.0.  IR (ATR): 𝜈max (cm−1) = 2956 (m), 2941 (s), 2888 (w), 2864 
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(s), 1677 (s), 1609 (m), 1487 (s), 1460 (m), 1405 (s), 1386 (m), 1367 (w), 1326 (w), 1271 
8w), 1246 (m), 1209 (s), 1173 (m), 1130 (w), 1074 (w), 1061 (w), 1012 (m), 995 (m), 944 
(s), 949 (m), 881 (vs), 854 (m), 800 (s), 688 (s). HRMS (EI): calc. for C26H48O3Si2 [M]+: 
464.3136; found: 464.3120. 
 
 
 
Acid 2.189: Diethylphosphonoacetic acid (35 µL, 0.215 mmol) was added dropwise to a 
solution of n-BuLi (2.34M, 0.19 mL, 0.452 mmol) in THF (0.5 mL) at –60 °C and the 
reaction was stirred for 30 min at that temperature before a solution of silyl ether 2.187 
(100 mg, 0.215 mmol) in THF (0.5 mL) was added dropwise. The reaction was stirred at 
–60 °C for 1 h and at room temperature overnight before it was diluted with H2O and 
acidified with aqueous HCl (1 M). The mixture was extracted with EtOAc and the 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (EtOAc:hexanes 15:85) gave acid 2.189 (72 mg, 0.142 mmol, 66%) as 
a colourless solid. 
Data for 2.189: 1H-NMR (400 MHz, CDCl3): 11.46 (s, 1H), 8.25 – 8.13 (m, 1H), 6.94 (s, 
1H), 6.63 (s, 1H), 6.20 (d, J = 16.1 Hz, 1H), 2.21 (s, 3H), 1.28 (ddt, J = 12.3, 7.0, 3.6 Hz, 
6H), 1.17 – 1.07 (m, 36H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 172.2, 149.4, 148.5, 
142.7, 133.7, 122.6, 121.7, 115.4, 114.9, 18.0, 18.0, 17.6, 13.0, 12.9. IR (ATR): 𝜈max 
(cm−1) = 2945 (s), 2893 (m), 2868 (s), 1684 (vs), 1620 (m), 1492 (s), 1464 (m), 1408 (s), 
1277 (m), 1246 (m), 1205 (vs), 1070 (w), 998(w), 932 (s), 882 (s), 809 (w), 724 (w), 683 
(m). HRMS (EI): calc. for C28H50O4Si2 [M]+: 506.3242, found: 506.3238. 
 
  
230 
 
Allylic ester 2.188:(A solution of DCC (11.2 mg, 0.545 mmol) in CH2Cl2 (5 mL) was 
added dropwise to an ice cooled solution of allylic alcohol 2.114 (173 mg, 0.489 mmol), 
acid 2.189 (248 mg, 0.489 mmol) and DMAP (41.3 mg, 0.338 mmol) in CH2Cl2 (5 mL) 
and the reaction was stirred for 30 min at that temperature and for 17 h at room 
temperature. The solids were removed by filtration and the solvent was evaporated under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 4:96) gave allylic ester 2.188 (387 mg, 0.459 mmol, 94%) as a colorless 
solid. 
Data for 2.188: 1H-NMR (400 MHz, CDCl3): 8.12 (d, J = 16.1 Hz, 1H), 6.92 (s, 1H), 6.62 
(s, 1H), 6.37 (d, J = 15.8 Hz, 1H), 6.19 (d, J = 16.1 Hz, 1H), 6.08 (dt, J = 15.8, 6.2 Hz, 
1H), 4.81 – 4.65 (m, 2H), 4.23 (t, J = 7.8 Hz, 1H), 4.13 (d, J = 4.6 Hz, 1H), 2.20 (s, 3H), 
1.93 (d, J = 7.8 Hz, 2H), 1.47 (s, 3H), 1.39 (s, 3H), 1.32 – 1.24 (m, 9H), 1.10 (d, J = 7.3 
Hz, 37H), 0.88 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 167.1, 149.1, 148.4, 144.0, 140.7, 133.1, 131.3, 125.7, 122.9, 121.7, 119.7, 115.5, 
115.1, 109.21, 78.3, 68.4, 64.8, 42.4, 28.7, 27.2, 25.8, 23.8, 18.1, 18.1, 18.0, 17.5, 13.0, 
12.9, –3.9, –4.8. IR (ATR): 𝜈max (cm−1) = 2944 (m), 2867 (m), 1711 (m), 1628 (s), 1491 
(m), 1463 (s), 1406 (m), 1368 (s), 1294 (s), 1250 (m), 1207 (vs), 1155 (s), 1072 (m), 
1031 (w), 990 (m), 935 (s), 880 (s), 836 (m), 812 (w), 755 (s). HRMS (EI): calc. for 
C36H82O7Si3 [M+H]+: 842.5363, found: 842.5370. [𝛂]𝑫
𝟐𝟎 = –4.34 ° (c = 0.044 g/mL). 
 
 
 
Triol 2.190: TBAF (1 M in THF, 0.30 mL, 0.30 mmol) was added to an ice cooled solution 
of allylic ester 2.188 (56 mg, 0.066 mmol) in THF (2 mL) and the solution was stirred at 
0 °C for 4 h before it was quenched with NHCl4 and extracted with EtOAc. The combined 
organic phases were washed with brine, dried over MgSO4 and concentrated under 
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reduced pressure. Purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 1:1) gave triol 2.190 (22.5 mg, 0.054 mmol, 82%) as a colorless oil. 
Data for 2.190: 1H-NMR (400 MHz, CDCl3): 7.88 (d, J = 16.0 Hz, 1H), 6.80 (s, 1H), 6.57 
(s, 1H), 6.36 – 6.23 (m, 2H), 6.06 (dt, J = 15.9, 6.1 Hz, 1H), 5.69 (d, J = 3.4 Hz, 1H), 4.68 
(t, J = 5.7 Hz, 2H), 4.39 (d, J = 3.4 Hz, 2H), 4.13 – 4.00 (m, 1H), 2.44 (dd, J = 15.2, 2.6 
Hz, 1H), 2.15 (s, 3H), 1.91 (dd, J = 15.1, 4.4 Hz, 1H), 1.46 (s, 3H), 1.39 (s, 6H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 168.3, 149.6, 148.0, 141.1, 138.3, 132.9, 129.7, 128.1, 
125.8, 119.7, 119.1, 116.4, 114.1, 110.4, 80.2, 78.2, 65.1, 63.6, 39.2, 29.5, 29.2, 26.7, 
16.4. IR (ATR): 𝜈max (cm−1) = 3334 (m), 2981 (w), 2932 (w), 1683 (m), 1618 (m), 1513 
(w), 1421 (m), 1374 (m), 1286 (m), 1262 (m), 1237 (m), 1198 (s) 1160 (vs), 1068 (m), 
1025 (m), 999 (m), 967 (m), 862 (m), 825(m), 750 (w), 696 (w). HRMS (ESI): calc. for 
C23H32IO7N [M+NH4]+: 434.2173, found: 434.2171. [𝛂]𝑫
𝟐𝟎 = –30.7 ° (c = 0.003 g/mL). 
 
 
 
Vinyl quinone 2.180: A suspension of triol 2.190 (5.0 mg, 0.012 mmol), Ag2O (28 mg, 
0.120 mmol) and MgSO4 (6 mg) in THF (1 mL) was stirred under an O2-atmosphere at 
room temperature for 45 min. The reaction mixture was filtered with the help of a syringe 
filter and concentrated under reduced pressure to give crude vinyl quinone 2.180 
(4.5 mg). The product proved to be unstable on silica. 
Data for 2.180: 1H-NMR (400 MHz, CDCl3): 7.51 (d, J = 16.3, 0.9 Hz, 1H), 6.87 – 6.81 
(m, 2H), 6.66 (q, J = 1.5 Hz, 1H), 6.31 (d, J = 15.9 Hz, 1H), 6.11 (dt, J = 15.8, 6.1 Hz, 
1H), 5.70 (d, J = 3.5 Hz, 1H), 4.80 (d, J = 6.2 Hz, 1H), 4.41 (d, J = 3.6 Hz, 1H), 4.33 (ddd, 
J = 10.8, 4.6, 2.6 Hz, 1H), 3.56 (d, J = 10.7 Hz, 1H), 2.45 (dd, J = 15.1, 2.6 Hz, 1H), 2.07 
(d, J = 1.6 Hz, 3H), 1.95 – 1.87 (m, 2H), 1.46 (d, J = 3.2 Hz, 3H), 1.41 (d, J = 2.2 Hz, 
3H), 1.39 (s, 3H). 
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Silyl ether 2.191: TBSCl (977 mg, 6.48 mmol) was added to an ice cooled solution of 
diol 2.186 (329 mg, 2.16 mmol) and imidazole (441 mg, 6.48 mmol9 in DMF (5 mL) and 
the reaction was stirred at room temperature overnight. The mixture was portioned 
between Et2O and H2O and the organic phase was washed with brine and dried over 
Na2SO4. Evaporation of the solvent under reduced pressure and purification of the 
resulting residue by flash column chromatography (Et2O:hexanes 3:97) gave silyl ether 
2.191 (340 mg, 0.893 mmol, 41%) as a colorless solid. 
Data for 2.191: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 10.32 (s, 1H), 7.14 (s, 1H), 6.66 
(s, 1H), 2.21 (s, 3H), 1.00 (d, J = 1.9 Hz, 19H), 0.24 (s, 6H), 0.22 (s, 6H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 189.7, 153.3, 148.6, 138.9, 125.5, 122.6, 115.6, 25.9, 25.8, 18.5, 
18.4, 18.0, –4.2, –4.2.  IR (ATR): 𝜈max (cm−1) = 2955 (m), 2932 (m), 1292 (w), 2858 (m), 
1682 (s), 1609 (w), 1485 (s) 1471 (m), 1404 (s), 1389 (w), 1322 (w), 1259 (s), 1244 (m), 
1217 (vs), 1171 (w), 1121 (w), 1006 (w), 938 (vs), 882 (w), 833 (vs), 781 (s), 680 (m). 
HRMS (EI): calc. for C19H33O3Si2 [M-CH3]+: 365.1963, found: 365.1981. 
 
 
 
Methyl ester 2.192: A solution of aldehyde 2.191 (274 mg, 0.720 mmol) and methyl 
(triphenylphosphoranylidene) acetate (481 mg, 1.44 mmol) in PhMe (8 mL) was stirred 
for 5 h at 100 °C, cooled to room temperature and concentrated under reduced pressure. 
Purification by flash column chromatography (Et2O:hexanes 4:96, Rf = 0.1) gave methyl 
ester 2.192 (280 mg, 0.641 mmol, 82%) as a colorless solid. 
Data for 2.192: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.99 (d, J = 16.2 Hz, 1H), 6.90 (s, 
1H), 6.61 (d, J = 0.9 Hz, 1H), 6.24 (d, J = 16.1 Hz, 1H), 3.79 (s, 3H), 2.17 (d, J = 0.6 Hz, 
3H), 1.03 (s, 9H), 1.01 (s, 9H), 0.20 (s, 6H), 0.19 (s, 6H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 168.0, 148.9, 148.4, 140.6, 133.6, 123.6, 122.5, 116.0, 51.7, 25.9, 18.4, 18.4, 
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17.4, –4.1, –4.1. IR (ATR): 𝜈max (cm−1) = 2953 (w), 2930 (w), 2858 (w), 1720 (m), 1629 
(w), 1492 (m), 1472 (w), 1434 (w), 1405 (m), 1294 (m), 1255 (m), 1204 (s), 1162 (s), 
1043 (w), 1004 (w), 959 (w), 920 (s), 829 (vs), 778 (vs), 680 (w). HRMS (EI): calc. for 
C23H40O4Si2 [M]+: 436.2460, found: 436.2462. 
 
 
 
Allylic alcohol 2.193: DIBAL-H (1.49M in PhMe, 0.86 mL, 1.28 mmol) was added 
dropwise to a stirred solution of methyl ester 2.192 (280 mg, 0.641 mmol) in CH2Cl2 
(9 mL) at –78 °C and the solution was stirred at that temperature for 2 h and for 1 h at 
room temperature before an aqueous saturated solution of Rochelle’s salt was added 
and the reaction was stirred for 1 h at room temperature. The mixture was extracted with 
CH2Cl2 and the organic phase was dried over MgSO4. Evaporation of the solvent under 
reduced pressure and purification of the resulting residue by flash column 
chromatography (EtOAc:hexanes 1:9) gave allylic alcohol 2.193 (230 mg, 0.563 mmol, 
88%) as a colourless solid. 
Data for 2.193: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 6.88 – 6.79 (m, 2H), 6.56 (d, J = 
0.9 Hz, 1H), 6.17 (dt, J = 16.0, 6.1 Hz, 1H), 4.29 (td, J = 6.0, 1.5 Hz, 2H), 2.14 (s, 3H), 
1.35 (t, J = 6.0 Hz, 1H), 1.01 (d, J = 1.9 Hz, 18H), 0.20 (s, 6H), 0.17 (s, 6H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 207.1, 148.1, 146.9, 129.6, 127.0, 126.9, 125.5, 121.9, 
115.6, 64.4, 31.0, 25.9, 25.8, 18.3, 18.3, 17.0, –4.2, –4.2. IR (ATR): 𝜈max (cm−1) = 326 
(w), 2955 (w), 2929 (m), 2886 (w), 2857 (w), 1492 (s), 1472 (m), 1463 (w), 1401 (s), 
1374 (w), 1362 (w), 1288 (w), 1252 (m), 1198 (s), 1184 (m), 1094 (m), 1032 (w), 1003 
(w), 966 (w), 924 (s), 882 (m), 830 (vs), 778 (vs), 726 (m), 684 (m). HRMS (EI): calc. for 
C22H40O3Si2 [M]+: 408.2510; found 408.2520. 
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Allylic ester 2.195: LiOH.H2O (23.6 mg, 0.563 mmol) was added to a solution of ethyl 
ester 2.146 (22 mg, 0.079 mmol) in THF (1 mL), MeOH (1 mL) and H2O (1 mL) and the 
solution was stirred at 60 °C for 3 h. The reaction was acidified with aqueous HCl (1 M) 
and extracted with EtOAc. The combined organic phases were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure to give crude acid 2.194 that was 
used in the next step without further purification. 
A solution of DCC (18 mg, 0.088 mmol) in CH2Cl2 (0.8 mL) was added dropwise to an 
ice cooled solution of acid 2.194, allylic alcohol 2.193 (32 mg, 0.079 mmol) and DMAP 
(6.7 mg, 0.055 mmol) in CH2Cl2 (0.8 mL) and the reaction was stirred for 30 min at 0 °C 
and for 17 h at room temperature. The mixture was filtered through a pad of celite and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (EtOAc:hexanes 1:9) gave allylic ester 2.195 (31 mg, 
0.048 mmol, 61% over 2 steps) as a colourless oil. 
Data for 2.195: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.31 (d, J = 15.9 Hz, 1H), 6.89 
(dt, J = 16.0, 1.4 Hz, 1H), 6.83 (s, 1H), 6.55 (d, J = 0.8 Hz, 1H), 6.28 (d, J = 15.9 Hz, 1H), 
6.09 (dt, J = 16.0, 6.4 Hz, 1H), 6.00 (d, J = 3.4 Hz, 1H), 4.80 (dd, J = 6.4, 1.4 Hz, 2H), 
4.43 (d, J = 3.3 Hz, 1H), 4.31 (ddd, J = 10.9, 4.6, 2.4 Hz, 1H), 3.55 (d, J = 10.8 Hz, 1H), 
2.47 (dd, J = 15.2, 2.4 Hz, 1H), 2.13 (s, 3H), 1.93 (dd, J = 15.2, 4.5 Hz, 1H), 1.47 (s, 3H), 
1.42 (s, 3H), 1.36 (s, 3H), 1.01 (s, 9H), 1.00 (s, 9H), 0.19 (s, 6H), 0.16 (s, 6H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 166.9, 148.2, 147.1, 144.3, 138.1, 134.3, 130.1, 129.5, 
125.4, 122.0, 121.8, 120.5, 115.7, 110.6, 80.1, 78.0, 65.8, 63.1, 39.1, 29.5, 29.2, 26.8, 
26.0, 26.0, 18.4, 18.4, 17.1, –4.0, –4.1.  IR (ATR): 𝜈max (cm−1) = 2955 (w), 2930 (m), 2896 
(w), 2858 (w), 1715 (m), 1639 (w), 1620 (w), 1494 (m), 1472 (w), 1463 (w), 1404 (m), 
1374 (w), 1300 (w), 1279 (w), 1254 (m), 1238 (m), 1222 (m), 1204 (s), 1168 (s), 1159 
(s), 1134 (w), 1088 (m), 1072 (m), 1056 (w), 1030 (m), 1004 (m), 972 (m), 930 (s), 880 
(m), 863 (w), 828 (vs), 779 (vs), 733 (s), 681 (m). HRMS (EI): calc. for C35H56O7Si2 [M]+: 
644.3565, found: 644.3564. [𝛂]𝑫
𝟐𝟎 = –9.2 ° (c = 0.009 g/mL). 
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Triol 2.196: HF.pyridine (70% HF in pyridine, 0.9 mL) was added to an ice cooled 
solution of allylic ester 2.195 (69 mg, 0.107 mmol) in THF (5.7 mL) and the reaction was 
stirred for 4 h at room temperature before it was diluted with aqueous saturated NH4Cl. 
The mixture was extracted with EtOAc and the combined organic phases were washed 
with NaHCO3 and brine. The organic phase was dried over MgSO4, concentrated under 
reduced pressure and purified by flash column chromatography (EtOAc:hexanes 1:1) to 
give triol 2.196 (37 mg, 0.089 mmol, 83%) as a colorless oil. 
Data for 2.196: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.29 (d, J = 16.0 Hz, 1H), 6.82 (d, 
J = 16.0 Hz, 1H), 6.76 (s, 1H), 6.55 (s, 1H), 6.24 (d, J = 16.0 Hz, 1H), 6.13 (dt, J = 15.9, 
6.6 Hz, 1H), 6.00 (d, J = 3.4 Hz, 1H), 5.64 (s, 1H), 5.37 (s, 1H), 4.75 (ddd, J = 6.6, 3.7, 
1.4 Hz, 2H), 4.43 (d, J = 3.3 Hz, 1H), 4.34 (ddd, J = 10.7, 4.5, 2.5 Hz, 1H), 3.83 (d, J = 
10.6 Hz, 1H), 2.48 (dd, J = 15.3, 2.5 Hz, 1H), 2.16 (s, 3H), 1.93 (dd, J = 15.2, 4.5 Hz, 
1H), 1.47 (s, 3H), 1.42 (s, 3H), 1.36 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
167.2, 147.9, 147.2, 144.3, 137.8, 134.6, 129.1, 126.0, 122.9, 121.8, 120.4, 118.7, 113.1, 
110.7, 80.1, 77.9, 66.0, 63.2, 38.9, 31.1, 29.5, 29.1, 26.7, 16.1. IR (ATR): 𝜈max (cm−1) = 
3366 (m), 1984 (w), 2934 (w), 1695 (s), 1637 (w), 1621 (w), 1421 (m), 1375 (m), 1302 
(m), 1280 (m), 1237 (m), 1172(vs), 1087 (m), 1069 (m), 1029 8m), 1002 (m), 972 (m), 
944 (w), 909 (m), 864 (m), 826 (m), 729 (vs), 702 (w). HRMS (ESI): calc. for C23H32IO7N 
[M+NH4]+: 434.2173, found: 434.2176. [𝛂]𝑫
𝟐𝟎 = –25-7 ° (c = 0.007 g/mL). 
 
 
 
Vinyl quinone 2.197: A solution of PIFA (9.7 mg, 12 µmol) in H2O (0.10 mL) and THF 
(0.20 mL) was added to an ice cooled solution of triol 2.196 (5 mg, 12 µmol) in H2O 
(0.25 mL) and THF (0.50 mL) and the solution was stirred at 0 °C for 20 min. The reaction 
mixture was diluted with EtOAc, washed with saturated aqueous NaHCO3 and brine, 
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dried over MgSO4 and concentrated under reduced pressure to give vinyl quinone 2.197 
as a yellow solid. The product proved to be unstable on silica. 
Data for 2.197: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.32 (d, J = 15.9 Hz, 1H), 6.72-6-
67 (m, 1H), 6.64-6.56 (m, 2H), 6.28 (d, J = 15.9 Hz, 1H), 6.07-5.98 (m, 2H), 4.83 (dd, J 
= 5.4, 1.5 Hz, 1H), 4.44 (d, J = 3.4 Hz, 1H), 2.48 (dd, J = 15.2, 2.4 Hz, 1H), 2.05 (s, 3H), 
1.94 (dd, J = 15.2, 4.6 Hz, 1H), 1.47 (s, 1H), 1.42 (s, 3H), 1.36 (s. 3H). 
 
 
 
Vinyl quinone 2.200: Methyl ester 2.185 (200 mg, 0.846 mmol) and oxone® (2.14 g, 
3.48 mmol) was added to a solution of 4-iodophenoxyacetic acid (11.6 mg, 42.5 µmol) in 
TFE (3 mL) and H2O (6 mL) and the reaction was stirred at room temperature for 90 min. 
The reaction mixture was diluted with EtOAc, washed with H2O, NaHCO3 and brine, dried 
over MgSO4 and concentrated under reduced pressure to give vinyl quinone 2.200 
(174 mg, 0.844 mmol, 100%) as a yellow solid. The product proved unstable on silica. 
Data for 2.200: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.51 (dd, J = 16.2, 0.8 Hz, 1H), 
6.86 (s, 1H), 6.82 (d, J = 16.2 Hz, 1H), 6.66 (q, J = 1.5 Hz, 1H), 3.81 (s, 3H), 2.08 (d, J 
= 1.6 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 187.8, 186.1, 166.3, 146.4, 139.5, 
135.8, 133.9, 133.5, 127.3, 52.3, 15.7. 
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6.4 Experimental data for chapter III 
6.4.1 Photoswitchable dopamine agonist 
 
1,6-Dihydroxynaphthalene 4: Dimethylsulfate (43.3 mL, 468 mmol) was added to a 
suspension of potassium carbonate (75.5 g, 548 mmol) and 1,6-dihydroxynaphthalene 
(25 g, 156 mmol) in acetone (250 mL). The mixture was heated at 70 °C for 3.5 h, cooled 
to room temperature and filtered. The solvent was evaporated under reduced pressure 
and the resulting residue was redissolved in ethyl acetate. The solution was washed with 
a solution of sodium hydroxide (1 M) and brine and dried over MgSO4. Evaporation of 
the solvent under reduced pressure and purification of the resulting residue by flash 
column chromatography (EtOAc:pentane 0:100–20:80, Rf = 0.7 (EtOAc:pentane 20:80)) 
gave 1,6-dihydroxynaphthalene 4 (27.6 g, 147 mmol, 94%) as a colorless solid. 
Data for 4: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.17 (dt, J = 8.8, 0.8 Hz, 1H), 7.38 – 
7.31 (m, 2H), 7.15 – 7.10 (m, 2H), 6.70 (dd, J = 6.9, 1.7 Hz, 1H), 3.99 (s, 3H), 3.92 (s, 
3H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 158.2, 155.8, 136.0, 126.8, 123.8, 120.9, 
119.4, 117.6, 105.8, 102.1, 55.6, 55.4. IR (ATR): 𝜈max (cm−1) = 2997 (w), 2966 (w), 2836 
(w), 1929 (w), 1625(m), 1599 (m), 1581 (s), 1510 (w), 1468 (w), 1451 (s), 1430 (s), 1372 
(s), 1386 (w), 1372 (s), 1254 (m), 1220 (vs), 1199 (m), 1165 (m), 1143 (m), 1098 (m), 
1070 (m), 1026 (vs), 988 (m), 935 (m), 871 (m), 839 (m), 828 (s), 782 (vs), 748 (s), 727 
(m), 695 (m). HRMS (EI): calc. for C12H12O2 [M]+: 188.0837, found: 188.0819. 
 
 
 
3,4-Dihydronaphthalenone 5: Sodium (33.69 g, 1.47 mol) was added portionwise to a 
solution of 1,6-dimethoxynaphthalene 4 (27.6 g, 147 mmol) in ethanol (400 mL) at 50 °C 
and the mixture was then stirred at 80 °C for 2.5 h. After cooling down to room 
temperature the mixture was acidified with concentrated hydrochloric acid to pH = 1, 
heated at 80 °C for 30 min and stirred at room temperature overnight. The solution was 
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diluted with water (230 mL) and extracted with CH2Cl2. The organic phase was washed 
with a solution of sodium chloride (10%) and brine and dried over MgSO4. Evaporation 
of the solvent under reduced pressure and purification of the resulting residue by flash 
column chromatography (EtOAc:pentane 0:100–10:90, Rf = 0.5 (EtOAc:pentane 10:90) 
gave 3,4-dihydronaphthalenone 5 (15.94 g, 90.47 mmol, 62%) as a yellow oil. 
Data for 5: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.16 (t, J = 7.9 Hz, 1H), 6.76 (dd, J = 
8.2, 1.0 Hz, 1H), 6.70 (dd, J = 7.6, 1.0 Hz, 1H), 3.83 (s, 3H), 3.52 (s, 2H), 3.06 (t, J = 6.8 
Hz, 2H), 2.48 (dd, J = 7.4, 6.2 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 210.4, 
156.2, 134.8, 127.3, 124.8, 120.2, 108.2, 55.2, 44.4, 44.4, 37.6, 37.6, 20.8. IR (ATR): 
𝜈max (cm−1) = 2957 (w), 2904 (w), 2838 (w), 1713 (vs), 1587 (s), 1471 (s), 1441 (m), 1403 
(w), 1344(w), 1299 (w), 1263 (vs), 1237 (m), 1197 (w), 1172 (w), 1087 (vs), 1076 (s), 
1025 (w), 977 (w), 963 (m), 849 (m), 778 (s), 745 (m), 724 (m), 695 (m). MS (EI): calc. 
for C11H12O2 [M]+: 176.08, found: 176.03. 
 
 
 
Secondary amine 6: Propylamine (2.1 mL, 25.54 mmol) and NaBH(OAc)3 (6.50 g, 
30.66 mmol) were sequentially added to a solution of 3,4-dihydronaphthalenone 5 
(3.00 g, 17.02 mmol) in DCE (100 mL) and the reaction was stirred at room temperature 
overnight. The solvent was removed under reduced pressure and the resulting residue 
was portioned between EtOAc and aqueous NaHCO3 solution. The organic phase was 
washed with brine, dried over MgSO4 and concentrated under reduced pressure to yield 
secondary amine 6 (2.99 g, 13.62 mmol, 80%) as a colorless oil. 
Data for 6: 1H NMR (400 MHz, d4-MeOH): δ (ppm) = 7.07 (t, J = 7.9 Hz, 1H), 6.69 (dd, 
J = 13.6, 7.9 Hz, 2H), 3.79 (s, 3H), 2.98 (ddddd, J = 27.8, 20.8, 17.7, 5.4, 2.6 Hz, 3H), 
2.81 – 2.69 (m, 2H), 2.57 (ddd, J = 30.0, 16.8, 8.0 Hz, 2H), 2.16 (ddt, J = 11.9, 5.7, 2.9 
Hz, 1H), 1.69 – 1.48 (m, 3H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, d4-MeOH): δ 
(ppm) = 158.6, 136.7, 127.6, 125.5, 122.4, 108.3, 55.6, 54.9, 49.4, 36.2, 29.1, 23.3, 23.2, 
12.0. IR (ATR): 𝜈max (cm−1) = 2936 (m), 2875 (w), 2835 (m), 2792 (m), 2734 (m), 2537 
(w), 2445 (w), 1587 (s), 1468 (vs), 1438 (s), 1395 (w), 1382 (w), 1346 (w), 1312 (w), 
1284 (w), 1258 (vs), 1094 (s), 1068 (m), 1036 (m), 987 (m), 954 (m), 914 (w), 892 (w), 
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876 (w), 832 (w), 765 (vs), 709 (m), 694 (m). HRMS (EI): calc. for C14H22NO+ [M+H]+: 
220.1696, found: 220.1696. 
 
 
 
Azobenzene 8: DMP (8.33 g, 21.06 mmol) was added to a solution of (E)-2-(4-((4-
nitrophenyl)diazenyl)phenyl) ethan-1-ol (1.90 g, 7.02 mmol) in CH2Cl2 and the reaction 
was stirred at room temperature for 3 h. The mixture was washed with aqueous Na2S2O3 
solution, water and brine, dried over magnesium sulfate and evaporated to dryness. The 
resulting residue was redissolved in DCE (100 mL), secondary amine 6 (700 mg, 
3.19 mmol) and NaBH(OAc)3 (2.23 g, 10.53 mmol) were sequentially added and the 
reaction mixture was stirred at room temperature overnight. The solvent was removed 
under reduced pressure and the residue was portioned between EtOAc and aqueous 
NaHCO3 solution. The organic phase was washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resultant residue by flash 
column chromatography (MeOH:CH2Cl2 3:97, Rf = 0.3) gave azobenzene 8 (1.49 g, 
3.16 mmol, 99%) as a red solid. 
Data for 8: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.42 – 8.38 (m, 2H), 8.06 – 8.02 (m, 
2H), 7.94 – 7.90 (m, 2H), 7.43 – 7.38 (m, 2H), 7.11 (t, J = 7.9 Hz, 1H), 6.72 (dd, J = 7.6, 
1.0 Hz, 1H), 6.67 (d, J = 8.1 Hz, 1H), 3.83 (s, 3H), 3.01 (dddd, J = 10.8, 8.6, 5.5, 2.7 Hz, 
2H), 2.87 (s, 5H), 2.81 – 2.71 (m, 1H), 2.62 – 2.49 (m, 3H), 2.07 (ddd, J = 14.5, 4.6, 2.0 
Hz, 1H), 1.63 – 1.48 (m, 3H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ 
(ppm) = 157.4, 156.0, 151.0, 148.7, 146.6, 138.1, 130.0, 126.3, 125.4, 124.9, 123.6, 
123.5, 121.8, 107.1, 56.7, 55.4, 52.8, 52.6, 36.3, 32.5, 25.9, 24.0, 22.4, 12.1. IR (ATR): 
𝜈max (cm−1) = 2931 (m), 2836 (w), 1738 (vw), 1602 (w), 1586 (m), 1521 (s), 1499 (w), 
1468 (m), 1438 (w), 1416 (vw), 1360 (vs), 1259 (m), 1218 (w), 1143 (m), 1106 (m), 1093 
(m), 1071 (m), 1008 (w), 963 (w), 908 (w), 858 (s), 766 (w), 754 (w), 729 (s), 710 (w), 
688 (w). HRMS (EI): calc. for C28H33N4O3+ [M+H]+: 473.2547, found: 473.2543.  
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Aniline 9: A suspension of azobenzene 8 (500 mg, 1.06 mmol) and sodium sulfide (2.33 
mg, 2.12 mmol) in 1,4-dioxane (50 mL) and water (50 mL) was stirred at 90 °C overnight. 
The reaction was cooled to room temperature, diluted with aqueous NaOH (1 M) and 
extracted with EtOAc. The organic phase was washed with water and brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resultant residue 
by flash column chromatography (MeOH:CH2Cl2 2:98, Rf=0.2) gave aniline 9 (341 mg, 
0.770 mmol, 73%) as a red solid. 
Data for 9: 1H NMR (400 MHz, CDCl3): δ (ppm) 7.80 (t, J = 8.3 Hz, 4H), 7.32 (d, J = 8.2 
Hz, 2H), 7.10 (t, J = 7.8 Hz, 1H), 6.73 (dd, J = 8.3, 6.5 Hz, 3H), 6.66 (d, J = 8.1 Hz, 1H), 
4.03 (s, 2H), 3.81 (s, 3H), 3.12 – 2.94 (m, 2H), 2.94 – 2.71 (m, 6H), 2.68 – 2.44 (m, 3H), 
2.08 (dt, J = 13.7, 4.2 Hz, 1H), 1.68 – 1.46 (m, 3H), 0.91 (t, J = 7.3 Hz, 3H). 13C NMR 
(100 MHz, CDCl3): δ (ppm) = 157.3, 151.4, 149.5, 145.7, 143.2, 138.1, 129.5, 126.3, 
125.3, 125.1, 122.4, 121.8, 114.8, 107.0, 67.2, 56.8, 55.3, 52.8, 35.9, 32.4, 25.9, 24.0, 
22.3, 12.1. IR (ATR): 𝜈max (cm−1) = 3336 (w), 2933 (m), 2837 (vw), 2508 (w), 2246 (vw), 
2212 (vw), 1623 (w), 1586 (m), 1516 (m), 1468 (m), 1438 (w), 1378 (vw), 1346 (vw), 
1260 (m), 1216 (vw), 1180 (vw), 1128 (vw), 1094 (m), 1071 (m), 96.2 (vw), 907 (s), 826 
(m), 768 (m), 700 (vs). HRMS (EI): calc. for C28H35N4O+ [M+H]+: 443.2805, found: 
443.2811. 
 
 
 
Phenol 10: BBr3 (1M in CH2Cl2, 3.18 mL, 3.18 mmol) was added to a solution of aniline 
9 (704 mg, 1.59 mmol) in CH2Cl2 (30 mL) at –78 °C and the reaction was stirred 1 h at 
the same temperature and 1 h at room temperature. The reaction mixture was diluted 
with MeOH (5 mL) and aqueous NaHCO3 solution and extracted with EtOAc. The organic 
phase was washed with brine, dried over MgSO4 and concentrated under reduced 
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pressure. Purification by flash column chromatography (MeOH:CH2Cl2 = 2:98 to 6:94, Rf 
= 0.6 (MeOH:CH2Cl2 6:94)) gave phenol 10 (440 mg, 1.03 mmol, 65%) as a red solid. 
Data for 10: 1H NMR (400 MHz, CDCl3): δ (ppm) 7.81 (t, J = 7.6 Hz, 4H), 7.31 (d, J = 
8.0 Hz, 2H), 6.99 (t, J = 7.8 Hz, 1H), 6.73 (d, J = 8.3 Hz, 2H), 6.68 (d, J = 7.6 Hz, 1H), 
6.58 (d, J = 7.9 Hz, 1H), 4.04 (s, 2H), 3.09 – 2.73 (m, 8H), 2.59 (ddd, J = 23.4, 10.2, 5.8 
Hz, 3H), 2.12 (dd, J = 12.5, 5.5 Hz, 1H), 1.70 – 1.47 (m, 3H), 0.92 (t, J = 7.3 Hz, 3H). 13C 
NMR (100 MHz, CDCl3): δ (ppm) = 153.7, 151.4, 149.5, 145.6, 143.0, 138.9, 129.5, 
126.5, 125.1, 123.3, 122.5, 121.6, 114.8, 112.1, 56.8, 52.7, 52.6, 35.5, 32.2, 25.8, 23.8, 
21.9, 12.1. IR (ATR): 𝜈max (cm−1) = 3370 (w), 2313 (w), 3027 (w), 2930 (m), 2870 (w), 
1907 (vw), 1726 (vw), 1619 (m), 1598 (vs), 1505 (m), 1463 (s), 1428 (m), 1404 (w), 1374 
(w), 1341 (w), 1297 (m), 1275 (s), 1138 (vs), 1083 (m), 1065 (m), 1012 (m), 949 (w), 836 
(s), 751 (vs), 711 (m), 666(w). HRMS (EI): calc. for C27H33N4O+ [M+H]+: 429.2649, found: 
429.2645. 
 
 
 
MalAzoPPHT (1): Oxalylchloride (0.05 mL, 0.610 mmol) and DMF (1 drop) were added 
sequentially to a solution of 2-maleimidoacetic acid (73 mg, 0.469 mmol) in CH2Cl2 
(5 mL) and the reaction mixture was stirred for 2 h at room temperature. The solvent was 
evaporated in vacuo and the resulting residue was redissolved in THF (3 mL). The 
solution was added dropwise to an ice cooled solution of phenol 10 (67 mg, 0.156 mmol) 
and DIPEA (0.10 mL, 0.610 mmol) in THF (3 mL) and the reaction was stirred for 30 min 
at room temperature. The solvent was evaporated under reduced pressure and the 
resulting residue was purified by flash column chromatography (MeOH:CH2Cl2 3:97, Rf 
= 0.25) to give MalAzoPPHT (1) (41 mg, 0.072 mmol, 46%) as a red solid. 
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Data for 1: 1H NMR (400 MHz, CDCl3): δ (ppm) 8.00 (s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 
7.80 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.98 (t, J = 7.7 
Hz, 1H), 6.79 (s, 2H), 6.67 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 7.9 Hz, 1H), 5.56 (s, 1H), 4.37 
(s, 2H), 3.04 – 2.70 (m, 8H), 2.62 – 2.50 (m, 3H), 1.61 (tt, J = 12.1, 6.2 Hz, 1H), 1.50 (p, 
J = 7.4 Hz, 2H), 0.89 (t, J = 7.3 Hz, 3H).13C NMR (100 MHz, CDCl3): δ (ppm) = 170.3, 
164.5, 153.6, 151.1, 138.5, 134.7, 129.7, 126.5, 124.3, 124.0, 123.1, 122.9, 122.7, 121.8, 
121.7, 120.1, 112.1, 56.7, 52.7, 52.6, 41.4, 35.9, 32.3, 25.8, 23.8, 22.2, 12.1. IR (ATR): 
𝜈max (cm−1) = 2933(m), 1741(s), 1595 (vs), 1560 (s), 1501 (m), 1464 (m), 1408 (s), 1301 
(s), 1253 (s), 1156 (s), 1012 (w), 846 (s), 771 (m), 676 (w). HRMS (ESI): calc. for 
C33H36N5O4+ [M+H]+: 566.2762, found: 566.2763. 
 
 
 
AP 2 (2): NaHB(OAc)3 (103 mg, 0.46 mmol) was added to a solution of amine 11 (73 mg, 
0.32 mmol) and 5-hydroxytetralone (50 mg, 0.31 mmol) in DCE (2 mL) and the resulting 
suspension was stirred at room temperature overnight. The reaction mixture was 
portioned between EtOAc and aqueous. NaHCO3 solution and the organic phase was 
further washed with aqueous. NaHCO3 solution. a solution of sodium chloride (10%) and 
brine. The solution was dried over Na2SO4 and concentrated under reduced pressure 
yielding the crude alkylation product as an orange oil, which was immediately transferred 
to the next step. 
The freshly prepared secondary amine (described above) was redissolved in DCE 
(1.5 mL) and treated with propionaldehyde (25 µL, 0.34 mmol) followed by NaHB(OAc)3 
(103 mg, 0.46 mmol). After 5 h, the reaction was quenched and worked up as described 
above yielding the crude product tertiary amine. Medium pressure chromatography 
(Biotage, 25 g SiO2 column, EtOAc:hexanes 10:90–100:0, Rf= 0.6 EtOAc:hexanes 1:1) 
afforded AP 2 (2) as an orange oil (110 mg, 0.27 mmol, 87% over 2 steps). 
Data for 2: 1H NMR (600 MHz, CDCl3): δ (ppm) = 7.94 – 7.89 (m, 2H), 7.89 – 7.83 (m, 
2H), 7.54 – 7.49 (m, 2H), 7.49 – 7.44 (m, 1H), 7.37 – 7.32 (m, 2H), 6.99 (t, J=7.8, 1H), 
6.68 (d, J=7.7, 1H), 6.60 (d, J=7.9, 1H), 5.40 (s, 1H), 3.06 – 2.87 (m, 3H), 2.85 (s, 4H), 
2.82 – 2.66 (m, J=28.9, 15.2, 9.4, 1H), 2.63 – 2.53 (m, 3H), 2.13 – 2.07 (m, 1H), 1.68 – 
1.57 (m, 1H), 1.57 – 1.47 (m, 2H), 0.91 (t, J=7.3, 3H). 13C NMR (100 MHz, CDCl3): δ 
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(ppm) = 153.46, 152.72, 151.07, 144.48, 138.37, 130.72, 129.52, 129.04, 126.40, 
122.94, 122.83, 122.73, 121.68, 111.97, 56.58, 52.62, 52.54, 35.81, 32.24, 25.70, 23.60, 
22.08, 11.93. IR (ATR): 𝜈max (cm−1) = 3043 (w), 2931 (m), 1585 (s), 1499 (w), 1484 (w), 
1464 (s), 1373 (m), 1340 (m), 1277 (s), 1221 (w), 1154 (m), 1104 (w), 1070 (w), 1012 
(m), 919 (w), 836 (m), 808 (w), 766 (vs), 712 (w), 687 (vs). HRMS (ESI): calc. for 
C27H32N3O+ [M+H]+: 414.2545, found: 414.2537. 
 
 
 
Benzylamine S3.1: To a solution of tetralone 5 (6.13 g, 34.81 mmol, 1.0 eq) in DCE (90 
mL) was added benzyl amine (4.95 mL, 4.85 g, 45.3 mmol, 1.3 eq) followed by 
NaBH(OAc)3 (13.3 g, 62.7 mmol, 1.8 eq). The reaction mixture was stirred over night at 
room temperature and then partitioned between saturated NaHCO3(aq) (90 mL) and 
EtOAc (90 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (4 x 90 mL). The combined organic layers were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. The resulting crude material was 
purified by flash chromatography (SiO2, gradient 0 to 10 % MeOH in DCM + 1% NEt3). 
Benzylamine S3.1 was obtained as a brown oil (8.1 g, 30.2 mmol, 87 %). 
Data for S3.1: Rf: 0.7 (MeOH:CH2Cl2:NEt3 4:95:1), 1H NMR (400 MHz, dmso-d6): δ 
(ppm) = 7.34 (dd, J=3.2, 5.2, 2H), 7.30 – 7.24 (m, 2H), 7.21 – 7.15 (m, 1H), 7.02 (t, J=7.9, 
1H), 6.68 (d, J=8.0, 1H), 6.62 (d, J=7.6, 1H), 3.77 (s, 2H), 3.71 (s, 3H), 2.91 (dd, J=4.2, 
16.0, 1H), 2.79 – 2.69 (m, 2H), 2.52 – 2.34 (m, 2H), 2.03 – 1.92 (m, 1H), 1.44 (dtd, J=5.8, 
10.2, 12.7, 1H). 13C NMR (101 MHz, dmso-d6): δ (ppm) = 157.10, 141.70, 137.02, 
128.48, 128.37, 126.84, 126.52, 124.77, 121.66, 107.59, 55.49, 52.12, 50.53, 36.52, 
28.83, 22.12. HRMS (EI): calc. for C18H21NO [M]–: 267.1623; found: 267.1625. 
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Secondary amine S3.2: The partially enriched aminotetraline from the resolution above 
was free based and treated with 1 eq (-)-di-O-4-toluoyl-L-tartaric acid. The precipitated 
tartrate salt was recrystallized until optical rotation was constant. 
[𝛂]𝑫
𝟐𝟎  (HCl salt) = - 58.4 ° (c = 2, MeOH). 
 
 
 
Tertiary amine S3.3: Propionaldehyde (0.28 mL, 3.96 mmol) and sodium 
triacetoxyborohydride (1.05 g, 4.96 mmol) were added to a solution of secondary amine 
S3.2 (1.0 g, 3.29 mmol) and triethylamine (0.9 mL, 65.8 mmol) in dichloroethane 
(35 mL). The solution was stirred at room temperature overnight before the solvent was 
evaporated in vacuum. The resulting residue was portioned between a saturated solution 
of ammonium chloride and ethyl acetate. The organic phase was washed with a 
saturated solution of sodium bicarbonate and brine and dried over MgSO4. Evaporation 
of the solvent under reduced pressure gave tertiary amine S3.3 (995 mg, 3.22 mmol, 
98%) as a colorless oil. 
Data for S3.3: 1H-NMR (400 MHz, CDCl3, 23 °C): δ (ppm) =7.31 (m, 4H), 7.24 (m, 1H), 
7.09 (t, J = 7.9 Hz, 1H), 6.69 (m, 2H), 3.91 (s, 2H), 3.81 (s, 3H), 2.97 (m, 3H), 2.61 (m, 
2H), 2.10 (m, 1H), 1.63 (m, 1H), 13C-NMR (400 MHz, CDCl3, 23 °C): δ (ppm) = 157.4, 
140.9, 136.9, 128.7, 128.4, 127.1, 126.4, 125.3, 121.8, 76.9, 55.4, 52.6, 51.4, 37.0, 29.3, 
22.3. HRMS (ESI): calc. for C21H28NO [M+H]+:310.2165, found: 310.2164. 
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Propylamine 3.6: Palladium on charcoal (10%, 170 mg) was added to a solution of 
tertiary amine S3.3 (509 mg, 1.64 mmol) in methanol (7 mL). The flask was flushed three 
times with hydrogen and the reaction was stirred under a hydrogen atmosphere at room 
temperature overnight. Filtration over celite and subsequent removal of the solvent under 
reduced pressure gave propylamine 3.6 (337 mg, 1.54 mmol, 94%) as a colorless oil. 
Data for 3.6: 1H-NMR (400 MHz, CDCl3, 23 °C): δ (ppm) =7.07 (t, J= 7.9 Hz, 1H), 6.69 
(dd, J= 13.6, 7.9 Hz, 2H), 3.79 s, 3H), 3.10-2.87 (m, 3H), 2.80-2.70 (m, 2H), 2.68-2.48 
(m, 2H), 2.17 (dt, J= 9.4, 3.1 Hz, 1H), 1.68-1.48 (m, 3H), 0.99 (t, J= 7.4 Hz, 3H). 13C-
NMR (400 MHz, CDCl3, 23 °C): δ (ppm) = 158.6, 136.7, 127.6, 125.5, 122.4, 108.3, 55.6, 
54.9, 49.4, 36.2, 29.1, 23.3, 23.2, 12.0. IR (ATR): 𝜈max (cm−1) = 2936 (m), 2875 (w), 2835 
(m), 2792 (m), 2734 (m), 2537 (w), 2445 (w), 1587 (s), 1468 (vs), 1438 (s), 1395 (w), 
1382 (w), 1346 (w), 1312 (w), 1284 (w), 1258 (vs), 1094 (s), 1068 (m), 1036 (m), 987 
(m), 954 (m), 914 (w), 892 (w), 876 (w), 832 (w), 765 (vs), 709 (m), 694 (m). HRMS (ESI): 
calc. for C14H22NO [M+H]+: 220.1696, found: 220.1696. 
 
 
 
Nitrobenzene 3.4: DMP (3.50 g, 8.22 mmol) was added to a solution of 2-(4-
nitrophenyl)ethan-1-ol (457 g, 2.74 mmol) in CH2Cl2 and the reaction was stirred at room 
temperature for 3 h. The mixture was washed with aqueous Na2S2O3 solution, water and 
brine, dried over MgSO4 and evaporated to dryness.  
The resulting residue was redissolved in DCE (150 mL). 5-methoxy-N-propyl-1,2,3,4-
tetrahydronaphthalen-2-amine (250 mg, 1.14 mmol) and NaBH(OAc)3 (300 g, 
1.56 mmol) were sequentially added and the reaction mixture was stirred at room 
temperature overnight. The solvent was removed in vacuum and the residue was 
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portioned between EtOAc and aqueous NaHCO3 solution. The organic phase was 
washed with brine, dried over MgSO4 and concentrated under reduced pressure to yield 
nitrobenzene 3.4 (172 mg, 0.46 mmol, 41%) as a yellow solid. 
Data for 3.4: 1H-NMR (400 MHz, CDCl3, 23 °C): δ = 8.19 – 8.10 (m, 2H), 7.41 – 7.32 (m, 
2H), 7.09 (t, J = 7.9 Hz, 1H), 6.67 (dd, J = 14.0, 7.9 Hz, 2H), 3.81 (s, 3H), 2.96 (dddd, J 
= 13.9, 11.5, 5.2, 2.4 Hz, 2H), 2.90 – 2.76 (m, 5H), 2.70 (dd, J = 16.1, 11.2 Hz, 1H), 2.51 
(ddd, J = 21.4, 10.3, 6.2 Hz, 3H), 1.99 (ddt, J = 12.7, 4.8, 2.4 Hz, 1H), 1.55 (tt, J = 12.1, 
6.1 Hz, 1H), 1.49 – 1.38 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H). 13C-NMR (400 MHz, CDCl3, 23 
°C): δ = 157.3, 149.2, 146.5, 137.9, 129.8, 126.3, 125.3, 123.6,121.7, 107.1, 76.8, 56.5, 
55.4, 52.6, 52.2, 36.0, 32.3, 25.7, 23.9, 22.2, 12.0. IR (ATR): 𝜈max (cm−1) = 2932 (w), 
2838 (m), 2361 (w), 1734 (w), 1670 (w), 1654 (w), 1600 (m), 1586 (m), 1517 (s), 1469 
(m), 1438 (m), 1344 (vs), 1260 (s), 1217 (w), 1167 (w), 1095 (m), 1072 (w), 1015 (vw), 
964 (vw), 856 (m), 767 (m), 748 (vw), 711 (vw), 698 (w), 668 (vw). HRMS (ESI): calc. for 
C22H29N2O [M+H]+: 369.2173, found: 369.2178. [𝛂]𝑫
𝟐𝟎  =–27.5 ° (c=0.4, MeOH) 
 
 
 
Aniline 3.8: A suspension of Pd/C (30 mg) and nitrobenzene 3.4 (150 mg, 0.41 mmol) 
in ethyl acetate (30 mL) was stirred under a hydrogen atmosphere at room temperature 
overnight. The reaction was filtered over celite and the resulting filtrate was concentrated 
under reduced pressure to yield aniline 3.8 (80 mg, 0.24 mmol,58%) as a yellow oil. 
Data for 3.8: 1H-NMR (400 MHz, CDCl3, 23 °C): δ (ppm)= 7.09 (t, J=7.9 Hz, 1H), 6.98 
(d, J=7.9 Hz, 2H), 6.68 (dd, J=22.0, 7.9 Hz, 2H), 6.60 (d, J=7.9 Hz, 2H), 3.79 (s, 3H), 
3.65 (s, 2H), 3.17 (s, 1H), 3.09-2.96 (m, 2H), 2.95-2.66 (m, 7H), 2.55 (td, J=12.0, 6.0 Hz, 
1H), 2.31-2.14 (m, 1H), 1.77-1.57 (m, 3H), 0.94 (t, J=7.3 Hz, 3H). 13C-NMR (400 MHz, 
CDCl3, 23 °C): δ (ppm) = 170.9, 157.0, 144.9, 129.3, 126.3, 124.5, 121.4, 115.1, 107.0, 
60.2, 57.5, 55.0, 52.8, 52.3, 31.3, 24.9, 23.4, 20.8, 14.0, 11.6. IR (ATR): 𝜈max (cm−1) = 
3336 (w), 2933 (m), 2508 (w), 2246 (vw), 1623 (m), 1586 (m), 1516 (s), 1486 8s), 1438 
(m), 1378 (w), 1346 (w), 1260 (s), 1216 (m), 1180 (m), 1128 (m), 1094 (s), 1071 (m), 926 
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(w), 907 (vs), 826 (m), 768 (s). HRMS (ESI): calc. for C22H31N2O3 [M+H]+: 339.2431, 
found: 339.2436. [𝛂]𝑫
𝟐𝟎 =–26.8 ° (c=0.3, MeOH) 
 
 
 
Dimethylaniline 3.7: TFA (0.06 mL, 0.75 mmol) and tBuNO2 (0.04 mL, 0.50 mmol) were 
sequentially added to an ice cooled solution of aniline 3.8 (80 mg, 0.24 mmol) in MeCN 
(25 mL) and the reaction was stirred for 1 h at 0 °C. N,N-dimethylaniline (0.63 mL, 
4.94 mmol) was added to the solution and the reaction was stirred at 0 °C for 1 h. The 
mixture was extracted with EtOAc and the organic phase was washed with aqueous 
NaOH (1 M), aqueous HCl (1 M) and brine, dried over MgSO4 and concentrated under 
reduced pressure. The resulting residue was redissolved in CH2Cl2 (40 mL) and cooled 
to –78 °C. BBr3 (1 M in CH2Cl2, 1 mL, 1 mmol) was added and the reaction was stirred 
90 min at –78 °C and 1 h at room temperature. The mixture was quenched with MeOH 
(10 mL) and the reaction was extracted with CH2Cl2. The organic phase was dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resulting residue 
by flash column chromatography (MeOH:CH2Cl2 2:98, Rf =0.2) gave dimethylaniline 3.7 
(90 mg, 0.20 mmol, 85% over 2 steps) as a red solid. 
Data for 3.7: 1H-NMR (400 MHz, CDCl323 °C): δ (ppm) = 7.88 (d, J = 9.0 Hz, 2H), 7.78 
(d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 6.99 (t, J = 7.8 Hz, 1H), 6.76 (d, J = 9.1 Hz, 
2H), 6.69 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 7.9 Hz, 1H), 3.08 (s, 6H), 3.05 – 2.95 (m, 2H), 
2.94 – 2.89 (m, 1H), 2.84 (s, 4H), 2.77 (dd, J = 16.1, 11.4 Hz, 1H), 2.58 (ddd, J = 17.6, 
10.6, 6.1 Hz, 3H), 2.19 – 2.04 (m, 1H), 1.59 (ddt, J = 41.0, 15.0, 6.9 Hz, 3H), 0.91 (t, J = 
7.3 Hz, 3H). 13C-NMR (400 MHz, CDCl323 °C): δ (ppm) = 153.6, 152.4, 151.7, 143.8, 
142.6, 138.5, 129.5, 126.5, 124.9, 123.1, 122.3, 121.8, 112.1, 111.6, 76.84, 56.8, 52.8, 
40.5, 35.8, 32.3, 25.8, 23.8, 22.1, 12.1. IR (ATR): 𝜈max (cm−1) = 3028 (w), 2930 (m), 2870 
(m), 2245 (w), 1904 (vw), 1586 (m), 1660 (w), 1598 (vs), 1516 (s), 1463 (m), 1444 (m), 
1426 (m), 1402 (m), 1361 (s), 1312 (m), 1275 (s), 1248 (m), 1229 (m), 1138 8vs), 1083 
(m9, 1063 (s), 1012 (m), 944 (m), 906 (s), 821 (s), 768 (s). MS (ESI): calc. for C29H37N4O 
[M+H]+: 457.2962, found: 457.2968. [𝛂]𝑫
𝟐𝟎  =–26 ° (c=0.1, MeOH)  
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Amine 3.12: Bromoacetylbromide (0.06 mL, 0.699 mmol) was added dropwise to an ice 
cooled solution of phenol 3.10 (214 mg, 0.499 mmol) and DIPEA (0.12 mL, 0.699 mmol) 
in THF (8 mL) and the resulting solution was stirred for 10 min at that temperature and 
for 8 h at room temperature. The reaction was diluted with EtOAc and washed with a 
saturated aqueous solution of NaHCO3 and brine. The organic phase was dried over 
MgSO4 and concentrated under reduced pressure. The resulting residue was redissolved 
in THF (11 mL) and cooled to 0 °C. Ammonia (7 M in MeOH, 4.00 mL, 28.0 mmol) was 
added and the mixture was stirred at room temperature overnight. The reaction was 
diluted with H2O and extracted with EtOAc. The combined organic phases were washed 
with brine, dried over MgSO4 and concentrated under reduced pressure. Purification of 
the resulting residue by flash column chromatography (MeOH:CH2Cl2:NH3 (aq.) 4:96:1-
7:93:1, Rf (MeOH:CH2Cl2:NH3 (aq.) 8:92:1) = 0.6) gave amine 3.12 (125 mg, 0.257 mmol, 
52%) as an orange solid). 
Data for 3.12: 1H NMR (600 MHz, d4-MeOH): δ (ppm) = 7.87 (d, J = 8.6 Hz, 2H), 7.78 
(dd, J = 10.5, 8.4 Hz, 4H), 7.35 (d, J = 8.1 Hz, 2H), 6.88 (t, J = 7.8 Hz, 1H), 6.55 (dd, J = 
7.8, 3.5 Hz, 2H), 3.44 (s, 2H), 2.95 (dtd, J = 13.7, 7.3, 6.2, 3.5 Hz, 2H), 2.82 (s, 5H), 2.69 
(dd, J = 15.7, 11.4 Hz, 1H), 2.63 – 2.55 (m, 2H), 2.49 (ddd, J = 17.6, 12.7, 6.2 Hz, 1H), 
2.14 – 2.02 (m, 1H), 1.57 – 1.44 (m, 3H), 0.91 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, 
d4-MeOH): δ (ppm) = 173.7, 155.9, 152.4, 150.1, 145.5, 142.4, 138.6, 130.7, 127.2, 
124.7, 124.3, 123.8, 121.6, 120.9, 112.6, 58.24, 53.7, 53.6, 45.7, 35.9, 33.3, 26.9, 24.8, 
22.7, 12.3. IR (ATR): 𝜈max (cm−1) = 3224 (w), 2918 (w), 1666 (s), 1584 (s), 1524 (vs), 
1463 (s). 1404 (m), 1301 (m), 1278 (s), 1153 (m), 1083 (m), 1018 (w), 846 (s), 818 (m), 
769 (s). HRMS (ESI): calc. for C29H36N5O2+ [M+H]+: 486.2864, found: 486.2861. 
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Azide 3.14: DIPEA (0.03 mL, 0.16 mmol) was added to a stirred solution of amine 3.12 
(39.0 mg, 0.08 mmol) and Azido-(PEG)12-NHS-ester (60.0 mg, 0.08 mmol) in DMF 
(0.5 mL) and the resulting solution was stirred at room temperature overnight. The 
reaction was diluted with EtOAc and washed with brine. The organic phase was dried 
over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by reverse phase column chromatography (MeCN:HCl (aq. 0.1%) )0:100-40:60) 
gave azide 3.14 (60 mg, 0.054 mmol, 67%) as an orange solid. 
Data for 3.14: 1H NMR (600 MHz, d4-MeOH): δ (ppm) = 7.90 (td, J = 5.7, 3.0 Hz, 4H), 
7.84 – 7.74 (m, 2H), 7.54 (d, J = 7.9 Hz, 2H), 6.98 (t, J = 7.8 Hz, 1H), 6.67 (dd, J = 8.0, 
2.1 Hz, 1H), 6.62 (d, J = 7.9 Hz, 1H), 4.09 (s, 2H), 3.81 (t, J = 5.8 Hz, 3H), 3.76 – 3.49 
(m, 48H), 3.48 – 3.32 (m, 4H), 3.31 – 3.05 (m, 8H), 2.75 – 2.51 (m, 3H), 2.40 (d, J = 11.8 
Hz, 1H), 2.02 – 1.80 (m, 3H), 1.09 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, d4-MeOH): δ 
(ppm) = 174.81, 169.83, 156.08, 153.09, 149.95, 142.64, 140.87, 134.77, 131.03, 
127.99, 124.83, 124.24, 123.01, 121.28, 121.09, 113.40, 71.53, 71.48, 71.45, 71.43, 
71.38, 71.31, 71.26, 71.10, 68.22, 68.05, 67.60, 61.98, 61.93, 54.10, 53.86, 53.31, 53.02, 
51.76, 44.33, 41.89, 37.25, 35.67, 32.20, 32.05, 30.88, 30.76, 25.00, 24.84, 23.76, 20.05, 
19.87, 11.53. IR (ATR): 𝜈max (cm−1) = 3186 (w), 2972 (w), 2944 (w), 2878 (m), 2819 (m), 
2533 (w), 2101 (m), 1946 (w), 1732 (s), 1662 (m), 1593 (m), 1541 (m), 1502 (m), 1464 
(m), 1407 (w), 1347 (m), 1301 (m), 1284 (m), 1264 (w), 1247 (m), 1217 (m), 1192 (m), 
1086 (s), 1030 (m), 991 8w), 946 (m), 849 (m), 810 (w), 774 (m), 734 (w). HRMS (ESI): 
calc. for C56H87N8O15+ [M+H]+: 1111.6285, found: 1111.6261. 
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Acid 3.16: A solution of [Cu(MeCN)4]PF6 (12.4 mg, 0.033 mmol) in degassed t-
BuOH/H2O (2:1 3 mL) was added slowly to a solution of azide 3.14 (35 mg, 0.031 mmol), 
4-pentynoic acid (6.2 mg, 0.063 mmol) and TBTA (17.7 mg, 0.033 mmol) in degassed t-
BuOH (H2O (2:2, 3 mL) and degassed DMSO (1 mL) at 0 °C and the mixture was stirred 
at room temperature for 24 h. The reaction was diluted with EtOAc and washed with 
brine. The organic phase was dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resulting residue by reverse phase column chromatography 
(MeCN:HCl (aq. 0.1%) ) 0:100-40:60) gave acid 3.16 (17 mg, 0.014 mmol, 45%) as an 
orange solid. 
Data for 3.16: 1H NMR (600 MHz, d4-MeOH): δ (ppm) = 8.50 (s, 1H), 7.91 (td, J = 6.7, 
3.5 Hz, 4H), 7.84 – 7.76 (m, 2H), 7.59 – 7.54 (m, 2H), 7.00 (t, J = 7.8 Hz, 1H), 6.68 (dt, 
J = 7.6, 1.7 Hz, 1H), 6.64 (d, J = 7.9 Hz, 1H), 4.83 – 4.73 (m, 2H), 4.11 (s, 2H), 3.98 (dd, 
J = 5.5, 4.2 Hz, 2H), 3.82 (t, J = 5.9 Hz, 3H), 3.78 – 3.34 (m, 46H), 3.27 (dt, J = 12.5, 4.5 
Hz, 3H), 3.23 – 3.06 (m, 5H), 2.82 (t, J = 6.9 Hz, 2H), 2.76 – 2.64 (m, 1H), 2.61 (t, J = 
5.9 Hz, 2H), 2.42 (t, J = 8.0 Hz, 1H), 2.01 – 1.87 (m, 3H), 1.13 – 1.07 (m, 3H). 13C NMR 
(100 MHz, d4-MeOH): δ (ppm) = 174.8, 173.8, 169.9, 156.2, 153.2, 150.0, 142.7, 140.9, 
140.9, 134.8, 130.9, 128.4, 128.0, 124.8, 124.2, 123.0, 121.3, 121.1, 113.4, 71.5, 71.5, 
71.4, 71.4, 71.3, 69.4, 68.2, 62.0, 62.0, 54.1, 54.0, 53.7, 53.2, 52.9, 44.3, 37.3, 32.9, 
32.1, 32.0, 30.8, 30.7, 25.0, 24.8, 23.7, 20.2, 20.0, 19.8, 11.4, 11.4. IR (ATR): 𝜈max (cm−1) 
= 3230 (br), 2878 (m), 1733 (m), 1669 (m), 1599 (m), 1543 (m), 1503 (m), 1465 (m), 
1349 8m), 1300 (m), 1281 (m), 1251 (m), 1090 (vs), 950 (w), 852 (m), 780 (w). HRMS 
(ESI): calc. for C61H94N8O17+ [M+H]2+: 605.3363, found: 605.3363. 
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BGAP (3.18): DIPEA (0.02 mL, 115 µmol) was added to a solution of acid 3.16 (9.0 mg, 
7.40 µmol), amine 3.1793 (4.0 mg, 14.9 µmol) and TBTU (5.2 mg, 16.0 µmol) in DMF 
(0.7 mL) and the resulting solution was stirred at room temperature overnight. Purification 
by reverse phase HPLC (MeCN:H2O:HCOOH 10:90:0.1-100:0:0.1) gave BGAP (3.18) 
(5.0 mg, 3.40 µmol, 46%) as an orange solid. 
Data for 3.18: 1H NMR (600 MHz, d4-MeOH): δ (ppm) = 8.50 (s, 2H), 7.88 (ddt, J = 9.1, 
6.8, 2.5 Hz, 5H), 7.83 – 7.75 (m, 2H), 7.69 (s, 1H), 7.52 – 7.44 (m, 4H), 7.23 – 7.16 (m, 
2H), 6.96 (t, J = 7.8 Hz, 1H), 6.66 – 6.59 (m, 2H), 5.53 (s, 2H), 4.44 (dd, J = 5.5, 4.5 Hz, 
2H), 4.33 (s, 2H), 4.08 (s, 2H), 3.81 – 3.74 (m, 4H), 3.67 – 3.50 (m, 48H), 3.43 (dd, J = 
10.3, 6.5 Hz, 2H), 3.13 (dddd, J = 24.0, 16.8, 9.8, 4.5 Hz, 6H), 3.00 (t, J = 7.3 Hz, 2H), 
2.59 (td, J = 6.6, 5.9, 4.2 Hz, 4H), 2.38 – 2.28 (m, 1H), 1.86 – 1.79 (m, 2H), 1.05 (t, J = 
7.3 Hz, 3H). 13C NMR (100 MHz, d4-MeOH): δ (ppm) = 174.8, 174.3, 170.1, 170.0, 169.9, 
161.7, 161.4, 156.1, 153.1, 150.1, 147.4, 142.7, 141.6, 140.1, 137.0, 135.4, 130.8, 129.7, 
128.7, 127.9, 124.8, 124.4, 124.2, 123.3, 121.3, 121.2, 113.3, 71.4, 71.4, 71.3, 70.3, 
68.5, 68.2, 61.3, 53.8, 53.1, 51.3, 44.3, 43.8, 37.4, 36.4, 32.8, 31.2, 25.2, 23.9, 22.6, 
20.4, 11.5. IR (ATR): 𝜈max (cm−1) = 2870 (s), 2361 (m), 1586 (vs), 1506 (w), 1465 (s), 
1350 (m), 1280 (w), 1106 (s), 949 (w), 851 (w), 668 (w). HRMS (ESI): calc. for 
C74H106N14O17+ [M+2H]2+: 731.3916, found: 731.3925. 
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Amide 3.22: DCC (8.00 g, 38.62 mmol) was added portionwise to an ice cooled solution 
of 3,4-diemethoxyphenylamine (7.00 g, 38.62 mmol), 4-nitrophenylacetic acid (7.00 g, 
38.62 mmol) and HOBt (7.58 g, 50.20 mmol) in MeCN (355 mL) and the reaction was 
stirred at room temperature for 20 h. The resulting precipitate was removed by filtration 
and the solvent was removed under reduced pressure. Purification of the resulting 
residue by flash column chromatography (MeOH : CH2Cl2 4:96, Rf = 0.3) gave amide 
3.22 (13.07 g, 37.95 mmol, 98%) as a white solid. 
Data for 3.22: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.23 – 8.13 (m, 2H), 7.43 – 7.34 
(m, 2H), 6.75 (d, J = 8.1 Hz, 1H), 6.66 (d, J = 2.0 Hz, 1H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H), 
5.47 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.61 (s, 2H), 3.52 (td, J = 6.9, 5.7 Hz, 2H), 2.75 
(t, J = 6.9 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 169.1, 149.2, 147.9, 147.3, 
142.4, 130.9, 130.3, 124.1, 120.7, 111.8, 111.2, 56.0, 56.0, 43.5, 40.9, 35.1. IR (ATR): 
𝜈max (cm−1) = 3298 (m), 1655 (m), 1644 (m), 1611 (m), 1537 (vs), 1516 (s), 1464 (m), 
1438 (w), 1418 (m), 1350 (vs), 1263 (s), 1231 (s), 1191 (m), 1155 (m), 1140 (s), 1107 
(m), 1028 (s), 1013 (m), 945 (w), 872 (w), 858 (s), 848 (m), 807 (m), 765 (m), 708 (s). 
HRMS (ESI): calc. for C18H20N2O5+ [M]+: 344.1367, found: 344.1367. 
 
 
 
Carbamate 3.24: BH3.Me2S (0.83 mL, 8.71 mmol) was added dropwise to an ice cooled 
solution of amide 3.22 (3.00 g, 8.71 mmol) in THF (380 mL) and the reaction was stirred 
at 65 °C for 3 h. The mixture was cooled to 0 °C and MeOH (25 mL) and an aqueous 
solution of NaOH (1M, 50 mL) were sequentially added. The reaction was stirred for 2 h 
at 65 °C and concentrated under reduced pressure. The resulting residue was portioned 
between EtOAc and H2O and the organic phase was dried over MgSO4 and concentrated 
under reduced pressure to give crude secondary amine 3.23 which was used in the next 
step without further purification. 
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Boc2O (2.03 g, 9.28 mmol) was added to an ice cooled solution of crude amine 3.23 in 
THF (70 mL) and aqueous NaOH (1M, 22 mL) and the reaction was stirred at room 
temperature for 3.5 h. The mixture was extracted with EtOAc, the organic phase was 
washed with brine and dried over MgSO4. Evaporation of the solvent under reduced 
pressure and purification of the resulting residue by flash column chromatography 
(EtOAc:hexanes 1:3, Rf = 0.3) gave carbamate 3.24 (2.65 g, 6.16 mmol, 72% over 2 
steps) as a colourless solid. The product was received as mixture of rotamers. 
Data for 3.24: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.13 (d, J = 8.3 Hz, 2H), 7.37 – 
7.25 (m, 2H), 6.75 – 6.61 (m, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.31 (ddt, J = 29.7, 14.5, 
7.3 Hz, 4H), 2.93 – 2.67 (m, 4H), 1.41 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 
155.2, 155.1, 148.9, 147.6, 147.6, 147.2, 147.1, 146.6, 131.6, 129.7, 123.7, 120.69, 
112.0, 111.9, 111.3, 79.7, 55.9, 55.8, 50.1, 49.6, 49.2, 48.9, 35.2, 34.9, 34.6, 34.1, 28.4. 
IR (ATR): 𝜈max (cm−1) = 2973 (w), 2936 (w), 2835 (w), 1685 (s), 1599 (m), 1514 (vs), 1465 
(m), 1452 (m), 1414 (s), 1365 (m), 1344 (vs), 1260 (s), 1235 (s), 1155 (vs), 1109 (m), 
1028 (s), 940 (w), 894 (w), 855 (m), 806 (m), 764 (m), 748 (w), 699 (w). HRMS (ESI): 
calc. for C18H23N2O4+ [M–Boc+H]+: 331.1652, found: 331.1651. 
 
 
 
Aniline 3.25: A suspension of carbamate 3.24 (2.44 g, 5.67 mmol) and Pd/C (250 mg, 
10w%) in EtOAc (80 mL) was stirred under a H2-atmosphere at room temperature 
overnight. Filtration of the reaction mixture over a pad of celite and evaporation of the 
solvent under reduced pressure gave aniline 3.25 (2.16 g, 5.39 mmol, 95%) as a slightly 
yellowish oil. The product was received as mixture of rotamers. 
Data for 3.25: 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.98 (d, J = 8.4 Hz, 1H), 6.94 – 
6.87 (m, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.75 – 6.64 (m, 2H), 6.64 – 6.60 (m, 2H), 3.86 (s, 
3H), 3.85 (s, 3H), 3.37 – 3.21 (m, 4H), 2.80 – 2.61 (m, 4H), 1.45 (s, 9H). 13C NMR (100 
MHz, CDCl3): δ (ppm) = 155.5, 148.9, 147.6, 147.5, 144.7, 144.6, 132.06, 129.8, 129.5, 
129.4, 120.8, 115.4, 112.1, 111.3, 79.4, 56.0, 55.9, 50.2, 50.1, 49.9, 49.7, 35.0, 34.6, 
34.3, 34.0, 28.6. IR (ATR): 𝜈max (cm−1) = 3460 (w), 3368 (w), 2971 (w), 1684 (vs), 1625 
(w), 1589 (w), 1516 (s), 1470 (m), 1460 (w) 1445 (w), 1365 (m), 1310 (w), 1286 (w), 1259 
(s), 1232(s), 1164 (s), 1154 (s), 1138 (s), 1106 (w), 1024 (s), 969 (w), 939 (w), 917 (w), 
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879 (w), 856 (w), 817 (m), 778 (w), 763 (w). HRMS (ESI): calc. for C18H25N2O2+ [M–
Boc+H]+: 309.1911, found: 301.1910. 
 
 
 
Azobenzene 3.27: A solution of aniline 3.25 (2.50 g, 6.24 mmol), 4-
nitro(nitrosobenzene) (1.90 g, 12.48 mmol) and AcOH (20 mL) in CH2Cl2 (20 mL) and 
MeOH (30 mL) has been stirred at room temperature overnight and concentrated. The 
resulting residue was portioned between EtOAc and aqueous saturated NaHCO3 and 
the organic phase was washed with brine and dried over MgSO4. Evaporation of the 
solvent and purification by flash column chromatography (EtOAc:hexanes 20:80-30:70, 
Rf = 0.3) gave azobenzene 3.27 (2.50 g, 4.68 mmol, 75%) as a red solid. The product 
was received as mixture of rotamers. 
Data for 3.27: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.40 – 8.35 (m, 2H), 8.04 – 7.99 
(m, 2H), 7.93 – 7.87 (m, 2H), 7.41 – 7.28 (m, 2H), 6.79 (d, J = 8.0 Hz, 1H), 6.75 – 6.62 
(m, 2H), 3.86 (d, J = 1.5 Hz, 3H), 3.85 (s, 3H), 3.36 (s, 4H), 2.97 – 2.66 (m, 5H), 1.45 (s, 
10H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 155.9, 155.4, 151.2, 149.0, 148.7, 147.6, 
144.8, 144.6, 131.9, 130.0, 124.9, 123.8, 123.5, 120.8, 112.1, 111.4, 79.7, 56.1, 56.0, 
50.3, 50.3, 49.6, 49.4, 35.5, 35.0, 34.9, 34.3, 28.6. IR (ATR): 𝜈max (cm−1) = 3006 (w), 
28975 (w), 2934 (w), 1682 (s), 1590 (m), 1514 (s), 1456 (m), 1445 (s), 1413 (s), 1363 
(m), 1343 (s), 1308 (m), 1260 (m), 1236 (vs), 1199 (w), 1152 (vs), 1143 (s), 111 (s) 1027 
(s), 934 (m), 878 (w), 857 (m), 851 (m), 823 (w), 798 (m), 755 (s), 728 (w), 686 (m). 
HRMS (ESI): calc. for C29H33N4O6– [M–H]–: 533.2406, found: 533.2418. 
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Amine 3.28: Na2S.xH2O (812 mg, 8.45 mmol) was added to a suspension of 
azobenzene 3.27 (2.26 g, 4.23 mmol) in dioxane (30 mL) and H2O (30 mL) and the 
reaction was stirred at 100 °C for 4 h. After cooling to room temperature, the reaction 
was extracted with EtOAc and the combined organic layers were washed with aqueous 
NaOH (1M), aqueous Na2S2O3 (20%)and brine and dried over MgSO4. Evaporation of 
the solvent under reduced pressure and purification of the resulting residue by flash 
column chromatography (MeOH:CH2Cl2 0:100-2:98) gave amine 3.28 (1.80 g, 
3.57 mmol, 84%) as a red solid. The product was received as mixture of rotamers. 
Data for 3.28: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.87 – 7.70 (m, 4H), 7.30 (d, J = 
8.3 Hz, 3H), 6.83 – 6.56 (m, 5H), 4.05 (s, 2H), 3.91 – 3.82 (m, 6H), 3.47 – 3.14 (m, 4H), 
2.97 – 2.58 (m, 4H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 155.3, 151.6, 
149.5, 148.8, 147.5, 145.5, 141.6, 141.4, 131.8, 129.5, 125.0, 122.5, 120.7, 114.6, 112.0, 
111.2, 79.5, 77.4, 77.0, 76.7, 55.9, 55.8, 50.2, 49.7, 49.7, 49.5, 35.3, 34.6, 34.6, 34.2, 
28.5. IR (ATR): 𝜈max (cm−1) = 3448 (w), 3358 (w), 3236 (w) 2970 (w), 2934 (w), 1674 (s), 
1629 (m) 1599 (vs) 1507 (s), 1464 (m) 1415 (s), 1365 (m), 1297 (m), 1260 (m), 1234 (s), 
1154 (s), 1137 (vs), 1096 (m), 1026 (s), 940 (w), 892 (w), 838 (m), 807 (w), 764 (m). 
HRMS (ESI): calc. for C29H37N4O4+ [M+H]+: 505.2809, found: 505.2804. 
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Silyl ether 3.29: BBr3 (1 M in CH2Cl2, 15.2 mL, 15.2 mmol) was added to a solution of 
amine 3.28 (1.53 g, 3.03 mmol) in CH2Cl2 (30 mL) at –78 °C and the reaction was stirred 
for 1 h at that temperature and for 2 h at room temperature. The reaction was quenched 
by the slow addition of MeOH (3 mL) and concentrated under reduced pressure. 
The resulting residue was redissolved THF (20 mL) and aqueous saturated NaHCO3 
(10 mL) and Boc2O (728 mg, 3.34 mmol) was added. The reaction was stirred for 2 h at 
room temperature and extracted with EtOAc. The combined organic layers were washed 
with brine, dried over MgSO4 and concentrated under reduced pressure. 
The resulting residue was redissolved in MeCN (30 mL) and imidazole (727 mg, 
10.79 mmol) and TBSCl (1.45 g, 10.0 mmol) were added sequentially. The reaction was 
stirred for 5 h at room temperature and diluted with aqueous saturated NH4Cl (30 mL). 
The mixture was extracted with EtOAc and the combined organic layers were washed 
with brine, dried over MgSO4 and concentrated under reduced pressure. Purification of 
the resulting residue by flash column chromatography (EtOAc:hexanes 1:4) gave silyl 
ether 3.29 (1.66 g, 2.35 mmol, 78%) as a red solid. The product was received as mixture 
of rotamers. 
Data for 3.29: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.83 – 7.72 (m, 4H), 7.28 (d, J = 
7.8 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 6.77 – 6.70 (m, 3H), 6.65 – 6.55 (m, 2H), 4.04 (s, 
2H), 3.28 (dd, J = 47.0, 8.6 Hz, 4H), 2.89 – 2.59 (m, 4H), 1.50 – 1.45 (m, 9H), 0.98 (s, 
9H), 0.96 (s, 9H), 0.17 (s, 6H), 0.16 (s, 6H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 
155.4, 151.6, 149.5, 146.7, 145.7, 145.4, 141.7, 132.8, 132.4, 129.6, 125.1, 122.6, 121.9, 
121.8, 121.1, 114.8, 79.5, 77.2, 50.5, 50.1, 49.8, 49.8, 35.3, 34.8, 34.7, 34.1, 28.6, 28.5, 
26.1, 26.0, 18.6, 18.6, –3.9, –4.0. IR (ATR): 𝜈max (cm−1) = 3358 (w), 2956 (w), 2929 (w), 
2858 (w), 1678 (m), 1622 (w), 1600 (s), 1578 (w), 1507 (s), 1472 (m), 1418 (m), 1391 
(w), 1365 (m), 1296 (s), 1252 (s), 1156 (s), 1140 (s), 1096 (w), 1013 (w), 979 (w), 906 
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(m), 836 (vs), 780 (s), 733 (m). HRMS (ESI): calc. for C39H61NO4Si2+ [M+H]+: 705.4226, 
found: 705.4222. 
 
 
 
Amide 3.31: A solution of acid chloride 3.3094 (172 mg, 0.992 mmol) in THF (2 mL) was 
added dropwise to an ice cooled solution of silyl ether 3.29 (350 mg, 0.496 mmol) and 
NEt3 (0.14 mL, 0.992 mmol) in THF (7 mL) and the reaction was stirred for 10 min at 0 °C 
and for 2 h at room temperature. H2O (10 mL) was added and the reaction was extracted 
with EtOAc. The combined organic layers were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (EtOAc:hexanes 1:2, Rf=0.2) gave amide 3.31 (353 mg, 
0.419 mmol, 85%) as a red solid. The product was received as mixture of rotamers. 
Data for 3.31: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.28 – 7.97 (m, 1H), 7.82 – 7.54 
(m, 4H), 7.48 (d, J = 8.4 Hz, 2H), 7.10 (dd, J = 21.4, 8.0 Hz, 2H), 6.64 (s, 2H), 6.57 (d, J 
= 8.1 Hz, 1H), 6.50 – 6.38 (m, 2H), 4.22 (s, 2H), 3.32 – 2.99 (m, 4H), 2.80 – 2.36 (m, 
4H), 1.31 (d, J = 11.3 Hz, 9H), 0.81 (s, 9H), 0.80 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 
(ppm) = 170.3, 164.5, 155.5, 151.3, 149.4, 146.8, 145.5, 142.7, 139.7, 134.7, 134.6, 
132.7, 132.3, 129.7, 124.0, 123.1, 121.9, 121.8, 121.1, 120.1, 79.7, 77.5, 77.2, 76.8, 
50.4, 49.9, 49.7, 49.5, 41.3, 35.2, 34.8, 34.7, 34.1, 28.6, 26.1, 18.6, 18.5, –3.9, –4.0. IR 
(ATR): 𝜈max (cm−1) = 2956 (w), 2929 (w), 2858 (w), 1704 (s), 1601 (m), 1538 (m), 1510 
(s), 1472 (m), 1417 (s), 1390 (w), 1364 (s), 1299 (s), 1250 (s), 1154 (s), 1126 (w), 1110 
(w), 1096 (w), 1011 (w), 980 (w), 901 (m), 833 (vs), 779 (s), 696 (s). HRMS (ESI): calc. 
for C45H64N5O7Si2+ [M+H]+: 842.4339, found: 842.4331. 
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MADA (3.19): HF (60% in H2O, 0.15 mL) was added to an ice cooled solution of amide 
3.31 (140 mg, 0.166 mmol) in MeCN (1 mL) and the reaction was stirred for 6 h at room 
temperature. The resulting precipitate was collected and washed with MeCN to give 
MADA (3.19) as a red solid (43 mg, 0.083 mmol, 50%). 
Data for 3.19: 1H NMR (400 MHz, d4-MeOH): δ (ppm) = 10.66 (s, 1H), 8.49 (s, 2H), 7.91 
– 7.83 (m, 4H), 7.81 – 7.73 (m, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.16 (s, 2H), 6.68 (d, J = 
7.9 Hz, 1H), 6.63 (d, J = 2.1 Hz, 1H), 6.50 (dd, J = 8.0, 2.1 Hz, 1H), 4.33 (s, 2H), 3.25 
(dd, J = 9.7, 5.4 Hz, 2H), 3.17 – 3.08 (m, 2H), 3.01 (dd, J = 9.5, 6.5 Hz, 2H), 2.74 (dd, J 
= 9.5, 6.7 Hz, 2H). 13C NMR (100 MHz, d4-MeOH): δ (ppm) = 170.7, 165.5, 151.0, 147.8, 
145.4, 144.2, 141.5, 140.5, 135.1, 129.9, 127.6, 123.8, 122.7, 119.5, 119.4, 116.1, 115.7, 
79.2, 48.3, 47.5, 40.5, 31.5, 31.2. IR (ATR): 𝜈max (cm−1) = 3162 (br), 2361 (w), 1705 (s), 
1602 (m), 1547 (m), 1434 (m), 1366 (w), 1322 (w), 1302 (w), 1260 (w), 1200 (w), 1156 
(w), 1119 (w), 906 (w), 846 (m), 710 (s), 694 (s). HRMS (ESI): calc. for C28H28N5O5+ 
[M+H]+: 514.2085, found: 514.2079. 
 
 
 
Tetralone 3.34: Oxalylchloride (2 M in CH2Cl2, 30.6 mL, 61.2 mmol) and DMF (0.2 mL) 
were added to an ice cooled solution of 3,4-dimethoxyphenylacetic acid (10.0 g, 
50.97 mmol) in CH2Cl2 (150 mL) and the reaction was stirred for 10 min at that 
temperature and for 3 h at room temperature. Removal of the solvent under reduced 
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pressure gave crude acid chloride which was used in the next step without further 
purification. 
A solution of crude acid chloride in CH2Cl2 (50 mL) was added slowly to an ice cooled 
suspension of AlCl3 (27.2 g, 200 mmol) in CH2Cl2 (600 mL) and the reaction was purged 
with ethylene. The mixture was stirred for 4 h under an ethylene atmosphere at 0 °C 
before it was diluted with H2O (160 mL) and extracted with CH2Cl2. The combined organic 
layers were washed with aqueous 1M HCl, aqueous saturated NaHCO3 and brine and 
dried over MgSO4. Evaporation of the solvent under reduced pressure and purification of 
the resulting residue by flash column chromatography (EtOAc:hexanes 3:7) gave 
tetralone 3.34 (2.87 g, 13.92 mmol, 27% over 2 steps) as a brownish solid. 
Data for 3.34: Rf: 0.1 (hexanes:EtOAc 7:3). 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.74 
(s, 1H), 6.62 (s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.51 (s, 2H), 3.00 (t, J = 6.7 Hz, 2H), 2.55 
(dd, J = 7.2, 6.2 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 211.0, 148.0, 147.8, 
128.6, 125.1, 111.4, 111.1, 56.12, 56.1, 44.4, 38.7, 28.3. IR (ATR): 𝜈max (cm−1) = 1712 
(s), 1610 (w), 1514 (vs), 1465 (m), 1416 (w), 1338 (m), 1291 (w), 1270 (m), 1247 (s), 
1218 (m), 1193 (m), 1110 (s), 1027 (w), 1005 (w), 966 (w), 882 (w), 844 (w), 755 (w). 
HRMS (EI): calc. for C12H14O3+ [M]+: 206.0937, found: 206.0934. 
 
 
 
Secondary amine 3.35: NaBH(OAc)3 (5.19 g, 24.4 mmol) was added portionwise to a 
solution of tetralone 3.34 (2.80 g, 13.58 mmol) and benzylamine (1.92 mL, 17.7 mmol) 
in DCE (45 mL) and the reaction was stirred for 4 h at room temperature and 
concentrated. The resulting residue was portioned between aqueous saturated NaHCO3 
and EtOAc. The organic layer was washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (MeOH:CH2Cl2 3:97) gave secondary amine 3.35 (3.60 g, 
12.1 mmol, 89%) as a brownish wax. 
Data for 3.35: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.37 – 7.31 (m, 4H), 7.26 (s, 1H), 
6.58 (s, 1H), 6.57 (s, 1H), 3.91 (s, 2H), 3.84 (s, 3H), 3.84 (s, 3H), 3.03 – 2.92 (m, 2H), 
2.78 (pd, J = 11.2, 4.8 Hz, 2H), 2.66 – 2.54 (m, 1H), 2.12 – 2.02 (m, 1H), 1.65 (dtd, J = 
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12.7, 10.0, 6.0 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 147.2, 147.2, 140.7, 
128.6, 128.3, 128.1, 127.1, 127.0, 112.1, 111.5, 56.0, 56.0, 53.0, 51.3, 36.4, 29.7, 27.7. 
IR (ATR): 𝜈max (cm−1) = 29.15 (m), 2833 (w), 1609 (w), 1516 (vs), 1464 (m), 1452 (m), 
1409 (w), 1353 (w), 1327 (w), 1289 (w), 1265 (m), 1248 (s), 1223 (s), 1113 (s), 1018 (w), 
971 (w), 907 (w), 849 (w), 737 (m), 699 (m). HRMS (ESI): calc. for C19H24NO2+ [M+H]+: 
298.1802, found: 298.1800. 
 
 
 
Tertiary amine 3.36: NaBH(OAc)3 (4.51 g, 21.3 mmol) was added portionwise to a 
solution of secondary amine 3.35 (3.52 g, 11.8 mmol) and propionaldehyde (1.11 mL, 
15.4 mmol) in DCE (70 mL) and the reaction was stirred at room temperature overnight 
and concentrated under reduced pressure. The organic layer was washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (MeOH:CH2Cl2 2:98) gave tertiary amine 3.36 
(3.98 g, 11.7 mmol, 99%) as a brownish wax. 
Data for 3.36: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.39 (d, J = 7.5 Hz, 2H), 7.30 (t, J 
= 7.4 Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 6.58 (s, 1H), 6.55 (s, 1H), 3.84 (s, 3H), 3.83 (s, 
3H), 3.72 (q, J = 9.9, 8.7 Hz, 2H), 2.96 (dd, J = 14.2, 5.7 Hz, 1H), 2.87 – 2.70 (m, 4H), 
2.52 (t, J = 7.2 Hz, 2H), 2.09 – 2.03 (m, 1H), 1.64 (tt, J = 12.0, 6.1 Hz, 1H), 1.46 (h, J = 
7.3 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 147.1, 141.6, 
128.5, 128.4, 128.2, 126.6, 112.2, 111.4, 56.1, 56.0, 56.0, 54.6, 52.1, 43.6, 31.7, 29.8, 
25.6, 21.8, 12.0. IR (ATR): 𝜈max (cm−1) = 2931 (m), 2832 (w), 1609 (w), 1515 (vs), 1494 
(w), 1463 (m), 1452 (m), 1408 (w), 1355 (w), 1333 (w), 1264 (s), 1245 (s), 1226 (s), 1209 
(s), 1114 (s), 1070 (w), 1018 (m), 972 (w), 936 (w), 906 (w), 847 (m), 824 (w), 735 (m), 
697 (m). HRMS (ESI): calc. for C22H30NO2+ [M+H]+: 340.2271, found: 230.2270. 
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Azobenzene 3.39: Pd/C (340 mg) was added to a solution of tertiary amine (3.40 g, 
10.0 mmol) in MeOH (30 mL) and the reaction was purged with H2. The mixture was 
stirred at room temperature under H2 overnight, filtered over a pad of celite and 
concentrated under reduced pressure to give crude secondary amine 3.37 that was used 
in the next step without further purification. 
NaBH(OAc)3 (3.98 g, 18.8 mmol) was added portionwise to a stirred solution of 
secondary amine 3.37 and freshly prepared homobenzylic aldehyde 3.38 (2.56 g, 
9.50 mmol) in DCE (150 mL) and the reaction was stirred at room temperature overnight 
and concentrated under reduced pressure. The organic layer was washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (MeOH:CH2Cl2 2:98) gave azobenzene 3.39 
(4.94 g, 9.82 mmol, 98% over 2 steps) as a brownish wax. 
Data for 3.39: 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.38 – 8.31 (m, 2H), 7.99 (d, J = 
8.8 Hz, 2H), 7.90 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 6.57 (d, J = 1.6 Hz, 2H), 
3.83 (d, J = 1.5 Hz, 6H), 3.00 (tdd, J = 11.6, 5.1, 2.5 Hz, 1H), 2.89 – 2.64 (m, 8H), 2.57 
(dd, J = 8.5, 6.3 Hz, 2H), 1.99 (dq, J = 13.7, 3.4, 3.0 Hz, 1H), 1.48 (p, J = 7.4 Hz, 3H), 
0.90 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 155.8, 150.9, 148.5, 
147.1, 147.1, 146.5, 129.9, 128.2, 128.1, 124.7, 123.5, 123.3, 112.1, 111.4, 77.4, 57.1, 
55.9, 52.7, 52.5, 36.2, 31.7, 29.6, 26.3, 22.3, 12.0. HRMS (ESI): calc. for C29H35N4O4+ 
[M+H]+: 503.2653. found: 503.2657. 
 
  
262 
 
Aniline 3.40: Na2S.xH2O (1.28 g, 13.3 mmol) was added to a suspension of azobenzene 
3.39 (3.35 g, 6.67 mmol) in dioxane (47 mL) and H2O (47 mL) and the reaction was 
stirred at 100 °C for 4 h. After cooling to room temperature, the reaction was extracted 
with EtOAc and the combined organic layers were washed with aqueous NaOH (1 M), 
aqueous Na2S2O3 (20%) and brine and dried over MgSO4. Evaporation of the solvent 
under reduced pressure and purification of the resulting residue by flash column 
chromatography (MeOH:CH2Cl2 0:100-3:97) gave aniline 3.40 (2.94 g, 6.22 mmol, 93%) 
as a red solid.  
Data for 3.40: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.84 – 7.72 (m, 4H), 7.36 – 7.28 
(m, 2H), 6.77 – 6.70 (m, 2H), 6.57 (s, 2H), 4.04 (s, 2H), 3.83 (s, 6H), 3.06 – 2.96 (m, 1H), 
2.85 – 2.64 (m, 8H), 2.57 (dd, J = 8.5, 6.6 Hz, 2H), 2.06 – 1.96 (m, 1H), 1.56 (dq, J = 
40.3, 7.1 Hz, 3H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 151.4, 
149.5, 147.1, 145.7, 143.3, 129.5, 128.2, 125.1, 122.4, 114.8, 112.2, 111.4, 67.2, 57.2, 
56.0, 52.8, 36.0, 31.8, 31.1, 29.7, 26.3, 22.3, 12.1. IR (ATR): 𝜈max (cm−1) = 3370 (m), 
2933 (m), 2834 (w), 1621 (m), 1599 (vs), 1515 (s), 1506 (s), 1463 (m), 1429 (w), 1406 
(w), 1297 (w), 1264 (m), 1244 (m), 1227 (s), 1153 (m), 1139 (s), 1113 (s), 1076 (w), 1015 
(w), 972 (w), 909 (m), 838 (s), 729 (s). HRMS (ESI): calc. for C29H37N4O2+ [M+H]+: 
473.2911, found: 473.2907. 
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Silyl ether 3.41: BBr3 (1 M in CH2Cl2, 5.30 mL, 5.30 mmol) was added slowly to a stirred 
solution of aniline 3.40 (500 mg, 1.058 mmol) in CH2Cl2 (30 mL) at –78 °C and the 
resulting solution was stirred for 1 h at that temperature and for 4 h at room temperature. 
The reaction was quenched with MeOH (5 mL), diluted with EtOAc and washed with 
aqueous saturated NaHCO3 and brine. The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure to give crude catechol which was used in the next 
step without further purification. 
TBSCl (1.59 g, 10.6 mmol) was added to an ice cooled solution of crude catechol and 
imidazole (1.20 g, 17.7 mmol) in DMF (20 mL) and the reaction was stirred at room 
temperature overnight. The reaction was hydrolysed with H2O (30 mL) and extracted with 
EtOAc. The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (EtOAc:hexanes 1:3) gave silyl ether 3.41 (823 mg, 1.22 mmol, 
58% over 2 steps) as a red solid. 
Data for 3.41: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.79 (t, J = 8.8 Hz, 4H), 7.31 (d, J 
= 8.0 Hz, 2H), 6.74 (d, J = 8.4 Hz, 2H), 6.51 (d, J = 2.6 Hz, 2H), 4.03 (s, 2H), 2.83 – 2.53 
(m, 10H), 1.95 (d, J = 7.7 Hz, 1H), 1.63 – 1.45 (m, 6H), 0.98 (s, 18H), 0.90 (t, J = 7.2 Hz, 
3H), 0.18 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 151.5, 149.5, 145.7, 144.7, 
143.3, 129.7, 129.6, 129.1, 125.1, 124.6, 122.5, 121.5, 120.7, 114.8, 57.4, 52.9, 36.2, 
31.5, 29.4, 26.4, 26.1, 22.4, 18.6, 12.1, –3.9, –3.97, –3.98. IR (ATR): 𝜈max (cm−1) = 2929 
(m), 2858 (m), 2360 (w), 1621 (w), 1600 (s), 1509 (s), 1472 (w), 1411 (w), 1313 (w), 
1254 (m), 1140 (m), 930 (m), 838 (s), 782 (m). HRMS (ESI): calc. for C39H61N4O2Si2+ 
[M+H]+: 673.4328, found: 673.4323. 
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Maleimide 3.42: A solution of acid chloride 3.3094 (77.4 mg, 0.446 mmol) in THF (2 mL) 
was added slowly to an ice cooled solution of silyl ether 3.41 (200 mg, 0.297 mmol) and 
NEt3 (52.0 µL, 0.370 mmol) in THF (3 mL) and the reaction was stirred at room 
temperature for 2 h before it was hydrolysed with H2O (4 mL) and extracted with EtOAc. 
The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (MeOH:CH2Cl2 3:97) gave maleimide 3.42 (145 mg, 
0.179 mmol, 60%) as a red solid. 
Data for 3.42: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.83 (dd, J = 21.8, 8.3 Hz, 4H), 
7.64 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 6.77 (s, 2H), 6.52 (d, J = 2.1 Hz, 2H), 
4.37 (s, 2H), 2.99 (p, J = 7.4, 5.6 Hz, 1H), 2.82 (s, 4H), 2.75 – 2.62 (m, 4H), 2.56 (dd, J 
= 8.8, 6.2 Hz, 2H), 1.97 (d, J = 12.3 Hz, 1H), 1.65 – 1.44 (m, 3H), 0.98 (s, 19H), 0.89 (t, 
J = 7.3 Hz, 3H), 0.18 (s, 12H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 172.8, 172.4, 
163.8, 151.2, 149.2, 144.9, 140.3, 137.3, 130.5, 129.6, 128.8, 124.0, 123.0, 121.4, 120.7, 
120.1, 117.9, 57.7, 54.7, 52.74, 52.65, 42.2, 36.9, 31.1, 29.8, 29.2, 26.1, 21.9, 18.6, 12.0, 
–3.95, –3.98. IR (ATR): 𝜈max (cm−1) = 2955 (w), 2929 (m), 2857 (w), 1716 (s), 1598 (m), 
1551 (w), 1512 (m), 1472 (w), 1463 (w), 1414 (m), 1362 (w), 1317 (m), 1253 (s), 1228 
(m), 1201 (w), 1170 (m), 1114 (w), 1083 (w), 1048 (w), 1011 (w), 926 (m), 909 (s), 837 
(vs), 780 (s), 732 (s), 697 (w), 661 (w). HRMS (ESI): calc. for C45H62N5O2Si2– [M–H]–: 
808.4295; found: 808.4310. 
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Catechol 3.32: HF (48% in H2O, 1 mL) was added slowly to an ice cooled solution of 
maleimide 3.42 (100 mg, 0.123 mmol9 in MeCN (1 mL) and the reaction was stirred for 
30 min at that temperature and for 3 h at room temperature. The reaction was cooled to 
0 °C, diluted with EtOAc and carefully washed with NaHCO3. The organic phase was 
dried over Na2SO4 and concentrated under reduced pressure to give catechol 3.32 
(60 mg, 0.103 mmol, 84%) as a red solid. 
Data for 3.32: 1H NMR (400 MHz, d4-MeOH): δ (ppm) = 7.77 – 7.68 (m, 4H), 7.60 (d, J 
= 8.5 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 6.79 (s, 2H), 6.46 (d, J = 3.6 Hz, 1H), 6.41 (s, 
1H), 4.27 (s, 2H), 3.63 (dt, J = 13.6, 6.5 Hz, 1H), 3.37 (ddq, J = 39.0, 12.8, 6.0, 5.5 Hz, 
2H), 3.26 – 2.98 (m, 5H), 2.96 – 2.77 (m, 2H), 2.69 (dq, J = 8.5, 4.6 Hz, 2H), 2.22 – 2.07 
(m, 1H), 1.73 (ttd, J = 19.6, 13.2, 12.6, 7.7 Hz, 3H), 0.95 (t, J = 7.3 Hz, 3H). 13C NMR 
(100 MHz, d4-MeOH): δ (ppm) = 171.9, 167.4, 153.0, 150.0, 145.3, 144.9, 142.2, 140.6, 
135.7, 130.8, 127.0, 124.8, 124.2, 124.1, 121.0, 116.6, 115.8, 62.3, 54.1, 53.2, 41.3, 
32.1, 29.8, 28.6, 25.3, 19.8, 11.3. IR (ATR): 𝜈max (cm−1) = 3346 (br), 1709 (vs), 1596 (s), 
1527 (s), 1502 (m), 1431 (s), 1303 (m), 1255 (m), 1190 (w), 1152 (s), 1051 (s), 904 (w), 
847 (s), 828 (s), 729 8m), 696 (s). HRMS (ESI): calc. for C33H36N5O5+ [M+H]+: 582.2711, 
found: 582.2707. 
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6.4.2 Photoswitchable mAChR agonists 
 
Alcohol 3.45113: Dimethylamine hydrochloride (8.72 g, 0.107) was dissolved in H2O 
(15 mL) and the pH was adjusted to 9 using NaOH (1 M). Formaline (37%, 11.2 mL. 
0.15 mmol), propargyl alcohol (5.15 mL, 89.19 mmol) and a solution of copper sulfate 
pentahydrate (690 mg, 2.76 mmol) in H2O (4.46 mL) were sequentially added, the pH 
was adjusted to 8 with NaOH (1 M) and the solution was stirred at 80 °C for 1 h. The 
solution was cooled to room temperature, poured into aqueous ammonia (25%, 30 mL) 
and extracted with Et2O. The combined organic phases were dried over MgSO4 and 
evaporated to dryness to give alcohol 3.45 (3.78 g, 33.4 mmol, 37%) as a yellow oil. 
Data for 3.45: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.28 (t, J = 1.9 Hz, 2H), 3.26 (t, J 
= 2.0 Hz, 2H), 2.29 (s, 6H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 83.9, 80.6, 51.0, 48.2, 
44.3. IR (ATR): 𝜈max (cm−1) = 3175 (m), 2947 (w), 2861 (m), 2828 (m), 2782 (m), 1661 
(w), 1628 (w), 1460 (m), 1356 (m), 1332 (m), 1258 (w), 1232 (w), 1177 (w), 1156 (w), 
1135 (m), 1101 (s), 1109 (vs), 975 (m), 953 (w), 860 (s), 810 (s). HRMS (ESI): calc. for 
C6H12NO [M+H]+: 114.0913, found: 114.0914. 
 
 
 
Dihydroisoxazol 3.46113: 1-bromo-3-chloropropane (4.1 mL, 50.81 mmol) was added 
dropwise to a solution of NaNO2 (7.17 g, 50.0 mmol) and isopentyl nitrite (7.0 mL, 
52.0 mmol) in DMSO (50 mL) and the reaction was stirred at room temperature for 24 h. 
The reaction mixture was poured into ice water and extracted with CH2Cl2. The combined 
organic phases were dried over MgSO4 and evaporated to dryness to give 
dihydrosioxazol 3.46 (3.00 g, 25.84 mmol, 51%) as a yellow oil. 
Data for 3.46: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.90 (t, J = 10.9 Hz, 2H), 3.51 (t, J = 
10.9 Hz, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 164.2, 75.7, 30.8. IR (ATR): 𝜈max 
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(cm−1) = 1607 (m), 1529 (vs), 1471 (w), 1437 (m), 1364 (s), 1293 (s), 1221 (w), 1169 
(w), 999 (w), 961 (s), 932 (m), 848 (s), 805 (vs), 725 (m). HRMS (EI): calc. for C3H12NO 
[M]+: 116.0216, found: 116.0218. 
 
 
 
Dimethylamine 3.43113: Sodium hydride (60% suspension in paraffin, 525 mg, 
13.5 mmol) was added to a solution of alcohol 3.45 (1.50 g, 13.26 mmol) in THF (20 mL) 
and the resulting solution was stirred for 1 h at room temperature. A solution of isoxazol 
3.46 (1.53 g, 13.18 mmol) in THF (10 mL) was added and the reaction was stirred at 
60 °C for 3 h before it was poured onto ice and extracted with CHCl3. The combined 
organic phases were dried over MgSO4 and evaporated to dryness. Purification by flash 
column chromatography (CH2Cl2:MeOH 9:1, Rf=0.5) gave dimethylamine 3.43 (2.02 g, 
11.09 mmol, 84%) as an orange oil. 
Data for 3.43: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 4.77 (t, J = 1.9 Hz, 1H), 4.38 (t, J = 9.6 
Hz, 1H), 3.27 (t, J = 2.0 Hz, 1H), 2.96 (t, J = 9.6 Hz, 1H), 2.26 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 167.0, 83.4, 78.7, 69.9, 58.2, 48.0, 44.3, 33.2. IR (ATR): 𝜈max (cm−1) = 2941 (m), 2878 
(w), 2824 (w), 2777 (w), 1625 (s), 1454 (w), 1438 (m), 1402 (s), 1340 (vs), 1259 (m), 
1178 (w), 1155 (w), 1123 (w), 1099 (w), 1033 (m), 1001 (m), 963 /s), 929 (s), 863 (m), 
841 (m), 816 (w). HRMS (ESI): calc. for C9H15N2O2 [M+H]+: 183.1128, found: 183.1128. 
 
 
 
Iperoxo (3.42)113: Iodomethane (0.17 mL, 2.74 mmol) was added to a solution of 
dimethylamine 3.43 (200 mg, 1.10 mmol) in EtOAc (3.5 mL) and the reaction was stirred 
at room temperature for 24 h. The resulting precipitate was collected and dried and high 
vacuum to give Iperoxo (3.42) (310 mg, 0.956 mmol, 87%) as a white solid. 
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Data for 3.42: 1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 4.94 (t, J = 1.8 Hz, 2H), 4.45 
(t, J = 1.9 Hz, 2H), 4.32 (t, J = 9.6 Hz, 2H), 3.12 (s, 9H), 3.02 (t, J = 9.6 Hz, 2H). 
 13C-NMR (100 MHz, d6-DMSO): δ (ppm) = 166.8, 86.0, 76.3, 69.7, 57.3, 55.1, 52.0, 
32.3. IR (ATR): 𝜈max (cm−1) = 3418 (m), 2922 (s), 2852 (m), 1625 (s), 1604 (m), 1584 (m), 
1504 (m), 1472 (m), 1465 (m), 1437 (w), 1411 (m), 1346 (vs), 1255 (vs), 1144 (s), 1106 
(w), 1069 (w), 1037 (w), 1014 (m), 1000 (m), 974 (m), 961 (s), 927 (s), 899 (m), 876 (w), 
861 (m), 842 (s), 818 (w), 790 (w), 782 (m), 723 (m), 693 (s). HRMS (ESI): calc. for 
C10H17N2O2 [M]+: 197.1285, found: 197.1284. 
 
 
 
Azoiperoxo 1 (3.48): A solution of dimethylamine 3.43 (23 mg, 0.127 mmol) and 
azobenzene benzylbromide 3.49 (100 mg, 0.363 mmol) in EtOAc (5 mL) was stirred at 
room temperature for 24 h. The resulting precipitate was collected and dried under high 
vacuum to give azoiperoxo 1 (3.48) (50 mg, 0.109 mmol, 86%) as an orange solid. 
Data for azoiperoxo 1 (3.48): 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 8.11 – 8.04 (m, 
2H), 8.01 – 7.92 (m, 2H), 7.85 – 7.79 (m, 2H), 7.63 – 7.54 (m, 3H), 4.99 (t, J = 1.7 Hz, 
2H), 4.73 (s, 2H), 4.41 (t, J = 9.6 Hz, 2H), 4.35 (t, J = 1.8 Hz, 2H), 3.21 (s, 6H), 3.07 (t, J 
= 9.6 Hz, 2H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 168.8, 155.2, 153.9, 135.2, 
133.1, 131.0, 130.4, 124.5, 124.1, 88.7, 76.9, 71.2, 67.5, 58.3, 54.9, 50.9, 33.7. IR (ATR): 
𝜈max (cm−1) = 2913 (w), 1626 (s), 1474 (w), 1444 (w), 1414 (m), 1350 (s), 1302 (w), 1268 
(w), 1216 (w), 1166 (w), 1021 (w), 1000 (m), 977 (m), 961 (m), 930 (m), 885 (w), 860 (s), 
824 (w), 770 (s), 721 (m)=, 686 (vs), 658 (w). HRMS (ESI): calc. for C22H25N4O2 [M]+: 
377.1972, found: 377.1973. 
 
 
 
Alkyl bromide 3.50: 1,3-dibromopropane (0.41 mL, 4.05 mmol) was added to a 
suspension of 4-hydroxyazobenzene (200 mg, 1.01 mmol) and K2CO3 (699 mg, 
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5.06 mmol) in acetone (5 mL) and the reaction was stirred at 60 °C overnight. The 
resulting precipitate was removed by filtration and the solvent was removed under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(Et2O:hexanes 3:97, Rf = 0.3) gave alkyl bromide 3.50 (317 mg, 0.993 mmol, 98%) as 
an orange solid. 
Data for 3.50: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.96 – 7.90 (m, 2H), 7.90 – 7.85 
(m, 2H), 7.55 – 7.47 (m, 2H), 7.47 – 7.40 (m, 1H), 7.06 – 6.98 (m, 2H), 4.20 (t, J = 5.8 
Hz, 2H), 3.64 (t, J = 6.4 Hz, 2H), 2.37 (p, J = 6.1 Hz, 2H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) = 161.3, 152.9, 147.3, 130.6, 129.2, 124.9, 122.7, 114.9, 65.7, 32.4, 30.0. IR 
(ATR): 𝜈max (cm−1) = 2924 (m), 2853 (m), 1626 (w), 1602 (m), 1581 (m), 1498 (m), 1464 
(m), 1440 (m), 1412 (w), 1383 (w), 1348 (m), 1326 (w), 1296 (w), 1245 (s), 1210 (m), 
1140 (m), 1107 (w), 1055 (w), 1025 (m), 1016 (w), 921 (m), 835 (s), 818 (m), 794 (w), 
765 (s), 718 (m), 684 (vs), 666 (w). HRMS (EI): calc. for C15H15N2OBr [M]+: 318.0368, 
found: 318.0362. 
 
 
 
Azoiperoxo 3 (3.55): A solution of dimethylamine 3.43 (57 mg, 0.313 mmol) and alkyl 
bromide 3.50 (100 mg, 0.313 mmol) in EtOAc (5 mL) was stirred at 70 °C overnight. The 
resulting precipitate was collected and dried under high vacuum to give azoiperoxo 3 
(3.55) (45 mg, 0.090 mmol, 70%) as an orange solid. The resulting product is in a light 
driven equilibrium with its double bond isomer. The major trans isomer is described. 
Data for azoiperoxo 3 (3.55): 1H-NMR (400 MHz,d4-MeOH): δ (ppm) = 7.95 – 7.90 (m, 
2H), 7.89 – 7.83 (m, 2H), 7.60 – 7.43 (m, 3H), 7.18 – 7.09 (m, 2H), 6.94 – 6.81 (m, 1H), 
4.92 (t, J = 1.7 Hz, 2H), 4.50 (t, J = 1.8 Hz, 2H), 4.34 (dt, J = 12.5, 9.5 Hz, 2H), 4.25 (t, J 
= 5.7 Hz, 2H), 3.79 – 3.70 (m, 2H), 3.68 (s, 0H), 3.27 (s, 6H), 3.04 – 2.97 (m, 2H), 2.35 
(dq, J = 11.5, 5.6 Hz, 2H).13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 168.7, 162.4, 154.0, 
148.6, 131.8, 130.2, 125.8, 123.5, 116.0, 88.0, 76.5, 71.2, 66.0, 63.0, 58.2, 55.3, 51.3, 
33.7, 24.0. IR (ATR): 𝜈max (cm−1) = 3384 (m), 2966 (w), 2928 (w), 2884 (w), 1624 (m), 
1597 (s), 1501 (m), 1472 (m), 1441 (w), 1400 (m), 1341 (s), 1302 (w), 1246 (vs), 1150 
(m), 1139 (s), 1108 (w), 1056 (m), 1001 (w), 965 (m), 929 (w), 917 (m), 884 (w), 864 (w), 
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838 (s), 772 (s), 721 (w), 689 (s). HRMS (ESI): calc. for C24H29N4O3 [M]+: 421.2234, 
found: 421.2236. 
 
 
 
Alkyl bromide 3.51: 1,5-dibromopentane (0.83 mL, 6.08 mmol) was added to a 
suspension of 4-hydroxyazobenzene (300 mg, 1.51 mmol) and K2CO3 (1.05 g, 
7.59 mmol) in acetone (7 mL) and the reaction was stirred at 60 °C overnight. The 
resulting precipitate was removed by filtration and the solvent was removed under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(Et2O:hexanes 6:97, Rf = 0.3) gave alkyl bromide 3.51 (484 mg, 1.39 mmol, 92%) as an 
orange solid. 
Data for 3.51: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.96 – 7.85 (m, 4H), 7.55 – 7.47 
(m, 2H), 7.47 – 7.40 (m, 1H), 7.04 – 6.97 (m, 2H), 4.06 (t, J = 6.3 Hz, 2H), 3.46 (t, J = 
6.7 Hz, 2H), 1.96 (dt, J = 14.9, 6.8 Hz, 2H), 1.86 (dq, J = 8.3, 6.2 Hz, 2H), 1.73 – 1.61 
(m, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 161.6, 152.9, 147.0, 130.5, 129.2, 124.9, 
122.7, 114.8, 68.0, 33.7, 32.6, 28.5, 24.9. IR (ATR): 𝜈max (cm−1) = 2946 (w), 2863 (w), 
1602 (m), 1580 (m), 1501 (m), 1471 (w), 1489 (m), 1435 (w), 1412 (m), 1329 (w), 1322 
(w), 1306 (w), 1298 (w), 1257 (s), 1200 (m), 1137 (m), 1068 (w), 1036 (w), 1017 (m), 998 
(w), 927 (w), 837 (s), 805 (m), 763 (s), 730 (m), 720 (m), 688 (vs). HRMS (EI): calc. for 
C17H19N2OBr [M]+: 346.0681, found: 346.0676. 
 
 
 
Azoiperoxo 5 (3.56): A solution of dimethylamine 3.43 (105 mg, 0.576 mmol) and alkyl 
bromide 3.51 (200 mg, 0.576 mmol) in EtOAc (5 mL) was stirred at 70 °C for 5 d. The 
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resulting precipitate was collected and dried under high vacuum to give azoiperoxo 5 
(3.56) (211 mg, 0.399 mmol, 69%) as an orange solid. 
Data for azoiperoxo 5 (3.56): 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 8.08 – 7.72 (m, 
4H), 7.67 – 7.40 (m, 3H), 7.09 (dd, J = 9.3, 2.4 Hz, 2H), 4.91 (d, J = 1.9 Hz, 2H), 4.48 – 
4.33 (m, 4H), 4.15 (t, J = 6.1 Hz, 2H), 3.19 (d, J = 3.0 Hz, 6H), 3.02 (t, J = 9.6 Hz, 2H), 
2.04 – 1.80 (m, 4H), 1.63 (p, J = 7.6 Hz, 2H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 
168.7, 163.1, 154.1, 148.2, 131.7, 125.8, 123.5, 115.9, 87.8, 76.6, 68.9, 65.3, 58.2, 55.1, 
51.2, 49.3, 33.7, 29.7, 24.0, 23.4. IR (ATR): 𝜈max (cm−1) = 1628 (m), 1607 (m), 1587 (w), 
1501 (w), 1478 (m), 1460 (w), 1439 (w), 1416 (m), 1385 (w), 1351 (s), 1307 (w), 1251 
(vs), 1188 (w), 1162 (m), 1147 (m), 1106 (w), 1048 (w), 1010 (m), 974 (m), 931 (s), 897 
(w), 864 (w), 828 (vs), 783 (s), 738 (w), 720 (w), 694 (s). HRMS (ESI): calc. for 
C26H33N4O3 [M]+: 449.2547, found: 449.2548. 
 
 
 
Alkyl bromide 3.52: 1,7-dibromoheptane (1.04 mL, 6.08 mmol) was added to a 
suspension of 4-hydroxyazobenzene (300 mg, 1.51 mmol) and K2CO3 (1.05 g, 
7.59 mmol) in acetone (7 mL) and the reaction was stirred at 60 °C overnight. The 
resulting precipitate was removed by filtration and the solvent was removed under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(Et2O:hexanes 2:98, Rf = 0.2) gave alkyl bromide 3.52 (467 mg, 1.24 mmol, 82%) as an 
orange solid. 
Data for 3.52: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.96 – 7.85 (m, 4H), 7.55 – 7.47 
(m, 2H), 7.47 – 7.41 (m, 1H), 7.04 – 6.95 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.43 (t, J = 
6.8 Hz, 2H), 1.85 (ddt, J = 22.8, 8.2, 6.3 Hz, 4H), 1.56 – 1.38 (m, 6H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 161.7, 152.9, 147.0, 130.4, 129.2, 124.9, 122.7, 114.8, 68.3, 
34.1, 32.8, 29.2, 28.7, 28.2, 26.0. IR (ATR): 𝜈max (cm−1) = 2939 (m), 2852 (w), 1601 (m), 
1581 (m), 1501 (m), 1463 (m), 1442 (w), 1433 (w), 1412 (w), 1389 (w), 1323 (w), 1296 
(w), 1254 (s), 1233 (m), 1195 (m), 1141 (s), 1107 (m), 1070 (w), 1057 (w), 1021 (m), 989 
(w), 923 (w), 835 (s), 810 (m), 790 (w), 769 (s), 720 (m), 686 (vs), 656 (w). HRMS (EI): 
calc. for C19H23N2OBr [M]+: 374.0994, found: 374.0988. 
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Azoiperoxo 7 (3.57): A solution of dimethylamine 3.43 (97 mg, 0.533 mmol) and alkyl 
bromide 3.52 (200 mg, 0.533 mmol) in EtOAc (5 mL) was stirred at 70 °C for 5 d. The 
resulting precipitate was collected and dried under high vacuum to give azoiperoxo 7 
(3.57) (193 mg, 0.346 mmol, 65%) as an orange solid. The resulting product is in a light 
driven equilibrium with its double bond isomer. The major trans isomer is described. 
Data for azoiperoxo 7 (3.57): 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.95 – 7.90 (m, 
2H), 7.90 – 7.84 (m, 2H), 7.59 – 7.44 (m, 3H), 7.14 – 7.04 (m, 2H), 4.92 (t, J = 1.8 Hz, 
2H), 4.45 – 4.35 (m, 5H), 4.13 (t, J = 6.3 Hz, 2H), 3.54 – 3.41 (m, 2H), 3.18 (d, J = 3.9 
Hz, 7H), 3.04 (t, J = 9.6 Hz, 2H), 1.91 – 1.80 (m, 4H), 1.61 – 1.44 (m, 6H). 13C-NMR (100 
MHz, d4-MeOH): δ (ppm) = 168.7, 163.3, 154.1, 148.1, 130.2, 125.8, 123.5, 115.8, 87.7, 
76.6, 71.2, 69.3, 65.4, 58.2, 55.0, 51.1, 33.7, 30.1, 29.8, 27.2, 26.9, 23.6. IR (ATR): 𝜈max 
(cm−1) = 2940 (w), 1911 (w), 1624 (s), 1604 (s), 1580 (m), 1499 (w), 1472 (m), 1462 (w), 
1414 (m), 1346 (s), 1313 (w), 1300 (m), 1255 (s), 1162 (w), 1148 (s), 1106 (w), 1070 (w), 
1032 (m), 1011 (w), 991 (w), 969 (s), 928 (s), 894 (m), 878 (m), 840 (m), 832 (vs), 787 
(s), 723 (m), 697 (s). HRMS (ESI): calc. for C28H37N4O3 [M]+: 477.2860, found: 477.2856. 
 
 
 
Alkyl bromide 3.53: 1,9-dibromononane (1.24 mL, 6.08 mmol) was added to a 
suspension of 4-hydroxyazobenzene (300 mg, 1.51 mmol) and K2CO3 (1.05 g, 
7.59 mmol) in acetone (7 mL) and the reaction was stirred at 60 °C overnight. The 
resulting precipitate was removed by filtration and the solvent was removed under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(Et2O:hexanes 4:96, Rf = 0.2) gave alkyl bromide 3.53 (400 mg, 0.992 mmol, 66%) as 
an orange solid. 
Data for 3.53: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.96 – 7.83 (m, 4H), 7.54 – 7.47 
(m, 2H), 7.47 – 7.41 (m, 1H), 7.04 – 6.96 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.41 (td, J = 
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6.9, 2.6 Hz, 4H), 1.93 – 1.77 (m, 6H), 1.53 – 1.29 (m, 15H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 161.8, 152.9, 147.0, 130.4, 129.2, 124.9, 122.7, 114.8, 68.4, 34.2, 34.2, 32.9, 
32.9, 29.5, 29.4, 29.4, 29.3, 28.8, 28.8, 28.3, 28.2, 26.1. IR (ATR): 𝜈max (cm−1) = 2936 
(m), 1822 (m), 2851 (w), 1612 (m), 1581 (m), 1502 (m), 1490 (m), 1464 (m), 1443 (w), 
1414 (w), 1425 (w), 1388 (w), 1327 (w), 1296 (m), 1253 (s), 1233 (s), 1152 (w), 1340 
(m), 1107 (w), 1069 (w), 1059 (w), 1016 (w), 842 (s), 810 (s), 788 (w), 770 (s), 754 (w), 
721 (m), 686 (vs), 656 (m). HRMS (EI): calc. for C21H27N2OBr [M]+: 402.1307, found: 
402.1300. 
 
 
 
Azoiperoxo 9 (3.58): A solution of dimethylamine 3.43 (136 mg, 0.744 mmol) and alkyl 
bromide 3.53 (200 mg, 0.496 mmol) in EtOAc (5 mL) was stirred at 70 °C for 3 d. The 
resulting precipitate was collected and dried under high vacuum to give azoiperoxo 9 
(3.58) (280 mg, 0.478 mmol, 96%) as an orange solid.  
Data for azoiperoxo 9 (3.58): 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.93 – 7.83 (m, 
4H), 7.54 – 7.45 (m, 2H), 7.45 – 7.39 (m, 1H), 7.03 – 6.96 (m, 2H), 4.95 (d, J = 1.8 Hz, 
2H), 4.84 – 4.80 (m, 3H), 4.45 – 4.39 (m, 3H), 4.03 (t, J = 6.5 Hz, 2H), 3.66 – 3.59 (m, 
2H), 3.43 (d, J = 5.8 Hz, 7H), 3.01 (td, J = 9.7, 3.6 Hz, 3H), 1.99 – 1.70 (m, 8H), 1.50 – 
1.31 (m, 13H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 166.8, 161.8, 152.8, 146.9, 130.5, 
129.2, 124.9, 122.6, 114.8, 86.7, 77.5, 77.2, 76.8, 76.1, 70.2, 68.4, 64.3, 57.3, 55.0, 50.7, 
50.6, 33.1, 29.4, 29.3, 29.2, 26.3, 26.1, 23.0. IR (ATR): 𝜈max (cm−1) = 3403 (m), 2937 (m), 
2925 (m), 2858 (w), 1627 (s), 1607 (m), 1581 (m), 1504 (w), 1476 (m), 1461 (m), 1439 
(w), 1414 (s), 1347 (vs), 1307 (w), 1263 (vs), 1162 (m), 1148 (s), 1105 (w), 1070 (w), 
1018 (s), 1002 (m), 972 (s), 829 (s), 900 (m), 882 (m), 863 (m), 836 (m), 826 (s), 785 (s), 
851 (w), 722 (m), 696 (s). HRMS (ESI): calc. for C30H41N4O3 [M]+: 505.3173, found: 
505.3173 
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Alkyl bromide 3.54: 1,11-dibromoundecane (0.75 mL, 3.18 mmol) was added to a 
suspension of 4-hydroxyazobenzene (157 mg, 0.790 mmol) and K2CO3 (549 mg, 
0.790 mmol) in acetone (5 mL) and the reaction was stirred at 60 °C overnight. The 
resulting precipitate was removed by filtration and the solvent was removed under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(Et2O:hexanes 4:96, Rf = 0.2) gave alkyl bromide 3.54 (324 mg, 0.751 mmol, 95%) as 
an orange solid. 
Data for 3.54: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.98 – 7.84 (m, 4H), 7.57 – 7.40 
(m, 3H), 7.07 – 6.97 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.41 (t, J = 6.8 Hz, 4H), 1.93 – 1.79 
(m, 6H), 1.54 – 1.25 (m, 22H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 161.9, 152.9, 
147.0, 130.5, 129.2, 124.9, 122.7, 114.83, 8.16, 68.5, 34.3, 33.0, 31.1, 29.7, 29.6, 29.6, 
29.5, 29.5, 29.3, 28.9, 28.3, 26.2. IR (ATR): 𝜈max (cm−1) = 3919 (s), 2850 (m), 1603 (m), 
1583 (m), 1502 (m), 1466 (s), 1441 (w), 1414 (w), 1389 (w), 1322 (w), 1298 (m), 1271 
(w), 1249 (s), 1240 (w), 1212 (m), 1190 (w), 1142 (s), 1106 (m), 1070 (w), 1054 (w), 
1027 (m), 1017 (m), 1007 (m9, 976 (w), 982 (w), 921 (w), 842 (vs), 818 (m), 790 (m), 
769 (vs), 721 (s), 685 (vs). HRMS (EI): calc. for C23H31N2OBr [M]+: 430.1620, found: 
430.1631. 
 
 
 
Azoiperoxo 11 (3.59): A solution of dimethylamine 3.43 (200 mg, 655 mmol) and alkyl 
bromide 3.54 (200 mg, 0.496 mmol) in EtOAc (5 mL) was stirred at 70 °C for 3 d. The 
resulting precipitate was collected and dried under high vacuum to give azoiperoxo 11 
(3.59) (210 mg, 0.342 mmol, 74%) as an orange solid.  
Data for azoiperoxo 11 (3,59): 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.96 – 7.85 
(m, 4H), 7.59 – 7.45 (m, 3H), 7.12 – 7.06 (m, 2H), 4.46 – 4.37 (m, 10H), 4.16 – 4.07 (m, 
3H), 3.52 – 3.40 (m, 5H), 3.19 (d, J = 6.2 Hz, 15H), 3.05 (td, J = 9.6, 5.3 Hz, 6H), 1.91 – 
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1.75 (m, 7H), 1.50 – 1.34 (m, 25H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 167.3, 
162.0, 152.7, 146.7, 130.2, 128.8, 124.4, 122.1, 114.4, 86.2, 75.2, 69.8, 68.0, 64.0, 60.1, 
56.8, 53.6, 49.7, 32.3, 29.2, 29.1, 29.0, 28.9, 28.8, 28.8, 25.9, 25.7, 22.3. IR (ATR): 𝜈max 
(cm−1) = 3418 (w), 2923 (m), 2853 (w), 1625 (s), 1604 (m), 1585 (w), 1504 (w), 1465 (m), 
1472 (m), 1437 (w), 1411 (m), 1345 (vs), 1311 (w), 1299 (w), 1256 (vs), 1155 (m), 1144 
(m), 1106 (w), 1068 (w), 1036 (w), 1014 (m), 1000 (w), 974 (s), 961 (s), 926 (s), 898 (m), 
876 (m), 862 (m), 842 (s), 818 (w), 790 (w), 782 (m), 736 (w), 723 (m), 693 (m). HRMS 
(ESI): calc. for C32H44N4O3 [M]+: 533.3486, found: 533.3484. 
 
 
6.4.3 Photoswitchable TAS2R agonists 
 
Aniline 3.64: A solution of NaNO2 (8.86 g, 128 mmol) in H2O (5 mL) was added dropwise 
to an ice cooled solution of aniline (9.80 mL, 107 mmol) and aqueous HCl (conc. 27 mL, 
321 mmol) in H2O (20 mL) and the reaction was stirred at 0 °C for 1 h. The mixture was 
added slowly to an ice cooled solution of 2,6-dimethylaniline and (13.0 g, 107 mmol) and 
NaOH (7.70 g, 193 mmol) in H2O (100 mL) and the reaction mixture was stirred at 0 °C 
for 1 h. The resulting precipitate was collected and purified by flash column 
chromatography (hexanes:EtOAc 5:1, Rf = 0.2) to give aniline 3.64 (8.35 g, 37.1 mmol, 
35%) as a red solid. 
Data for 3.64: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.88 – 7.81 (m, 2H), 7.64 (s, 2H), 
7.48 (dd, J = 8.5, 6.9 Hz, 2H), 7.42 – 7.37 (m, 1H), 4.05 (s, 2H), 2.27 (s, 6H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 153.2, 146.5, 144.9, 129.7, 129.1, 124.0, 122.4, 121.5, 
17.8. IR (ATR): 𝜈max (cm−1) = 3397 (w), 2916 (w), 1619 (s), 1590 (m), 1479 (s), 1442 (m), 
1412 (m), 1379 (w), 1298 (s), 1273 (m), 1120 (s), 1090 (m), 1029 (w), 894 (m), 759 (s), 
734 (s), 690 (s). HRMS (EI): calc. for C14H15N3 [M]+: 225.1260, found: 225.1259. 
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Diethylamine 3.65: Bromoacetyl bromide (0,19 mL, 2.22 mmol) was added dropwise to 
an ice cooled solution of aniline 3.64 (500 mg, 2.22 mmol) and DIPEA (0.45 mL, 
2.66 mmol) in THF (10 mL) and the reaction was stirred at room temperature for 30 min. 
Diethylamine (2.32 mL, 22.2 mmol) and PhMe (20 mL) were added and the reaction was 
stirred at 100 °C for 2 h. The reaction was cooled to room temperature, the resulting 
precipitate was removed by filtration and the filtrate was extracted with aqueous HCl 
(3 M). The aqueous phase was basified with aqueous NaOH (4 M) and extracted with 
EtOAc. The combined organic phases were dried over MgSO4 and concentrated under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(CH2Cl2:MeOH 96:4, Rf= 0.2) gave diethylamine 3.65 (300 mg, 0.886 mmol, 40%) as an 
orange solid, 
Data for 3.65: 1H-NMR (400 MHz, CDCl3): δ (ppm) = δ 9.06 (s, 1H), 7.94 – 7.86 (m, 2H), 
7.68 (s, 2H), 7.54 – 7.44 (m, 3H), 3.25 (s, 2H), 2.72 (q, J = 7.1 Hz, 4H), 2.34 (s, 6H), 1.16 
(t, J = 7.1 Hz, 7H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 170.4, 152.8, 151.0, 136.8, 
136.0, 131.0, 129.2, 122.9, 122.8, 57.6, 49.1, 19.0, 12.8. IR (ATR): 𝜈max (cm−1) = 3394 
(br), 1976 (m), 1744 (m), 1684 (m), 1630 (s), 1531 (w), 1476 (s), 1454 (s), 1381 (m), 
1208 (s), 1149 (w), 1119 (w), 1088 (w), 1069 (w), 1032 (m), 980 (w), 923 (w), 894 (w), 
773 (s), 690 (s). HRMS (ESI): calc. for C20H27N4O [M+H]+: 339.2179, found: 339.2178. 
 
 
 
Arylamide 3.61: Benzyl bromide (0.08 mL, 0.680 mmol) was added to a solution of 
diethylamine 3.65 (230 mg, 0.680 mmol) in DMF (7 mL) and the solution was stirred at 
80 °C overnight. Evaporation and purification of the resulting residue by reverse phase 
column chromatography (MeCN:H2O (containing 0.1 M HCl) 0:100-40:60) gave 
arylamide 3.61 (248 mg, 0.578 mmol, 85%) as an orange solid. 
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Data for 3.61: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 1H NMR (400 MHz, Methanol-
d4) δ 7.92 (d, J = 7.3 Hz, 2H), 7.72 (s, 2H), 7.58 (dq, J = 21.3, 7.9, 7.5 Hz, 8H), 4.20 (s, 
2H), 3.72 – 3.60 (m, 4H), 2.39 (s, 6H), 1.54 (t, J = 6.4 Hz, 6H). 13C-NMR (100 MHz, d4-
MeOH): δ (ppm) = 164.0, 153.9, 152.8, 137.9, 136.7, 134.0, 132.4, 132.2, 130.7, 130.3, 
128.6, 123.8, 123.5, 63.5, 56.8, 55.8, 18.9, 8.5. IR (ATR): 𝜈max (cm−1) = 3377 (br), 2978 
(m), 1682 (s), 1603 (w), 1533 (s), 1474 (s), 1456 (s), 1395 (m), 1292 (m), 1241 (m), 1150 
(w), 1118 (w), 1071 (w), 1029 (w), 1002 (w), 967 (w), 868 (w), 767 (m), 150 (m), 724 (m), 
703 (s), 689 (s). HRMS (ESI): calc. for C27H33N4O [M]+: 429.2649, found: 429.2649. 
 
 
 
Arylamide 3.62: A solution of azobenzene benzylbromide (117 mg, 0.427 mmol) and 
lidocaine (100 mg, 0.427 mmol) in DMF (3 mL) was stirred at 80 °C overnight. 
Evaporation and purification of the resulting residue by reverse phase column 
chromatography (MeCN:H2O (containing 0.1 M HCl) 0:100-40:60) gave arylamide 3.62 
(143 mg, 0.308 mmol, 72%) as an orange solid. 
Data for 3.62: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 11.50 (s, 1H), 8.82 (d, J = 8.1 
Hz, 2H), 8.78 – 8.70 (m, 2H), 8.66 (d, J = 8.2 Hz, 2H), 8.45 (h, J = 3.8 Hz, 3H), 7.93 (s, 
3H), 5.75 (s, 2H), 5.15 (s, 2H), 4.37 (dt, J = 9.5, 6.5 Hz, 4H), 3.03 (s, 6H), 2.27 (t, J = 7.1 
Hz, 6H). 13C-NMR (100 MHz, d4-MeOH): δ (ppm) = 171.8, 162.2, 161.4, 144.5, 143.8, 
143.1, 141.7, 140.2, 139.1, 137.4, 136.6, 132.4, 132.3, 70.5, 65.2, 64.0, 27.8, 17.5. IR 
(ATR): 𝜈max (cm−1) = 3364 (br), 2978 (w), 1679 (s), 1536 (m), 1469 (s), 1444 (m), 1279 
(w), 1236 (w), 1156 (w), 1094 (w), 1070 (w), 1018 (w), 871 (w), 853 (w), 769 (s), 720 (m), 
688 (s). HRMS (ESI): calc. for C27H33N4O [M]+: 429.2649, found: 429.2652. 
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6.5 Experimental data for chapter IV 
6.5.1 Photoswitches based on A-803467 
 
Chloride 4.10134: n-BuLi (2.39 M in hexanes, 1.64 mL, 3.92 mmol) was added dropwise 
to an ice cooled solution of furan (0.34 mL, 4.70 mmol) in THF (6.0 mL) and the reaction 
was stirred at 0 °C for 30 min. The resulting solution was added via a syringe pump to a 
solution of 1-bromo-4-chlorobenzene (500 mg, 2.61 mmol), Pd2(dba)3 (60 mg, 
0.066 mmol) and P(t-Bu)3 (1 M in PhMe, 0.198 mL, 0.198 mmol) in PhMe (5 mL) over the 
course of 1 h at room temperature. After the addition was completed, the reaction was 
diluted with saturated aqueous NH4Cl and extracted with Et2O. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure. Purification 
of the resulting residue by flash column chromatography (pentane Rf= 0.5) gave chloride 
4.10 (319 mg, 1.79 mmol, 69%) as a colorless solid. 
Data for 4.10: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.60 (dd, J = 8.3, 1.2 Hz, 2H), 7.47 
(d, J = 1.8 Hz, 1H), 7.35 (dd, J = 8.4, 1.2 Hz, 2H), 6.64 (d, J = 3.2 Hz, 1H), 6.48 (dt, J = 
3.1, 1.4 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 153.0, 142.5, 133.1, 129.5, 
129.0, 125.1, 111.9, 105.6. IR (ATR): 𝜈max (cm−1) = 1682 (s), 1589 (s), 1571 (w), 1482 
(s), 1410 (m), 1361 (w), 1282 (w), 1215 (m), 1758 (m), 1129 (w), 1094 (vs), 1012 (s), 
814 (s), 790 (m), 761 (m), 733 (w), 682 (w). HRMS (EI): calc. for C10H7OCl [M]+: 
178.0180, found: 178.0186. 
 
 
 
Aryl bromide 4.11: NBS (219 mg, 1.23 mmol) was added portionwise to a stirred 
solution of chloride 4.10 (200 mg, 1.12 mmol) in DMF (3 mL) and the solution was stirred 
at room temperature for 72 h. The reaction mixture was poured into cold water and 
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extracted with Et2O. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure to give aryl bromide 4.11 (176 mg, 0.683 mmol, 
61%) as a colorless solid. 
Data for 4.11: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.54 (dd, J = 8.5, 1.4 Hz, 2H), 7.38 
– 7.31 (m, 2H), 6.58 (dd, J = 3.5, 1.2 Hz, 1H), 6.39 (dd, J = 3.5, 1.2 Hz, 1H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 154.9, 133.5, 129.1, 128.5, 124.8, 122.0, 113.6, 107.9. IR 
(ATR): 𝜈max (cm−1) = 1674 (s), 1586 (s), 1570 (m), 1489 (w), 1466 (w), 1401 (m), 1296 
(w), 1282 (w), 1270 (w), 1210 (w), 1191 (w), 1175 (w), 1090 (s), 1009 (m), 972 (m), 917 
(w), 882 (w), 841 (m), 820 (m), 761 (m) 729 (w). HRMS (EI): calc. for C10H6OBrCl [M]+: 
255.9285, found: 255.9231. 
 
 
 
Diazonium salt 4.12: A solution of NaNO2 (451 mg, 6.53 mmol) in H2O (1 mL) was 
added dropwise to an ice cooled solution of 3,5-dimethoxyaniline (1.00 g, 6.53 mmol) 
and aqueous HBF4 (50%, 2.2 mL) in H2O (3 mL) and the reaction was stirred for 30 min 
at 0 °C. The resulting precipitate was collected, washed with cold H2O and redissolved 
in acetone (3 mL). Et2O was added to the solution until no further precipitation could be 
observed, the resultant residue was collected, washed with Et2O and dried under 
reduced pressure to give diazonium salt 4.12 (490 mg, 1.94 mmol, 30%) as a red solid. 
 
 
 
Azobenzene 4.7: i-PrMgCl.LiCl (1.3 M in THF, 0.15 mL, 0.15 mmol) was added to a 
solution of aryl bromide 4.11 (50 mg, 0.194 mmol) in THF (5 mL) at –15 °C and the 
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solution was stirred for 1 h at that temperature and for 1 h at room temperature. The 
reaction was cooled to –78 °C and a suspension of diazonium salt 4.12 (49 mg, 
0.194 mmol) in THF (1 mL) was added. The mixture was stirred at –78 °C for 1 h and 
warmed to room temperature. The reaction was quenched with saturated aqueous NH4Cl 
and extracted with EtOAc. The combined organic phases were washed with H2O and 
brine, dried over MgSO4 and concentrate under reduced pressure. Purification of the 
resulting residue by flash column chromatography (hexanes:EtOAc 9:1, Rf = 0.3) gave 
azobenzene 4.7 (20 mg, 0.064 mmol, 33%) as an orange solid. 
Data for 4.7: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.82 – 7.72 (m, 2H), 7.45 – 7.38 (m, 
2H), 7.17 (d, J = 3.7 Hz, 1H), 7.11 (t, J = 1.5 Hz, 2H), 6.92 (d, J = 3.7 Hz, 1H), 6.57 (q, J 
= 2.0 Hz, 1H), 3.88 (s, 6H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 161.2, 160.0, 155.2, 
154.2, 135.1, 129.3, 128.0, 126.3, 115.2, 109.9, 104.1, 100.8, 55.7. IR (ATR): 𝜈max (cm−1) 
= 1601 (s), 1590 (s), 1562 (w), 1512 (w), 1468 (s), 1440 (w), 1425 (w), 1394 (s), 1361 
(m), 1340 (w), 1310 (m), 1301 (m), 1264 (w), 1239 (w), 1200 (s), 1150 (s), 1116 (m), 
1089 (m), 1054 (m), 1042 (s), 1010 (m), 971 (m), 939 (w), 913 (w), 884 (w), 870 (w), 828 
(m), 818 (m), 801 (vs), 732 (w), 682 (w), 666 (s). HRMS (EI): calc. for C10H7OCl [M]+: 
342.0766, found: 342.0763. 
 
 
6.5.2 Photoswitches based on bupivacain 
 
Pipecolic amide 4.14: HCl (4.00 M in dioxane, 10.3 mL, 41.3 mmol) was added 
dropwise to a stirred suspension of pipecolic acid (4.84 g, 37.5 mmol) in PhMe (75 mL). 
The mixture was heated to 55 °C, SOCl2 (2.72 mL, 37.5 mmol) and DMF (0.04 mL, 
0.509 mmol) were sequentially added and the reaction mixture was stirred at that 
temperature for 3 h. A solution of 2-bromo-4,6-dimethylaniline (15.0 g, 75.0 mmol) in 
toluene (15 mL) was slowly added and the reaction was stirred at 55 °C overnight. The 
mixture was cooled to room temperature and the precipitate was collected, washed with 
PhMe and redissolved in water. The pH was adjusted to 5 utilizing aqueous NaOH (1 M) 
and the solution was washed with PhMe. The aqueous phase was basified to pH 14 with 
aqueous NaOH (4 M) and extracted with EtOAc. The combined organic phases were 
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washed with brine, dried over MgSO4 and concentrated to give crude pipecolic amide 
4.14 (2.44 g) as a white solid which was used in the next step without further purification. 
An analytical sample was purified by flash column chromatography (EtOAc:NEt3 98:2, 
Rf=0.2). 
Data for 4.14: Rf: 0.2 (EtOAc:NEt3 98:2) 1H-NMR (400 MHz, CDCl3):  (ppm) =7.27 (s, 
2H), 3.45 (dd, J = 10.5, 3.2 Hz, 1H), 3.18 – 3.08 (m, 1H), 2.69 (ddd, J = 12.7, 11.3, 2.8 
Hz, 1H), 2.19 (s, 5H), 2.04 (d, J = 8.8 Hz, 1H), 1.92 (ddd, J = 7.6, 4.3, 1.7 Hz, 1H), 1.68 
– 1.55 (m, 2H), 1.55 – 1.42 (m, 1H). 13C-NMR (100 MHz, CDCl3):  (ppm) = 172.6, 137.4, 
133.0, 131.0, 120.5, 76.8, 60.6, 45.9, 30.4, 23.0, 24.1, 18.5. IR (ATR): 𝜈max (cm−1) = 2919 
(m), 1637 (vs), 1574 (m), 1468 (m), 1438 (m), 1391 (s), 1366 (m), 1258 (m), 1199 (s), 
1108 (m), 1092 (s), 1065 (m), 1031 (w), 990 (w), 945 (w), 896 (w), 854 (s), 770 (m), 740 
(m), 732 (w), 695 (w). HRMS (ESI): calc. for C14H18ON2Br [M–H]–: 309.0608, found: 
309.0611. 
 
 
 
Tertiary amine 4.15: n-Butylbromide (1.30 mL, 10.5 mmol) was added to a suspension 
of pipecolic amide 4.14 (2.44 g used crude from the previous step) and potassium 
carbonate (1.74 g, 12.6 mmol) in DMF (23 mL) and the reaction mixture was stirred at 
80 °C for 90 min. The suspension was cooled to room temperature, filtered and 
concentrated. The resulting residue was purified by flash column chromatography 
(hexanes:EtOAc 2:1 to 1:1, Rf = 0.3 (hexanes:EtOAc 1:1) to yield tertiary amine 4.15 
(2.15 g, 5.85 mmol, 16% over 2 steps) as a yellow oil. 
Data for 4.15: Rf: 0.3 (hexanes:EtOAc 1:1) 1H-NMR (400 MHz, CDCl3):  (ppm) = 8.12 
(s, 1H), 3.27 – 3.13 (m, 1H), 2.87 (dd, J = 10.3, 3.7 Hz, 1H), 2.78 (ddd, J = 12.5, 10.6, 
5.9 Hz, 1H), 2.30 – 2.23 (m, 1H), 2.21 (s, 5H), 2.11 – 2.01 (m, 2H), 1.79 – 1.63 (m, 3H), 
1.53 – 1.40 (m, 1H), 1.38 – 1.25 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3):  (ppm) = 173.3, 137.6, 133.0, 131.2, 120.5, 68.6, 57.7, 51.7, 30.8, 29.9, 25.0, 
23.6, 20.8, 18.7, 14.3. IR (ATR): 𝜈max (cm−1) = 3167 (w), 2933 (m), 2860 (w), 1803 (w), 
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1652 (vs), 1594 (w), 1577 (w), 1526 (m), 1470 (s), 1434 (m), 1404 (w), 1374 (w), 1314 
(w), 1287 (w), 1254 (w), 1230 (s), 1126 (w), 1092 (w), 1042 (w), 1012 (w), 998 (w), 967 
(w), 945 (w), 879 (w), 864 (s), 853 (s), 808 (m), 774 (m), 731 (m), 716 (w), 702 (w). 
HRMS (ESI): calc. for C18H28ON2Br [M+H]+: 367.1380, found: 367.1357. 
 
 
 
Aniline 4.16: LiHMDS (1.00 M in THF, 12.9 mL, 12.9 mmol) was added to a solution of 
tertiary amine 4.15 (2.15 g, 5.85 mmol), Pd(dba)2 (168 mg, 0.293 mmol) and Pd(t-Bu3P)2 
(151 mg, 0.293 mmol) in PhMe (14.6 mL) and the reaction was stirred at 60 °C for 20 h. 
The solution was cooled to room temperature, aqueous HCl (1.00 M, 10.0 mL) was added 
and the reaction mixture was stirred for 30 min at room temperature. The reaction was 
diluted with EtOAc, washed with aqueous NaOH (1 M) and brine and dried over MgSO4. 
Evaporation of the solvent under reduced pressure and purification of the resulting 
residue by flash column chromatography (EtOAc:pentane:NEt3 100:100:5, Rf=0.2) gave 
aniline 4.16 (1.72 g, 5.67 mmol, 97%) as a white solid. 
Data for 4.16: Rf: 0.2 (pentane:EtOAc:NEt3 100:100:5) 1H-NMR (400 MHz, CDCl3):  
(ppm) = 7.97 (s, 1H), 6.39 (s, 2H), 3.37 (s, 0H), 3.23 – 3.14 (m, 1H), 2.89 – 2.74 (m, 2H), 
2.27 – 2.17 (m, 1H), 2.13 (s, 6H), 2.08 – 1.96 (m, 2H), 1.78 – 1.57 (m, 2H), 1.53 – 1.39 
(m, 1H), 1.36 – 1.26 (m, 1H), 0.90 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3):  
(ppm) = 173.6, 145.4, 136.6, 124.7, 114.9, 68.9, 57.67, 51.9, 31.1, 29.8, 25.1, 23.7, 20.8, 
18.9, 14.3. IR (ATR): 𝜈max (cm−1) = 3430 (w), 3346 (m), 2952 (m), 2932 (m), 2858 (w), 
2812(w), 2784 (w), 1738 (w), 1669 (vs), 1630 (m), 1601 (s), 1496 (s), 1468(m), 1444 
(m), 1374 (m), 1344 (m), 1327 (m), 1303 8w), 1271 (w), 1258 (m), 1233 (m), 1219 (m), 
1184 8w), 1161 (w), 1136 (w), 1096 (m), 1050 (m), 1030 (m), 990 (w), 960 (w), 941 (w), 
885 (w), 865 (w), 542 (m), 786 (w), 733 (w), 670 (w), 678 (w). HRMS (ESI): calc. for 
C18H30ON3 [M+H]+: 304.2383, found: 304.2383. 
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Dimethylaniline 4.18: TFA (40.0 µL, 0.495 mmol) and t-BuONO (240. µl, 0.084 mmol) 
were sequentially added to an ice cooled solution of aniline 4.16 (50.0 mg, 0.165 mmol) 
in acetonitrile (5 mL) and the reaction was stirred for 1 h at 0 °C. Dimethylaniline 
(0.210 mL, 1.65 mmol) was added and the mixture was stirred at room temperature for 
1 h. The reaction was diluted with water and extracted with EtOAc. The organic phase 
was washed with aqueous HCl (1 M), water and brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (pentane:EtOAc 2:1, Rf=0.3) gave dimethylaniline 4.18 
(47.0 mg, 0.108 mmol, 65%) as a red solid. 
Data for 4.18: Rf: 0.3 (pentane:EtOAc 2:1) 1H-NMR (400 MHz, CDCl3):  (ppm) = 8.25 
(s, 1H), 7.86 (d, J = 9.1 Hz, 2H), 7.58 (s, 2H), 6.75 (d, J = 9.1 Hz, 2H), 3.28 – 3.19 (m, 
1H), 3.08 (s, 6H), 2.96 – 2.79 (m, 2H), 2.32 (s, 7H), 2.19 – 2.00 (m, 2H), 1.82 – 1.46 (m, 
7H), 1.33 (tdd, J = 24.6, 13.9, 4.7 Hz, 4H), 0.93 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3):  (ppm) = 173.2, 152.5, 151.6, 143.8, 136.0, 135.0, 125.0, 122.2, 111.6, 68.7, 
57.7, 51.8, 40.5, 30.8, 23.9, 25.0 23.7, 20.8, 19.1, 18.9, 14.3. IR (ATR): 𝜈max (cm−1) = 
3260 (w), 2929 (m), 2857 (w), 2811 (w), 1668 (m), 1599 (vs), 1564 (w), 1515 (s), 1485 
(s), 1444 (s), 1402 (m), 1360 (s), 1309 (w), 1264 (w), 1149 (vs), 1111 (m), 1054 (w), 
1026 (w), 944 (m), 875 (w), 820 (s), 732 (s), 639 (w), 612 (w). HRMS (ESI): calc. for 
C26H37ON5 [M+H]+: 436.3072, found: 436.3071. 
 
 
 
Azobenzene 4.17: AcOH (0.30 mL) was added to a solution of aniline 4.16 (20.0 mg, 
0.066 mmol) and nitrosobenzene (14.0 mg, 0.131 mmol) in CH2Cl2 (4 mL) and the 
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solution was stirred at room temperature for 24 h. The reaction was diluted with EtOAc, 
washed with NaHCO3 and brine and dried over MgSO4. Removal of the solvent under 
reduced pressure followed by purification of the resultant residue by flash column 
chromatography (hexanes:EtOAc 1:1, Rf=0.2) gave azobenzene 4.17 (7.4 mg, 
0.019 mmol, 29%) as an orange solid. 
Data for 4.17: Rf: 0.2 (hexanes :EtOAc 1:1) 1H-NMR (400 MHz, CDCl3):  (ppm) = 8.31 
(s, 1H), 7.94 – 7.85 (m, 2H), 7.67 (s, 2H), 7.50 (dt, J = 13.6, 7.0 Hz, 3H), 3.22 (d, J = 
11.8 Hz, 1H), 2.91 (dd, J = 10.2, 3.6 Hz, 1H), 2.83 (td, J = 11.6, 5.8 Hz, 1H), 2.35 (s, 6H), 
2.31 – 2.24 (m, 1H), 2.16 – 2.06 (m, 2H), 1.82 – 1.70 (m, 3H), 1.65 (tq, J = 8.9, 5.1, 4.5 
Hz, 1H), 1.51 (ddd, J = 12.1, 8.9, 3.7 Hz, 2H), 1.42 – 1.28 (m, 3H), 0.94 (t, J = 7.3 Hz, 
3H). 13C-NMR (100 MHz, CDCl3):  (ppm) = 173.2, 152.8, 151.0, 136.5, 136.2, 131.0, 
129.2, 122.9, 122.9, 68.6, 57.7, 51.7, 30.7, 23.9, 25.0, 23.6, 20.9, 19.2. IR (ATR): 𝜈max 
(cm−1) = 2244 (m), 2932 (s), 2858 (w), 2812 (w), 1666 (s), 1301 (w), 1482 (vs), 1416 (w), 
1376 (w), 1311 (w), 1291 (w), 1258 (w), 1236 (w), 1185 (w), 1149 (w), 118 (w), 1097 (w), 
1054 (w), 1041 (w), 1021 (w), 922 (w), 877 (m), 826 (w), 768 (s), 711 (w), 689 (w). HRMS 
(ESI): calc. for C24H32ON4 [M+H]+: 393.2650, found: 393.2649. 
 
 
 
Nitrobenzene 4.20: A solution of aniline 4.16 (1.20 g, 3.95 mmol) and p-nitro-
nitrosobenzene (901 mg, 5.93 mmol) in CH2Cl2 (70 mL) and AcOH (3.7 mL) was stirred 
at room temperature for 24 h before it was quenched with NaHCO3. The mixture was 
extracted with CH2Cl2, the organic phase was dried over MgSO4 and concentrated under 
reduced pressure. Purification of the resultant residue by flash column chromatography 
(CH2Cl2:MeOH 99:1 to 98:2, Rf=0.3 ) gave nitrobenzene 4.20 (1.21 g, 2.77 mmol, 70%) 
as a red solid. 
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Data for 4.20: Rf: 0.3 (CH2Cl2:MeOH 98:2) 1H-NMR (400 MHz, CDCl3):  (ppm) = 8.42 
– 8.30 (m, 3H), 7.99 (d, J = 8.7 Hz, 2H), 7.69 (s, 2H), 3.21 (dt, J = 12.1, 3.8 Hz, 1H), 2.92 
(dd, J = 10.0, 3.6 Hz, 1H), 2.81 (ddd, J = 12.5, 10.7, 5.8 Hz, 1H), 2.35 (s, 7H), 2.09 (td, 
J = 11.4, 2.8 Hz, 2H), 1.83 – 1.69 (m, 3H), 1.64 (tt, J = 10.5, 5.6 Hz, 1H), 1.58 – 1.45 (m, 
2H), 1.43 – 1.28 (m, 3H), 0.93 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3):  (ppm) 
= 173.07, 155.81, 150.66, 148.61, 138.00, 136.35, 124.79, 123.45, 123.44, 68.44, 57.66, 
51.61, 30.52, 29.86, 24.84, 23.52, 20.82, 19.13, 14.28. IR (ATR): 𝜈max (cm−1) = 3250 (w), 
2934 (m), 2860 (w), 2814 (w), 1670 (m), 1607 (w), 1590 (w), 1523 (s), 1482 (m), 1457 
(m), 1418 (w), 1378 (w), 1343 (vs), 1296 (w), 1235 (w), 1184 (w), 1122 (w), 1107 (w), 
1054 (w), 1008 (w), 963 (w), 878 (w), 861 (w), 826 (w), 156 (w), 732 (w), 690 (w), 713 
(w), 666 (w). HRMS (ESI): calc. for C24H32O3N5 [M+H]+: 438.2500, found: 483.2499. 
 
 
 
Aniline 4.21: A solution of azobenzene 4.20 (1.21 g, 2.77 mmol) and Na2Sx9H2O 
(531 mg, 5.55 mmol) in 1,4-dioxane (19.5 mL) and H2O (19.5 mL) was stirred at 90 °C 
for 2 h. After cooling to room temperature, the reaction was extracted with EtOAc and 
the organic phase was washed with aqueous NaOH (1 M) and brine and dried over 
MgSO4. Removal of the solvent under reduced pressure and purification of the resultant 
residue by flash column chromatography (CH2Cl2:MeOH 98:2 to 97:3, Rf=0.3 ) gave 
aniline 4.21 (886 mg, 2.17 mmol, 78%) as a red solid. 
Data for 4.21: Rf: 0.3 (CH2Cl2:MeOH 97:3) 1H-NMR (400 MHz, CDCl3):  (ppm) = 7.80 
(d, J = 8.4 Hz, 2H), 7.60 (s, 2H), 6.73 (d, J = 8.6 Hz, 2H), 4.10 (s, 2H), 3.24 (dt, J = 11.9, 
3.7 Hz, 1H), 2.97 – 2.80 (m, 2H), 2.35 (s, 7H), 2.17 – 2.04 (m, 2H), 1.83 – 1.71 (m, 3H), 
1.70 – 1.61 (m, 1H), 1.59 – 1.47 (m, 2H), 1.42 – 1.29 (m, 3H), 0.95 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3):  (ppm) = 173.20, 151.34, 149.71, 145.58, 136.05, 135.31, 
125.13, 122.31, 114.70, 68.66, 57.72, 51.72, 30.76, 29.89, 24.97, 23.62, 20.82, 19.11, 
14.31. IR (ATR): 𝜈max (cm−1) = 3340 (m), 3223 (w), 2933 (m), 2858 (w), 2814 (w), 1668 
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(m), 1624 (m), 1599 (vs), 1505 (s), 1489 (s), 1460 (m), 1428 (m), 1378 (w), 1300 (m), 
1212 (m), 1184 (w), 1145 (s), 1115 (m), 1097 (m), 1053 (w), 1027 (w), 960 (w), 876 (w), 
836 (m9), 735 (w), 701 (w). HRMS (ESI): calc. for C24H34ON5 [M+H]+: 408.2758, found: 
408.2759. 
 
 
 
Chloride 4.22: NEt3 (0.49 mL, 3.58 mmol) and chloroacetyl chloride (0.122 mL, 
1.55 mmol) were sequentially added to an ice cooled solution of aniline 4.21 (486 mg, 
1.19 mmol) and DMAP (10 mg, 0.082 mmol) in CH2Cl2 and the solution was stirred for 
10 min at 0 °C and for 3 h at room temperature. The mixture was diluted with EtOAc and 
washed with NaHCO3 and brine, dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resultant residue by flash column chromatography 
(CH2Cl2:MeOH 96:4, Rf= 0.3) gave chloride 4.22 (300 mg, 0.620 mmol, 52%) as a red 
solid. 
Data for 4.22: Rf: 0.3 (CH2Cl2:MeOH 96:4) 1H-NMR (400 MHz, CDCl3):  (ppm) = 8.78 
(s, 1H), 8.44 (s, 1H), 7.80 (d, J = 8.7 Hz, 2H), 7.63 – 7.51 (m, 4H), 4.20 (s, 2H), 3.23 (dt, 
J = 12.1, 3.9 Hz, 1H), 2.95 (dd, J = 10.0, 3.7 Hz, 1H), 2.91 – 2.79 (m, 1H), 2.33 (s, 7H), 
2.15 – 2.07 (m, 2H), 1.84 – 1.70 (m, 3H), 1.70 – 1.60 (m, 1H), 1.51 (td, J = 10.5, 9.4, 5.4 
Hz, 2H), 1.36 (tdd, J = 16.6, 11.1, 8.1 Hz, 3H), 0.94 (t, J = 7.3 Hz, 3H). 13C-NMR (100 
MHz, CDCl3):  (ppm) = 173.6, 164.4, 151.2, 149.4, 139.6, 136.3, 136.1, 124.0, 122.8, 
120.1, 68.5, 57.7, 51.7, 43.2, 30.5, 29.9, 24.8, 23.6, 20.8, 19.1, 14.3. IR (ATR): 𝜈max 
(cm−1) = 3269 (w), 3199(w), 3030 (w), 3070 (w), 2934 (w), 2860 (w), 2815 (w), 1659 (s), 
1596 (s), 1545 (s), 1501 (s), 1408 (m), 1377 (w), 1330 (m), 1296 (w), 1272 (w), 1250 
(m), 1186 (w), 1151 (m), 1109 (w), 1097 (w), 1054 (w), 1029 (w), 1013 (w), 963 (w), 907 
(m), 878 (w), 846 M), 778 (w), 728 (vs), 686 (w). HRMS (ESI): calc. for C26H35O2N5Cl 
[M+H]+: 484.2479, found: 484.2474.  
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Amine 4.23: A suspension of chloride 4.22 (296 mg, 0.612 mmol) and NaI (137 mg, 
0.917 mmol) in acetone (16 mL) was stirred for at room temperature in the dark 
overnight. The reaction mixture was washed with H2O, dried over MgSO4 and 
concentrated under reduced pressure to give iodide S4.1 which was used in the next 
step without further purification. 
NH3 (7 M in MeOH, 1.4 mL, 9.80 mmol) was slowly added to an ice cooled solution of 
iodide S4.1 in THF (4.3 mL) and the resulting solution was stirred for 15 min at 0 °C and 
for 4 h at room temperature. The reaction was diluted with EtOAc, washed with H2O and 
brine, dried over MgSO4 and concentrated under reduced pressure. Purification of the 
resultant residue by reverse phase column chromatography (MeCN:aqHCl (0.1 M) gave 
amine 4.23 (153 mg, 0.329 mmol, 77%) as a red solid. 
Data for 4.23: 1H-NMR (400 MHz, d4-MeOH):  (ppm) = 7.92 (d, J = 8.7 Hz, 2H), 7.82 
(d, J = 8.6 Hz, 2H), 7.67 (s, 2H), 4.35 – 4.25 (m, 1H), 3.94 (s, 2H), 3.70 (d, J = 12.4 Hz, 
1H), 3.21 (dd, J = 14.8, 9.1 Hz, 2H), 2.46 (d, J = 12.7 Hz, 1H), 2.34 (s, 6H), 2.15 (s, 1H), 
2.04 – 1.72 (m, 7H), 1.42 (q, J = 7.4 Hz, 2H), 1.29 (s, 2H), 1.00 (t, J = 7.3 Hz, 3H). 13C-
NMR (100 MHz, d4-MeOH):  (ppm) = 168.4, 165.8, 152.8, 150.3, 142.2, 137.7, 136.54, 
124.9, 123.4, 121.0, 67.3, 57.4, 53.3, 42.4, 30.6, 26.8, 23.8, 22.6, 21.0, 18.9, 13.9. IR 
(ATR): 𝜈max (cm−1) = 2956(s), 2872 (m), 1685 (s), 1596 (s), 1547 (vs), 1501 (s), 1475 
(m), 1410 (m), 1303 (s), 1255 (s), 1208 (m), 1151 (s), 1026 (m), 936 (m), 899 (m), 846 
(s), 707 (m). HRMS (ESI): calc. for C26H37O2N6 [M+H]+: 465.2973, found: 465.7979. 
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6.5.3 Photoswitches based on raxatrigine 
 
Pyroglutamate 4.25: SOCl2 (55.6 mL, 775 mmol) was added slowly to an ice cooled 
solution of L-pyroglutamate (25.0 g, 194 mmol) in EtOH (360 mL) and the reaction was 
stirred at room temperature for 3 h. The reaction mixture was slowly quenched with 
saturated aqueous NaHCO3 and extracted with CH2Cl2. The combined organic phases 
were dried over MgSO4 and concentrated under reduced pressure to give crude ethyl 
ester 4.36 (27.2 g) which was used in the next step without further purification. 
A solution of crude ethyl ester 4.36 (27.2 g), DMAP (21.1 g, 173 mmol), NEt3 (24.0 mL, 
173 mmol) and di-tert-butyldicarbonate (75.5 g, 346 mmol) in CH2Cl2 (370 mL) was 
stirred at room temperature overnight. The reaction mixture was washed with aqueous 
citric acid (10%) and brine, dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (hexanes:EtOAc 
3:2, Rf = 0.4) gave pyroglutamate 4.25 (37.5 g, 146 mmol, 75% over 2 steps) as colorless 
oil. 
Data for 4.25: 1H-NMR (400 MHz, CDCl3): δ (ppm) =4.55 (dd, J = 9.5, 2.9 Hz, 1H), 4.19 
(q, J = 7.1 Hz, 2H), 2.58 (ddd, J = 17.5, 10.2, 9.6 Hz, 1H), 2.44 (ddd, J = 17.4, 9.4, 
3.5 Hz, 1H), 2.28 (ddt, J = 13.4, 10.3, 9.4 Hz, 1H), 2.02 – 1.94 (m, 1H), 1.44 (s, 9H), 1.25 
(t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 173.7, 171.7, 149.6, 83.8, 
62.0, 59.3, 3.5, 28.2, 21.9, 14.5. IR (ATR): 𝜈max (cm−1) = 2981 (W), 1791 (S), 1742 (S), 
1715 (S), 1477 (W), 1460 (W), 1394 (W), 1369 (M), 1359 (W), 1307 (S), 1285 (S), 1255 
(S), 1189 (S), 1144 (VS), 1097 (W), 1043 (M), 1019 (S), 960 (W), 913 (W), 880 (W), 843 
(M), 820 (W), 777 (M), 747 (M), 720 (W). HRMS (ESI): calc. for C12H20NO5 [M+H]+: 
258.1336, found: 258.1331. [𝛂]𝑫
𝟐𝟓 = –41.2 (CHCl3). 
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Ketone 4.28: n-BuLi (2.30 M in hexanes, 3.36 mL, 7.77 mmol) was added to a solution 
of 1-bromo-4-iodobenzene (2.74 g, 7.77 mmol) in THF (20 mL) at –78 °C and the 
reaction was stirred at that temperature for 1 h. The resulting solution was slowly added 
to a solution of pyroglutamate 4.25 (2.00 g, 7.77 mmol) in THF (20 mL) at –78 °C and 
the reaction was stirred at that temperature for 3 h. The reaction mixture was quenched 
with saturate aqueous NHCl4, diluted with H2O and extracted with EtOAc. The combined 
organic phases were dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (hexanes:EtOAc 
5:1, Rf = 0.3) gave ketone 4.28 (1.59 g, 3.85 mmol, 50%) as a colorless solid. 
Data for 4.28: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.81 (d, J = 8.6 Hz, 2H), 7.60 (d, 
J = 8.4 Hz, 2H), 5.15 (d, J = 8.4 Hz, 1H), 4.40 – 4.28 (m, 1H), 4.20 (q, J = 7.1 Hz, 2H), 
3.14 – 2.95 (m, 2H), 2.35 – 2.26 (m, 1H), 2.05 (dtd, 14.3, 8.5, 5.9 Hz, 1H), 1.41 (s, 10H), 
1.26 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 198.3, 172.8, 155.9, 
135.8, 132.4, 130.0, 126.6, 80.5, 62.0, 53.5, 35.0, 28.7, 27.5, 14.6. IR (ATR): 𝜈max (cm−1) 
= 3365 (VW), 2979 (W), 2934 (W), 1709 (S), 1687 (S), 1586 (M), 1569 (W), 1504 (M), 
1448 (M), 1393 (M), 1366 (S), 1348 (M), 1300 (M), 1249 (M), 1205 (S), 1161 (VS), 1114 
(W), 1095 (M), 1070 (S), 1049 (M), 1026 (S), 1009 (S), 988 (M), 859 (W), 815 (M), 779 
(M), 735 (S), 702 (M), 658 (W).  HRMS (ESI): calc. for C18H25BrNO5 [M+H]+: 414.0911, 
found: 414.0916. [𝛂]𝑫
𝟐𝟓 = +4.2 (CHCl3). 
 
 
 
Pyrrolidine 4.29: TFA (4.07 mL, 53.2 mmol) was added dropwise to an ice cooled 
solution ketone 4.28 (1.46 g, 3.54 mmol) in CH2Cl2 (30 mL) and the reaction was allowed 
to warm to room temperature over 90 min. Evaporation of the volatiles under reduced 
pressure gave crude imine 4.37 as yellow oil which was used in the next step without 
further purification. 
290 
A suspension of crude imine 4.37 and PtO2 (17 mg, 1.16w%) in MeOH was stirred under 
H2-atmosphere overnight, filtered over a pad of celite and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(hexanes:EtOAc 1:2-1.4) gave pyrrolidine 4.29 (1.07 g, 3.60 mmol, 100%) as a colorless 
solid. 
Data for 4.29: Rf: 0.5 (hexanes:EtOAc 1:2) 1H-NMR (400 MHz, CDCl3): δ (ppm) = 9.73 
(s, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 4.84 – 4.78 (m, 1H), 
4.62 – 4.56 (m, 1H), 4.29 (q, J = 7.2 Hz, 2H), 2.58 (s, 1H), 2.44 – 2.39 (m, 2H), 2.13 (dt, 
J = 12.3, 6.0 Hz, 1H), 1.33 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
170.2, 132.8, 132.3, 129.2, 123.8, 63.5, 63.0, 59.0, 30.4, 28.9, 13.7. IR (ATR): 𝜈max (cm−1) 
= 2968 (W), 1746 (M), 1718 (W), 1655 (S), 1637 (M), 1577 (W), 1559 (W), 1490 (W), 
1466 (W), 1457 (W), 1433 (M), 1381 (W), 1305 (W), 1297 (W), 1235 (W), 1196 (S), 1170 
(S), 1135 (VS), 1096 (M), 1084 (M), 1073 (M), 1061 (M), 1024 (W), 1012 (M), 988 (W), 
853 (W), 835 (M), 816 (M), 796 (S), 720 (S), 698 (W), 686 (W).  HRMS (EI): calc. for 
C13H16BrNO2 [M]+: 297.0359, found: 297.0360. [𝛂]𝑫
𝟐𝟓 = –12.6 (CHCl3). 
 
 
 
Benzylamide 4.30: PMB-Cl (0.60 mL, 4.47 mmol) was added dropwise to a suspension 
of pyrrolidine 4.29 (1.02 g, 3.44 mmol), K2CO3 (713 mg, 5.16 mmol and NaI (155 mg, 
1.03 mmol) in DMF (20 mL) and the reaction was stirred at room temperature overnight. 
The resulting solution was diluted with H2O and extracted with EtOAc. The combined 
organic phases were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Purification of the resulting residue by flash column chromatography 
(hexanes:EtOAc 10:1, Rf = 0.4) gave benzylamide 4.30 (547 mg, 1.31 mmol, 38%) as a 
colorless oil. 
Data for 4.30: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.48 – 7.42 (m, 4H), 7.08 (d, 
J = 8.5 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 3.97 (qd, J = 7.1, 1.2 Hz, 2H), 3.81 (d, 
J = 5.7 Hz, 1H), 3.77 (s, 3H), 3.72 (dd, J = 9.5, 5.8 Hz, 1H), 3.46 – 3.41 (m, 2H), 
2.12 – 1.91 (m, 3H), 1.87 – 1.75 (m, 1H), 1.17 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = 174.7, 160.7, 142.6, 131.3, 130.5, 129.4, 129.2, 120.5, 113.1, 67.9, 
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64.2, 60.2, 55.4, 55.0, 35.2, 28.8, 14.0. IR (ATR): 𝜈max (cm−1) = 2956 (W), 2835 (W), 1725 
(S), 1611 (M), 1586 (W), 1511 (VS), 1486 (M), 1464 (M), 1442 (M), 1408 (W), 1370 (W), 
1353 (W), 1301 (M), 1246 (VS), 1216 (M), 1170 (VS), 1106 (M), 1096 (M), 1069 (M), 
1033 (S), 1010 (S), 819 (VS), 757 (M), 716 (W), 703 (W).  HRMS (EI): calc. for 
C21H24BrNO3 [M]+: 417.0934, found: 417.0946. [𝛂]𝑫
𝟐𝟓 = +24.8 (CHCl3). 
 
 
 
Carbamate 4.31: BrettPhos Pd G3 (15.7 mg, 0.02 mmol), BrettPhos (14.7 mg, 0.02), t-
butylcarbamate, Cs2CO3 and benzylamide 4.30 (360 mg, 0.86 mmol) were suspended in 
degassed 1,4-dioxane and submitted to three additional freeze-pump-thaw cycles. The 
reaction was stirred at 100 °C overnight, filtered over a pad of celite and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (hexanes:EtOAc 6:1, Rf= 0.3) gave carbamate 4.31 (344 mg, 
0.76 mmol, 88%) as ayellowish ol. 
Data for 4.31: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.48 (d, J = 8.1 Hz, 2H), 7.34 (d, 
J = 8.1 Hz, 2H), 7.08 (d, J = 8.2 Hz, 2H), 6.79 – 6.74 (m, 2H), 3.94 (q, J = 6.9 Hz, 2H), 
3.83 – 3.78 (m, 1H), 3.77 (s, 3H), 3.68 (dd, J = 9.5, 5.5 Hz, 1H), 3.42 – 3.34 (m, 2H), 
2.11 – 1.99 (m, 2H), 1.99 – 1.89 (m, 1H), 1.88 – 1.72 (m, 1H), 1.52 (s, 9H), 1.16 (t, 
J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 175.5, 159.0, 153.3, 138.6, 
137.7, 131.2, 130.2, 128.7, 119.2, 113.7, 80.9, 77.7, 68.6, 64.8, 60.8, 55.7, 35.7, 29.4, 
28.8, 14.6. IR (ATR): 𝜈max (cm−1) = 3343 (VW), 2977 (W), 1708 (S), 1612 (M), 1597 (W), 
1558 (VW), 1525 (M), 1511 (S), 1464 (W), 1457 (W), 1444 (W), 1414 (M), 1392 (W), 
1366 (M), 1312 (M), 1233 (S), 1156 (VS), 1110 (M), 1104 (M), 1050 (M), 1028 (M), 1017 
(M), 902 (W), 836 (M), 822 (M), 766 (W). HRMS (EI): calc. for C26H34N2O5 [M]+: 454.2462, 
found: 454.2475. [𝛂]𝑫
𝟐𝟓 = +18.7 (CHCl3). 
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Azobenzene 3.43: TFA (4.07 mL, 53.2 mmol) was added dropwise to an ice cooled 
solution of carbamate 4.31 (290 mg, 0.64 mmol) and anisole (2.08 mL, 19.2 mmol) in 
CH2Cl2 (30 mL) and the reaction was allowed to warm to room temperature over 2.5 h. 
The volatiles were removed under reduced pressure and the resulting residue was 
purified by flash column chromatography (CH2Cl2:MeOH 96:4-94:6) gave crude aniline 
4.32 (310 mg) that was used in the next step without further purification. 
AcOH (0.3 mL) was added to a solution of crude aniline 4.32 (310 mg) and 1-fluoro-2-
nitrosobenzene (130 mg, 1.05 mmol) in MeOH (10 mL) and the reaction was stirred at 
room temperature overnight. The volatiles were removed under reduced pressure, the 
resulting residue was redissolved in EtOAc and washed with saturated aqueous NaHCO3 
and brine. The organic phase was dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(hexanes:EtOAc 8:1, Rf = 0.3) gave azobenzene 4.34 (144 mg, 0.31 mmol, 49%) as an 
orange oil. The resulting product is in a light driven equilibrium with its double bond 
isomer.  
Data for 4.34: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.94 (dd, J = 8.7, 2.1 Hz, 2H), 
7.81 – 7.75 (m, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.26 – 7.19 (m, 1H), 7.12 (d, J = 8.6 Hz, 
2H), 7.05 – 6.98 (m, 1H), 6.94 – 6.89 (m, 1H), 6.79 (d, J = 8.6 Hz, 2H), 3.99 (q, 
J = 7.1 Hz, 2H), 3.87 – 3.84 (m, 1H), 3.77 (s, 3H), 3.74 – 3.67 (m, 1H), 3.52 – 3.45 (m, 
2H), 2.21 – 1.73 (m, 4H), 1.19 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 175.3, 161.7, 159.2, 159.1, 152.7, 148.2, 141.2, 132.7, 132.6, 131.1, 128.7, 124.7, 
123.7, 120.9, 118.2, 117.56, 117.4, 113.78, 68.9, 65.0, 60.9, 56.2, 55.7, 35.8, 29.5, 14.6. 
IR (ATR): 𝜈max (cm−1) = 2953 (W), 2835 (W), 2361 (VW), 1727 (M), 1701 (W), 1684 (VW), 
1654 (VW), 1604 (M), 1587 (W), 1559 (VW), 1540 (VW), 1511 (S), 1496 (M), 1483 (M), 
1464 (M), 1458 (M), 1441 (M), 1419 (W), 1394 (VW), 1370 (W), 1349 (W), 1301 (M), 
1266 (M), 1246 (S), 1227 (S), 1174 (S), 1149 (S), 1128 (S), 1102 (S), 1069 (W), 1032 
(S), 1012 (M), 947 (W), 912 (VW), 892 (VW), 845 (S), 820 (M), 757 (VS), 722 (W), 659 
(VW). HRMS (EI): calc. for C27H27FN3O3 [M]+: 461.2109, found: 461.2117. [𝛂]𝑫
𝟐𝟓 = +11.9 
(CHCl3). 
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Amide 4.35: A solution of azobenzene 4.34 (111 mg, 0.24 mmol) and LiOH.H2O 
(200 mg, 4.80 mmol) in THF (1.5 mL), H2O (0.7 mL) and MeOH (0.7 mL) was stirred at 
room temperature for 2.5 h. The reaction was acidified with aqueous HCl (1 M) and 
extracted with EtOAc. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure to give crude acid 4.38 (103 mg) which was used 
in the next step without further purification. 
DIPEA (0.08 mL, 0,36 mmol) was added to a stirred solution of crude acid 4.38 (103 mg) 
and TBTU (84.0 mg, 0.26 mmol) in DMF (3 mL) and the reaction was stirred for 30min 
at room temperature. HMDS (0.07 mL, 0.360 mmol) was added to the solution and the 
reaction was stirred 2 h at room temperature before saturated aqueous NaHCO3 (3 mL) 
was added and the reaction was stirred at room temperature for 30 min. The resulting 
solution was diluted with H2O and extracted with EtOAc. The combined organic phases 
were washed with brine, dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (hexanes:EtOAc 
1:6, Rf = 0.2) gave amide 4.35 (54 mg, 0.13 mmol, 52%) as an orange oil. The resulting 
product is in a light driven equilibrium with its double bond isomer. 
 
Data for 4.35: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.97 (d, J = 8.4 Hz, 2H), 7.78 (td, 
J = 7.8, 1.8 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.50 – 7.43 (m, 1H), 7.03 (d, J = 8.4 Hz, 
2H), 6.96 – 6.88 (m, 1H), 6.80 (d, J = 8.4 Hz, 2H), 6.78 – 6.73 (m, 1H), 5.16 (s, 1H), 3.88 
(dd, J = 10.4, 5.6 Hz, 1H), 3.77 (s, 3H), 3.76 – 3.63 (m, 1H), 3.53 – 3.46 (m, 2H), 
2.35 – 2.23 (m, 1H), 2.22 – 1.96 (m, 2H), 1.85 – 1.69 (m, 1H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = IR (ATR): 𝜈max (cm−1) = 3517 (W), 3398 (W), 3074 (VW), 3035 (W), 
3014 (VW), 2961 (W), 2945 (W), 2923 (W), 2878 (W), 2870 (W), 2840 (W), 1685 (VS), 
1654 (W), 1647 (W), 1637 (W), 1611 (M), 1602 (M), 1585 (M), 1550 (M), 1513 (S), 1499 
(W), 1482 (S), 1464 (M), 1457 (M), 1449 (M), 1440 (M), 1419 (W), 1371 (M), 1320 (W), 
1302 (W), 1278 (W), 1266 (M), 1249 (VS), 1214 (S), 1178 (M), 1150 (M), 1133 (M), 1122 
(M), 1109 (M), 1102 (M), 1067 (W), 1031 (S), 1010 (M), 990 (W), 957 (W), 942 (W), 922 
(W), 859 (M), 845 (S), 820 (S), 788 (W), 768 (VS), 740 (M), 719 (W). HRMS (EI): calc. 
for C25H25FN4O2 [M]+: 258.1336, found: 432.1958. [𝛂]𝑫
𝟐𝟓 = +44.3 (CHCl3).  
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Azoraxatrigine 4.24: a-Chloroethylchloroformate (0,13 mL, 1.16 mmol) was added 
dropwise to a stirred solution of amide 4.35 (50 mg, 0.12 mmol) and the resulting solution 
was stirred at 80 °C for 6 h. The volatiles were removed under reduced pressure and the 
resulting residue was portioned between EtOAc and brine. Concentration of the organic 
phase under reduced pressure and purification of the resulting residue by flash column 
chromatography (CH2Cl2:MeOH 98:2-92:8) gave azoraxatrigine 4.24 (5.0 mg, 
0.02 mmol, 14%) as an orange solid. The resulting product is in a light driven equilibrium 
with its double bond isomer. The major trans isomer is described. 
Data for 4.24: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.93 (d, J = 8.0 Hz, 2H), 7.76 (td, 
J = 7.8, 1.8 Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.49 – 7.40 (m, 1H), 7.28 (d, J = 9.0 Hz, 
1H), 6.89 (d, J = 9.0 Hz, 1H), 5.52 (d, J = 19.5 Hz, 1H), 4.44 (dd, J = 9.9, 5.8 Hz, 1H), 
3.94 (dd, J = 10.0, 3.8 Hz, 1H), 2.40 – 2.27 (m, 1H), 2.27 – 2.08 (m, 2H), 1.75 – 1.66 (m, 
1H). IR (ATR): 𝜈max (cm−1) = 3426 (W), 3322 (W), 3196 (W), 3064 (W), 2955 (M), 2924 
(S), 2853 (M), 1737 (W), 1676 (VS), 1604 (M), 1589 (M), 1511 (W), 1500 (W), 1483 (M), 
1464 (W), 1442 (W), 1413 (W), 1377 (W), 1366 (W), 1303 (W), 1267 (M), 1226 (M), 1151 
(W), 1102 (M), 1029 (VW), 1013 (VW), 845 (W), 831 (W), 760 (M).  HRMS (ESI): calc. 
for C17H17FN4O [M+H]+: 313.1459, found: 313.1460  
 
 
 
Carbamate 3.44: NEt3 (5.04 mL, 36.2 mmol) was added to a solution of pyrrolidine 4.29 
(5.60 g, 17.8 mmol), di-tert-butyldicarbonate (15.9 g, 72.2 mmol) and DMAP (4.40 g, 
36.2 mmol) in CH2Cl2 (300 mL) and the reaction was stirred at room temperature 
overnight. The reaction mixture was washed with aqueous citric acid (10%) and brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (pentane:EtOAc 5:1, Rf = 0.3) gave carbamate 
4.44 (3.00 g, 7.53 mmol, 43%) as a yellowish oil. The product was obtained as a mixture 
of Boc rotamers. 
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Data for 4.44: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.45 (d, J = 4.4 Hz, 4H), 4.95 – 
4.67 (m, 1H), 4.49 – 4.31 (m, 1H), 4.26 (q, J = 7.2 Hz, 2H), 2.31 (dq, J = 13.7, 7.2 Hz, 
1H), 2.23 – 2.14 (m, 1H), 2.06 – 1.96 (m, 1H), 1.87 (dd, J = 12.3, 6.3 Hz, 1H), 1.40 (t, 
9H), 1.16 (d, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 173.0, 154.23 143.3, 131.4, 
131.1, 128.1, 127.9, 120.3, 80.5, 80.3, 62.4, 61.8, 61.2, 61.1, 60.8, 60.4, 35.5, 34.4, 29.0, 
28.7, 28.2, 28.0, 14.3, 14.2. IR (ATR): 𝜈max (cm−1) = 2978 (W), 1744 (M), 1694 (VS), 1489 
(M), 1478 (W), 1454 (W), 1389 (S), 1291 (M), 1257 (W), 1189 (S), 1153 (VS), 1119 (M), 
1102 (M), 1073 (M), 1032 (M), 1010 (M), 933 (W), 893 (VW), 858 (W), 821 (M), 752 (M), 
716 (W), 701 (W), 665 (W). HRMS (EI): calc. for C18H24BrNO4 [M]+: 397-0889, found: 
397.0891. [𝛂]𝑫
𝟐𝟓 = +22-3 (CHCl3). 
 
 
 
Phenylhydrazine 4.40: A solution of 1-fluoro-2-iodobenzene (2.62 mL, 22.5 mmol), t-
butylcarbazate (4.18 g, 31.5 mmol), Cs2CO3 (20.3 g, 62.0 mmol), 1.10-phen (815 mg, 
4.45 mmol) and CuI (95.0 mg, 0.450 mmol) in DMF (45 mL) was stirred at 80°C 
overnight. The reaction mixture was diluted with H2O and extracted with EtOAc. The 
combined organic phases were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (hexanes:EtOAc 4:1, Rf = 0.4) gave phenylhydrazine 4.40 (856 mg, 
3.77 mmol, 17%) as a red solid. 
Data for 4.40: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.31 (td, J = 7.8, 1.6 Hz, 1H), 7.24 
– 7.16 (m, 1H), 7.15 – 7.02 (m, 2H), 4.88 – 4.14 (m, 2H), 1.43 (s, 9H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 158.4, 155.9, 155.8, 131.3, 131.2, 128.2, 128.1, 124.0, 124.0, 
116.1, 115.9, 81.7, 28.1. IR (ATR): 𝜈max (cm−1) = 3341 (W), 2979 (W), 2933 (W), 1697 
(VS), 1630 (W), 1592 (W), 1501 (S), 1479 (W), 1456 (W), 1392 (M), 1367 (S), 1344 (S), 
1291 (M), 1263 (M), 1222 (M), 1189 (S), 1178 (S), 1148 (VS), 1106 (M), 1053 (M), 1025 
(M), 933 (W), 863 (W), 836 (M), 795 (W), 753 (S), 657 (M). MS (EI): calc. for C11H15FN2O2 
[M]+: 227.11, found: 227.09. 
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Diphenylhdrazine 4.39: A mixture of phenylhydrazine 4.40 (80 mg, 0.35 mmol), 
carbamate 4.44 (20.0 mg, 0.300 mmol), Pd(OAc)2 (13.0 mg, 0.060 mmol), (t-Bu)3P (1 M, 
PhMe, 0.060 mL, 0.060 mmol) and Cs2CO3 (187 mg, 0.390 mmol) in PhMe (24 mL) was 
stirred at room temperature for 30 min and at 110 °C for 2.5 h. The resulting suspension 
was cooled to room temperature, diluted with EtOAc and filtered over a pad of celite. 
Removal of the solvent under reduced pressure and purification of the resulting residue 
by flash column chromatography (hexanes:EtOAc 4:1, Rf = 0.3) gave diphenylhydrazine 
4.39 (166 mg, 0.310 mmol, 89%) as a brown solid. The product was obtained as a 
mixture of Boc rotamers. 
Data for 4.39: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.44 (s, 2H), 7.22 – 7.12 (m, 2H), 
7.09 (d, J = 7.7 Hz, 2H), 6.86 (d, J = 7.2 Hz, 2H), 6.46 (s, 1H), 4.72 – 4.40 (m, 1H), 4.34 
– 4.18 (m, 3H), 2.21 (ddd, J = 25.1, 12.4, 6.2 Hz, 2H), 2.14 – 1.83 (m, 1H), 1.39 (s, 18H), 
1.14 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 173.4, 173.3, 154.6, 154.6, 153.9, 
146.6, 146.5, 137.0, 135.9, 127.4, 127.2, 124.3, 113.1, 82.4, 82.3, 80.2, 80.00, 62.7, 
61.9, 61.2, 61.0, 60.5, 35.7, 34.6, 29.1, 28.8, 28.4, 28.2, 28.1, 14.4, 14.3. IR (ATR): 𝜈max 
(cm−1) = 3312 (W), 2979 (W), 2189 (VW), 2103 (VW), 1691 (M), 1701 (W), 1615 (W), 
1515 (W), 1498 (M), 1478 (W), 1456 (W),1392 (M), 1366 (M), 1336 (M), 1301 (M), 1285 
(W), 1246 (W), 1152 (S), 1128 (S), 1108 (M), 1074 (W), 1017 (M), 934 (W), 912 (VW), 
832 (W), 845 (S), 799 (W), 754(M). HRMS (ESI): calc. for C29H42F4O6 [M+H]+: 561.3083, 
found: 561.3084. [𝛂]𝑫
𝟐𝟓 = +66.0 (CHCl3). 
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Amide 4.42: A solution of LiOH.H2O (100 mg, 2.44 mmol) in H2O (2.5 mL) was added to 
a solution of diphenylhydrazine 4.39 (435 mg, 0.080 mmol) in THF (5.0 mL) and MeOH 
(2.5 mL) and the solution was stirred at room temperature overnight. The reaction was 
acidified with aqueous HCl (1 M) and extracted with EtOAc. The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure to give crude acid 4.41 that was used in the next step without further purification. 
DIPEA (22.5 µL, 1.35 mmol) was added to a solution of crude acid 4.41 and HATU 
(281 mg, 1.02 mmol) in DMF and the solution was stirred at room temperature for 30 min. 
HMDS (197 µL, 1.02 mmol) was added and the reaction was stirred at room temperature 
for 1.5 h, diluted with NaHCO3 and H2O and extracted with EtOAc. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure. Purification 
of the resulting residue by flash column chromatography (hexanes:EtOAC 1:2, Rf = 0.4) 
gave amide 4.42 (177 mg, 0.34 mmol, 55% over 2 steps) as an orange solid. The product 
was obtained as a mixture of Boc rotamers. 
Data for 4.42: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.45 – 7.39 (m, 1H), 7.25 – 7.16 
(m, 1H), 7.17 – 7.08 (m, 4H), 6.87 – 6.82 (m, 2H), 6.52 (s, 1H), 5.50 (s, 1H), 4.62 (s, 1H), 
4.45 (s, 1H), 2.49 (s, 1H), 2.31 – 2.20 (m, 1H), 1.97 (q, J = 9.7, 8.3 Hz, 2H), 1.63 (d, J = 
4.7 Hz, 1H), 1.39 (s, 9H), 1.20 (s, 9H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 174.5, 
158.1, 155.6, 154.4, 146.7, 136.23, 130.7, 130.6, 128.2, 128.2, 127.5, 127.2, 124.1, 
116.2, 116.0, 113.1, 82.2, 80.8, 63.2, 61.2, 28.0, 27.9. IR (ATR): 𝜈max (cm−1) = 2974 (W), 
2410 (W), 1667 (M), 1614 (W), 1514 (W), 1499 (W), 1480 (W), 1455 (W), 1392 (M), 1366 
(M), 1338 (M), 1283 (W), 1263 (M), 1218 (W), 1151 (S), 1106 (M), 1102 (M), 1015 (W), 
943 (W), 922 (W), 840 (M), 801 (W), 753 (S), 665 (M). HRMS (ESI): calc. for C27H39FN5O5 
[M+NH4]+: 532.2930, found: 532.2935. [𝛂]𝑫
𝟐𝟓 = +4.8 (CHCl3). 
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Azoraxatrigine 4.24: A solution of amide 4.42 (581 mg, 1.13 mmol), Cs2CO3 (1.53 g, 
4.69 mmol) and CuI (900 mg, 4.69 mmol) in DMF (16 mL) was stirred at 140 °C for 24 h. 
After cooling to room temperature, the reaction mixture was diluted with EtOAc and 
filtered over a pad of silica. Removal of the solvent under reduced pressure and 
purification of the resulting residue by flash column chromatography (CH2Cl2:MeOH 98:2-
97:3, Rf = 0.4) gave crude azobenzene 4.43 which was used in the next step without 
further purification. 
TFA (15 mL) was added to an ice cooled solution of crude azobenzene 4.43 in CH2Cl2 
(29 mL) and the reaction was stirred at 0 °C for 30 min and at room temperature for 3 h. 
The mixture was diluted with saturated aqueous NaHCO3 and extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (CH2Cl2:MeOH 96:4, Rf = 0.4) gave azoraxatrigine 4.24 (166 mg, 
0.53 mmol, 47%) as an orange solid. The resulting product is in a light driven equilibrium 
with its double bond isomer. The major trans isomer is described. 
Data for 4.24: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.95 – 7.89 (m, 2H), 7.77 (td, J 
= 7.8, 1.7 Hz, 1H), 7.68 – 7.63 (m, 2H), 7.53 (dddd, J = 8.6, 6.9, 5.0, 1.8 Hz, 1H), 7.37 – 
7.25 (m, 2H), 4.37 (dd, J = 9.7, 6.0 Hz, 1H), 3.83 (dd, J = 9.6, 4.5 Hz, 1H), 2.33 (dtd, J = 
12.4, 9.9, 7.4 Hz, 1H), 2.23 (dddd, J = 12.1, 7.3, 6.0, 2.9 Hz, 1H), 2.07 (dddd, J = 12.3, 
7.5, 4.5, 2.9 Hz, 1H), 1.67 (dtd, J = 12.1, 9.9, 8.0 Hz, 1H). 13C-NMR (100 MHz, d4-MeOH): 
δ (ppm) = 181.1, 162.7, 160.2, 153.3, 149.4, 133.9, 128.6, 125.6, 124.2, 118.6, 118.2, 
118.0, 64.1, 61.4, 35.2, 32.1. IR (ATR): 𝜈max (cm−1) = 3406 (W), 3190 (W), 3067 (W), 
2929 (W), 2870 (W), 1687(M), 1654 (S), 1602 (M), 1588 (M), 1498 (M), 1480 (M), 1439 
(M), 1400 (W), 1385 (M), 1350 (M), 1325 (M), 1299 (M), 1264 (M), 1243 (M), 1217 
(M),1181 (M),1099 (M), 1029 (W), 1012 (W), 947 (W), 906 (W), 839 (M), 785 (M), 756 
(VS), 728 (S), 717 (S), 661 (W). HRMS (ESI): calc. for C17H18FN4 O [M+H]+: 313.1459, 
found: 313.1459. [𝛂]𝑫
𝟐𝟓 = +84.0 (CHCl3). 
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Ketone S4.2: n-BuLi (2.21 M in hexanes, 9.30 mL, 19.4 mmol) was added to a solution 
of 1,3-dibromobenzene (4.85 g, 19.4 mmol) in THF (60 mL) at –78 °C and the reaction 
was stirred at that temperature for 30 min. The resulting solution was slowly added to a 
solution of pyroglutamate 4.25 (5.00 g, 19.4 mmol) in THF (60 mL) at –78 °C and the 
reaction was stirred at that temperature for 1.5 h. The reaction mixture was quenched 
with saturate aqueous NHCl4, diluted with H2O and extracted with EtOAc. The combined 
organic phases were dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (hexanes:EtOAc 
4:1, Rf = 0.3) gave ketone S4.2 (6.61 g, 16.04 mmol, 83%) as a yellowish oil. 
Data for S4.2: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.07 (t, J = 1.8 Hz, 1H), 7.87 (ddd, 
J = 7.8, 1.7, 1.0 Hz, 1H), 7.69 (ddd, J = 8.0, 2.0, 1.1 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 
5.14 (d, J = 8.3 Hz, 1H), 4.36 (q, J = 7.7, 5.6 Hz, 1H), 4.22 – 4.13 (m, 2H), 3.17 – 2.94 
(m, 2H), 2.31 (ddt, J = 11.7, 8.4, 6.2 Hz, 1H), 1.42 (s, 9H), 1.28 – 1.25 (m, 3H). 13C-NMR 
(400 MHz, CDCl3): δ (ppm): = 197.5, 172.3, 155.5, 138.4, 136.0, 131.5, 131.1, 130.2, 
126.5, 123.0, 80.0, 61.6, 53.0, 34.6, 28.3, 27.0, 14.2. IR (ATR): 𝜈max (cm−1) = 3376 (w), 
2980 (w), 2940 (w), 2894 (w),1744 (m), 1686 (vs), 1569 (w), 1511 (s), 1476 (w), 1446 
(m), 1423 (m), 1409 (w),1300 (m), 1251 (s), 1216 (s), 1166 (s), 1110 (m), 1082 (m), 1067 
(m), 1050 (s), 1029 (s), 1018 (s), 996 (s), 959 (m), 901 (m), 871 (m), 860 (m), 827 (m), 
802 (w), 785 (m), 770 (s), 757 (s), 678 (vs). HRMS (EI): calc. for C18H24BrNO5 [M]+: 
413.0832, found: mass could not be found. [𝛂]𝑫
𝟐𝟓 = +1.4 (CHCl3). 
 
 
 
Pyrrolidine S4.4: TFA (11.5 mL, 146 mmol) was added dropwise to an ice cooled 
solution ketone S4.2 (4.00 g, 9.70 mmol) in CH2Cl2 (50 mL) and the reaction was allowed 
to warm to room temperature over 90 min. Evaporation of the volatiles under reduced 
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pressure gave crude imine S4.3 as yellow oil which was used in the next step without 
further purification. 
A suspension of crude imine S4.3 and PtO2 (106 mg, 4.64w%) in MeOH (38 mL) was 
stirred under H2-atmosphere overnight, filtered over a pad of celite and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (hexanes:EtOAc 1:2-1.4) gave pyrrolidine S4.4 (1.15 g, 3.86 mmol, 
40%) as a brownish solid. 
Data for S4.4: Rf: 0.4 (hexanes:EtOAc 1:4) 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.07 
(t, J = 1.8 Hz, 1H), 7.87 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.69 (ddd, J = 8.0, 2.0, 1.1 Hz, 
1H), 7.34 (t, J = 7.9 Hz, 1H), 5.14 (d, J = 8.3 Hz, 1H), 4.36 (q, J = 7.7, 5.6 Hz, 1H), 4.22 
– 4.13 (m, 2H), 3.17 – 2.94 (m, 2H), 2.31 (ddt, J = 11.7, 8.4, 6.2 Hz, 1H), 1.42 (s, 9H), 
1.28 – 1.25 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 175.1, 146.3, 130.3, 130.1, 
130.0, 125.5, 122.7, 63.0, 61.2, 60.20, 34.4, 30.5, 14.4. IR (ATR): 𝜈max (cm−1) = 3451 ( 
w), 3365 (w), 3059 (w), 3038 (w), 2977 (m), 2947 (w), 2919 (w), 2877 (w), 2828 (w), 
1887 (w), 1733(vs),1692 (m), 1590 (m), 1453 (m), 1567 (m), 1465 (m), 1453 (m), 1420 
(m), 1356 (w), 1342 (w), 1309 (w), 1270 (w), 1242 (w), 1206 (s), 1192 (vs), 1177 (vs), 
1138 (vs), 1114 (s), 1065 (m), 1048 (s), 1030 (m), 944 (m), 977(m), 950 (w), 936 (w), 
901 (m), 880 (w), 854 (m), 822 (s), 780 (vs), 742 (m), 701 (s), 686 (s). HRMS (ESI): calc. 
for C13H17BrNO2 [M+H]+: 298.0437, found: 298.0438. [𝛂]𝑫
𝟐𝟓 = –4.0 (CHCl3). 
 
 
 
Carbamate S4.5: NEt3 (0.90 mL, 6.46 mmol) was added to a solution of pyrrolidine S4.4 
(1.00 g, 3.35 mmol), di-tert-butyldicarbonate (2.84 g, 12.9 mmol) and DMAP (790 mg, 
6.46 mmol) in CH2Cl2 (57 mL) and the reaction was stirred at room temperature 
overnight. The reaction mixture was washed with aqueous citric acid (10%) and brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resulting 
residue by flash column chromatography (pentane:EtOAc 5:1, Rf = 0.3) gave carbamate 
S4.5 (877 mg, 2.20 mmol, 66%) as a yellowish oil. The product was obtained as a 
mixture of Boc rotamers. 
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Data for S4.5: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.71 (dt, J = 5.9, 1.8 Hz, 1H), 7.50 
(dd, J = 14.7, 7.8 Hz, 1H), 7.39 – 7.31 (m, 1H), 7.22 – 7.15 (m, 1H), 4.73 – 4.39 (m, 1H), 
4.27 (tt, J = 6.8, 4.2 Hz, 2H), 2.37 – 2.27 (m, 1H), 2.27 – 2.16 (m, 1H), 2.06 (qd, J = 11.4, 
8.6, 3.9 Hz, 1H), 1.92 (tdt, J = 16.0, 6.6, 4.1 Hz, 1H), 1.49 – 1.18 (m, 9H), 1.16 (s, 6H). 
13C-NMR (100 MHz, CDCl3): δ (ppm) = 172.8, 154.0, 153.6, 146.4, 145.4, 129.6, 129.3, 
128.9, 124.8, 124.5, 122.4, 121.9, 80.4, 80.1, 61.0, 60.2, 28.7, 28.0, 14.2. IR (ATR): 𝜈max 
(cm−1) = 3058 (w); 2978 (w), 2935 (w)1742 (m), 1694 (vs), 1596 (w), 1571 (w), 1476 (w), 
1448 (w), 1431 (w), 1387 (vs), 1366 (s), 1340 (m), 1288 (m), 1256 (w), 1188 (s), 1153 
(vs), 1118 (m), 1092 (m), 1072 (m), 1032 (m), 1021 (m), 996(w), 933 (w), 912 (w), 875 
(w), 858 (w), 823 (w), 781(m), 756 (m), 696 (w), 665 (w). HRMS (ESI): calc. for 
C18H24BrNO4 [M+H]+: 397.0889, found: 397.0894. [𝛂]𝑫
𝟐𝟓 = +24.3 (CHCl3). 
 
 
 
Diphenylhdrazine S4.6: A mixture of phenylhydrazine 4.40 (530 mg, 2.34 mmol), 
carbamate S4.6 (943 mg, 2.13 mmol), Pd(OAc)2 (96.2 mg, 0.430 mmol), (t-Bu)3P (3 M, 
PhMe, 0.16 mL, 0.430 mmol) and Cs2CO3 (943 mg, 2.88 mmol) in PhMe (177 mL) was 
stirred at room temperature for 30 min and at 110 °C for 2.5 h. The resulting suspension 
was cooled to room temperature, diluted with EtOAc and filtered over a pad of celite. 
Removal of the solvent under reduced pressure and purification of the resulting residue 
by flash column chromatography (hexanes:EtOAc 4:1, Rf = 0.3) gave diphenylhydrazine 
S4.6 (840 mg, 1.54 mmol, 72%) as a brown solid. The product was obtained as a mixture 
of Boc rotamers. 
Data for S4.6: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.53 (dt, J = 14.6, 7.0 Hz, 1H), 
1.16 – 1.15 (m, 1H), 1.15 – 1.14 (m, 1H), 7.34 (td, J = 7.8, 1.8 Hz, 1H), 7.23 (ddt, J = 
10.2, 5.5, 3.3 Hz, 3H), 7.13 – 7.10 (m, 1H), 6.81 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 6.51 (d, 
J = 3.1 Hz, 1H), 4.71 (t, J = 6.9 Hz, 1H), 4.55 (s, 2H), 2.31 – 2.16 (m, 2H), 2.12 – 1.99 
(m, 2H), 1.92 (dt, J = 10.9, 5.1 Hz, 1H), 1.50 – 1.35 (m, 18H), 1.34 – 1.28 (m, 3H). 13C-
NMR (100 MHz, CDCl3): δ (ppm) = 173.0, 172.8, 158.3, 158.2, 155.9, 155.7, 154.5, 
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153.8, 147.8, 147.6, 145.3, 144.4, 131.3, 131.2, 130.9, 130.7, 129.1, 128.8, 128.4, 128.1, 
128.0, 127.8, 124.1, 124.0, 123.9, 119.1, 118.9, 116.1, 115.9, 111.3, 111.2,111.1, 110.9, 
82.0, 81.6, 80.1, 79.9, 63.0, 62.1, 60.9, 35.4, 34.3, 30.8, 29.7, 28.9, 28.6, 28.2, 28.1, 
28.0, 24.9, 14.2. IR (ATR): 𝜈max (cm−1) = 3336 (w), 2978 (w), 2933 (w), 1692 (s), 1609 
(w), 1596 (w), 1499 (m), 1478 (w), 1455 (w), 1391 (m), 1366 (s), 1336 (s), 1290 (m), 
1256 (m), 1221 (m), 1150 (s), 1128 (s), 1107 (m), 1073 (w), 1046 (w), 1018 (m), 937 (w), 
859 (w), 838 (w), 782 (m), 754 (vs), 701 (m), 655 (w). HRMS (ESI): calc. for C29H42FN4O6 
[M+NH4]+: 561.3083, found: 561.3083. [𝛂]𝑫
𝟐𝟓 = +48.1 (CHCl3). 
 
 
 
 Amide S4.8: A solution of LiOH.H2O (172 mg, 4.14 mmol) in H2O (5.0 mL) was added 
to a solution of diphenylhydrazine S4.6 (740 mg, 1.36 mmol) in THF (9.5 mL) and MeOH 
(5.0 mL) and the solution was stirred at room temperature overnight. The reaction was 
acidified with aqueous HCl (1 M) and extracted with EtOAc. The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure to give crude acid S4.7 that was used in the next step without further 
purification. 
DIPEA (460 µL, 2.72 mmol) was added to a solution of crude acid S4.7 and HATU 
(327 mg, 0.860 mmol) in DMF (5.6 mL) and the solution was stirred at room temperature 
for 30 min. HMDS (400 µL, 2.11 mmol) was added and the reaction was stirred at room 
temperature for 1.5 h, diluted with NaHCO3 and H2O and extracted with EtOAc. The 
combined organic phases were dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resulting residue by flash column chromatography 
(hexanes:EtOAC 1:2, Rf = 0.4) gave amide S4.8 (461 mg, 0.900 mmol, 66% over 2 
steps) as an orange solid. The product was obtained as a mixture of Boc rotamers. 
Data for S4.8: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.45 – 7.41 (m, 1H), 7.23 – 7.04 
(m, 5H), 6.80 (d, J = 13.6 Hz, 2H), 5.31 (s, 1H), 4.62 (s, 1H), 4.45 (s, 1H), 2.52 – 2.19 
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(m, 2H), 1.92 (s, 3H), 1.54 (s, 9H), 1.37 (s, 9H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
154.4, 147.9, 129.1, 128.3, 128.2, 127.6, 124.2, 124.1, 119.0, 116.2, 116.0, 111.9, 110.5, 
82.3, 80.9, 28.0, 27.9. IR (ATR): 𝜈max (cm−1) = 3308 (w), 2976 (w), 2932 (w), 1675 (s), 
1608 (m), 1498 (m), 1478 (w), 1455 (w), 1392 (m), 1366 (s), 1339 (s), 1256 (m), 1220 
(m), 1157 (s), 1066 (w), 1045 (w), 1017 (m), 939 (w), 842 (w), 754 (s), 702 (m), 655 (w). 
HRMS (ESI): calc. for C27H39FN5O5 [M+NH4]+: 532.2930, found: 532.2928. [𝛂]𝑫
𝟐𝟓 = +12.6 
(CHCl3). 
 
 
 
m-Azoraxatrigine 4.45: A solution of amide S4.8 (138 mg, 0.330 mmol), Cs2CO3 
(503 mg, 1.54 mmol) and CuI (299 mg, 1.54 mmol) in DMF (6 mL) was stirred at 140 °C 
for 24 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc 
and filtered over a pad of silica. Removal of the solvent under reduced pressure and 
purification of the resulting residue by flash column chromatography (CH2Cl2:MeOH 98:2-
97:3, Rf = 0.3) gave crude azobenzene S4.9 which was used in the next step without 
further purification. 
TFA (7 mL) was added to an ice cooled solution of crude azobenzene S4.9 in CH2Cl2 
(20 mL) and the reaction was stirred at 0 °C for 30 min and at room temperature for 3 h. 
The mixture was diluted with saturated aqueous NaHCO3 and extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (CH2Cl2:MeOH 100:0-92:8, Rf = 0.4) gave m-azoraxatrigine 4.45 
(56.0 mg, 0.180 mmol, 55%) as an orange solid. The resulting product is in a light driven 
equilibrium with its double bond isomer. The major trans isomer is described. 
Data for 4.45: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 8.16 (t, J = 1.9 Hz, 1H), 8.02 
(dt, J = 7.9, 1.4 Hz, 1H), 7.79 (td, J = 7.3, 6.8, 5.6 Hz, 2H), 7.69 (t, J = 7.8 Hz, 1H), 7.63 
– 7.53 (m, 1H), 7.39 – 7.29 (m, 2H), 7.23 – 7.13 (m, 1H), 7.04 – 6.94 (m, 1H), 4.50 (dd, 
J = 9.3, 3.4 Hz, 1H), 2.61 (td, J = 14.3, 11.2, 6.1 Hz, 1H), 2.53 (dd, J = 13.3, 6.9 Hz, 1H), 
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2.48 – 2.39 (m, 1H), 2.29 (qd, J = 12.8, 12.1, 7.4 Hz, 2H). 13C-NMR (100 MHz, d4-MeOH): 
δ (ppm) = 171.1, 161.5, 159.0, 153.1, 140.3, 135.9, 127.3, 123.6, 120.3, 117.2, 115.9, 
63.7, 30.2. IR (ATR): 𝜈max (cm−1) = 3665 (w), 3200 (w), 2752 (w), 2366 (w), 1663 (vs), 
1485 (w), 1453 (w), 1386 (w), 1336 (w), 1269 (w), 1191 (vs), 1133 (vs), 1019 (w), 950 
(w), 899 (w), 846 m), 799 (s), 761 (m), 723 (m), 691 (m). HRMS (ESI): calc. for 
C17H18FN4O [M+H]+: 313.1459, found: 313.1458. [𝛂]𝑫
𝟐𝟓 = +11.2 (CHCl3). 
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6.6 Experimental data for chapter V 
6.6.1 Photoswitches based on CK-636 and CK-666 
 
Methyl ester 5.14: SOCl2 (8.90 mL, 116 mmol) was slowly added to an ice cooled 
solution of thiophene 5.6 (2.00 g, 11.6 mmol) in MeOH (20 mL) and the solution was 
stirred at 60 C overnight. The reaction was cooled to room temperature, carefully 
quenched with aqueous NaHCO3 and extracted with CH2Cl2. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure to yield methyl 
ester 5.14 (1.63 g, 8.73 mmol, 76%) as a pale yellow solid. 
Data for 5.14: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.87 (d, J = 4.3 Hz, 1H), 7.70 (d, J 
= 4.3 Hz, 1H), 3.95 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 161.2, 138.5, 131.9, 
128.1, 53.3. IR (ATR): 𝜈max (cm−1) = 3115 (w), 3099 (w), 1727 (s), 1704 (s), 1535 (m), 
1504 (s), 1445 (m), 1423 (m), 1355 (m), 1339 (m), 1280 (s), 1247 (s), 1216 (m), 1189 
(m), 1121 (m), 1082 (m), 1034 (m), 945 (w), 924 (m), 841 (m), 816 (m), 794 (w), 746 (s), 
731 (s), 680 (w), 671 (w). HRMS (EI): calc. for C6H5NO432S [M]+: 186.9934, found: 
186.9944. 
 
 
 
Amine 5.5: A suspension of methyl ester 5.14 (1.50 g, 8.01 mmol) and Pd/C (300 mg) 
in MeOH (100 mL) was stirred under a H2-atmosphere at room temperature for 3 d. The 
reaction was filtered over celite and the solvent was removed under reduced pressure. 
Purification of the resultant residue by flash column chromatography (hexanes:EtOAc 
2:1, Rf= 0.3) gave amine 5.5 (1.05 g, 6.68 mmol, 83%) as a pale yellow solid. 
Data for 5.5: Rf: 0.3 (hexanes:EtOAc 2:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.45 
(d, J = 4.0 Hz, 1H), 6.09 (d, J = 4.0 Hz, 1H), 4.31 (s, 2H), 3.81 (s, 3H). 13C-NMR (100 
MHz, CDCl3): δ (ppm) = 163.3, 159.4, 135.2, 117.0, 107.8, 51.8. IR (ATR): 𝜈max (cm−1) = 
3336 (w), 1674 (s), 1619 (m), 1454 (s), 1433 (s), 1383 (m), 1278 (s), 1222 (m), 1187 (m), 
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1092 (s), 1032 (w), 976 (w), 958 (w), 924 (w), 784 (m), 745 (w), 689 (w). HRMS (EI): 
calc. for C6H7NO232S [M]+: 157.0192, found: 157.0195. 
 
 
 
Dimethylaniline 5.9: TFA (290 µL, 3.82 mmol) and t-BuONO (180 µL, 1.52 mL) were 
sequentially added to an ice cooled solution of amine 5.5 (200 mg, 1.27 mmol) in MeCN 
(5 mL) and the solution was stirred 0 °C for 2 h. Dimethylaniline (1.60 mL, 12.7 mmol) 
was added and the reaction was warmed to room temperature overnight. The mixture 
was acidified with aqueous HCl (1 M) and extracted with EtOAc. The combined organic 
phases were washed with saturated aqueous NaHCO3 and brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resultant residue by flash 
column chromatography (hexanes:EtOAc 9:1, Rf= 0.3) gave dimethylaniline 5.9 (90 mg, 
0.311 mmol, 24%) as a deep red solid.  
Data for 5.9: Rf: 0.3 (hexanes:EtOAc 9:1); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.86 
– 7.80 (m, 2H), 7.78 (d, J = 4.1 Hz, 1H), 7.52 (d, J = 4.1 Hz, 1H), 6.79 – 6.70 (m, 2H), 
3.90 (s, 3H), 3.12 (s, 6H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 165.9, 163.3, 152.9, 
143.0, 133.4, 131.4, 127.2, 125.9, 111.9, 77.3, 52.4, 40.5. IR (ATR): 𝜈max (cm−1) = 1714 
(s), 1607 (m), 1522 (w), 1453 (w), 1381 (w), 1357 (w), 1338 (m), 1313 (w), 1247 (s), 
1192 (w), 1156 (m), 1094 (m), 949 (w), 823 (m), 809 (s), 742 (s). HRMS (EI): calc. for 
C14H15N3O232S [M]+: 289.0879, found: 289.0872. 
 
 
 
Thiophene 5.11: A solution of dimethylaniline 5.9 (21.1 mg, 0.073 mmol) and LiOH.H2O 
(30.6 mg, 0.730 mmol) in MeOH (1 mL), THF (1 mL) and H2O (1 mL) was stirred at 60 °C 
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overnight. The reaction mixture was cooled to room temperature, acidified with aqueous 
HCl (1 M) and extracted with EtOAc. The combined organic phases were dried over 
MgSO4 and concentrated under reduced pressure to give crude acid 5.15 which was 
used in the next step without further purification. 
NEt3 (30.0 µL, 0.218 mmol) was added to a solution of crude acid 5.15, 2-
methyltryptamine (13.0 mg, 0,073 mmol) and HBTU (83.0 mg, 0.218 mmol) in DMF 
(2 mL) and the solution was stirred at room temperature overnight. Removal of the 
solvent under reduced pressure and purification of the resulting residue by reverse phase 
HPLC (MeCN:H2O (0.1% formic acid) 0:100 to 100:0) gave thiophene 5.11 (7.2 mg, 
0.017 mmol, 23%) as a red solid. 
Data for 5.11: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.80 (s, 1H), 7.77 – 7.69 (m, 2H), 
7.48 (dd, J = 7.4, 1.3 Hz, 1H), 7.36 (dd, J = 29.1, 4.0 Hz, 2H), 7.24 (dt, J = 8.2, 0.9 Hz, 
1H), 7.12 – 7.00 (m, 2H), 6.70 – 6.61 (m, 2H), 5.96 (t, J = 5.9 Hz, 1H), 3.62 (q, J = 6.4 
Hz, 2H), 3.04 (s, 6H), 2.96 (t, J = 6.6 Hz, 2H), 2.32 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 163.6, 162.3, 152.9, 142.9, 136.6, 135.5, 132.3, 128.7, 128.6, 127.4, 125.7, 
121.5, 119.7, 118.0, 111.7, 110.5, 108.5, 40.6, 40.5, 24.2, 11.9. IR (ATR): 𝜈max (cm−1) = 
1627 (w), 1596 (s), 1511 (m), 1460 (m), 1438 (w), 1351 (m), 1329 (w), 1308 (m), 1281 
(m), 1211 (w), 1145 (vs), 1033 (w), 943 (w), 848 (m), 822 (s), 807 (m), 750 (m). HRMS 
(ESI): calc. for C13H14N4O32S [M+H]+: 431.1774, found: 274.0883. 
 
 
 
Diethanolamine 5.10: TFA (290 µL, 3.82 mmol) and t-BuONO (180 µL, 1.52 mL) were 
sequentially added to an ice cooled solution of amine 5.5 (200 mg, 1.27 mmol) in MeCN 
(5 mL) and the solution was stirred 0 °C for 2 h. N-Phenyldiethanolamine (2.31 g, 
12.7 mmol) was added and the reaction was warmed to room temperature overnight. 
The mixture was acidified with aqueous HCl (1 M) and extracted with EtOAc. The 
combined organic phases were washed with saturated aqueous NaHCO3 and brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the resultant 
residue by flash column chromatography (hexanes:EtOAc 1:3, Rf= 0.3) gave 
diethanolamine 5.10 (370 mg, 1.06 mmol, 83%) as a deep red solid.  
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Data for 5.10: Rf: 0.3 (hexanes:EtOAc 1:3); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.85 
– 7.76 (m, 3H), 7.55 (d, J = 4.1 Hz, 1H), 6.78 – 6.73 (m, 2H), 3.96 (t, J = 4.9 Hz, 4H), 
3.90 (s, 3H), 3.73 (t, J = 4.9 Hz, 4H), 2.93 (s, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 165.7, 163.3, 151.1, 143.4, 133.4, 131.8, 127.7, 125.9, 112.4, 60.9, 55.3, 52.5. HRMS 
(ESI): calc. for C16H20N3O432S [M+H]+: 350.1169, found:3501173. 
 
 
 
Thiophene 5.12: A solution of diethanolamine 5.10 (25.7 mg, 0.078 mmol) and 
LiOH.H2O (32.7 mg, 0.780 mmol) in MeOH (1 mL), THF (1 mL) and H2O (1 mL) was 
stirred at 60 °C overnight. The reaction mixture was cooled to room temperature, 
acidified with aqueous HCl (1 M) and extracted with EtOAc. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure to give crude 
acid 5.16 which was used in the next step without further purification. 
NEt3 (30.0 µL, 0.218 mmol) was added to a solution of crude acid 5.16, 2-
methyltryptamine (14.0 mg, 0,078 mmol) and HBTU (83.0 mg, 0.218 mmol) in DMF 
(2 mL) and the solution was stirred at room temperature overnight. Removal of the 
solvent under reduced pressure and purification of the resulting residue by reverse phase 
HPLC (MeCN:H2O (0.1% formic acid) 0:100 to 100:0) gave thiophene 5.12 (7.2 mg, 
0.017 mmol, 23%) as a red solid. 
Data for 5.12: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.80 – 7.72 (m, 2H), 7.57 (d, J 
= 4.1 Hz, 1H), 7.52 – 7.47 (m, 2H), 7.23 (dt, J = 8.0, 1.0 Hz, 1H), 7.04 – 6.92 (m, 2H), 
6.91 – 6.85 (m, 2H), 3.79 (t, J = 5.8 Hz, 4H), 3.69 (t, J = 5.9 Hz, 4H), 3.54 (dd, J = 7.8, 
6.7 Hz, 2H), 3.01 (t, J = 7.3 Hz, 2H), 2.37 (s, 3H). 13C-NMR (100 MHz, d4-MeOH): δ 
(ppm) = 165.3, 164.6, 152.8, 144.0, 138.8, 137.2, 133.3, 123.0, 129.4, 128.4, 126.6, 
121.4, 119.5, 118.4, 113.0, 111.3, 108.8, 60.3, 55.0, 42.0, 25.2, 11.4. IR (ATR): 𝜈max 
(cm−1) = 3283 (br), 2919 (w), 1594 (s), 1541 (m), 1511 (m), 1461 (w), 1400 (w), 1350 
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(m), 1304 (m), 1146 (vs), 1043 (m), 1001 (m), 822 (m), 741 (m). HRMS (ESI): calc. for 
C26H30N5O332S [M+H]+: 492.2064, found: 492.2063. 
 
 
 
Carboxylic acid 5.21: Aqueous conc. HCl (0.95 mL) was added to an ice cooled solution 
of 3-amino-2-fluorobenzoic acid (550 mg, 3.55 mmol) in MeCN (7 mL) and the solution 
was stirred for 5 min at that temperature. Isoamylnitrite (0.48 mL, 3.55 mmol) was added 
and the reaction was stirred for 1 h at 0 °C. The resulting suspension was added 
dropwise to an ice cooled solution of phenol (334 mg, 3.55 mmol) in aqueous NaOH (2 M, 
6.6 mL) and H2O (0.4 mL) and the reaction was stirred for 1 h at 0 °C. The mixture was 
acidified with aqueous HCl (1 M) and extracted with EtOAc. The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resultant residue by flash column chromatography 
(CH2Cl2:MeOH:AcOH 96:4:0.1 to 94:6:0.1) gave carboxylic acid 5.21 (588 mg, 
2.26 mmol, 64%) as a red solid. 
Data for 5.21: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 8.02 – 7.94 (m, 1H), 7.90 – 7.81 
(m, 3H), 7.29 (td, J = 7.9, 1.0 Hz, 1H), 6.96 – 6.88 (m, 2H). 13C-NMR (100 MHz, d4-
MeOH): δ (ppm) = 167.0, 167.0, 162.9, 161.5, 158.8, 147.7, 143.0, 142.9, 134.5, 126.6, 
125.0, 124.9, 122.7, 122.1, 122.0, 116.8. IR (ATR): 𝜈max (cm−1) = 3079 (br), 1688 (vs), 
1599 (s), 1590 (s), 1526 (w), 1502 (m), 1482 (m), 1460 (m), 1420 (w), 1358 (w), 1286 
(m), 1243 (s), 1215 (m), 1163 (w), 1143 (s), 1102 (w), 841 (m), 764 (m), 667 (w). HRMS 
(ESI): calc. for C13H8N2O3F [M–H]–:259.0524, found:259.0526. 
 
 
 
Amide 5.23: DIPEA (180 µL, 1.03 mmol) was added to a solution of carboxylic acid 5.21 
(60.0 mg, 0.342 mmol), 2-methyltryptamine (89.0 mg, 0,342 mmol) and TBTU (165 mg, 
0.517 mmol) in DMF (3.5 mL) and the solution was stirred at room temperature overnight. 
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The reaction was diluted with EtOAc and washed with aqueous HCl (1 M) and brine. The 
organic phase was dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resultant residue by flash column chromatography (CH2Cl2:acetone 
93:7 and CH2Cl2:MeOH 98:2) gave amide 5.23 (97 mg, 0.233 mmol, 68%) as an orange 
solid.  
Data for 5.23: Rf: 0.2 (CH2Cl2:acetone 93:7); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.11 
– 8.00 (m, 2H), 7.94 (s, 1H), 7.89 – 7.83 (m, 2H), 7.80 (td, J = 7.7, 1.9 Hz, 1H), 7.54 (dd, 
J = 7.5, 1.3 Hz, 1H), 7.26 (s, 2H), 7.09 (dtd, J = 16.2, 7.1, 1.3 Hz, 2H), 7.03 – 6.95 (m, 
3H), 3.85 – 3.77 (m, 2H), 3.08 (t, J = 6.8 Hz, 2H), 2.37 (s, 3H). 13C-NMR (100 MHz, 
CDCl3): δ (ppm) = 207.6, 163.5, 160.2, 158.9, 156.4, 147.1, 141.2, 141.1, 135.5, 133.4, 
132.4, 128.4, 125.7, 124.7, 124.6, 121.4, 121.1, 119.5, 118.0, 116.2, 110.5, 108.3, 40.8, 
24.2, 11.8. IR (ATR): 𝜈max (cm−1) = 3260 (br), 1641 (m), 1586 (s), 1532 (m), 1504 (m), 
1460 (m), 1428 (m), 1365 (w), 1274 (m), 1233 (m), 1206 (s), 1140 (vs), 1099 (w), 1010 
(w), 843 (m), 822 (w), 743 (s), 668 (w). HRMS (ESI): calc. for C24H22N4O2F 
[M+H]+:417.1721, found:417.1718. 
 
 
 
Chloride 5.25: 4-(2-Hydroxyethyl)morpholine (5.00 g, 38.1 mmol) was added dropwise 
to ice cooled SOCl2 (50 mL, 689 mmol) and the reaction was stirred at 60 °C overnight. 
The volatiles were removed under reduced pressure and the resultant residue was 
portioned between CH2Cl2 and aqueous Na2CO3. The organic phase was washed with 
H2O and brine, dried over MgSO4 and concentrated under reduced pressure to give 
chloride 5.25 (4.71 g, 31.5 mmol, 83%) as a grey solid. 
Data for 5.25: 1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 4.05 (t, J = 6.8 Hz, 2H), 3.93 
(s, 2H), 3.80 (dd, J = 19.9, 8.6 Hz, 2H), 3.49 (t, J = 6.8 Hz, 2H), 3.43 (s, 2H), 3.21 – 
3.04 (m, 2H). 13C-NMR (100 MHz, d6-DMSO): δ (ppm) = 63.1, 56.2, 51.2, 37.0. IR 
(ATR): 𝜈max (cm−1) = 2961 (w), 1855 (w), 2809 (w), 1450 (m), 1304 (m), 1271 (w), 1114 
(vs), 1070 (m), 1006 (s), 913 (m), 866 (s), 806 (w), 732 (m), 666 (m). HRMS (ESI): 
calc. for C6H13NOCl [M+H]+:150.0680, found:150.0680. 
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Morpholine 5.24: A solution of amide 5.23 (45.0 mg, 0,108 mmol), Cs2CO3 (106 mg, 
0.324 mmol) and KI (10 mg, 60.0 µM) in DMF (3 mL) was stirred at room temperature 
for 10 min. Chloride 5.25 (32 mg, 0.216 mmol) was added and the solution was stirred 
at 80 °C overnight. After cooling to room temperature the reaction was diluted with EtOAc 
and washed with H2O and brine. The organic phase was dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resultant residue by flash 
column chromatography (CH2Cl2:MeOH 98:2) gave morpholine 5.24 (39 mg, 
0.074 mmol, 69%) as an orange solid. The product was obtained as a mixture of cis and 
trans conformers.  
Data for 5.24: Rf: 0.4 (CH2Cl2:MeOH 96:4); 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.19 
– 8.12 (m, 1H), 7.98 – 7.88 (m, 3H), 7.82 (td, J = 7.6, 1.9 Hz, 1H), 7.59 – 7.54 (m, 1H), 
7.33 – 7.26 (m, 2H), 7.15 – 7.06 (m, 2H), 7.04 – 7.00 (m, 2H), 6.93 – 6.85 (m, 1H), 4.21 
(t, J = 5.7 Hz, 2H), 3.82 – 3.74 (m, 6H), 3.08 (t, J = 6.8 Hz, 2H), 2.86 (t, J = 5.7 Hz, 2H), 
2.62 (t, J = 4.7 Hz, 4H), 2.41 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 163.1, 
161.9, 159.0, 156.4, 147.3, 141.1, 141.0, 135.5, 133.7, 132.3, 128.5, 125.4, 124.6, 124.6, 
123.3, 123.0, 122.9, 121.3, 120.9, 119.5, 118.0, 115.0, 110.4, 108.4, 67.0, 66.3, 57.6, 
54.2, 40.7, 24.3, 11.8. IR (ATR): 𝜈max (cm−1) = 3301 (br), 2919 (w), 2853 (w), 1648 (s), 
1598 (s), 1582 (w), 1527 (m), 1500 (s), 1462 (m), 1452 (m), 1358 (w), 1298 (m), 1250 
(vs), 1142 8vs), 1114 (s), 1068 (w), 1036 (w), 1010 (w), 954 (w), 915 (w), 838 (m), 741 
(s), 679 (w). HRMS (ESI): calc. for C30H33N5O3F [M+H]+:530.2562, found:530.2557. 
 
  
312 
6.6.1 Photoswitches based on blebbistatin 
 
Methyl ester 5.32: Thionylchloride (27 mL, 372 mmol) was added to an ice cooled 
solution of 5-methyl-2-nitro-benzoate (7.46 g, 41.18 mmol) in methanol (100 mL). They 
solution was heated at 60 °C for 20 h, quenched with saturated aqueous NaHCO3 and 
extracted with CH2Cl2. The organic phase was washed with brine, dried MgSO4 and 
concentrated under reduced pressure to give methyl ester 5.32 (7.58 g, 38.85 mmol, 
94%) as a colorless solid. 
Data for 5.32: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.83 (d, J = 8.3 Hz, 1H), 7.45 (m, 
1H), 7.37 (m, 1H), 3.89 (s, 3H), 2.44 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
166.6, 145.8, 1444.8, 132.1, 130.2, 128.3, 124.3, 53.4, 21.6. IR (ATR): 𝜈max (cm−1) = 
1722 (vs), 1590 (w), 1535 (s), 1492 (w), 1440 (s), 1378 (m), 1291 (vs), 1207 (s), 1137 
(m), 1067 )m), 971 (s), 902 (w), 838 (vs), 783 (s), 741 (m), 705 (m), 670 (m), 618 (s). 
HRMS (EI): calc. for C9H9NO4 [M]+: 195.0526, found: 195.0529.  
 
 
 
Aniline 5.28: A suspension of methyl ester 5.32 (1.29 g, 6.61 mmol) and Pd/C (400 mg) 
in EtOAc (20 mL) was purged with H2 and stirred under a H2-atmosphere at room 
temperature overnight. The reaction mixture was filtered over a pad of celite and 
concentrated under reduced pressure to give aniline 5.28 (1.06 g, 6.39 mmol, 97%) as 
colorless solid. 
Data for 5.28: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.64 (m, 1H), 7.07 (m, 1H), 6.57 
(d, J = 8.3 Hz, 1H), 5.52 (bs, 1H), 3.84 (s, 3H), 2.21 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ (ppm) = 168.6, 148.3, 135.2, 130.8, 125.4, 51.5, 20.3. IR (ATR): 𝜈max (cm−1) = 3472 
(m), 3365 (m), 2946 (w), 2915 (vw), 2856 (vw), 1681 (s), 1625 (m), 1577 (m), 1559 (s), 
1500 (m), 1455 (w), 1438 (s), 1380 (w), 1348 (w), 1293 (s), 1237 (s), 1201 (vs), 1186 
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(s), 1162 (s), 1087 (s), 1005 (m), 968 (m), 897 (m), 825 (s), 791 (s), 766 (m), 704 (m), 
678 (m). HRMS (EI): calc. for C9H11NO2 [M]+: 165.0784, found: 165.0790.  
 
 
 
Amidine 5.30167: POCl3 (0.69 mL, 7.44 mmol) was added to a solution of 1-phenyl-2-
pyrrolidinone (1.00 g, 6.20 mmol) in CHCl3 (10 ml) and the reaction was stirred at room 
temperature for 3 h. A solution of aniline 5.28 (1.02 g, 6.20 mmol) in CHCl3 (10 mL) was 
added and the reaction was stirred at 60 °C overnight. Evaporation of the volatiles under 
reduced pressure and purification of the resulting residue by flash column 
chromatography (CH2Cl2:MeOH 96:4) gave amidine 5.30 (1.07 g, 3.48 mmol, 56%) as a 
colorless solid. Note: Prolonged exposure to silica led to hydrolysis of the product. 
Data for 5.30: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.81 (d, J = 7.9 Hz, 2H), 7.66 (d, J 
= 2.1 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.18 (ddd, J = 8.1, 2.2, 0.7 Hz, 1H), 7.10 – 6.99 (m, 
1H), 6.72 (d, J = 8.1 Hz, 1H), 3.87 (t, J = 6.9 Hz, 2H), 3.82 (s, 3H), 2.46 (t, J = 7.8 Hz, 
2H), 2.32 (s, 3H), 2.10 – 1.98 (m, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 168.0, 
159.9, 150.7, 141.6, 133.6, 131.2, 128.7, 123.2, 123.1, 122.1, 120.4, 51.9, 50.8, 29.3, 
20.7, 19.9. HRMS (EI): calc. for C19H20N2O2 [M]+: 308.1519, found: 308.1481.  
 
 
 
Enone 5.33167: LiHMDS (1 M in THF, 4.77 mL, 4.77 mmol) was added dropwise to a 
solution of amidine 5.30 (680 mg, 2.21 mmol) in THF (30 mL) at –78 °C. The solution 
was allowed to warm to 0 °C over 5 h before it was quenched with saturated aqueous 
NH4Cl (8 mL) and extracted with CH2Cl2. The combined organic phases were washed 
with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Purification of the resulting residue by flash column chromatography (acetone Rf = 0.3) 
enone 5.33 (316 mg, 1.14 mmol, 72%) as a yellow solid. 
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Data for 5.33: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 7.94 (m, 1H), 7.51 (m, 2H), 7.43 
(m, 2H), 7.34 (m. 3H), 4.12 (dd, J = 9.1, 8.1 Hz, 2H), 3.14 (dd, 9.2, 8.0, 2H).13C-NMR 
(100 MHz, d4-MeOH): δ (ppm) = 171.3, 156.2, 141.2, 137.8, 134.4, 132.8, 131.3, 127.8, 
124.8, 124.7, 124.7,118.8, 105.5, 55.2, 24.3, 21.3. IR (ATR): 𝜈max (cm−1) = 2900 (vw), 
2852 (vw), 1626 (w), 1611 (w), 1598 (w), 1569 (s), 1546 (m), 1520 (m), 1494 (s), 1467 
(m), 1451 (s), 1410 (m), 1375 (s), 1341 (m), 1307 (vs), 1292 (s), 1235 (m), 1181 (m), 
1154 (m), 1127 (m), 1112 (m), 1058 (m), 989 (w), 955 (m), 912 (w), 878 (w), 857 (w), 
817 (m), 784 (w), 775 (w), 751 (vs), 730 (m), 687 (vs), 668 (m). HRMS (EI): calc. for 
C18H16N2O [M]+: 276.1257, found: 276.1204.  
 
 
 
(S)-Blebbistatin (5.26) 167: LiHMDS (1.0 M in THF, 2.28 mL, 2.28 mmol) was added 
dropwise to a solution of enone 5.33 (316 mg, 1.14 mmol) in THF (5.0 mL) at –78 °C. 
The reaction was stirred at that temperature for 30 min, a solution of (−)-(8,8-
Dichlorocamphorylsulfonyl) oxaziridine (817 mg, 2.74 mmol) in THF (10 mL) was added 
and the mixture was stirred at –10 °C for 16 h. The reaction was diluted with saturated 
aqueous NH4Cl and ether, warmed to room temperature, diluted with aqueous NaS2O3 
and extracted with EtOAc. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. The resulting residue was portioned between 
CH2Cl2 and aqueous HCl (0.3 M). The aqueous phase was basified with aqueous NaOH 
(4 M) and extracted with EtOAc. The organic phase was dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by 
recrystallization from MeCN gave (S)-blebbistatin (5.26) (147 mg, 0.502 mmol, 44%) as 
a bright yellow solid. 
Data for 5.26: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.85 (m, 2H), 7.61 (m, 1H), 7.41 
(m, 2H), 7.15 (m, 2H), 6.98 (d, J = 8.1 Hz, 1H), 4.03 (bs, 1H), 3.80 (m, 2H), 2.38(m, 1H), 
2.30 (s, 3H), 2.19 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 194.5, 164.8, 148.7, 
140.1. 137.5 133.7 129.0. 127.4 126.3, 124.8, 120.5, 120.3, 73.9, 48.3, 29.2, 20.9. IR 
(ATR): 𝜈max (cm−1) = 3060 (br), 1691 (s), 1592 (s), 1579 (s), 1481 (s), 1452 (w), 1433 
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(m), 1317 (m), 1297 (s), 1263 (m), 1223 (w), 1206 (m), 1192 (w), 1158 (m), 1108 (m), 
1085 (w), 1060 (w), 979 (w), 939 (w), 904 (w), 844 (m), 800 (m), 758 (s), 734 (m), 706 
(m), 692 (vs), 658 (m). HRMS (ESI): calc. for C18H17N2O2 [M+H]+: 293.1285, found: 
293.1281.  
 
 
 
Nitrobenzene 5.35: A solution of (S)-blebbistatin (5.26) (142 mg, 0.486 mmol) in HNO3 
(65%, 5 mL) was stirred for 20 h at 50 °C, cooled to room temperature and poured onto 
ice. The resulting mixture was carefully basified with aqueous NaOH (1 M) and extracted 
with EtOAc. The combined organic phases were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (pentane:EtOAc 1:3, Rf = 0.25) gave nitrobenzene 5.35 
(162 mg, 0.481 mmol, 99%) as a red solid. 
Data for 5.35: 1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 8.07 – 7.99 (m, 2H), 7.84 (dd, 
J = 2.0, 0.8 Hz, 1H), 7.77 (dd, J = 2.1, 0.8 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.23 – 7.14 (m, 
1H), 7.09 (s, 1H), 4.13 (td, J = 9.9, 5.9 Hz, 1H), 4.04 (dd, J = 10.1, 8.8 Hz, 1H), 2.42 (dd, 
J = 13.5, 9.2 Hz, 1H), 2.36 (s, 3H), 2.26 (dd, J = 13.3, 5.7 Hz, 1H). 13C-NMR (100 MHz, 
d6-DMSO): δ (ppm) = 192.3, 166.5, 145.3, 141.7, 139.8, 132.1, 130.0, 129.2, 128.7, 
124.4, 122.8, 119.9, 73.4, 48.0, 27.9, 19.9. HRMS (ESI): calc. for C18H16N3O4 [M+H]+: 
338.1135, found: 338.1138.  
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Aniline 5.31: A suspension of nitrobenzene 5.35 (200 mg, 0.659 mmol) and Pd/C 
(20 mg) in EtOAc (20 mL) was purged with H2 and stirred under a H2-atmosphere at room 
temperature for 2 h. The reaction mixture was filtered over a pad of celite and 
concentrated under reduced pressure to give aniline 5.31 (192 mg, 0.623 mmol, 95%) 
as a red solid. 
Data for 5.31: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.95 – 7.83 (m, 2H), 7.46 – 7.35 
(m, 2H), 7.19 – 7.12 (m, 1H), 7.12 – 7.08 (m, 1H), 6.77 (d, J = 1.9 Hz, 1H), 4.21 (td, J = 
9.8, 5.9 Hz, 1H), 3.95 (t, J = 9.1 Hz, 1H), 2.46 (dd, J = 13.9, 5.8 Hz, 1H), 2.30 (ddd, J = 
13.9, 9.9, 8.5 Hz, 1H), 2.24 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 195.1, 162.7, 
141.5, 140.5, 135.6, 134.1, 129.0, 124.3, 122.7, 120.3, 120.0, 117.3, 73.8, 48.1, 28.9, 
21.1. IR (ATR): 𝜈max (cm−1) = 3317 (br), 2918 (br), 1675 (m), 1623 (s), 1590 (s), 1491 (m), 
1473 (m), 1441 (w), 1417 (m), 1342 (w), 1301 (vs), 1267 (m), 1230 (w), 1211 (m), 1188 
(w), 1156 (w), 1102 (w), 1043 (w), 985 (w), 946 (w), 846 (w), 793 (m), 751 (s), 716 (s). 
HRMS (ESI): calc. for C18H18N3O2 [M+H]+: 308.1394, found: 308.1391.  
 
 
 
Azobenzene 5.37: A solution of aniline 5.31 (20 mg, 0.065 mmol) and 4-nitroso-1-
nitrobenzene (20 mg, 0.130 mmol) in CH2Cl2 (2 mL) and AcOH (1 mL) was stirred at 
room temperature overnight. The reaction mixture was diluted with saturated aqueous 
NaHCO3 and extracted with EtOAc. The combined organic payers were washed with 
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brine, dried over MgSO4 and concentrated under reduced pressure. Purification of the 
resulting residue by flash column chromatography (pentane:EtOAc 3:1, Rf = 0.35) gave 
azobenzene 5.37 (16 mg, 0.036 mmol, 56%) as a red solid. 
Data for 5.37: 1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 8.57 – 8.52 (m, 2H), 8.36 – 
8.31 (m, 2H), 8.20 – 8.14 (m, 2H), 7.82 (d, J = 2.2 Hz, 1H), 7.71 – 7.67 (m, 1H), 7.53 – 
7.45 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 7.06 (s, 1H), 4.10 (q, J = 9.5, 8.1 Hz, 2H), 2.39 (s, 
3H), 2.36 – 2.28 (m, 2H). 13C-NMR (100 MHz, d6-DMSO): δ (ppm) = 193.6, 165.3, 155.7, 
148.4, 147.1, 145.3, 140.4, 132.3, 131.4, 128.7, 125.3, 124.0, 123.3, 123.1, 122.5, 119.5, 
73.0, 47.4, 28.1, 20.3. IR (ATR): 𝜈max (cm−1) = 2918 (w), 2364 (m), 2168 (m), 1669 (m), 
1618 (w), 1522 (w), 1494 (w), 1465 (w), 1419 (w), 1340 (s), 1260 (m), 1102 (s), 1023 (s), 
858 (w), 802 (s), 754 (m). HRMS (ESI): calc. for C24H20N5O4 [M+H]+: 442.1510, found: 
442.1507.  
 
 
 
Pyrrolidinone 5.42: NEt3 (0.78 mL, 5.57 mmol) and 4-chlorobutyryl chloride (0.60 mL, 
5.36 mmol) were sequentially added to an ice cooled solution of 4-aminoazobenzene 
(1.00 g, 5.07 mmol) in EtOAc (15 mL) and the reaction was stirred at room temperature 
for 4 h. The reaction mixture was washed with H2O and brine, dried over MgSO4 and 
concentrated under reduced pressure. The resulting residue was redissolved in i-PrOH 
(10 mL) and aqueous NaOH (6 M, 10 mL) and stirred at room temperature for 5 h. The 
reaction mixture was extracted with EtOAc and the combined organic phases were 
washed with aqueous citric acid (5%) and brine, dried over MgSO4 and concentrated 
under reduced pressure. Purification of the resulting residue by flash column 
chromatography (pentane:EtOAc 1:1, Rf = 0.35) gave pyrrolidinone 5.42 (891 mg, 
3.36 mmol, 66% over 2 steps) as an orange solid. 
Data for 5.42: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.99 – 7.94 (m, 2H), 7.93 – 7.88 
(m, 2H), 7.84 – 7.79 (m, 2H), 7.55 – 7.43 (m, 3H), 3.92 (t, J = 7.0 Hz, 2H), 2.65 (t, J = 
8.1 Hz, 2H), 2.25 – 2.13 (m, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 174.7, 152.8, 
148.9, 142.0, 130.9, 129.2, 123.8, 122.9, 119.7, 48.8, 33.0, 18.0. IR (ATR): 𝜈max (cm−1) 
= 1682 (s), 1598 (m), 1500 (m), 1480 (w), 1462 (m), 1442 (w), 1417 (w), 1389 (m), 1325 
(m), 1301 (m), 1223 (m), 1176 (w), 1154 (m), 1141 (m), 1120 (w), 1073 (w), 1026 (w), 
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1018 (w), 929 (w), 837 (s), 765 (s), 722 (m). HRMS (EI): calc. for C16H15N3O [M]+: 
265.1210, found: 265.1207.  
 
 
 
Amidine 5.44: POCl3 (0.26 mL, 2.83 mmol) was added to a solution of pyrrolidinone 5.42 
(500 mg, 1.88 mmol) in CH2Cl2 (20 ml) and the reaction was stirred at room temperature 
for 3 h. A solution of aniline 5.28 (467 mg, 2.83 mmol) in CH2Cl2 (10 mL) was added and 
the reaction was stirred at 45 °C overnight. The reaction was diluted with CH2Cl2, washed 
with saturated aqueous NaHCO3, dried over MgSO4 and concentrated under reduced 
pressure. Purification of the resulting residue by reverse phase column chromatography 
(MeCN:H2O 0:100-100:0) gave amidine 5.44 (140 mg, 0.334 mmol, 18%) as an orange 
solid. 
Data for 5.44: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.07 – 8.01 (m, 2H), 7.99 – 7.92 
(m, 2H), 7.92 – 7.87 (m, 2H), 7.69 (d, J = 2.1 Hz, 1H), 7.50 (dd, J = 8.4, 6.6 Hz, 2H), 7.47 
– 7.42 (m, 1H), 7.22 (dd, J = 8.1, 2.2 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 3.95 (t, J = 6.8 
Hz, 2H), 3.83 (s, 3H), 2.51 (t, J = 7.8 Hz, 2H), 2.34 (s, 3H), 2.09 (p, J = 7.4 Hz, 2H). 13C-
NMR (100 MHz, CDCl3): δ (ppm) = 167.8, 160.0, 153.0, 150.2, 147.9, 144.3, 133.8, 
131.6, 131.3, 130.5, 129.2, 123.8, 122.8, 121.8, 119.9, 52.0, 50.7, 29.4, 20.8, 19.8. 
HRMS (EI): calc. for C25H25N4O2 [M+H]+: 413.1972, found: 413.1972.  
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Tertiary alcohol 5.48: LiHMDS (1 M, in THF, 0.58 mL, 0.582 mmol) was added dropwise 
to a solution of amidine 5.44 (80 mg, 0.194 mmol) in THF (15 mL) at –78 °C and the 
reaction was allowed to warm to 0 °C over 3 h before it was quenched with saturated 
aqueous NH4Cl. The mixture was extracted with EtOAc and the combined organic 
phases were washed with H2O and brine, dried over MgSO4 and concentrated under 
reduced pressure to give crude enone 5.46 that was used in the next step without further 
purification. 
LiHMDS (1 M, in THF, 0.44 mL, 0.44 mmol) was added dropwise to a solution of crude 
enone 5.46 in THF (10 mL) at –78 °C and the solution was stirred at that temperature for 
30 min. A solution of (−)-(8,8-Dichlorocamphorylsulfonyl) oxaziridine (160 mg, 
0.535 mmol) in THF (5 mL) was added and the mixture was stirred at –10 °C overnight. 
After warming to room temperature, the reaction was quenched with aqueous NaS2O3 
and extracted with Et2O. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by 
recrystallization from MeCN gave tertiary alcohol 5.48 (20 mg, 0.050 mmol, 26% over 2 
steps) as an orange solid. 
Data for 5.48: 1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 8.40 – 8.33 (m, 2H), 8.03 – 
7.97 (m, 2H), 7.89 (dd, J = 7.2, 1.8 Hz, 2H), 7.64 – 7.53 (m, 4H), 7.43 (dd, J = 8.2, 2.1 
Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 6.98 – 6.91 (m, 1H), 4.10 (ddt, J = 15.7, 11.7, 5.9 Hz, 
2H), 2.36 – 2.27 (m, 5H). 13C-NMR (100 MHz, d6-DMSO): δ (ppm) = 194.4, 165.4, 152.1, 
148.4, 147.3, 143.4, 136.6, 133.2, 131.2, 129.5, 126.5, 126.3, 123.5, 122.5, 121.2, 119.7, 
72.8, 47.6, 28.2, 20.3. IR (ATR): 𝜈max (cm−1) = 1692 (m), 1618 (w), 1595 (m), 1575 (w), 
1506 (w), 1482 (m), 1455 (w), 1426 (w), 1298 (m), 1234 (s), 1194 (m), 1158 (m), 1108 
(s), 982 (s), 841 (m), 804 (m), 764 (m), 723 (w), 707 (w), 682 (m). HRMS (EI): calc. for 
C24H21N4O2 [M+H]+: 397.1659, found: 397.1664.   
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Acetamide S5.1: A solution of nitrosobenzene (7.01 g, 46.7 mmol) and 3-
aminoacetanilide (5.00 g, 46.7 mmol) in AcOH (50 mL) was stirred at 40 °C for 24 h and 
concentrated under reduced pressure. The resulting residue was portioned between 
saturated aqueous NaHCO3 and EtOAc. The organic phase was washed with saturated 
aqueous NaHCO3, aqueous HCl (1 M), aqueous NaOH (1 M), H2O and brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resulting residue 
by flash column chromatography (CH2Cl2:MeOH 96:4m Rf = 0.1) gave acetamide S5.1 
(3.77 g, 15.8 mmol, 34%) as a red solid. 
Data for S5.1: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.02 (s, 1H), 7.92 (s, 1H), 7.90 – 
7.83 (m, 2H), 7.72 (dt, J = 8.0, 1.4 Hz, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.53 – 7.42 
(m, 4H), 2.20 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 169.0, 153.2, 152.5, 138.9, 
131.3, 129.7, 129.2, 123.0, 122.5, 119.7, 113.5, 24.7. IR (ATR): 𝜈max (cm−1) = 3300 (w), 
3066 (w), 1666 (s), 1596 (s), 1547 (s), 1490 (m), 1479 (m), 1414 (m), 1370 (m), 1322 
(m), 1300 (m), 1286 (m), 1265 (m), 1150 (w), 1070 (w), 1020 (w), 1000 (w), 907 (w), 889 
(w), 791 (m), 765 (m), 731 (m), 690 (s). HRMS (EI): calc. for C14H13N3O [M]+: 239.1053, 
found: 239.1050.  
 
 
 
Aniline S5.2: A solution of acetamide S5.1 (3.77 g, 15.76 mmol) in MeOH (20 mL) and 
aqueous HCl (6 M, 20 mL) was stirred at 100 °C for 3 h. After cooling to room 
temperature, the reaction was extracted with EtOAc. The combined organic phases were 
washed with saturated aqueous NaHCO3, H2O and brine, dried over MgSO4 and 
concentrated under reduced pressure to give aniline S5.2 (3.09 g, 15.7 mmol, 99%) as 
a red solid. 
Data for S5.2: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.94 – 7.86 (m, 2H), 7.56 – 7.45 
(m, 3H), 7.37 (dt, J = 7.9, 1.4 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.23 (t, J = 2.1 Hz, 1H), 
6.81 (ddd, J = 7.8, 2.4, 1.1 Hz, 1H), 3.83 (s, 2H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 
153.9, 152.8, 147.3, 131.0, 130.0, 129.2, 122.9, 118.0, 115.2, 107.5. IR (ATR): 𝜈max 
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(cm−1) = 3399 (w), 333 (w), 1621 (s), 1606 (s), 1495 (w), 1480 (m), 1324 (w), 1308 (m), 
1273 (s), 1149 (w), 1073 (w), 1023 (w), 993 (w), 955 (w), 920 (w), 864 (m), 756 (s), 767 
(s). HRMS (EI): calc. for C14H13N3O [M]+: 239.1053, found: 239.1050.  
 
 
 
Pyrrolidinone 5.41: NEt3 (0.78 mL, 5.57 mmol) and 4-chlorobutyryl chloride (0.60 mL, 
5.36 mmol) were sequentially added to an ice cooled solution of 3-aminoazobenzene 
S5.2 (1.00 g, 5.07 mmol) in EtOAc (15 mL) and the reaction was stirred at room 
temperature for 4 h. The reaction mixture was washed with H2O and brine, dried over 
MgSO4 and concentrated under reduced pressure. The resulting residue was redissolved 
in i-PrOH (10 mL) and aqueous NaOH (6 M, 10 mL) and stirred at room temperature for 
5 h. The reaction mixture was extracted with EtOAc and the combined organic phases 
were washed with aqueous citric acid (5%) and brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by flash 
column chromatography (CH2Cl2 98:2, Rf = 0.5) gave pyrrolidinone 5.41 (713 mg, 
2.69 mmol, 66% over 2 steps) as an orange solid. 
Data for 5.41: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.01 (t, J = 2.1 Hz, 1H), 7.97 (ddd, 
J = 8.2, 2.3, 1.0 Hz, 1H), 7.95 – 7.90 (m, 2H), 7.72 (ddd, J = 7.9, 1.8, 1.0 Hz, 1H), 7.55 
– 7.47 (m, 4H), 3.97 (t, J = 7.0 Hz, 2H), 2.66 (t, J = 8.1 Hz, 2H), 2.24 – 2.17 (m, 2H). 13C-
NMR (100 MHz, CDCl3): δ (ppm) = 174.6, 153.1, 152.7, 140.4, 131.3, 129.6, 129.2, 
123.1, 122.6, 119.3, 113.5, 48.9, 33.0, 18.1. IR (ATR): 𝜈max (cm−1) = 1682 (vs), 1594 (m), 
1480 (s), 1447 (w),m 1397 (s), 1332 (m), 1317 (m), 1301 (w), 1280 (w), 1226 (s), 1169 
(w), 1100 (w), 1022 (w), 32 (w), 898 (w), 883 (w), 790 (s), 767 (s), 729 (w). HRMS (ESI): 
calc. for C16H16N3O [M+H]+: 266,1288, found: 266,1287.  
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Amidine 5.43: POCl3 (0.32 mL, 3.39 mmol) was added to a solution of pyrrolidinone 5.41 
(600 mg, 2.26 mmol) in benzene (30 ml) and the reaction was stirred at room 
temperature for 3 h. A solution of aniline 5.28 (560 mg, 3.39 mmol) in benzene (20 mL) 
was added and the reaction was stirred at 80 °C overnight. The reaction was diluted with 
EtOAc, washed with saturated aqueous NaHCO3 and brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification of the resulting residue by reverse 
phase column chromatography (MeCN:H2O 0:100-100:0) gave amidine 5.43 (118 mg, 
0.286 mmol, 13%) as an orange solid. 
Data for 5.43: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 8.26 (d, J = 8.2 Hz, 1H), 8.18 (s, 
1H), 7.96 – 7.90 (m, 2H), 7.71 – 7.67 (m, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.49 (dt, J = 14.2, 
6.8 Hz, 4H), 7.20 (dd, J = 8.3, 2.2 Hz, 1H), 6.75 (d, J = 8.1 Hz, 1H), 3.95 (t, J = 6.8 Hz, 
2H), 3.84 (s, 3H), 2.50 (t, J = 7.8 Hz, 2H), 2.33 (s, 3H), 2.07 (q, J = 7.3 Hz, 2H). 13C-NMR 
(100 MHz, CDCl3): δ (ppm) = 167.9, 160.0, 153.0, 152.7, 142.3, 133.7, 131.2, 131.0, 
129.3, 129.1, 123.4, 123.0, 122.9, 122.0, 117.6, 114.1, 51.9, 50.8, 29.3, 20.7, 19.8. 
HRMS (EI): calc. for C25H25N4O2 [M+H]+: 413.1974, found: 413.1972.  
 
 
 
Enone 5.45: LiHMDS (1 M, in THF, 0.86 mL, 0.86 mmol) was added dropwise to a 
solution of amidine 5.43 (118 mg, 0.286 mmol) in THF (10 mL) at –78 °C and the reaction 
was allowed to warm to room temperature and was stirred at that temperature for 7 h 
before it was quenched with saturated aqueous NH4Cl. The mixture was extracted with 
EtOAc and the combined organic phases were washed with H2O and brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification of the resulting residue 
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by flash column chromatography (pentane:EtOAc 2:1, Rf = 0.3) gave crude enone 5.45 
(43 mg, 0.113 mmol, 40%) as an orange solid. 
Data for 5.45: 1H-NMR (400 MHz, CDCl3): δ (ppm) = 7.87 (d, J = 1.9 Hz, 1H), 7.77 (dd, 
J = 7.3, 2.4 Hz, 2H), 7.72 (s, 1H), 7.48 – 7.35 (m, 6H), 7.26 – 7.13 (m, 3H), 3.85 (t, J = 
8.4 Hz, 2H), 3.02 (t, J = 8.4 Hz, 2H), 2.29 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ (ppm) 
= 171.3, 153.8, 153.3, 152.3, 141.4, 132.4, 131.4, 131.2, 129.9, 129.1, 128.8, 127.5, 
123.7, 123.2, 123.0, 120.4, 119.2, 114.1, 104.4, 60.5, 23.3, 21.2. HRMS (EI): calc. for 
C24H27N4O [M+H]+: 381.1710, found: 381.1713.  
 
 
 
Tertiary alcohol 5.47: LiHMDS (1 M, in THF, 0.22 mL, 0.22 mmol) was added dropwise 
to a solution of enone 5.45 (43 mg, 0.113 mmol) in THF (10 mL) at –78 °C and the 
solution was stirred at that temperature for 30 min. A solution of (−)-(8,8-
Dichlorocamphorylsulfonyl) oxaziridine (81 mg, 0.271 mmol) in THF (5 mL) was added 
and the mixture was stirred at –10 °C overnight. After warming to room temperature, the 
reaction was quenched with aqueous NaS2O3 and extracted with Et2O. The combined 
organic phases were dried over MgSO4 and concentrated under reduced pressure. 
Purification of the resulting residue by recrystallization from MeCN gave tertiary alcohol 
5.47 (23 mg, 0.058 mmol, 51%) as an orange solid. 
Data for 5.47: 1H-NMR (400 MHz, d4-MeOH): δ (ppm) = 8.55 (t, J = 2.1 Hz, 1H), 8.17 
(dd, J = 8.2, 2.0 Hz, 1H), 7.95 (d, J = 7.4 Hz, 2H), 7.75 (d, J = 7.9 Hz, 1H), 7.66 – 7.53 
(m, 5H), 7.42 – 7.37 (m, 1H), 7.20 (d, J = 8.1 Hz, 1H), 4.23 (td, J = 9.8, 6.1 Hz, 1H), 4.11 
(t, J = 8.8 Hz, 1H), 2.42 (dt, J = 16.1, 7.8 Hz, 2H), 2.35 (s, 3H). 13C-NMR (100 MHz, d4-
MeOH): δ (ppm) = 195.2, 165.7, 153.1, 152.5, 149.0, 141.4, 136.6, 133.2, 131.1, 129.2, 
128.9, 126.5, 125.7, 123.1, 122.5, 121.0, 118.5, 114.7, 73.2, 28.6, 19.3. IR (ATR): 𝜈max 
(cm−1) = 1683 (m), 1622 (s), 1590 (s), 1475 (s), 1452 (s), 1406 (m), 1325 (m), 1298 (s), 
1266 (m), 1194 (w), 1142 (w), 1110 (w), 1069 (w), 1015 (w), 927 (w), 868 (w), 833 (w), 
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789 (m), 764 (m), 734 (w), 690 (s). HRMS (EI): calc. for C24H21N4O2 [M+H]+: 397.1659, 
found: 397.1659.  
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7.1 Crystallographic Data 
 Tetrahydrothiopene 17 (CCDC 1563493) 
 
Figure 7.1. ORTEP of the molecular structure of tetrahydrothiophene 17. 
 
Table 7.1. Crystallographic data for tetrahydrothiophene 17. 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
μ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
C17H26O2S 
294.44 
0.100 × 0.080 × 0.030 
100.(2) 
MoKα 
'Bruker D8 Venture TXS' 
monoclinic 
'P 1 21/n 1' 
13.4104(4) 
9.3905(3) 
13.4470(3) 
90 
105.0380(10) 
90 
1635.39(8) 
4 
1.196 
0.198 
Multi-Scan 
0.9076–0.9705 
20641 
0.0399 
0.0305 
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θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
 
3.137–27.484 
3149 
0.0404, 0.8932 
constr 
3742 
186 
0 
0.0359 
0.0948 
1.038 
0.002 
0.354 
−0.258 
 
 
 
 Vinylogous carbonate 20 (CCDC 1563492)  
 
Figure 7.2. ORTEP of the molecular structure of tricycle 20. 
 
Table 7.2. Crystallographic data for tricycle 20. 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
C19H28O3S 
336.47 
0.100 × 0.090 × 0.070 
100.(2) 
MoKα 
'Bruker D8 Venture TXS' 
triclinic 
'P -1' 
9.6756(5) 
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b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
μ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
 
9.9965(5) 
10.5598(6) 
73.852(2) 
71.287(2) 
71.142(2) 
897.95(8) 
2 
1.244 
0.193 
Multi-Scan 
0.9062–0.9705 
10749 
0.0311 
0.0350 
3.303–26.342 
3111 
0.0396, 0.5084 
constr 
3637 
213 
0 
0.0356 
0.0954 
1.062 
0.001 
0.337 
−0.257 
 
 
 
 
 Enone 2.100 
 
Figure 7.3. ORTEP of the molecular structure of enone 2.100. 
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Table 7.3. Crystallographic data for enone 2.100. 
net formula C10H13IO3 
Mr/g mol−1 308.10 
crystal size/mm 0.100 × 0.080 × 0.050 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 5.5298(4) 
b/Å 12.2048(10) 
c/Å 16.1544(12) 
α/° 90 
β/° 94.678(2) 
γ/° 90 
V/Å3 1086.63(14) 
Z 4 
calc. density/g cm−3 1.883 
μ/mm−1 2.927 
absorption correction Multi-Scan 
transmission factor range 0.5958–0.6367 
refls. measured 20258 
Rint 0.0530 
mean σ(I)/I 0.0329 
θ range 3.338–30.501 
observed refls. 3010 
x, y (weighting scheme) 0.0244, 0.5259 
hydrogen refinement constr 
refls in refinement 3298 
parameters 130 
restraints 0 
R(Fobs) 0.0212 
Rw(F2) 0.0561 
S 1.043 
shift/errormax 0.001 
max electron density/e Å−3 0.902 
min electron density/e Å−3 −0.570 
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 Allylic alcohol 2.108 
 
Figure 7.4. ORTEP of the molecular structure of allylic alcohol 2.108. 
 
Table 7.4. Crystallographic data for allylic alcohol 2.108. 
net formula C10H15IO3 
Mr/g mol−1 310.12 
crystal size/mm 0.100 × 0.080 × 0.020 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 8.0873(5) 
b/Å 12.0960(9) 
c/Å 12.4087(9) 
α/° 104.002(2) 
β/° 103.200(2) 
γ/° 92.314(2) 
V/Å3 1140.79(14) 
Z 4 
calc. density/g cm−3 1.806 
μ/mm−1 2.788 
absorption correction Multi-Scan 
transmission factor range 0.5733–0.7454 
refls. measured 19827 
Rint 0.0403 
mean σ(I)/I 0.0341 
θ range 3.158–26.372 
observed refls. 4077 
x, y (weighting scheme) 0.0417, 0.8914 
hydrogen refinement constr 
refls in refinement 4630 
parameters 261 
restraints 0 
R(Fobs) 0.0286 
Rw(F2) 0.0756 
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S 1.063 
shift/errormax 0.001 
max electron density/e Å−3 1.314 
min electron density/e Å−3 −1.036 
 
 
 Allylic ester 2.146 
 
Figure 7.5. ORTEP of the molecular structure of allylic alcohol 2.146. 
 
Table 7.5. Crystallographic data for allylic ester 2.146. 
net formula C15H22O5 
Mr/g mol−1 282.32 
crystal size/mm 0.100 × 0.100 × 0.020 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21 1' 
a/Å 14.0914(7) 
b/Å 7.2146(3) 
c/Å 15.0038(8) 
α/° 90 
β/° 105.2139(18) 
γ/° 90 
V/Å3 1471.88(12) 
Z 4 
calc. density/g cm−3 1.274 
μ/mm−1 0.095 
absorption correction Multi-Scan 
transmission factor range 0.8883–0.9593 
332 
refls. measured 18843 
Rint 0.0477 
mean σ(I)/I 0.0506 
θ range 3.155–26.370 
observed refls. 4963 
x, y (weighting scheme) 0.0318, 2.7949 
hydrogen refinement mixed 
Flack parameter 0.5 
refls in refinement 5822 
parameters 375 
restraints 2 
R(Fobs) 0.0707 
Rw(F2) 0.1579 
S 1.154 
shift/errormax 0.001 
max electron density/e Å−3 0.529 
min electron density/e Å−3 −0.287 
C-H: constr, O-H: refxyz, U(H)=1.5U(O), one O-H distance fixed with DFIX. Refined as 
racemic twin. 
 
 
 Tertiary alcohol 5.48 
 
Figure 7.6. ORTEP of the molecular structure of allylic alcohol 5.48. 
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Table 7.6. Crystallographic data for tertiary alcohol 5.48. 
net formula C24H20N4O2 
Mr/g mol−1 396.441 
crystal size/mm 0.180 × 0.120 × 0.020 
T/K 173(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Quest' 
crystal system monoclinic 
space group P21 
a/Å 5.8301(3) 
b/Å 27.1534(14) 
c/Å 6.1864(3) 
α/° 90 
β/° 92.7670(15) 
γ/° 90 
V/Å3 978.21(9) 
Z 2 
calc. density/g cm−3 1.34596(12) 
μ/mm−1 0.088 
absorption correction multi-scan 
transmission factor range 0.9081–0.9579 
refls. measured 16076 
Rint 0.0392 
mean σ(I)/I 0.0298 
θ range 3.00–25.07 
observed refls. 3101 
x, y (weighting scheme) 0.0391, 0.1704 
hydrogen refinement mixed 
Flack parameter −0.3(11) 
refls in refinement 3441 
parameters 276 
restraints 1 
R(Fobs) 0.0343 
Rw(F2) 0.0779 
S 1.058 
shift/errormax 0.001 
max electron density/e Å−3 0.171 
min electron density/e Å−3 −0.180 
C-H: constr, O-H: refall. 
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7.2 1H and 13C NMR spectra 
  
335 
7.2.1 1H and 13C NMR spectra of Chapter I 
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7.2.2 1H and 13C NMR spectra of Chapter II 
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7.2.3 1H and 13C NMR spectra of Chapter III 
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7.2.4 1H and 13C NMR spectra of Chapter IV 
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7.2.5 1H and 13C NMR spectra of Chapter V 
 
 
  
13C-NMR, 100 MHz, CDCl3 
1H-NMR, 400 MHz, CDCl3 
511 
 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
512 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
513 
 
 
 
  
13C-NMR, 100 MHz, CDCl3 
1H-NMR, 400 MHz, CDCl3 
514 
 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
515 
 
 
 
  
13C-NMR, 100 MHz, d4-MeOH 
1H-NMR, 400 MHz, d4-MeOH 
516 
 
 
 
  
1H-NMR, 400 MHz, d4-MeOH 
13C-NMR, 100 MHz, d4-MeOH 
517 
 
 
 
  
13C-NMR, 100 MHz, CDCl3 
1H-NMR, 400 MHz, CDCl3 
518 
 
 
 
  
1H-NMR, 400 MHz, d6-DMSO 
13C-NMR, 100 MHz, d6-DMSO 
519 
 
 
 
  
13C-NMR, 100 MHz, CDCl3 
1H-NMR, 400 MHz, CDCl3 
520 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
521 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
522 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
523 
 
 
  
1H-NMR, 400 MHz, d4-MeOH 
13C-NMR, 100 MHz, d4-MeOH 
524 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
525 
 
 
  
1H-NMR, 400 MHz, d6-DMSO 
13C-NMR, 100 MHz, CDCl3 
526 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
527 
 
 
  
1H-NMR, 400 MHz, d6-DMSO 
13C-NMR, 100 MHz, d6-DMSO 
528 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
529 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
530 
 
 
  
1H-NMR, 400 MHz, d6-DMSO 
13C-NMR, 100 MHz, d6-DMSO 
531 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
532 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
533 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
534 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
535 
 
 
  
1H-NMR, 400 MHz, CDCl3 
13C-NMR, 100 MHz, CDCl3 
536 
 
 
  
1H-NMR, 400 MHz, d4-MeOH 
13C-NMR, 100 MHz, d4-MeOH 
537 
7.3 Literature 
1. Kobayashi, M.; Kondo, K.; Kitagawa, I., Antifungal peroxyketal acids from an 
okinawan marine sponge of plakortis sp. Chem. Pharm. Bull. 1993, 41 (7), 1324-1326. 
2. Davidson, B. S., Cytotoxic five-membered cyclic peroxides from a Plakortis 
sponge. The Journal of Organic Chemistry 1991, 56 (23), 6722-6724. 
3. Rahm, F.; Harges, P. Y.; Kitching, W., Metabolites from marine Sponges of the 
genus plakortis. Heterocycles 2004, 64, 523-575. 
4. Piao, S. J.; Song, Y. L.; Jiao, W. H.; Yang, F.; Liu, X. F.; Chen, W. S.; Han, B. N.; 
Lin, H. W., Hippolachnin A, a new antifungal polyketide from the South China Sea sponge 
Hippospongia lachne. Org Lett 2013, 15 (14), 3526-9. 
5. Wilson, D., Endophyte. Oikos 1995, 73 (2), 274-276. 
6. Arnone, A.; Nasini, G.; Panzeri, W.; de Pava, O. V.; Malpezzi, L., Acremine G, 
dimeric metabolite from cultures of Acremonium byssoides A20. J Nat Prod 2008, 71 (1), 
146-9. 
7. Wu, P.; Xue, J.; Yao, L.; Xu, L.; Li, H.; Wei, X., Bisacremines E-G, Three 
Polycyclic Dimeric Acremines Produced by Acremonium persicinum SC0105. Org Lett 
2015, 17 (19), 4922-5. 
8. Higgs, M. D.; Faulkner, D. J., Plakortin, an antibiotic from Plakortis 
halichondrioides. The Journal of Organic Chemistry 1978, 43 (18), 3454-3457. 
9. Cafieri, F.; Fattorusso, E.; Taglialatela-Scafati, O.; Ianaro, A., Metabolites from 
the sponge Plakortis simplex. Determination of absolute stereochemistry of plakortin. 
Isolation and stereostructure of three plakortin related compounds. Tetrahedron 1999, 
55 (22), 7045-7056. 
10. Campagnuolo, C.; Fattorusso, E.; Romano, A.; Taglialatela-Scafati, O.; Basilico, 
N.; Parapini, S.; Taramelli, D., Antimalarial Polyketide Cycloperoxides from the Marine 
SpongePlakortis simplex. European Journal of Organic Chemistry 2005, 2005 (23), 
5077-5083. 
11. Patil, A. D.; Freyer, A. J.; Bean, M. F.; Carte, B. K.; Westley, J. W.; Johnson, R. 
K.; Lahouratate, P., The plakortones, novel bicyclic lactones from the sponge Plakortis 
halichondrioides: Activators of cardiac SR-Ca2+-pumping ATPase. Tetrahedron 1996, 
52 (2), 377-394. 
12. Ueoka, R.; Nakao, Y.; Kawatsu, S.; Yaegashi, J.; Matsumoto, Y.; Matsunaga, S.; 
Furihata, K.; van Soest, R. W.; Fusetani, N., Gracilioethers A-C, antimalarial metabolites 
from the marine sponge Agelas gracilis. J Org Chem 2009, 74 (11), 4203-7. 
13. Festa, C.; De Marino, S.; D'Auria, M. V.; Deharo, E.; Gonzalez, G.; Deyssard, C.; 
Petek, S.; Bifulco, G.; Zampella, A., Gracilioethers E–J, new oxygenated polyketides 
538 
from the marine sponge Plakinastrella mamillaris. Tetrahedron 2012, 68 (49), 10157-
10163. 
14. Festa, C.; D'Amore, C.; Renga, B.; Lauro, G.; De Marino, S.; D'Auria, M. V.; 
Bifulco, G.; Zampella, A.; Fiorucci, S., Oxygenated polyketides from Plakinastrella 
mamillaris as a new chemotype of PXR agonists. Mar Drugs 2013, 11 (7), 2314-27. 
15. Rasik, C. M.; Brown, M. K., Total synthesis of gracilioether F: development and 
application of lewis Acid promoted ketene-alkene [2+2] cycloadditions and late-stage C-
H oxidation. Angew Chem Int Ed Engl 2014, 53 (52), 14522-6. 
16. Norris, M. D.; Perkins, M. V.; Sorensen, E. J., Biomimetic total synthesis of 
gracilioethers B and C. Org Lett 2015, 17 (3), 668-71. 
17. Ruider, S. A.; Carreira, E. M., A Unified Strategy to Plakortin Pentalenes: Total 
Syntheses of (+/-)-Gracilioethers E and F. Org Lett 2016, 18 (2), 220-3. 
18. Shen, X. Y.; Peng, X. S.; Wong, H. N., Total Synthesis of (+/-)-Gracilioether F. 
Org Lett 2016, 18 (5), 1032-5. 
19. Xu, Z. J.; Wu, Y., Efficient Synthetic Routes to (+/-)-Hippolachnin A, (+/-)-
Gracilioethers E and F and the Alleged Structure of (+/-)-Gracilioether I. Chemistry 2017, 
23 (9), 2026-2030. 
20. Ruider, S. A.; Sandmeier, T.; Carreira, E. M., Total synthesis of (+/-)-hippolachnin 
A. Angew Chem Int Ed Engl 2015, 54 (8), 2378-82. 
21. Festa, C.; Lauro, G.; De Marino, S.; D'Auria, M. V.; Monti, M. C.; Casapullo, A.; 
D'Amore, C.; Renga, B.; Mencarelli, A.; Petek, S.; Bifulco, G.; Fiorucci, S.; Zampella, A., 
Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class 
of marine ligands of peroxisome proliferator-activated receptor gamma. J Med Chem 
2012, 55 (19), 8303-17. 
22. Kubanek, J.; Andersen, R. J., Evidence for the Incorporation of Intact Butyrate 
Units in the Biosynthesis of Triophamine. Tetrahedron Letters 1997, 38 (36), 6327-6330. 
23. Stierle, D. B.; Faulkner, D. J., Metabolites of three marine sponges of the genus 
Plakortis. The Journal of Organic Chemistry 1980, 45 (17), 3396-3401. 
24. Akiyama, M.; Isoda, Y.; Nishimoto, M.; Kobayashi, A.; Togawa, D.; Hirao, N.; 
Kuboki, A.; Ohira, S., Stereocontrolled synthesis of (±)-methyl 3,6-epoxy-4,6,8-triethyl-
2,4,9-dodecatrienoate, a major metabolite of Caribbean sponge, Plakortis 
halichondrioides, using reactions of alkylidenecarbenes in one pot. Tetrahedron Letters 
2005, 46 (44), 7483-7485. 
25. Datta, R.; Dixon, R. J.; Ghosh, S., A convenient access to the tricyclic core 
structure of hippolachnin A. Tetrahedron Letters 2016, 57 (1), 29-31. 
539 
26. McCallum, M. E.; Rasik, C. M.; Wood, J. L.; Brown, M. K., Collaborative Total 
Synthesis: Routes to (+/-)-Hippolachnin A Enabled by Quadricyclane Cycloaddition and 
Late-Stage C-H Oxidation. J Am Chem Soc 2016, 138 (7), 2437-42. 
27. Govender, N. P.; Patel, J.; van Wyk, M.; Chiller, T. M.; Lockhart, S. R.; Group for 
Enteric, R.; Meningeal Disease Surveillance in South, A., Trends in antifungal drug 
susceptibility of Cryptococcus neoformans isolates obtained through population-based 
surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother 
2011, 55 (6), 2606-11. 
28. Loyse, A.; Thangaraj, H.; Easterbrook, P.; Ford, N.; Roy, M.; Chiller, T.; 
Govender, N.; Harrison, T. S.; Bicanic, T., Cryptococcal meningitis: improving access to 
essential antifungal medicines in resource-poor countries. The Lancet Infectious 
Diseases 2013, 13 (7), 629-637. 
29. Sabiiti, W.; Robertson, E.; Beale, M. A.; Johnston, S. A.; Brouwer, A. E.; Loyse, 
A.; Jarvis, J. N.; Gilbert, A. S.; Fisher, M. C.; Harrison, T. S.; May, R. C.; Bicanic, T., 
Efficient phagocytosis and laccase activity affect the outcome of HIV-associated 
cryptococcosis. J Clin Invest 2014, 124 (5), 2000-8. 
30. Li, S. S.; Mody, C. H., Cryptococcus. Proc Am Thorac Soc 2010, 7 (3), 186-96. 
31. Reetz, M. T.; Chatziiosifidis, I.; Schwellnus, K., A General Procedure for 
Intramolecularα-tert-Alkylation of Carbonyl Compounds. Angewandte Chemie 
International Edition in English 1981, 20 (8), 687-689. 
32. Dauben, W. G.; Koch, K.; Smith, S. L.; Chapman, O. L., Photoisomerizations in 
the α-Tropolone Series: The Mechanistic Path of the α-Tropolone Methyl Ether to Methyl 
4-Oxo-2-cyclopentenylacetate Conversion. Journal of the American Chemical Society 
1963, 85 (17), 2616-2621. 
33. Zweifel, G.; Steele, R. B., A new and convenient method for the preparation of 
isomerically pure .alpha.,.beta.-unsaturated derivatives via hydroalumination of alkynes. 
Journal of the American Chemical Society 1967, 89 (11), 2754-2755. 
34. Zhu, J.; Yang, J. Y.; Klunder, A. J. H.; Liu, Z. Y.; Zwanenburg, B., ChemInform 
Abstract: A Stereo- and Enantioselective Approach to Clavulones from 
Tricyclodecadienone Using Flash Vacuum Thermolysis. ChemInform 2010, 26 (37), no-
no. 
35. Demuynck, A. L. W.; Levecque, P.; Kidane, A.; Gammon, D. W.; Sickle, E.; 
Jacobs, P. A.; De Vos, D. E.; Sels, B. F., Retro-Diels-Alder Reactions of Masked 
Cyclopentadienones Catalyzed by Heterogeneous Brønsted Acids. Advanced Synthesis 
& Catalysis 2010, 352 (18), 3419-3430. 
540 
36. Krasovskiy, A.; Kopp, F.; Knochel, P., Soluble lanthanide salts (LnCl3.2LiCl) for 
the improved addition of organomagnesium reagents to carbonyl compounds. Angew 
Chem Int Ed Engl 2006, 45 (3), 497-500. 
37. Zhou, T.; Peters, B.; Maldonado, M. F.; Govender, T.; Andersson, P. G., 
Enantioselective synthesis of chiral sulfones by Ir-catalyzed asymmetric hydrogenation: 
a facile approach to the preparation of chiral allylic and homoallylic compounds. J Am 
Chem Soc 2012, 134 (33), 13592-5. 
38. Winter, N.; Trauner, D., Thiocarbonyl Ylide Chemistry Enables a Concise 
Synthesis of (+/-)-Hippolachnin A. J Am Chem Soc 2017, 139 (34), 11706-11709. 
39. Arnone, A.; Assante, G.; Bava, A.; Dallavalle, S.; Nasini, G., Acremines H–N, 
novel prenylated polyketide metabolites produced by a strain of Acremonium byssoides. 
Tetrahedron 2009, 65 (4), 786-791. 
40. Assante, G.; Dallavalle, S.; Malpezzi, L.; Nasini, G.; Burruano, S.; Torta, L., 
Acremines A–F, novel secondary metabolites produced by a strain of an endophytic 
Acremonium, isolated from sporangiophores of Plasmopara viticola in grapevine leaves. 
Tetrahedron 2005, 61 (32), 7686-7692. 
41. Suciati; Fraser, J. A.; Lambert, L. K.; Pierens, G. K.; Bernhardt, P. V.; Garson, M. 
J., Secondary metabolites of the sponge-derived fungus Acremonium persicinum. J Nat 
Prod 2013, 76 (8), 1432-40. 
42. Garson, M. J.; Hehre, W.; Pierens, G. K.; Suciati, Revision of the Structure of 
Acremine P from a Marine-Derived Strain of Acremonium persicinum. Molecules 2017, 
22 (4). 
43. Yurchenko, A. N.; Smetanina, O. F.; Kalinovsky, A. I.; Pushilin, M. A.; Glazunov, 
V. P.; Khudyakova, Y. V.; Kirichuk, N. N.; Ermakova, S. P.; Dyshlovoy, S. A.; Yurchenko, 
E. A.; Afiyatullov, S., Oxirapentyns F-K from the marine-sediment-derived fungus Isaria 
felina KMM 4639. J Nat Prod 2014, 77 (6), 1321-8. 
44. Wu, P.; Yao, L.; Xu, L.; Xue, J.; Wei, X., Bisacremines A-D, Dimeric Acremines 
Produced by a Soil-Derived Acremonium persicinum Strain. J Nat Prod 2015, 78 (9), 
2161-6. 
45. Mehta, G.; Sunil Kumar, Y. C.; Khan, T. B., Total syntheses of the fungal 
metabolites (±)-acremines A, B and I. Tetrahedron Letters 2010, 51 (39), 5112-5115. 
46. Arkoudis, E.; Lykakis, I. N.; Gryparis, C.; Stratakis, M., Biomimetic synthesis of 
dimeric metabolite acremine G via a highly regioselective and stereoselective Diels-Alder 
reaction. Org Lett 2009, 11 (14), 2988-91. 
47. Mehta, G.; Khan, T. B.; Sunil Kumar, Y. C., Total synthesis of the fungal 
metabolite (±)-acremine G: acceleration of a biomimetic Diels–Alder reaction on silica 
gel. Tetrahedron Letters 2010, 51 (39), 5116-5119. 
541 
48. Lei, X.; Johnson, R. P.; Porco, J. A., Jr., Total synthesis of the ubiquitin-activating 
enzyme inhibitor (+)-panepophenanthrin. Angew Chem Int Ed Engl 2003, 42 (33), 3913-
7. 
49. Magnuson, S. R.; Sepp-Lorenzino, L.; Rosen, N.; Danishefsky, S. J., A Concise 
Total Synthesis of Dysidiolide through Application of a Dioxolenium-Mediated 
Diels−Alder Reaction. Journal of the American Chemical Society 1998, 120 (7), 1615-
1616. 
50. Irngartinger, H.; Stadler, B., Synthesis, Structures and Topochemistry of 2-
Monovinyl-Substituted 1,4-Benzoquinones. European Journal of Organic Chemistry 
1998, 1998 (4), 605-626. 
51. Noland, W. E.; Kedrowski, B. L., Synthesis of Angular Quinoid Heterocycles from 
2-(2-Nitrovinyl)-1,4-benzoquinone. The Journal of Organic Chemistry 1999, 64 (2), 596-
603. 
52. Kienzler, M. A.; Suseno, S.; Trauner, D., Vinyl quinones as Diels-Alder dienes: 
concise synthesis of (-)-halenaquinone. J Am Chem Soc 2008, 130 (27), 8604-5. 
53. Lobermann, F.; Mayer, P.; Trauner, D., Biomimetic synthesis of (-)-
pycnanthuquinone C through the Diels-Alder reaction of a vinyl quinone. Angew Chem 
Int Ed Engl 2010, 49 (35), 6199-202. 
54. Zhang, Z.; Chen, J.; Yang, Z.; Tang, Y., Rapid biomimetic total synthesis of (+/-)-
rossinone B. Org Lett 2010, 12 (23), 5554-7. 
55. Lobermann, F.; Weisheit, L.; Trauner, D., Intramolecular vinyl quinone Diels-Alder 
reactions: asymmetric entry to the cordiachrome core and synthesis of (-)-
isoglaziovianol. Org Lett 2013, 15 (17), 4324-6. 
56. Woo, C. M.; Lu, L.; Gholap, S. L.; Smith, D. R.; Herzon, S. B., Development of a 
Convergent Entry to the Diazofluorene Antitumor Antibiotics: Enantioselective Synthesis 
of Kinamycin F. Journal of the American Chemical Society 2010, 132 (8), 2540-2541. 
57. Gassman, P. G.; Singleton, D. A.; Wilwerding, J. J.; Chavan, S. P., Acrolein 
acetals as allyl cation precursors in the ionic Diels-Alder reaction. Journal of the 
American Chemical Society 1987, 109 (7), 2182-2184. 
58. Gassman, P. G.; Lottes, A. C., Cyclobutane formation in the 2π + 2π cycloaddition 
of allyl and related cations to unactivated olefins. Evidence for the second step in the 
proposed mechanism of the ionic diels-alder reaction. Tetrahedron Letters 1992, 33 (2), 
157-160. 
59. Sammakia, T.; Berliner, M. A., Asymmetric Diels-Alder Reactions with 
.alpha.,.beta.-Unsaturated Acetals. The Journal of Organic Chemistry 1994, 59 (23), 
6890-6891. 
542 
60. Pabon, R. A.; Bellville, D. J.; Bauld, N. L., Cation radical Diels-Alder reactions of 
electron-rich dienophiles. Journal of the American Chemical Society 1983, 105 (15), 
5158-5159. 
61. Mlcoch, J.; Steckhan, E., Photochemically Initiated, Electron-Transfer-Catalyzed 
Diels-Alder Reactions of Electron-Rich Dienophiles. Angewandte Chemie International 
Edition in English 1985, 24 (5), 412-414. 
62. Nicewicz, D. A.; Nguyen, T. M., Recent Applications of Organic Dyes as 
Photoredox Catalysts in Organic Synthesis. ACS Catalysis 2013, 4 (1), 355-360. 
63. Bellville, D. J.; Bauld, N. L.; Pabon, R.; Gardner, S. A., Theoretical analysis of 
selectivity in the cation radical Diels-Alder. Journal of the American Chemical Society 
1983, 105 (11), 3584-3588. 
64. Drew, S. L.; Lawrence, A. L.; Sherburn, M. S., Total synthesis of kingianins A, D, 
and F. Angew Chem Int Ed Engl 2013, 52 (15), 4221-4. 
65. Grée, R.; Laabassi, M.; Mosset, P.; Carrié, R., Stereo- and enantioselective 
synthesis of some e,z dienols and ethers. Tetrahedron Letters 1985, 26 (19), 2317-2318. 
66. Wender, P. A.; Correia, C. R. D., Intramolecular photoinduced diene-diene 
cyaloadditions: a selective method for the synthesis of complex eight-membered rings 
and polyquinanes. Journal of the American Chemical Society 1987, 109 (8), 2523-2525. 
67. Hammond, G. S.; Turro, N. J.; Liu, R. S. H., Mechanisms of Photochemical 
Reactions in Solution. XVI.1Photosensitized Dimerization of Conjugated Dienes. The 
Journal of Organic Chemistry 1963, 28 (12), 3297-3303. 
68. Trecker, D. J.; Henry, J. P., Cumulative Effects in Small Ring Cleavage Reactions. 
A Novel Cyclobutane Rearrangement. Journal of the American Chemical Society 1964, 
86 (5), 902-905. 
69. Hammond, G. S.; DeBoer, C. D., Multiplicity of Mechanisms in the Cope 
Rearrangement. Journal of the American Chemical Society 1964, 86 (5), 899-902. 
70. Fleming, S. A.; Parent, A. A.; Parent, E. E.; Pincock, J. A.; Renault, L., 
Mechanistic analysis of the photocycloaddition of silyl-tethered alkenes. J Org Chem 
2007, 72 (25), 9464-70. 
71. Ward, S. C.; Fleming, S. A., [2 + 2] Photocycloaddition of Cinnamyloxy Silanes. 
The Journal of Organic Chemistry 1994, 59 (21), 6476-6479. 
72. Fleming, S. A.; Ward, S. C., Stereocontrolled photochemical [2 + 2] cycloaddition. 
Tetrahedron Letters 1992, 33 (8), 1013-1016. 
73. Nicolaou, K. C.; Snyder, S. A.; Montagnon, T.; Vassilikogiannakis, G., The Diels–
Alder Reaction in Total Synthesis. Angewandte Chemie International Edition 2002, 41 
(10), 1668-1698. 
543 
74. Barcellos, T.; Tauber, K.; Kroutil, W.; Andrade, L. H., Stereocomplementary 
asymmetric bioreduction of boron-containing ketones mediated by alcohol 
dehydrogenases. Tetrahedron: Asymmetry 2011, 22 (18-19), 1772-1777. 
75. Palczewski K, k. T., hori T, behnke CA, motoshima H, fox BA, trong IL, teller DC, 
okada T, stenkamp RE, yamamoto M, miyano M. , Crystal structure of rhodopsin: a G 
protein-coupled receptor. . American journal of ophthalmology 2000, 130 (6), 865. 
76. Wettschureck, N.; Offermanns, S., Mammalian G proteins and their cell type 
specific functions. Physiol Rev 2005, 85 (4), 1159-204. 
77. Philip, F.; Sengupta, P.; Scarlata, S., Signaling through a G Protein-coupled 
receptor and its corresponding G protein follows a stoichiometrically limited model. J Biol 
Chem 2007, 282 (26), 19203-16. 
78. Foord, S. M.; Bonner, T. I.; Neubig, R. R.; Rosser, E. M.; Pin, J. P.; Davenport, 
A. P.; Spedding, M.; Harmar, A. J., International Union of Pharmacology. XLVI. G protein-
coupled receptor list. Pharmacol Rev 2005, 57 (2), 279-88. 
79. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. 
S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C., High-
resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled 
receptor. Science 2007, 318 (5854), 1258-65. 
80. Jiang, M.; Bajpayee, N. S., Molecular mechanisms of go signaling. Neurosignals 
2009, 17 (1), 23-41. 
81. Beaulieu, J. M.; Gainetdinov, R. R., The physiology, signaling, and pharmacology 
of dopamine receptors. Pharmacol Rev 2011, 63 (1), 182-217. 
82. Missale, C.; Nash, S. R.; Robinson, S. W.; Jaber, M.; Caron, M. G., Dopamine 
receptors: from structure to function. Physiol Rev 1998, 78 (1), 189-225. 
83. Beaulieu, J. M.; Espinoza, S.; Gainetdinov, R. R., Dopamine receptors - IUPHAR 
Review 13. Br J Pharmacol 2015, 172 (1), 1-23. 
84. Rask-Andersen, M.; Almen, M. S.; Schioth, H. B., Trends in the exploitation of 
novel drug targets. Nat Rev Drug Discov 2011, 10 (8), 579-90. 
85. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; 
Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C., Structure of the human 
dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330 
(6007), 1091-5. 
86. Perreault, M. L.; Hasbi, A.; O'Dowd, B. F.; George, S. R., Heteromeric dopamine 
receptor signaling complexes: emerging neurobiology and disease relevance. 
Neuropsychopharmacology 2014, 39 (1), 156-68. 
544 
87. Cannon, J. G., Structure-activity relationships of dopamine agonists. Annu Rev 
Pharmacol Toxicol 1983, 23, 103-29. 
88. Seiler, M. P.; Stoll, A. P.; Closse, A.; Frick, W.; Jaton, A.; Vigouret, J. M., 
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives 
with functionalized N-alkyl substituents. Journal of Medicinal Chemistry 1986, 29 (6), 
912-917. 
89. van Vliet, L. A.; Tepper, P. G.; Dijkstra, D.; Damsma, G.; Wikstrom, H.; Pugsley, 
T. A.; Akunne, H. C.; Heffner, T. G.; Glase, S. A.; Wise, L. D., Affinity for dopamine D2, 
D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for 
determination of receptor subtype selectivity. J Med Chem 1996, 39 (21), 4233-7. 
90. Biswas, S.; Zhang, S.; Fernandez, F.; Ghosh, B.; Zhen, J.; Kuzhikandathil, E.; 
Reith, M. E.; Dutta, A. K., Further structure-activity relationships study of hybrid 7-{[2-(4-
phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-o l analogues: 
identification of a high-affinity D3-preferring agonist with potent in vivo activity with long 
duration of action. J Med Chem 2008, 51 (1), 101-17. 
91. Donthamsetti, P. C.; Winter, N.; Schonberger, M.; Levitz, J.; Stanley, C.; Javitch, 
J. A.; Isacoff, E. Y.; Trauner, D., Optical Control of Dopamine Receptors Using a 
Photoswitchable Tethered Inverse Agonist. J Am Chem Soc 2017, 139 (51), 18522-
18535. 
92. Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V., Polytriazoles as copper(I)-
stabilizing ligands in catalysis. Org Lett 2004, 6 (17), 2853-5. 
93. Zheng, J.; Li, Y.; Sun, Y.; Yang, Y.; Ding, Y.; Lin, Y.; Yang, W., A generic magnetic 
microsphere platform with "clickable" ligands for purification and immobilization of 
targeted proteins. ACS Appl Mater Interfaces 2015, 7 (13), 7241-50. 
94. Kassianidis, E.; Pearson, R. J.; Philp, D., Probing structural effects on replication 
efficiency through comparative analyses of families of potential self-replicators. 
Chemistry 2006, 12 (34), 8798-812. 
95. Charlton, J. L.; Koh, K.; Plourde, G. L., An asymmetric synthesis of 2-amino-6,7-
dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN). Canadian Journal of Chemistry 1990, 
68 (11), 2028-2032. 
96. Horn, A. S.; Grol, C. J.; Dijkstra, D.; Mulder, A. H., Facile syntheses of potent 
dopaminergic argonists and their effect on neurotransmitter release. J Med Chem 1978, 
21 (8), 825-8. 
97. Langmead, C. J.; Watson, J.; Reavill, C., Muscarinic acetylcholine receptors as 
CNS drug targets. Pharmacol Ther 2008, 117 (2), 232-43. 
98. P., C. M.; Birdsall, N. J., International Union of Pharmacology. XVII. Classiication 
of Muscarinic Acetylcholine Receptors. Pharmacological Reviews 1998, 50 (2), 279-290. 
545 
99. Smith, R. S.; Araneda, R. C., Cholinergic modulation of neuronal excitability in the 
accessory olfactory bulb. J Neurophysiol 2010, 104 (6), 2963-74. 
100. Ishii, M.; Kurachi, Y., Muscarinic Acetylcholine Receptors. Current 
Pharmaceutical Design 2006, 12, 3573-3581. 
101. Krejci, A.; Michal, P.; Jakubik, J.; Ricny, J.; Dolezal, V., Regulation of signal 
transduction at M2 muscarinic receptor. Physiological research 2004, 53 Suppl 1, S131-
40. 
102. Simon, M. I.; Strathmann, M. P.; Gautam, N., Diversity of G proteins in signal 
transduction. Science 1991, 252 (5007), 802-808. 
103. Dell'Acquat, M. L.; Caroll, R. C.; Peralta, E. G., Transfected m2 Muscarinic 
Acetylcholine Receptors Couple to Gis and Gi3 in CHinese Hamster Ovary Cells. The 
Journal of Biological Chemistry 1993, 268 (8), 5676-5685. 
104. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; 
Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T., Structure of the human 
M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482 (7386), 
547-51. 
105. Kruse, A. C.; Hu, J.; Pan, A. C.; Arlow, D. H.; Rosenbaum, D. M.; Rosemond, E.; 
Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, 
B. K., Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 
482 (7386), 552-6. 
106. Thal, D. M.; Sun, B.; Feng, D.; Nawaratne, V.; Leach, K.; Felder, C. C.; Bures, M. 
G.; Evans, D. A.; Weis, W. I.; Bachhawat, P.; Kobilka, T. S.; Sexton, P. M.; Kobilka, B. 
K.; Christopoulos, A., Crystal structures of the M1 and M4 muscarinic acetylcholine 
receptors. Nature 2016, 531 (7594), 335-40. 
107. Comings, D. E.; Wu, S.; Rostamkhani, M.; McGue, M.; Lacono, W. G.; Cheng, L. 
S.; MacMurray, J. P., Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in 
cognition. Mol Psychiatry 2003, 8 (1), 10-1. 
108. Dallanoce, C.; Conti, P.; De Amici, M.; De Micheli, C.; Barocelli, E.; Chiavarini, 
M.; Ballabeni, V.; Bertoni, S.; Impicciatore, M., Synthesis and functional characterization 
of novel derivatives related to oxotremorine and oxotremorine-M. Bioorganic & Medicinal 
Chemistry 1999, 7 (8), 1539-1547. 
109. Langmead, C. J.; Christopoulos, A., Supra-physiological efficacy at GPCRs: 
superstition or super agonists? Br J Pharmacol 2013, 169 (2), 353-6. 
110. Antony, J.; Kellershohn, K.; Mohr-Andra, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, 
E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Trankle, C.; Kostenis, E.; 
Christopoulos, A.; Holtje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K., 
546 
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. 
FASEB J 2009, 23 (2), 442-50. 
111. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U., 
Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010, 
159 (5), 997-1008. 
112. Disingrini, T.; Muth, M.; Dallanoce, C.; Barocelli, E.; Bertoni, S.; Kellershohn, K.; 
Mohr, K.; De Amici, M.; Holzgrabe, U., Design, synthesis, and action of oxotremorine-
related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med 
Chem 2006, 49 (1), 366-72. 
113. Kloeckner, J.; Schmitz, J.; Holzgrabe, U., Convergent, short synthesis of the 
muscarinic superagonist iperoxo. Tetrahedron Letters 2010, 51 (27), 3470-3472. 
114. Chandrashekar, J.; Mueller, K. L.; Hoon, M. A.; Adler, E.; Feng, L.; Guo, W.; 
Zuker, C. S.; Ryba, N. J. P., T2Rs Function as Bitter Taste Receptors. Cell 2000, 100 
(6), 703-711. 
115. Galindo, M. M.; Voigt, N.; Stein, J.; van Lengerich, J.; Raguse, J. D.; Hofmann, 
T.; Meyerhof, W.; Behrens, M., G protein-coupled receptors in human fat taste 
perception. Chem Senses 2012, 37 (2), 123-39. 
116. Meyerhof, W.; Batram, C.; Kuhn, C.; Brockhoff, A.; Chudoba, E.; Bufe, B.; 
Appendino, G.; Behrens, M., The molecular receptive ranges of human TAS2R bitter 
taste receptors. Chem Senses 2010, 35 (2), 157-70. 
117. Margolskee, R. F., Molecular mechanisms of bitter and sweet taste transduction. 
J Biol Chem 2002, 277 (1), 1-4. 
118. Deckmann, K.; Filipski, K.; Krasteva-Christ, G.; Fronius, M.; Althaus, M.; Rafiq, 
A.; Papadakis, T.; Renno, L.; Jurastow, I.; Wessels, L.; Wolff, M.; Schutz, B.; Weihe, E.; 
Chubanov, V.; Gudermann, T.; Klein, J.; Bschleipfer, T.; Kummer, W., Bitter triggers 
acetylcholine release from polymodal urethral chemosensory cells and bladder reflexes. 
Proc Natl Acad Sci U S A 2014, 111 (22), 8287-92. 
119. Zheng, K.; Lu, P.; Delpapa, E.; Bellve, K.; Deng, R.; Condon, J. C.; Fogarty, K.; 
Lifshitz, L. M.; Simas, T. A. M.; Shi, F.; ZhuGe, R., Bitter taste receptors as targets for 
tocolytics in preterm labor therapy. FASEB J 2017, 31 (9), 4037-4052. 
120. Waxman, S. G.; Dib-Hajj, S.; Cummins, T. R.; Black, J. A., Sodium channels and 
pain. Proceedings of the National Academy of Sciences 1999, 96 (14), 7635-7639. 
121. Waxman, S. G.; Zamponi, G. W., Regulating excitability of peripheral afferents: 
emerging ion channel targets. Nat Neurosci 2014, 17 (2), 153-63. 
122. Lai, H. C.; Jan, L. Y., The distribution and targeting of neuronal voltage-gated ion 
channels. Nat Rev Neurosci 2006, 7 (7), 548-62. 
547 
123. Catterall, W. A., From ionic currents to molecular mechanisms: the structure and 
function of voltage-gated sodium channels. Neuron 2000, 26 (1), 13-25. 
124. Long, S. B.; Tao, X.; Campbell, E. B.; MacKinnon, R., Atomic structure of a 
voltage-dependent K+ channel in a lipid membrane-like environment. Nature 2007, 450 
(7168), 376-82. 
125. Catterall, W. A.; Goldin, A. L.; Waxman, S. G., International Union of 
Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-
gated sodium channels. Pharmacol Rev 2005, 57 (4), 397-409. 
126. Payandeh, J.; Gamal El-Din, T. M.; Scheuer, T.; Zheng, N.; Catterall, W. A., 
Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. 
Nature 2012, 486 (7401), 135-9. 
127. Payandeh, J.; Scheuer, T.; Zheng, N.; Catterall, W. A., The crystal structure of a 
voltage-gated sodium channel. Nature 2011, 475 (7356), 353-8. 
128. Armstrong, C. M., Sodium channels and gating currents. Physiol Rev 1981, 61 
(3), 644-83. 
129. Kaczmarek, L. K., Non-conducting functions of voltage-gated ion channels. Nat 
Rev Neurosci 2006, 7 (10), 761-71. 
130. Dib-Hajj, S. D.; Yang, Y.; Black, J. A.; Waxman, S. G., The Na(V)1.7 sodium 
channel: from molecule to man. Nat Rev Neurosci 2013, 14 (1), 49-62. 
131. Browne, L. E.; Blaney, F. E.; Yusaf, S. P.; Clare, J. J.; Wray, D., Structural 
determinants of drugs acting on the Nav1.8 channel. J Biol Chem 2009, 284 (16), 10523-
36. 
132. Zimmermann, K.; Leffler, A.; Babes, A.; Cendan, C. M.; Carr, R. W.; Kobayashi, 
J.; Nau, C.; Wood, J. N.; Reeh, P. W., Sensory neuron sodium channel Nav1.8 is 
essential for pain at low temperatures. Nature 2007, 447 (7146), 855-8. 
133. Jarvis, M. F.; Honore, P.; Shieh, C. C.; Chapman, M.; Joshi, S.; Zhang, X. F.; 
Kort, M.; Carroll, W.; Marron, B.; Atkinson, R.; Thomas, J.; Liu, D.; Krambis, M.; Liu, Y.; 
McGaraughty, S.; Chu, K.; Roeloffs, R.; Zhong, C.; Mikusa, J. P.; Hernandez, G.; Gauvin, 
D.; Wade, C.; Zhu, C.; Pai, M.; Scanio, M.; Shi, L.; Drizin, I.; Gregg, R.; Matulenko, M.; 
Hakeem, A.; Gross, M.; Johnson, M.; Marsh, K.; Wagoner, P. K.; Sullivan, J. P.; Faltynek, 
C. R.; Krafte, D. S., A-803467, a potent and selective Nav1.8 sodium channel blocker, 
attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A 2007, 
104 (20), 8520-5. 
134. Giannerini, M.; Fananas-Mastral, M.; Feringa, B. L., Direct catalytic cross-
coupling of organolithium compounds. Nat Chem 2013, 5 (8), 667-72. 
548 
135. Ruetsch, Y.; Boni, T.; Borgeat, A., From Cocaine to Ropivacaine: The History of 
Local Anesthetic Drugs. Current Topics in Medicinal Chemistry 2001, 1 (3), 175-182. 
136. Solth, A.; Siebrands, C. C.; Friederich, P., Inhibition of Kv4.3/KChIP2.2 channels 
by bupivacaine and its modulation by the pore mutation Kv4.3V401I. Anesthesiology 
2005, 103 (4), 796-804. 
137. Punke, M. A.; Licher, T.; Pongs, O.; Friederich, P., Inhibition of human TREK-1 
channels by bupivacaine. Anesthesia and analgesia 2003, 96 (6), 1665-73, table of 
contents. 
138. González, T.; Longobardo, M.; Caballero, R.; Delpón, E.; Tamargo, J.; 
Valenzuela, C., Effects of Bupivacaine and a Novel Local Anesthetic, IQB-9302, on 
Human Cardiac K<sup>+</sup> Channels. Journal of Pharmacology and Experimental 
Therapeutics 2001, 296 (2), 573-583. 
139. Nilsson, J.; Madeja, M.; Arhem, P., Local anesthetic block of Kv channels: role of 
the S6 helix and the S5-S6 linker for bupivacaine action. Molecular pharmacology 2003, 
63 (6), 1417-29. 
140. Bagal, S. K.; Chapman, M. L.; Marron, B. E.; Prime, R.; Storer, R. I.; Swain, N. 
A., Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett 2014, 
24 (16), 3690-9. 
141. Large, C. H.; Bison, S.; Sartori, I.; Read, K. D.; Gozzi, A.; Quarta, D.; Antolini, M.; 
Hollands, E.; Gill, C. H.; Gunthorpe, M. J.; Idris, N.; Neill, J. C.; Alvaro, G. S., The efficacy 
of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the 
rat: potential for novel treatments for schizophrenia. J Pharmacol Exp Ther 2011, 338 
(1), 100-13. 
142. Keppel Hesselink, J. M., Moving targets in sodium channel blocker development: 
the case of raxatrigine: from a central NaV1.3 blocker via a peripheral NaV1.7 blocker to 
a less selective sodium channel blocker. Journal of Medicine and Therapeutics 2017, 1 
(1). 
143. King, G. F.; Vetter, I., No gain, no pain: NaV1.7 as an analgesic target. ACS Chem 
Neurosci 2014, 5 (9), 749-51. 
144. Fletcher, D. A.; Mullins, R. D., Cell mechanics and the cytoskeleton. Nature 2010, 
463 (7280), 485-92. 
145. Dominguez, R.; Holmes, K. C., Actin structure and function. Annu Rev Biophys 
2011, 40, 169-86. 
146. Otterbein, L. R.; Graceffa, P.; Dominguez, R., The crystal structure of 
uncomplexed actin in the ADP state. Science 2001, 293 (5530), 708-11. 
549 
147. Blanchoin, L.; Boujemaa-Paterski, R.; Sykes, C.; Plastino, J., Actin dynamics, 
architecture, and mechanics in cell motility. Physiol Rev 2014, 94 (1), 235-63. 
148. Goley, E. D.; Welch, M. D., The ARP2/3 complex: an actin nucleator comes of 
age. Nat Rev Mol Cell Biol 2006, 7 (10), 713-26. 
149. Borths, E. L.; Welch, M. D., Turning on the Arp2/3 Complex at Atomic Resolution. 
Structure (London, England : 1993) 2002, 10 (2), 131-135. 
150. Pollard, T. D., Regulation of actin filament assembly by Arp2/3 complex and 
formins. Annu Rev Biophys Biomol Struct 2007, 36, 451-77. 
151. Beach, J. R.; Bruun, K. S.; Shao, L.; Li, D.; Swider, Z.; Remmert, K.; Zhang, Y.; 
Conti, M. A.; Adelstein, R. S.; Rusan, N. M.; Betzig, E.; Hammer, J. A., Actin dynamics 
and competition for myosin monomer govern the sequential amplification of myosin 
filaments. Nat Cell Biol 2017, 19 (2), 85-93. 
152. Robinson, R. C.; Turbedsky, K.; Kaiser, D. A.; Marchand, J. B.; Higgs, H. N.; 
Choe, S.; Pollard, T. D., Crystal structure of Arp2/3 complex. Science 2001, 294 (5547), 
1679-84. 
153. Nolen, B. J.; Tomasevic, N.; Russell, A.; Pierce, D. W.; Jia, Z.; McCormick, C. D.; 
Hartman, J.; Sakowicz, R.; Pollard, T. D., Characterization of two classes of small 
molecule inhibitors of Arp2/3 complex. Nature 2009, 460 (7258), 1031-4. 
154. Baggett, A. W.; Cournia, Z.; Han, M. S.; Patargias, G.; Glass, A. C.; Liu, S. Y.; 
Nolen, B. J., Structural characterization and computer-aided optimization of a small-
molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton. 
ChemMedChem 2012, 7 (7), 1286-94. 
155. Hetrick, B.; Han, M. S.; Helgeson, L. A.; Nolen, B. J., Small molecules CK-666 
and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating 
conformational change. Chem Biol 2013, 20 (5), 701-12. 
156. Shutova, M.; Yang, C.; Vasiliev, J. M.; Svitkina, T., Functions of nonmuscle 
myosin II in assembly of the cellular contractile system. PLoS One 2012, 7 (7), e40814. 
157. Hartman, M. A.; Spudich, J. A., The myosin superfamily at a glance. J Cell Sci 
2012, 125 (Pt 7), 1627-32. 
158. Geeves, M. A., Review: The ATPase mechanism of myosin and actomyosin. 
Biopolymers 2016, 105 (8), 483-91. 
159. O'Connell, C. B.; Tyska, M. J.; Mooseker, M. S., Myosin at work: motor 
adaptations for a variety of cellular functions. Biochim Biophys Acta 2007, 1773 (5), 615-
30. 
160. Conti, M. A.; Adelstein, R. S., Nonmuscle myosin II moves in new directions. J 
Cell Sci 2008, 121 (Pt 1), 11-8. 
550 
161. Straight, A. F.; Cheung, A.; Limouze, J.; Chen, I.; Westwood, N. J.; Sellers, J. R.; 
Mitchison, T. J., Dissecting temporal and spatial control of cytokinesis with a myosin II 
Inhibitor. Science 2003, 299 (5613), 1743-7. 
162. Varkuti, B. H.; Kepiro, M.; Horvath, I. A.; Vegner, L.; Rati, S.; Zsigmond, A.; Hegyi, 
G.; Lenkei, Z.; Varga, M.; Malnasi-Csizmadia, A., A highly soluble, non-phototoxic, non-
fluorescent blebbistatin derivative. Sci Rep 2016, 6, 26141. 
163. Kovacs, M.; Toth, J.; Hetenyi, C.; Malnasi-Csizmadia, A.; Sellers, J. R., 
Mechanism of blebbistatin inhibition of myosin II. J Biol Chem 2004, 279 (34), 35557-63. 
164. Shu, S.; Liu, X.; Korn, E. D., Blebbistatin and blebbistatin-inactivated myosin II 
inhibit myosin II-independent processes in Dictyostelium. Proc Natl Acad Sci U S A 2005, 
102 (5), 1472-7. 
165. Ramamurthy, B.; Yengo, C. M.; Straight, A. F.; Mitchison, T. J.; Sweeney, H. L., 
Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb. Biochemistry 2004, 
43 (46), 14832-9. 
166. Allingham, J. S.; Smith, R.; Rayment, I., The structural basis of blebbistatin 
inhibition and specificity for myosin II. Nat Struct Mol Biol 2005, 12 (4), 378-9. 
167. Lucas-Lopez, C.; Allingham, J. S.; Lebl, T.; Lawson, C. P.; Brenk, R.; Sellers, J. 
R.; Rayment, I.; Westwood, N. J., The small molecule tool (S)-(-)-blebbistatin: novel 
insights of relevance to myosin inhibitor design. Org Biomol Chem 2008, 6 (12), 2076-
84. 
168. Kolega, J., Phototoxicity and photoinactivation of blebbistatin in UV and visible 
light. Biochem Biophys Res Commun 2004, 320 (3), 1020-5. 
169. Mikulich, A.; Kavaliauskiene, S.; Juzenas, P., Blebbistatin, a myosin inhibitor, is 
phototoxic to human cancer cells under exposure to blue light. Biochim Biophys Acta 
2012, 1820 (7), 870-7. 
170. Kepiro, M.; Varkuti, B. H.; Vegner, L.; Voros, G.; Hegyi, G.; Varga, M.; Malnasi-
Csizmadia, A., para-Nitroblebbistatin, the non-cytotoxic and photostable myosin II 
inhibitor. Angew Chem Int Ed Engl 2014, 53 (31), 8211-5. 
171. Kepiro, M.; Varkuti, B. H.; Bodor, A.; Hegyi, G.; Drahos, L.; Kovacs, M.; Malnasi-
Csizmadia, A., Azidoblebbistatin, a photoreactive myosin inhibitor. Proc Natl Acad Sci U 
S A 2012, 109 (24), 9402-7. 
172. Bass, R. J.; Gordon, D. W., A Convenient Route to Tropolone Ethers. Synthetic 
Communications 2006, 15 (3), 225-228. 
 
